0001503707-23-000034.txt : 20231113 0001503707-23-000034.hdr.sgml : 20231113 20231113160339 ACCESSION NUMBER: 0001503707-23-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NorthStar Healthcare Income, Inc. CENTRAL INDEX KEY: 0001503707 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 273663988 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55190 FILM NUMBER: 231398511 BUSINESS ADDRESS: STREET 1: 16 EAST 34TH ST STREET 2: 18TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 929-777-3135 MAIL ADDRESS: STREET 1: 16 EAST 34TH ST STREET 2: 18TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: NorthStar Healthcare Income Trust, Inc. DATE OF NAME CHANGE: 20120404 FORMER COMPANY: FORMER CONFORMED NAME: NorthStar Senior Care Trust, Inc. DATE OF NAME CHANGE: 20101119 FORMER COMPANY: FORMER CONFORMED NAME: NorthStar Healthcare Trust, Inc. DATE OF NAME CHANGE: 20101018 10-Q 1 nshi-20230930.htm 10-Q nshi-20230930
000150370712/31false2023Q3http://fasb.org/us-gaap/2023#RealEstateInvestmentPropertyNethttp://fasb.org/us-gaap/2023#RealEstateInvestmentPropertyNethttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilities000015037072023-01-012023-09-3000015037072023-11-13xbrli:shares00015037072023-09-30iso4217:USD00015037072022-12-310001503707us-gaap:RelatedPartyMember2023-09-300001503707us-gaap:RelatedPartyMember2022-12-310001503707us-gaap:NonrelatedPartyMember2023-09-300001503707us-gaap:NonrelatedPartyMember2022-12-31iso4217:USDxbrli:shares0001503707nshi:NorthstarHealthcareIncomeOperatingPartnershipLPMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-3000015037072023-07-012023-09-3000015037072022-07-012022-09-3000015037072022-01-012022-09-3000015037072023-09-302023-09-3000015037072022-09-302022-09-300001503707us-gaap:CommonStockMember2021-12-310001503707us-gaap:AdditionalPaidInCapitalMember2021-12-310001503707us-gaap:RetainedEarningsMember2021-12-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001503707us-gaap:ParentMember2021-12-310001503707us-gaap:NoncontrollingInterestMember2021-12-3100015037072021-12-310001503707us-gaap:CommonStockMember2022-01-012022-03-310001503707us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001503707us-gaap:ParentMember2022-01-012022-03-3100015037072022-01-012022-03-310001503707us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001503707us-gaap:RetainedEarningsMember2022-01-012022-03-310001503707us-gaap:CommonStockMember2022-03-310001503707us-gaap:AdditionalPaidInCapitalMember2022-03-310001503707us-gaap:RetainedEarningsMember2022-03-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001503707us-gaap:ParentMember2022-03-310001503707us-gaap:NoncontrollingInterestMember2022-03-3100015037072022-03-310001503707us-gaap:CommonStockMember2022-04-012022-06-300001503707us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001503707us-gaap:ParentMember2022-04-012022-06-3000015037072022-04-012022-06-300001503707us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001503707us-gaap:RetainedEarningsMember2022-04-012022-06-300001503707us-gaap:CommonStockMember2022-06-300001503707us-gaap:AdditionalPaidInCapitalMember2022-06-300001503707us-gaap:RetainedEarningsMember2022-06-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001503707us-gaap:ParentMember2022-06-300001503707us-gaap:NoncontrollingInterestMember2022-06-3000015037072022-06-300001503707us-gaap:CommonStockMember2022-07-012022-09-300001503707us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001503707us-gaap:ParentMember2022-07-012022-09-300001503707us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001503707us-gaap:RetainedEarningsMember2022-07-012022-09-300001503707us-gaap:CommonStockMember2022-09-300001503707us-gaap:AdditionalPaidInCapitalMember2022-09-300001503707us-gaap:RetainedEarningsMember2022-09-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001503707us-gaap:ParentMember2022-09-300001503707us-gaap:NoncontrollingInterestMember2022-09-3000015037072022-09-300001503707us-gaap:CommonStockMember2022-12-310001503707us-gaap:AdditionalPaidInCapitalMember2022-12-310001503707us-gaap:RetainedEarningsMember2022-12-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001503707us-gaap:ParentMember2022-12-310001503707us-gaap:NoncontrollingInterestMember2022-12-310001503707us-gaap:NoncontrollingInterestMember2023-01-012023-03-3100015037072023-01-012023-03-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001503707us-gaap:ParentMember2023-01-012023-03-310001503707us-gaap:RetainedEarningsMember2023-01-012023-03-310001503707us-gaap:CommonStockMember2023-03-310001503707us-gaap:AdditionalPaidInCapitalMember2023-03-310001503707us-gaap:RetainedEarningsMember2023-03-310001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001503707us-gaap:ParentMember2023-03-310001503707us-gaap:NoncontrollingInterestMember2023-03-3100015037072023-03-310001503707us-gaap:NoncontrollingInterestMember2023-04-012023-06-3000015037072023-04-012023-06-300001503707us-gaap:CommonStockMember2023-04-012023-06-300001503707us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001503707us-gaap:ParentMember2023-04-012023-06-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001503707us-gaap:RetainedEarningsMember2023-04-012023-06-300001503707us-gaap:CommonStockMember2023-06-300001503707us-gaap:AdditionalPaidInCapitalMember2023-06-300001503707us-gaap:RetainedEarningsMember2023-06-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001503707us-gaap:ParentMember2023-06-300001503707us-gaap:NoncontrollingInterestMember2023-06-3000015037072023-06-300001503707us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001503707us-gaap:ParentMember2023-07-012023-09-300001503707us-gaap:NoncontrollingInterestMember2023-07-012023-09-300001503707us-gaap:RetainedEarningsMember2023-07-012023-09-300001503707us-gaap:CommonStockMember2023-09-300001503707us-gaap:AdditionalPaidInCapitalMember2023-09-300001503707us-gaap:RetainedEarningsMember2023-09-300001503707us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001503707us-gaap:ParentMember2023-09-300001503707us-gaap:NoncontrollingInterestMember2023-09-300001503707nshi:AdvisoroftheRegistrantMember2023-01-012023-09-300001503707nshi:SpecialUnitsHolderMember2023-01-012023-09-300001503707nshi:NorthstarHealthcareIncomeOperatingPartnershipLPMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-01-012023-09-30xbrli:pure0001503707nshi:DividendReinvestmentPlanMember2023-01-012023-09-300001503707us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-09-300001503707nshi:EspressoJointVentureMember2023-01-012023-06-300001503707nshi:EspressoJointVentureMember2023-06-300001503707srt:MinimumMemberus-gaap:BuildingMember2023-09-300001503707srt:MaximumMemberus-gaap:BuildingMember2023-09-300001503707us-gaap:LandImprovementsMembersrt:MinimumMember2023-09-300001503707us-gaap:LandImprovementsMembersrt:MaximumMember2023-09-300001503707us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2023-09-300001503707us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2023-09-30nshi:property0001503707us-gaap:LeasesAcquiredInPlaceMember2023-09-300001503707us-gaap:LeasesAcquiredInPlaceMember2022-12-310001503707us-gaap:InterestRateCapMember2023-09-300001503707us-gaap:InterestRateCapMember2022-12-31nshi:day0001503707nshi:OperatingRealEstateNetMember2023-01-012023-09-300001503707nshi:RochesterPortfolioMembernshi:FacilityMember2023-01-012023-09-30nshi:facility0001503707nshi:RochesterPortfolioMembernshi:LandParcelMember2023-01-012023-09-300001503707nshi:OperatingRealEstateNetMember2022-01-012022-09-300001503707nshi:ArborsPortfolioMember2022-01-012022-09-300001503707nshi:WinterfellPortfolioMember2022-01-012022-09-300001503707nshi:RochesterPortfolioMember2022-01-012022-09-300001503707nshi:EspressoJointVentureMember2023-01-012023-09-300001503707nshi:EspressoJointVentureMember2023-09-300001503707nshi:DiversifiedUSUKMember2023-05-012023-05-31nshi:home0001503707nshi:DiversifiedUSUKMember2023-01-012023-09-300001503707us-gaap:BuildingAndBuildingImprovementsMember2023-09-300001503707us-gaap:BuildingAndBuildingImprovementsMember2022-12-310001503707nshi:TheTrilogyJointVentureMember2023-09-300001503707nshi:TheTrilogyJointVentureMember2022-12-310001503707nshi:EspressoJointVentureMember2022-12-310001503707nshi:SolsticeSeniorLivingLLCMember2023-09-300001503707nshi:SolsticeSeniorLivingLLCMember2022-12-310001503707nshi:TrilogyEspressoSolsticeMember2023-09-300001503707nshi:TrilogyEspressoSolsticeMember2022-12-310001503707nshi:EspressoJointVentureMember2023-06-012023-06-300001503707nshi:WinterfellPortfolioMembernshi:SolsticeSeniorLivingLLCMember2023-09-300001503707nshi:SolsticeSeniorLivingLLCMembernshi:WinterfellPortfolioMember2023-09-300001503707nshi:DiversifiedUSUKMember2023-09-300001503707nshi:DiversifiedUSUKMember2023-06-012023-06-300001503707nshi:EclipseJointVentureMember2023-09-300001503707nshi:EclipseJointVentureMember2023-06-012023-06-300001503707nshi:FormerSponsorAndAffiliatesMember2023-06-012023-06-300001503707nshi:FormerSponsorAndAffiliatesMember2023-09-300001503707nshi:TheTrilogyJointVentureMember2023-07-012023-09-300001503707nshi:TheTrilogyJointVentureMember2022-07-012022-09-300001503707nshi:TheTrilogyJointVentureMember2023-01-012023-09-300001503707nshi:TheTrilogyJointVentureMember2022-01-012022-09-300001503707nshi:EspressoJointVentureMember2023-07-012023-09-300001503707nshi:EspressoJointVentureMember2022-07-012022-09-300001503707nshi:EspressoJointVentureMember2022-01-012022-09-300001503707nshi:SolsticeSeniorLivingLLCMember2023-07-012023-09-300001503707nshi:SolsticeSeniorLivingLLCMember2022-07-012022-09-300001503707nshi:SolsticeSeniorLivingLLCMember2023-01-012023-09-300001503707nshi:SolsticeSeniorLivingLLCMember2022-01-012022-09-300001503707nshi:TrilogyEspressoSolsticeMember2023-07-012023-09-300001503707nshi:TrilogyEspressoSolsticeMember2022-07-012022-09-300001503707nshi:TrilogyEspressoSolsticeMember2023-01-012023-09-300001503707nshi:TrilogyEspressoSolsticeMember2022-01-012022-09-300001503707nshi:FriscoTXMembernshi:FriscoTXNonRecourseFebruary2026Memberus-gaap:MortgagesMember2023-09-300001503707nshi:FriscoTXMembernshi:FriscoTXNonRecourseFebruary2026Memberus-gaap:MortgagesMember2022-12-310001503707nshi:SecuredOvernightFinancingRateSOFRMembernshi:MilfordOHNonRecourseSeptember2026Membernshi:MilfordOHMemberus-gaap:MortgagesMember2023-01-012023-09-300001503707nshi:MilfordOHNonRecourseSeptember2026Membernshi:MilfordOHMemberus-gaap:MortgagesMember2023-09-300001503707nshi:MilfordOHNonRecourseSeptember2026Membernshi:MilfordOHMemberus-gaap:MortgagesMember2022-12-310001503707nshi:RochesterNYNonrecourseFebruary2025Membernshi:RochesterNYMemberus-gaap:MortgagesMember2023-09-300001503707nshi:RochesterNYNonrecourseFebruary2025Membernshi:RochesterNYMemberus-gaap:MortgagesMember2022-12-310001503707nshi:SecuredOvernightFinancingRateSOFRMembernshi:RochesterNYMemberus-gaap:MortgagesMembernshi:RochesterNYNonRecourseJuly2023Member2023-01-012023-09-300001503707nshi:RochesterNYMemberus-gaap:MortgagesMembernshi:RochesterNYNonRecourseJuly2023Member2023-09-300001503707nshi:RochesterNYMemberus-gaap:MortgagesMembernshi:RochesterNYNonRecourseJuly2023Member2022-12-310001503707nshi:SecuredOvernightFinancingRateSOFRMembernshi:RochesterNYMembernshi:RochesterNYNonrecourseAugust2024Memberus-gaap:MortgagesMember2023-01-012023-09-300001503707nshi:RochesterNYMembernshi:RochesterNYNonrecourseAugust2024Memberus-gaap:MortgagesMember2023-09-300001503707nshi:RochesterNYMembernshi:RochesterNYNonrecourseAugust2024Memberus-gaap:MortgagesMember2022-12-310001503707nshi:ArborsPortfolioMemberus-gaap:NonrecourseMemberus-gaap:MortgagesMember2023-09-300001503707nshi:ArborsPortfolioMemberus-gaap:NonrecourseMemberus-gaap:MortgagesMember2022-12-310001503707us-gaap:NonrecourseMembernshi:WinterfellPortfolioMemberus-gaap:MortgagesMember2023-09-300001503707us-gaap:NonrecourseMembernshi:WinterfellPortfolioMemberus-gaap:MortgagesMember2022-12-310001503707us-gaap:NonrecourseMemberus-gaap:MortgagesMembernshi:AvamerePortfolioMember2023-09-300001503707us-gaap:NonrecourseMemberus-gaap:MortgagesMembernshi:AvamerePortfolioMember2022-12-310001503707nshi:MortgagesAndOtherNotesPayableMember2023-09-300001503707nshi:MortgagesAndOtherNotesPayableMember2022-12-310001503707nshi:FloatingRateDebtOneMonthLIBORMemberus-gaap:MortgagesMember2023-09-300001503707nshi:SecuredOvernightFinancingRateSOFRMembernshi:FriscoTXMembernshi:FriscoTXNonRecourseFebruary2026Memberus-gaap:MortgagesMember2023-01-012023-09-300001503707nshi:RochesterNYMemberus-gaap:MortgagesMember2023-01-012023-09-30nshi:debt_instrument0001503707nshi:ArborsPortfolioMemberus-gaap:MortgagesMember2023-01-012023-09-300001503707nshi:WinterfellPortfolioMemberus-gaap:MortgagesMember2023-01-012023-09-300001503707nshi:WinterfellPortfolioMember2023-01-012023-09-300001503707us-gaap:MortgagesMembernshi:AvamerePortfolioMember2023-01-012023-09-300001503707nshi:RelatedPartyTransitionServicesAgreementMember2023-03-222023-03-220001503707nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMembernshi:AdvisoroftheRegistrantMember2022-12-310001503707nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMembernshi:AdvisoroftheRegistrantMembernshi:OperatingCostsIncurredMember2023-01-012023-09-300001503707nshi:OperatingCostsPaidMembernshi:GeneralAndAdministrativeExpensesAndTransactionCostsMembernshi:AdvisoroftheRegistrantMember2023-01-012023-09-300001503707nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMembernshi:AdvisoroftheRegistrantMember2023-09-300001503707nshi:IncentiveFeesMemberus-gaap:RelatedPartyMember2023-01-012023-09-300001503707nshi:SolsticeSeniorLivingLLCMembernshi:WinterfellPortfolioMember2023-09-300001503707nshi:SolsticeSeniorLivingLLCMembernshi:WinterfellPortfolioMember2023-09-300001503707nshi:SolsticeSeniorLivingLLCMembernshi:WinterfellPortfolioMember2023-01-012023-09-300001503707us-gaap:RestrictedStockMember2023-09-300001503707srt:DirectorMemberus-gaap:RestrictedStockMember2023-01-012023-09-300001503707srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001503707srt:DirectorMemberus-gaap:RestrictedStockMember2023-09-300001503707srt:DirectorMemberus-gaap:RestrictedStockUnitsRSUMember2023-09-300001503707us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001503707us-gaap:RestrictedStockMember2023-01-012023-09-300001503707us-gaap:RestrictedStockUnitsRSUMember2023-09-300001503707us-gaap:RestrictedStockUnitsRSUMember2022-12-310001503707us-gaap:CommonStockMember2015-12-172016-01-190001503707us-gaap:CommonStockMembernshi:DividendReinvestmentPlanMember2015-12-172023-06-300001503707nshi:DividendReinvestmentPlanMember2023-01-012023-09-3000015037072022-05-0200015037072023-06-302023-06-300001503707nshi:DiversifiedUSUKAndEclipseMember2023-09-300001503707nshi:DiversifiedUSUKAndEclipseMember2023-01-012023-09-300001503707us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateCapMember2023-09-300001503707us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel2Member2023-09-300001503707us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2023-09-300001503707us-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateCapMember2022-12-310001503707us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel2Member2022-12-310001503707us-gaap:InterestRateCapMemberus-gaap:FairValueInputsLevel3Member2022-12-310001503707us-gaap:FairValueInputsLevel1Membernshi:EspressoJointVentureMember2023-09-300001503707us-gaap:FairValueInputsLevel2Membernshi:EspressoJointVentureMember2023-09-300001503707nshi:EspressoJointVentureMemberus-gaap:FairValueInputsLevel3Member2023-09-300001503707us-gaap:FairValueInputsLevel1Membernshi:EspressoJointVentureMember2022-12-310001503707us-gaap:FairValueInputsLevel2Membernshi:EspressoJointVentureMember2022-12-310001503707nshi:EspressoJointVentureMemberus-gaap:FairValueInputsLevel3Member2022-12-310001503707us-gaap:MortgagesMember2023-09-300001503707us-gaap:MortgagesMember2022-12-310001503707us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:FairValueInputsLevel3Membernshi:OperatingRealEstateNetMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-01-012023-09-300001503707us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001503707us-gaap:FairValueInputsLevel3Membernshi:OperatingRealEstateNetMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-01-012022-12-310001503707us-gaap:CorporateJointVentureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-01-012023-09-300001503707us-gaap:CorporateJointVentureMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-01-012022-12-3100015037072022-01-012022-12-310001503707us-gaap:RealEstateInvestmentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMembernshi:TerminalCapitalizationRateMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:RealEstateInvestmentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembernshi:TerminalCapitalizationRateMembersrt:MaximumMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:RealEstateInvestmentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:RealEstateInvestmentMemberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707nshi:EclipseJointVentureMember2023-06-300001503707nshi:DiversifiedUSUKMember2022-01-012022-12-310001503707nshi:DiversifiedUSUKMember2022-12-310001503707us-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMemberus-gaap:CorporateJointVentureMembernshi:TerminalCapitalizationRateMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:CorporateJointVentureMembernshi:TerminalCapitalizationRateMembersrt:MaximumMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMemberus-gaap:CorporateJointVentureMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:CorporateJointVentureMembersrt:MaximumMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2023-07-012023-09-300001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2023-07-012023-09-300001503707us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2022-07-012022-09-300001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2022-07-012022-09-300001503707us-gaap:CorporateNonSegmentMember2022-07-012022-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2023-01-012023-09-300001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2023-01-012023-09-300001503707us-gaap:CorporateNonSegmentMember2023-01-012023-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2022-01-012022-09-300001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2022-01-012022-09-300001503707us-gaap:CorporateNonSegmentMember2022-01-012022-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2023-09-300001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2023-09-300001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2023-09-300001503707us-gaap:CorporateNonSegmentMember2023-09-300001503707us-gaap:OperatingSegmentsMembernshi:DirectInvestmentsNetLeaseMember2022-12-310001503707nshi:DirectInvestmentsOperatingMemberus-gaap:OperatingSegmentsMember2022-12-310001503707us-gaap:OperatingSegmentsMembernshi:UnconsolidatedInvestmentsSegmentMember2022-12-310001503707us-gaap:CorporateNonSegmentMember2022-12-310001503707nshi:SolsticeSeniorLivingLLCMember2023-09-30nshi:unit0001503707nshi:SolsticeSeniorLivingLLCMember2023-01-012023-09-300001503707nshi:SolsticeSeniorLivingLLCMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:WatermarkRetirementCommunitiesMember2023-09-300001503707nshi:WatermarkRetirementCommunitiesMember2023-01-012023-09-300001503707nshi:WatermarkRetirementCommunitiesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:AvamereHealthServicesMember2023-09-300001503707nshi:AvamereHealthServicesMember2023-01-012023-09-300001503707nshi:AvamereHealthServicesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:IntegralMember2023-09-300001503707nshi:IntegralMember2023-01-012023-09-300001503707nshi:IntegralMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:ArcadiaMember2023-09-300001503707nshi:ArcadiaMember2023-01-012023-09-300001503707nshi:ArcadiaMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:OtherPropertiesMember2023-09-300001503707nshi:OtherPropertiesMember2023-01-012023-09-300001503707nshi:OtherPropertiesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:TotalPropertiesMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-09-300001503707nshi:SolsticeSeniorLivingLLCMember2023-09-300001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembernshi:TheTrilogyJointVentureMember2024-01-012024-12-31nshi:campus0001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembersrt:MinimumMembernshi:TheTrilogyJointVentureMember2024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembersrt:MaximumMembernshi:TheTrilogyJointVentureMember2024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembernshi:March312024Memberus-gaap:SubsequentEventMembernshi:TheTrilogyJointVentureMember2024-01-012024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembernshi:December312024Membernshi:TheTrilogyJointVentureMember2024-01-012024-12-31nshi:uSDollarsPerDay0001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembernshi:TerminatedPriorToInitialOutsideDateMembernshi:TheTrilogyJointVentureMember2024-01-012024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembernshi:QualifyingIPOOf200MillionHasOccurredMemberus-gaap:SubsequentEventMembernshi:TheTrilogyJointVentureMember2024-01-012024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembernshi:TerminatedPriorToMarch312025Membernshi:TheTrilogyJointVentureMember2024-01-012024-12-310001503707srt:ScenarioForecastMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMembernshi:TerminatedPriorToSeptember302025Membernshi:TheTrilogyJointVentureMember2024-01-012024-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 000-55190
NORTHSTAR HEALTHCARE INCOME, INC.
(Exact Name of Registrant as Specified in its Charter)
Maryland27-3663988
(State or Other Jurisdiction of(IRS Employer
Incorporation or Organization)Identification No.)
16 East 34th Street, 18th Floor, New York, NY 10016
(Address of Principal Executive Offices, Including Zip Code)
(929) 777-3135
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.01 per shareNoneNone
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý   No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý   No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer¨Accelerated filer¨Non-accelerated filerýSmaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ý
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date:
The Company has one class of common stock, $0.01 par value per share, 185,712,103 shares outstanding as of November 13, 2023.

NORTHSTAR HEALTHCARE INCOME, INC.
FORM 10-Q
TABLE OF CONTENTS

IndexPage
Control and Procedures











2
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may,” “will,” “should,” “potential,” “intend,” “expect,” “seek,” “anticipate,” “estimate,” “believe,” “could,” “project,” “predict,” “continue,” “future” or other similar words or expressions. Forward-looking statements are not guarantees of performance and are based on certain assumptions, discuss future expectations, describe plans and strategies, contain projections of results of operations or of financial condition or state other forward-looking information. Such statements include, but are not limited to, those relating to our ability to make distributions to our stockholders; our ability to retain our senior executives and other sufficient personnel to manage our business; our ability to realize substantial efficiencies as well as anticipated strategic and financial benefits of the internalization of our management function as operating costs and business disruption may be greater than expected; the operating performance of our investments, our financing needs, the effects of our current strategies and investment activities and our ability to effectively deploy capital. Our ability to predict results or the actual effect of plans or strategies is inherently uncertain. Although we believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions, our actual results and performance could differ materially from those set forth in the forward-looking statements and you should not unduly rely on these statements. These forward-looking statements involve risks, uncertainties and other factors that may cause our actual results in future periods to differ materially from those forward-looking statements.
All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us on the date hereof and we are under no duty to update any of the forward-looking statements after the date of this report to conform these statements to actual results.
Factors that could have a material adverse effect on our operations and future prospects are set forth in our filings with the U.S. Securities and Exchange Commission, or the SEC, including Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in Part II, Item 1A of this Quarterly Report on Form 10-Q under the heading “Risk Factors.” The risk factors set forth in our filings with the SEC could cause our actual results to differ significantly from those contained in any forward-looking statement contained in this report.



3
PART I—Financial Information
Item 1. Financial Statements
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Dollars in Thousands, Except Per Share Data)
September 30, 2023 (Unaudited)
December 31, 2022
Assets 
Cash and cash equivalents$87,581 $103,926 
Restricted cash11,386 11,734 
Operating real estate, net894,245 933,002 
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)
128,026 176,502 
Receivables, net2,253 2,815 
Intangible assets, net2,000 2,253 
Other assets10,425 7,603 
Total assets(1)
$1,135,916 $1,237,835 
Liabilities
Mortgage notes payable, net$901,610 $912,248 
Due to related party292 469 
Escrow deposits payable1,023 993 
Accounts payable and accrued expenses23,967 21,034 
Other liabilities1,592 2,019 
Total liabilities(1)
928,484 936,763 
Commitments and contingencies (Note 12)
Equity
NorthStar Healthcare Income, Inc. Stockholders’ Equity
Preferred stock, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and December 31, 2022
— — 
Common stock, $0.01 par value, 400,000,000 shares authorized, 185,712,103 and 195,421,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively
1,857 1,954 
Additional paid-in capital1,716,701 1,729,589 
Retained earnings (accumulated deficit)(1,511,765)(1,428,840)
Accumulated other comprehensive income (loss)— (3,679)
Total NorthStar Healthcare Income, Inc. stockholders’ equity206,793 299,024 
Non-controlling interests639 2,048 
Total equity207,432 301,072 
Total liabilities and equity$1,135,916 $1,237,835 
_______________________________________
(1)Includes $174.4 million and $180.2 million of assets and liabilities, respectively, of certain VIEs that are consolidated by the Operating Partnership. Refer to Note 2, “Summary of Significant Accounting Policies.”











Refer to accompanying notes to consolidated financial statements (unaudited).



4
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in Thousands, Except Per Share Data)
(Unaudited)
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Property and other revenues
Resident fee income$11,966 $11,274 $35,655 $32,987 
Rental income40,330 36,165 115,897 103,001 
Other revenue1,078 300 2,893 457 
Total property and other revenues53,374 47,739 154,445 136,445 
Expenses
Property operating expenses36,890 35,134 106,993 101,258 
Interest expense14,250 11,014 37,143 31,877 
Transaction costs358 857 455 857 
Asset management fees - related party— 2,428 — 7,532 
General and administrative expenses2,921 2,859 10,424 10,300 
Depreciation and amortization9,848 9,642 29,305 29,105 
Impairment loss— 18,500 43,422 31,502 
Total expenses64,267 80,434 227,742 212,431 
Other income (loss)
Other income, net— — 202 77 
Gain (loss) on investments and other(347)325 (4,662)660 
Income (loss) before equity in earnings (losses) of unconsolidated ventures and income tax expense(11,240)(32,370)(77,757)(75,249)
Equity in earnings (losses) of unconsolidated ventures(127)2,872 (6,595)39,427 
Income tax expense(17)(15)(43)(45)
Net income (loss) (11,384)(29,513)(84,395)(35,867)
Net (income) loss attributable to non-controlling interests166 73 1,470 298 
Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders$(11,218)$(29,440)$(82,925)$(35,569)
Net income (loss) per share of common stock, basic/diluted(1)
$(0.06)$(0.15)$(0.43)$(0.18)
Weighted average number of shares of common stock outstanding, basic/diluted(1)
185,712,103 194,670,948 191,367,117 194,032,819 
Distributions declared per share of common stock$— $— $— $0.50 
_______________________________________
(1)     The Company issued 203,742 and 116,712 restricted stock units as of September 30, 2023 and September 30, 2022, respectively. The restricted stock units have been excluded from the diluted earnings per share calculation as their impact is anti-dilutive due to the net loss generated during the three and nine months ended September 30, 2023 and 2022.













Refer to accompanying notes to consolidated financial statements (unaudited).



5
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Dollars in Thousands)
(Unaudited)

Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Net income (loss)$(11,384)$(29,513)$(84,395)$(35,867)
Other comprehensive income (loss)
Foreign currency translation adjustments related to investment in unconsolidated venture— (1,664)3,679 (4,602)
Total other comprehensive income (loss)— (1,664)3,679 (4,602)
Comprehensive income (loss)(11,384)(31,177)(80,716)(40,469)
Comprehensive (income) loss attributable to non-controlling interests166 73 1,470 298 
Comprehensive income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders$(11,218)$(31,104)$(79,246)$(40,171)





































Refer to accompanying notes to consolidated financial statements (unaudited).



6
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Dollars and Shares in Thousands)

Common StockAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Accumulated Other Comprehensive Income (Loss)Total Company’s Stockholders’ EquityNon-controlling InterestsTotal Equity
SharesAmount
Balance as of December 31, 2021193,121 $1,930 $1,720,719 $(1,277,688)$(486)$444,475 $2,343 $446,818 
Share-based payment of advisor asset management fees698 7 2,722 — — 2,729 — 2,729 
Amortization of equity-based compensation— — 15 — — 15 — 15 
Non-controlling interests - contributions— — — — — — 64 64 
Non-controlling interests - distributions— — — — — — (53)(53)
Other comprehensive income (loss)— — — — (568)(568)— (568)
Net income (loss)— — — (12,936)— (12,936)(45)(12,981)
Balance as of March 31, 2022 (Unaudited)193,819 $1,937 $1,723,456 $(1,290,624)$(1,054)$433,715 $2,309 $436,024 
Share-based payment of advisor asset management fees637 8 2,507 — — 2,515 — 2,515 
Amortization of equity-based compensation— — 13 — — 13 — 13 
Non-controlling interests - contributions— — — — — — 113 113 
Non-controlling interests - distributions— — — — — — (61)(61)
Distributions declared— — — (97,052)— (97,052)— (97,052)
Other comprehensive income (loss)— — — — (2,370)(2,370)— (2,370)
Net income (loss)— — — 6,807 — 6,807 (180)6,627 
Balance as of June 30, 2022 (Unaudited)194,456 $1,945 $1,725,976 $(1,380,869)$(3,424)$343,628 $2,181 $345,809 
Share-based payment of advisor asset management fees623 6 2,407 — — 2,413 — 2,413 
Non-controlling interests - contributions— — — — — — 86 86 
Non-controlling interests - distributions— — — — — — (74)(74)
Other comprehensive income (loss)— — — — (1,664)(1,664)— (1,664)
Net income (loss)— — — (29,440)— (29,440)(73)(29,513)
Balance as of September 30, 2022 (Unaudited)195,079 $1,951 $1,728,383 $(1,410,309)$(5,088)$314,937 $2,120 $317,057 










Refer to accompanying notes to consolidated financial statements (unaudited).





7
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(Dollars and Shares in Thousands)

Common StockAdditional Paid-in CapitalRetained Earnings (Accumulated Deficit)Accumulated Other Comprehensive Income (Loss)Total Company’s Stockholders’ EquityNon-controlling InterestsTotal Equity
SharesAmount
Balance as of December 31, 2022195,422 $1,954 $1,729,589 $(1,428,840)$(3,679)$299,024 $2,048 $301,072 
Non-controlling interests - contributions— — — — — — 45 45 
Non-controlling interests - distributions— — — — — — (22)(22)
Other comprehensive income (loss)— — — — 1,248 1,248 — 1,248 
Net income (loss)— — — (13,926)— (13,926)(71)(13,997)
Balance as of March 31, 2023 (Unaudited)195,422 $1,954 $1,729,589 $(1,442,766)$(2,431)$286,346 $2,000 $288,346 
Non-controlling interests - contributions— — — — — — 55 55 
Non-controlling interests - distributions— — — — — — (33)(33)
Retirement of common stock (Note 8)(9,710)(97)(13,302)— — (13,399)— (13,399)
Other comprehensive income (loss)— — — — (844)(844)— (844)
Reclassification of accumulated other comprehensive loss(1)
— — — — 3,275 3,275 — 3,275 
Net income (loss)— — — (57,781)— (57,781)(1,233)(59,014)
Balance as of June 30, 2023 (Unaudited)185,712 $1,857 $1,716,287 $(1,500,547)$— $217,597 $789 $218,386 
Amortization of equity-based compensation— — 414 — — 414 — 414 
Non-controlling interests - contributions— — — — — — 44 44 
Non-controlling interests - distributions— — — — — — (28)(28)
Net income (loss)— — — (11,218)— (11,218)(166)(11,384)
Balance as of September 30, 2023 (Unaudited)185,712 $1,857 $1,716,701 $(1,511,765)$— $206,793 $639 $207,432 
_______________________________________
(1)The Company reclassified the accumulated other comprehensive loss related to foreign currency adjustments for an unconsolidated venture ownership interest that was sold during the three months ended June 30, 2023. The accumulated balance was reclassified to gain (loss) on investments and other on the consolidated statements of operations.






Refer to accompanying notes to consolidated financial statements (unaudited).



8
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Thousands)
(Unaudited)

Nine Months Ended September 30,
20232022
Cash flows from operating activities:
Net income (loss)$(84,395)$(35,867)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Equity in (earnings) losses of unconsolidated ventures6,595 (39,427)
Depreciation and amortization29,305 29,105 
Impairment loss43,422 31,502 
Amortization of below market debt2,487 2,428 
Amortization of deferred financing costs988 475 
Amortization of equity-based compensation170 150 
(Gain) loss on investments and other4,662 (660)
Change in allowance for uncollectible accounts 360 326 
Issuance of common stock as payment for asset management fees— 7,532 
Distributions from unconsolidated ventures10,640 — 
Changes in assets and liabilities:
Receivables203 (114)
Other assets(3,786)3,583 
Due to related party(177)(3,868)
Escrow deposits payable 30 256 
Accounts payable and accrued expenses2,640 (8,727)
Other liabilities (78)(298)
Net cash provided by (used in) operating activities13,066 (13,604)
Cash flows from investing activities:
Capital expenditures for operating real estate(28,425)(17,924)
Sales of real estate135 — 
Distributions from unconsolidated ventures13,472 42,173 
Sales of other assets 523 — 
Net cash provided by (used in) investing activities(14,295)24,249 
Cash flows from financing activities:
Repayments of mortgage notes (14,066)(16,514)
Payment of deferred financing costs(48)— 
Payments under finance leases(96)(36)
Acquisition and retirement of common stock(1,315)(408)
Distributions paid on common stock— (97,018)
Contributions from non-controlling interests144 263 
Distributions to non-controlling interests(83)(188)
Net cash provided by (used in) financing activities(15,464)(113,901)
Net increase (decrease) in cash, cash equivalents and restricted cash(16,693)(103,256)
Cash, cash equivalents and restricted cash-beginning of period115,660 210,938 
Cash, cash equivalents and restricted cash-end of period$98,967 $107,682 


Nine Months Ended September 30,
20232022
Supplemental disclosure of cash flow information:
Cash paid for interest$29,666 $28,625 
Cash paid for income taxes61 41 
Supplemental disclosure of non-cash investing and financing activities:
Accrued capital expenditures$540 $2,561 
Exchange of ownership interests in unconsolidated ventures for common stock 13,399 — 
Assets acquired under capital lease obligations25 — 


Refer to accompanying notes to consolidated financial statements (unaudited).



9
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Business and Organization
NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), owns a diversified portfolio of seniors housing properties, including independent living facilities (“ILF”), assisted living (“ALF”) and memory care facilities (“MCF”) located throughout the United States. In addition, the Company also has investments through non-controlling interests in joint ventures in a broader spectrum of healthcare real estate, including seniors housing properties, as well as skilled nursing (“SNF”) and ancillary services businesses, located throughout the United States.
The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company has conducted its operations, and intends to do so in the future, so as to continue to qualify as a REIT for U.S. federal income tax purposes.
Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”), which became indirect subsidiaries of the Company on June 9, 2023. NorthStar Healthcare Income Advisor, LLC invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which were collectively recorded as non-controlling interests on the accompanying consolidated balance sheets prior to June 9, 2023. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of September 30, 2023, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, was 100.0%.
The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.
The Company raised $2.0 billion in total gross proceeds from the sale of shares of common stock in its continuous, public offerings (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”).
The Internalization
From inception through October 21, 2022, the Company was externally managed by CNI NSHC Advisors, LLC or its predecessor (the “Former Advisor”), an affiliate of NRF Holdco, LLC (the “Former Sponsor”). The Former Advisor was responsible for managing the Company’s operations, subject to the supervision of the Company’s board of directors, pursuant to an advisory agreement. On October 21, 2022, the Company completed the internalization of the Company’s management function (the “Internalization”). In connection with the Internalization, the Company agreed with the Former Advisor to terminate the advisory agreement and arranged for the Former Advisor to continue to provide certain services for a transition period.
2. Summary of Significant Accounting Policies
Basis of Accounting
The accompanying consolidated financial statements and related notes of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures normally included in the consolidated financial statements prepared under U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 27, 2023.



10
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Principles of Consolidation
The consolidated financial statements include the accounts of the Company, the Operating Partnership and their consolidated subsidiaries. The Company consolidates entities in which it has a controlling financial interest by first considering if an entity meets the definition of a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary or if the Company has the power to control an entity through majority voting interest or other arrangements. All significant intercompany balances are eliminated in consolidation.
Variable Interest Entities
A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. A VIE is defined as an entity in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The determination of whether an entity is a VIE includes both a qualitative and quantitative analysis. The Company bases its qualitative analysis on its review of the design of the entity, its organizational structure including decision-making ability and relevant financial agreements and the quantitative analysis on the forecasted cash flow of the entity. The Company reassesses its initial evaluation of an entity as a VIE upon the occurrence of certain reconsideration events.
A VIE must be consolidated only by its primary beneficiary, which is defined as the party who, along with its affiliates and agents, has both the: (i) power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The Company determines whether it is the primary beneficiary of a VIE by considering qualitative and quantitative factors, including, but not limited to: which activities most significantly impact the VIE’s economic performance and which party controls such activities; the amount and characteristics of its investment; the obligation or likelihood for the Company or other interests to provide financial support; consideration of the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders and the similarity with and significance to the business activities of the Company and the other interests. The Company reassesses its determination of whether it is the primary beneficiary of a VIE each reporting period. Judgments related to these determinations include estimates about the current and future fair value and performance of investments held by these VIEs and general market conditions.
The Company evaluates its investments and financings, including investments in unconsolidated ventures and securitization financing transactions to determine whether each investment or financing is a VIE. The Company analyzes new investments and financings, as well as reconsideration events for existing investments and financings, which vary depending on type of investment or financing.
As of September 30, 2023, the Company has identified certain consolidated and unconsolidated VIEs. Assets of each of the VIEs, may only be used to settle obligations of the respective VIE. Creditors of each of the VIEs have no recourse to the general credit of the Company.
Consolidated VIEs
The most significant VIEs of the Company are certain entities that are consolidated by the Operating Partnership. These entities are VIEs because of non-controlling interests owned by third parties, which do not have substantive kick-out or participating rights. Included in operating real estate, net and mortgage notes payable, net on the Company’s consolidated balance sheet as of September 30, 2023 is $170.1 million and $172.0 million, respectively, related to such consolidated VIEs.
Unconsolidated VIEs
As of September 30, 2023, the Company identified unconsolidated VIEs related to its investments in unconsolidated ventures with a carrying value of $128.0 million. The Company’s maximum exposure to loss as of September 30, 2023 would not exceed the carrying value of its investment in the VIEs. The Company determined that it is not the primary beneficiary of these VIEs and, accordingly, they are not consolidated in the Company’s financial statements as of September 30, 2023. The Company did not provide financial support to its unconsolidated VIEs during the nine months ended September 30, 2023. As of September 30, 2023, there were no explicit arrangements or implicit variable interests that could require the Company to provide financial support to its unconsolidated VIEs.
Voting Interest Entities
A voting interest entity is an entity in which the total equity investment at risk is sufficient to enable it to finance its activities independently and the equity holders have the power to direct the activities of the entity that most significantly impact its



11
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity. The usual condition for a controlling financial interest in a voting interest entity is ownership of a majority voting interest. If the Company has a majority voting interest in a voting interest entity, the entity will generally be consolidated. The Company does not consolidate a voting interest entity if there are substantive participating rights by other parties and/or kick-out rights by a single party or through a simple majority vote.
The Company performs on-going reassessments of whether entities previously evaluated under the voting interest framework have become VIEs, based on certain events, and therefore subject to the VIE consolidation framework.
Investments in Unconsolidated Ventures
A non-controlling, unconsolidated ownership interest in an entity may be accounted for using the equity method or the Company may elect the fair value option.
The Company will account for an investment under the equity method of accounting if it has the ability to exercise significant influence over the operating and financial policies of an entity, but does not have a controlling financial interest. Under the equity method, the investment is adjusted each period for capital contributions and distributions and its share of the entity’s net income (loss). Capital contributions, distributions and net income (loss) of such entities are recorded in accordance with the terms of the governing documents. An allocation of net income (loss) may differ from the stated ownership percentage interest in such entity as a result of preferred returns and allocation formulas, if any, as described in such governing documents. Equity method investments are recognized using a cost accumulation model, in which the investment is recognized based on the cost to the investor, which includes acquisition fees. The Company records as an expense certain acquisition costs and fees associated with consolidated investments deemed to be business combinations and capitalizes these costs for investments deemed to be acquisitions of an asset, including an equity method investment.
The Company may elect the fair value option of accounting for an investment that would otherwise be accounted for under the equity method. The fair value option election allows an entity to make an irrevocable election of fair value for certain financial assets and liabilities on an instrument-by-instrument basis at the initial or subsequent measurement. The decision to elect the fair value option must be applied to an entire instrument and is irrevocable once elected. Under the fair value option, the Company records its share of the changes to fair value of the investment and any unrealized gains and losses.
On June 30, 2023, the Company elected the fair value option method to account for its investment in the Espresso joint venture, which is included in investments in unconsolidated ventures on the consolidated balance sheets. The fair value election was made based on the Company’s assessment that the expected return of investment was lower than the Company’s carrying value of its investment in the Espresso joint venture, which resulted in an impairment of $4.7 million and reduced the carrying value of its investment to recoverable fair value of $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. The Company will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations. During the three months ended September 30, 2023, the Company did not record any changes to the fair value of its investment in the Espresso joint venture. Refer to Note 4 “Investment in Unconsolidated Ventures” and Note 10 “Fair Value” for further discussion.
Non-controlling Interests
A non-controlling interest in a consolidated subsidiary is defined as the portion of the equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company. A non-controlling interest is required to be presented as a separate component of equity on the consolidated balance sheets and presented separately as net income (loss) and comprehensive income (loss) attributable to controlling and non-controlling interests. An allocation to a non-controlling interest may differ from the stated ownership percentage interest in such entity as a result of a preferred return and allocation formula, if any, as described in such governing documents.
Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.



12
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments with an original maturity date of three months or less to be cash equivalents. Cash, including amounts restricted, may at times exceed the Federal Deposit Insurance Corporation deposit insurance limit of $250,000 per institution. The Company mitigates credit risk by placing cash and cash equivalents with major financial institutions and money market funds invested in short-term U.S. government securities. To date, the Company has not experienced any losses on cash and cash equivalents.
Restricted cash consists of amounts related to operating real estate (escrows for taxes, insurance, capital expenditures, security deposits received from residents and payments required under certain lease agreements) and other escrows required by lenders of the Company’s borrowings.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):
September 30, 2023 (Unaudited)
December 31, 2022
Cash and cash equivalents$87,581 $103,926 
Restricted cash11,386 11,734 
Total cash, cash equivalents and restricted cash$98,967 $115,660 
Operating Real Estate
Operating real estate is carried at historical cost less accumulated depreciation. Major replacements and betterments which improve or extend the life of the asset are capitalized and depreciated over their useful life. Ordinary repairs and maintenance are expensed as incurred. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:
Category:Term:
Building
30 to 50 years
Building improvementsLesser of the useful life or remaining life of the building
Land improvements
9 to 15 years
Tenant improvementsLesser of the useful life or remaining term of the lease
Furniture, fixtures and equipment
5 to 14 years
Construction costs incurred in connection with the Company’s investments are capitalized and included in operating real estate, net on the consolidated balance sheets. Construction in progress is not depreciated until the asset is available for its intended use.
Lessee Accounting
A leasing arrangement, a right to control the use of an identified asset for a period of time in exchange for consideration, is classified by the lessee either as a finance lease, which represents a financed purchase of the leased asset, or as an operating lease. For leases with terms greater than 12 months, a lease asset and a lease liability are recognized on the balance sheet at commencement date based on the present value of lease payments over the lease term.
Lease renewal or termination options are included in the lease asset and lease liability only if it is reasonably certain that the option to extend would be exercised or the option to terminate would not be exercised. As the implicit rate in most leases are not readily determinable, the Company’s incremental borrowing rate for each lease at commencement date is used to determine the present value of lease payments. Consideration is given to the Company’s recent debt financing transactions, as well as publicly available data for instruments with similar characteristics, adjusted for the respective lease term, when estimating incremental borrowing rates.
Lease expense is recognized over the lease term based on an effective interest method for finance leases and on a straight-line basis for operating leases.



13
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Right of Use (“ROU”) - Finance Assets
The Company has entered into finance leases for equipment which are included in operating real estate, net on the Company’s consolidated balance sheets. As of September 30, 2023, furniture, fixtures and equipment under finance leases totaled $0.3 million. The leased equipment is amortized on a straight-line basis. Payments for finance leases totaled $0.1 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively.
The following table presents the future minimum lease payments under finance leases and the present value of the minimum lease payments, which are included in other liabilities on the Company’s consolidated balance sheets (dollars in thousands):
October 1 through December 31, 2023$18 
Years Ending December 31:
202469 
202538 
202633 
202718 
Thereafter10 
Total minimum lease payments$186 
Less: Amount representing interest(27)
Present value of minimum lease payments$159 
The weighted average interest rate related to the finance lease obligations is 6.8% with a weighted average lease term of 3.4 years.
As of September 30, 2023, there were no leases that had yet to commence which would create significant rights and obligations to the Company as lessee.
Intangible Assets and Deferred Costs
Deferred Costs
Deferred costs consist of deferred financing costs. Deferred financing costs represent commitment fees, legal and other third-party costs associated with obtaining financing. These costs are recorded against the carrying value of such financing and are amortized to interest expense over the term of the financing using the effective interest method. Unamortized deferred financing costs are expensed to gain (loss) on investments and other, when the associated borrowing is repaid before maturity. Costs incurred in seeking financing transactions which do not close are expensed in the period in which it is determined that the financing will not occur.
Identified Intangibles
The Company records acquired identified intangibles, such as the value of in-place leases and other intangibles, based on estimated fair value at the acquisition date. The value allocated to the identified intangibles is amortized over the remaining lease term. In-place leases are amortized into depreciation and amortization expense.
Impairment analysis for identified intangible assets is performed in connection with the impairment assessment of the related operating real estate. An impairment establishes a new basis for the identified intangible asset and any impairment loss recognized is not subject to subsequent reversal. Refer to “—Impairment on Operating Real Estate and Investments in Unconsolidated Ventures” for additional information.



14
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Identified intangible assets are recorded in intangible assets, net on the consolidated balance sheets. Intangible assets relate to the Company’s in-place lease values for the Company’s four net lease properties. The following table presents intangible assets, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
In-place lease value$120,149 $120,149 
Less: Accumulated amortization(118,149)(117,896)
Intangible assets, net$2,000 $2,253 
The Company recorded $0.1 million and $0.3 million of amortization expense for in-place leases for the three and nine months ended September 30, 2023 and 2022, respectively.
The following table presents future amortization of in-place lease value (dollars in thousands):
October 1 through December 31, 2023$84 
Years Ending December 31:
2024337 
2025337 
2026337 
2027337 
Thereafter568 
Total$2,000 
Derivative Instruments
The Company uses derivative instruments to manage its interest rate risk. The Company’s derivative instruments are recorded at fair value. The accounting for changes in fair value of derivatives depends upon whether or not the Company has elected to designate the derivative in a hedging relationship and the derivative qualifies for hedge accounting. Under hedge accounting, changes in fair value for derivatives are recorded through other comprehensive income. When hedge accounting is not elected, changes in fair value for derivatives are recorded through the income statement.
The Company has interest rate caps that have not been designated for hedge accounting. The fair value of the Company's interest rate caps totaled $0.8 million and $0.7 million as of September 30, 2023 and December 31, 2022, respectively, and are included in other assets on the consolidated balance sheets. Changes in fair value of derivatives have been recorded in gain (loss) on investments and other in the consolidated statements of operations. The Company recognized losses totaling $0.3 million and $0.5 million for the three and nine months ended September 30, 2023, respectively, and gains totaling $0.3 million and $0.6 million for the three and nine months ended September 30, 2022, respectively.
Revenue Recognition
Operating Real Estate
Rental income from operating real estate is derived from leasing of space to operators and residents, including rent received from the Company’s net lease properties and rent, ancillary service fees and other related revenue earned from ILF residents. Rental income recognition commences when the operator takes legal possession of the leased space and the leased space is substantially ready for its intended use. The leases are for fixed terms of varying length and generally provide for rentals and expense reimbursements to be paid in monthly installments. Rental income from leases, which includes community and move-in fees, is recognized over the term of the respective leases. ILF resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice.
The Company also generates revenue from operating healthcare properties. Revenue related to operating healthcare properties includes resident room and care charges, ancillary fees and other resident service charges. Rent is charged and revenue is recognized when such services are provided, generally defined per the resident agreement as of the date upon which a resident occupies a room or uses the services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Revenue derived from our ALFs and MCFs is recorded in resident fee income in the consolidated statements of operations.



15
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Revenue from operators and residents is recognized at lease commencement only to the extent collection is expected to be probable. This assessment is based on several qualitative and quantitative factors, including and as appropriate, the payment history, ability to satisfy its lease obligations, the value of the underlying collateral or deposit, if any, and current economic conditions. If collection is assessed to not be probable, thereafter lease income recognized is limited to amounts collected, with the reversal of any revenue recognized to date in excess of amounts received. If collection is subsequently reassessed to be probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable.
The operator of the Company’s four net lease properties failed to remit contractual monthly rent obligations and the Company deemed it not probable that these obligations will be satisfied in the foreseeable future. On March 27, 2023, the Company entered into a lease forbearance and modification agreement (the “Forbearance Agreement”) with the existing operator, pursuant to which, among other things, the Company will be entitled to receive all cash flow in excess of permitted expenses, and be required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. For the three and nine months ended September 30, 2023, the Company received excess cash flow of $0.8 million and $1.2 million, respectively, which was recorded as rental income.
For the three months ended September 30, 2023 and 2022, total property and other revenues includes variable lease revenue of $3.6 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, total property and other revenue includes variable lease revenue of $10.7 million and $9.2 million, respectively. Variable lease revenue includes ancillary services provided to operator/residents, as well as non-recurring services and fees at the Company’s operating facilities.
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures
At this time, it is difficult for the Company to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. The future economic effects will depend on many factors beyond the Company’s control and knowledge. The resulting effect on impairment of the Company's real estate held for investment and held for sale and investments in unconsolidated ventures may materially differ from the Company's current expectations and further impairment charges may be recorded in future periods.
Operating Real Estate
The Company’s real estate portfolio is reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of its operating real estate may be impaired or that its carrying value may not be recoverable. A property’s value is considered impaired if the Company’s estimate of the aggregate expected future undiscounted cash flow generated by the property is less than the carrying value. In conducting this review, the Company considers U.S. macroeconomic factors, real estate and healthcare sector conditions, together with asset specific and other factors. To the extent an impairment has occurred, the loss is measured as the excess of the carrying value of the property over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
Real estate held for sale is stated at the lower of its carrying amount or estimated fair value less disposal cost, with any write-down to disposal cost recorded as an impairment loss. For any increase in fair value less disposal cost subsequent to classification as held for sale, the impairment may be reversed, but only up to the amount of cumulative loss previously recognized.
The Company considered the potential impact of the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions on the future net operating income of its healthcare real estate held for investment as an indicator of impairment. Fair values were estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization rates.
During the nine months ended September 30, 2023, the Company recorded impairment losses on its operating real estate totaling $38.7 million, including impairment losses of $38.6 million for five facilities within the Rochester portfolio as a result of revised holding period assumptions. Additionally, the Company recorded impairment losses totaling $0.1 million for a land parcel within the Rochester portfolio as a result of lower estimated market value.
During the nine months ended September 30, 2022, the Company recorded impairment losses on its operating real estate totaling $31.5 million. The Company recorded impairment losses of $18.5 million, $8.5 million, and $3.9 million for facilities in its Arbors, Winterfell and Rochester portfolios, respectively, as a result of declining operating margins and lower projected future cash flows. In addition, the Company recorded impairment losses totaling $0.6 million for property damage sustained by facilities in its Winterfell portfolio.



16
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Investments in Unconsolidated Ventures
The Company reviews its investments in unconsolidated ventures on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value may be impaired or that its carrying value may not be recoverable. An investment is considered impaired if the projected net recoverable amount over the expected holding period is less than the carrying value. In conducting this review, the Company considers global macroeconomic factors, including real estate sector conditions, together with investment specific and other factors. To the extent an impairment has occurred on the Company’s investment in unconsolidated ventures, and is considered to be other than temporary, the loss is measured as the excess of the carrying value of the investment over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
During the nine months ended September 30, 2023, the Company recorded an impairment on its investment in the Espresso joint venture totaling $4.7 million, which reduced the carrying value of its investment to $3.1 million. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. During the nine months ended September 30, 2022, there was no impairment recorded on any of the Company’s investments in unconsolidated ventures.
The joint ventures underlying the Company’s unconsolidated ventures assess and record impairment and reserves on their respective real estate portfolios, goodwill, and other assets, and the Company recognizes its proportionate share through equity in earnings (losses). In May 2023, prior to the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”), the Diversified US/UK joint venture recorded impairment losses on its remaining properties, 48 care homes located in the United Kingdom (the “UK Portfolio”), due to, among other things, the extended period contemplated for the UK Portfolio to reach stabilization. The Company’s proportionate share of the impairment losses recorded by the Diversified US/UK portfolio totaled $11.4 million. The Company’s proportionate share of impairment and reserves recognized by the underlying joint ventures of its unconsolidated ventures during the nine months ended September 30, 2022 was de minimis.
Credit Losses on Receivables
The current expected credit loss model, in estimating expected credit losses over the life of a financial instrument at the time of origination or acquisition, considers historical loss experiences, current conditions and the effects of reasonable and supportable expectations of changes in future macroeconomic conditions. The Company assesses the estimate of expected credit losses on a quarterly basis or more frequently as necessary. The Company considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts.
The Company measures expected credit losses of receivables on a collective basis when similar risk characteristics exist. If the Company determines that a particular receivable does not share risk characteristics with its other receivables, the Company evaluates the receivable for expected credit losses on an individual basis.
When developing an estimate of expected credit losses on receivables, the Company considers available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both relating to past events, current conditions, and reasonable and supportable forecasts. The Company considers relevant qualitative and quantitative factors that relate to the environment in which the Company operates and are specific to the borrower.
Further, the fair value of the collateral, less estimated costs to sell, may be used when determining the allowance for credit losses for a receivable for which the repayment is expected to be provided substantially through the sale of the collateral when the borrower is experiencing financial difficulty.
As of September 30, 2023, the Company has not recorded an allowance for credit losses on its receivables.
Acquisition Fees and Expenses
The Company recorded an expense for certain acquisition costs and fees associated with transactions deemed to be business combinations in which it consolidated the asset and capitalized these costs for transactions deemed to be acquisitions of an asset, including an equity investment.
Equity-Based Compensation
The Company accounts for equity-based compensation awards using the fair value method, which requires an estimate of fair value of the award at the time of grant. All fixed equity-based awards to directors, which have no vesting conditions other than



17
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
time of service, are amortized to compensation expense over the awards’ vesting period on a straight-line basis. Equity-based compensation is classified within general and administrative expenses in the consolidated statements of operations.
Income Taxes
The Company elected to be taxed as a REIT and to comply with the related provisions of the Internal Revenue Code beginning in its taxable year ended December 31, 2013. Accordingly, the Company will generally not be subject to U.S. federal income tax to the extent of its distributions to stockholders as long as certain asset, gross income and share ownership tests are met. To maintain its qualification as a REIT, the Company must annually distribute dividends equal to at least 90.0% of its REIT taxable income (with certain adjustments) to its stockholders and meet certain other requirements. The Company believes that all of the criteria to maintain the Company’s REIT qualification have been met for the applicable periods, but there can be no assurance that these criteria will continue to be met in subsequent periods. If the Company were to fail to meet these requirements, it would be subject to U.S. federal income tax and potential interest and penalties, which could have a material adverse impact on its results of operations and amounts available for distributions to its stockholders. The Company’s accounting policy with respect to interest and penalties is to classify these amounts as a component of income tax expense, where applicable. The Company has assessed its tax positions for all open tax years, which include 2018 to 2022, and concluded there were no material uncertainties to be recognized.
The Company may also be subject to certain state, local and franchise taxes. Under certain circumstances, federal income and excise taxes may be due on its undistributed taxable income.
The Company made a joint election to treat certain subsidiaries as taxable REIT subsidiaries (“TRS”) which may be subject to U.S. federal, state and local income taxes. In general, a TRS of the Company may perform services for managers/operators/residents of the Company, hold assets that the Company cannot hold directly and may engage in any real estate or non-real estate related business.
Certain subsidiaries of the Company are subject to taxation by federal and state authorities for the periods presented. Income taxes are accounted for by the asset/liability approach in accordance with U.S. GAAP. Deferred taxes, if any, represent the expected future tax consequences when the reported amounts of assets and liabilities are recovered or paid. Such amounts arise from differences between the financial reporting and tax bases of assets and liabilities and are adjusted for changes in tax laws and tax rates in the period which such changes are enacted. A provision for income tax represents the total of income taxes paid or payable for the current period, plus the change in deferred taxes. Current and deferred taxes are provided on the portion of earnings (losses) recognized by the Company with respect to its interest in the TRS. Deferred income tax assets and liabilities are calculated based on temporary differences between the Company’s U.S. GAAP consolidated financial statements and the federal and state income tax basis of assets and liabilities as of the consolidated balance sheet date. The Company evaluates the realizability of its deferred tax assets (e.g., net operating loss and capital loss carryforwards) and recognizes a valuation allowance if, based on the available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. When evaluating the realizability of its deferred tax assets, the Company considers estimates of expected future taxable income, existing and projected book/tax differences, tax planning strategies available and the general and industry specific economic outlook. This realizability analysis is inherently subjective, as it requires the Company to forecast its business and general economic environment in future periods. Changes in estimate of deferred tax asset realizability, if any, are included in provision for income tax benefit (expense) in the consolidated statements of operations. The Company has a deferred tax asset, which as of September 30, 2023 totaled $15.9 million and continues to have a full valuation allowance recognized, as there are no changes in the facts and circumstances to indicate that the Company should release the valuation allowance.
The Company recorded an income tax expense of approximately $17,000 and $43,000 for the three and nine months ended September 30, 2023, respectively. The Company recorded an income tax expense of approximately $15,000 and $45,000 for the three and nine months ended September 30, 2022, respectively.
Comprehensive Income (Loss)
The Company reports consolidated comprehensive income (loss) in separate statements following the consolidated statements of operations. Comprehensive income (loss) is defined as the change in equity resulting from net income (loss) and other comprehensive income (loss) (“OCI”). The only component of OCI for the Company was foreign currency translation adjustments related to its investment in an unconsolidated venture.



18
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Foreign Currency
Assets and liabilities denominated in a foreign currency for which the functional currency is a foreign currency are translated using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are translated into U.S. dollars using the average currency exchange rate in effect during the period. The resulting foreign currency translation adjustment is recorded as a component of accumulated OCI in the consolidated statements of equity.
Assets and liabilities denominated in a foreign currency for which the functional currency is the U.S. dollar are remeasured using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are remeasured into U.S. dollars using the average currency exchange rate in effect during the period.
For the period December 31, 2022 through June 9, 2023, the Company had exposure to foreign currency through an investment in an unconsolidated venture, the effects of which were recorded as a component of accumulated OCI in the consolidated statements of equity and in equity in earnings (losses) in the consolidated statements of operations. As a result of the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”) in June 2023, the Company is no longer exposed to foreign currency as of September 30, 2023. The Company reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK joint venture, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other on the consolidated statements of operations.
Recent Accounting Pronouncements
Accounting Standards Adopted in 2023
In March 2020, the FASB issued an amendment to the reference rate reform standard, which provides the option for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on contract modifications and hedge accounting. An example of such reform is the market transition from the London Interbank Offered Rate (“LIBOR”) to alternative reference rates. Entities that make this optional expedient election would not have to remeasure the contracts at the modification date or reassess the accounting treatment if certain criteria are met and would continue applying hedge accounting for relationships affected by reference rate reform. In December 2022, the FASB extended the date for which this guidance can be applied from December 31, 2022 to December 31, 2024. The Company did not make the optional election of the aforementioned accounting standards.
Future Application of Accounting Standards
None.
3. Operating Real Estate
The following table presents operating real estate, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Land$121,424 $121,518 
Land improvements19,913 18,945 
Buildings and improvements932,261 957,924 
Tenant improvements372 372 
Construction in progress8,956 6,736 
Furniture, fixtures and equipment103,876 91,058 
Subtotal$1,186,802 $1,196,553 
Less: Accumulated depreciation(292,557)(263,551)
Operating real estate, net$894,245 $933,002 
For the three and nine months ended September 30, 2023, depreciation expense was $9.8 million and $29.1 million, respectively. For the three and nine months ended September 30, 2022, depreciation expense was $9.6 million and $28.9 million, respectively.
Within the table above, operating real estate has been reduced by accumulated impairment losses of $220.2 million and $181.5 million as of September 30, 2023 and December 31, 2022, respectively. Impairment losses on the Company’s operating real estate totaled $38.7 million and $31.5 million for the nine months ended September 30, 2023 and 2022, respectively, and are



19
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
recorded in impairment losses on the consolidated statements of operations. Refer to Note 2, “Summary of Significant Accounting Policies” for further discussion.
4. Investments in Unconsolidated Ventures
The Company’s investments in unconsolidated ventures are accounted for under the equity method or fair value option. The following table presents the Company’s investments in unconsolidated ventures (dollars in thousands):
Carrying Value
PortfolioAcquisition DateOwnershipSeptember 30, 2023 (Unaudited)December 31, 2022
Trilogy(1)
Dec-201523.4 %$124,670 $128,884 
Espresso(2)
Jul-201536.7 %3,075 18,019 
Solstice(3)
Jul-201720.0 %281 323 
Investments sold(4)
— 29,276 
Investments in Unconsolidated Ventures$128,026 $176,502 
_______________________________________
(1)The carrying value for the Company’s investment in the Trilogy joint venture includes $9.8 million of capitalized acquisition costs.
(2)In June 2023, the Company recorded an impairment of $4.7 million to reflect the fair value of its investment in the Espresso joint venture, based on the estimated cash distributions to be received from the joint venture. Based on the Company’s assessment, it elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.
(3)Represents the Company’s investment in Solstice Senior Living, LLC (“Solstice”), the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC (“ISL”), a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and the Company, which owns 20.0%.
(4)In June 2023, the Company sold its ownership interests in the Diversified US/UK and Eclipse joint ventures.
Sale of Minority Interests
In June 2023, the Company sold its 14% interest in Healthcare GA Holdings, General Partnership, which indirectly owned 48 care homes across the United Kingdom (the “Diversified US/UK Portfolio”), and its 6% interest in Eclipse Health, General Partnership, which indirectly owned 34 seniors housing facilities (the “Eclipse Portfolio”), together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates, including 9,709,553 shares of common stock of the Company, 100 common units in the Operating Partnership and 100 special units in the Operating Partnership (the “Sale of Minority Interests”).
The following table presents the results of the Company’s investment in unconsolidated ventures (dollars in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
PortfolioEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash Distribution
Trilogy$(146)$— $6,052 $2,300 $454 $4,668 $10,757 $6,900 
Espresso(1)
— — (242)1,375 9,228 19,444 33,711 32,363 
Solstice19 — 17 — (41)— (41)— 
Investments sold(2)
— — (2,955)358 (16,236)— (5,000)2,910 
Total$(127)$— $2,872 $4,033 $(6,595)$24,112 $39,427 $42,173 
_______________________________________
(1)The Espresso joint venture recognized net gains related to sub-portfolio sales, of which the Company’s proportionate share totaled $9.2 million and $32.0 million for the nine months ended September 30, 2023 and 2022, respectively. The Company was distributed its proportionate share of the net proceeds generated from the sales during the nine months ended September 30, 2023 and 2022, totaling $17.3 million and $27.4 million, respectively.
(2)In May 2023, the Diversified US/UK joint venture recognized impairment, of which the Company’s proportionate share totaled $11.4 million and is included in equity in earnings (losses) for the nine months ended September 30, 2023.



20
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
5. Borrowings
The following table presents the Company’s mortgage notes payable (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Recourse vs. Non-Recourse(1)
Initial
Maturity
Contractual
Interest Rate(2)
Principal
Amount(3)
Carrying
Value(3)
Principal
Amount(3)
Carrying
Value(3)
Aqua Portfolio
Frisco, TX(4)
Non-recourseFeb 20263.0%$26,000 $25,660 $26,000 $25,560 
Milford, OHNon-recourseSep 2026
SOFR + 2.79%
18,212 18,036 18,336 18,126 
Rochester Portfolio
Rochester, NYNon-recourseFeb 20254.25%17,657 17,629 18,206 18,165 
Rochester, NY(5)
Non-recourseJul 2023
SOFR + 2.45%
99,786 99,787 100,651 100,042 
Rochester, NYNon-recourseAug 2024
SOFR + 2.93%
10,922 10,891 11,336 11,315 
Arbors Portfolio(6)
Various locationsNon-recourseFeb 20253.99%81,912 81,680 83,423 83,051 
Winterfell Portfolio(7)
Various locationsNon-recourseJun 20254.17%586,773 581,157 596,408 588,306 
Avamere Portfolio(8)
Various locationsNon-recourseFeb 20274.66%67,025 66,770 67,995 67,683 
Mortgage notes payable, net$908,287 $901,610 $922,355 $912,248 
_______________________________________
(1)Subject to non-recourse carve-outs.
(2)Floating-rate borrowings total $128.9 million of principal outstanding and reference one-month SOFR as of September 30, 2023.
(3)The difference between principal amount and carrying value of mortgage notes payable is attributable to deferred financing costs, net for all borrowings, other than the Winterfell portfolio which is attributable to below market debt intangibles.
(4)The mortgage note carries a fixed interest rate of 3.0% through February 2024, followed by one-month adjusted SOFR, plus 2.80% through the initial maturity date of February 2026.
(5)Composed of seven individual mortgage notes payable (the “Rochester Sub-Portfolio Loan”) secured by seven healthcare real estate properties (the “Rochester Sub-Portfolio”), cross-collateralized and subject to cross-default. In July 2023, the Company elected not to pay debt service on the Rochester Sub-Portfolio Loan, which resulted in a default notice accelerating the maturity of the loan from its original terms of August 2027.
(6)Composed of four individual mortgage notes payable secured by four healthcare real estate properties, cross-collateralized and subject to cross-default.
(7)Composed of 32 individual mortgage notes payable secured by 32 healthcare real estate properties, cross-collateralized and subject to cross-default.
(8)Composed of five individual mortgage notes payable secured by five healthcare real estate properties, cross-collateralized and subject to cross-default.
The following table presents future scheduled principal payments on mortgage notes payable based on initial maturity as of September 30, 2023 (dollars in thousands):
October 1 through December 31, 2023$104,238 
Years Ending December 31:
202428,761 
2025667,741 
202645,151 
202762,396 
Total$908,287 
Beginning in February 2021, the operator of the four net lease properties in the Arbors portfolio was unable to satisfy its obligations under its leases and began remitting rent based on its available cash after satisfying property-level expenses, which resulted in a default under the mortgage notes collateralized by the properties. On March 27, 2023, with consent of the lender, the Company entered into a Forbearance Agreement relating to these defaults. During the nine months ended September 30, 2023, the Company remitted contractual debt service and is in compliance with the other contractual terms under the mortgage notes collateralized by the properties.



21
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
In July 2023, the Company elected not to pay July debt service on the Rochester Sub-Portfolio Loan in light of the continued negative cash flow generated by the Rochester Sub-Portfolio. The Rochester Sub-Portfolio Loan is non-recourse to the Company, subject to limited customary exceptions. As a result of the payment default, in July 2023, the Company received a notice of acceleration of the Rochester Sub-Portfolio Loan and reserving all rights and remedies under the applicable loan documents. Refer to Note 13, “Subsequent Events” for additional information.
6. Related Party Arrangements
Former Advisor
In connection with the Internalization, the advisory agreement was terminated on October 21, 2022. Prior to the Internalization, the Former Advisor was responsible for managing the Company’s affairs on a day-to-day basis and for identifying, acquiring, originating and asset managing investments on behalf of the Company. For such services, to the extent permitted by law and regulations, the Former Advisor received fees and reimbursements from the Company. Pursuant to the advisory agreement, the Former Advisor could defer or waive fees in its discretion.
Transition Services
In connection with the Internalization, on October 21, 2022, the Company, the Operating Partnership and the Former Advisor entered into a Transition Services Agreement (the “TSA”) to facilitate an orderly transition of the Company’s management of its operations. The TSA, as amended on March 22, 2023, provides for, among other things, the Former Advisor to provide certain services, including primarily technology and insurance, for a transition period of up to six months following the Internalization, with legal, treasury and accounts payable services to continue until the Company terminates these services or in other specified circumstances in accordance with the TSA. The Company will reimburse the Former Advisor for costs to provide the services, including the allocated cost of employee wages and compensation and incurred out-of-pocket expenses.
Summary of Fees and Reimbursements
The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):
Reimbursements to Former Advisor EntitiesDue to Related Party as of December 31, 2022Nine Months Ended September 30, 2023
Due to Related Party as of September 30, 2023 (Unaudited)
Financial Statement LocationIncurredPaid
   Operating costsGeneral and administrative expenses/ Transaction costs$469 $520 
(1)
$(697)$292 
_______________________________________
(1)Represents costs incurred under the TSA during the nine months ended September 30, 2023.
Incentive Fee
The Special Unit Holder, formerly an affiliate of the Former Advisor, was entitled to receive distributions equal to 15.0% of net cash flows of the Company, whether from continuing operations, repayment of loans, disposition of assets or otherwise, but only after stockholders have received, in the aggregate, cumulative distributions equal to their invested capital plus a 6.75% cumulative, non-compounded annual pre-tax return on such invested capital. From inception through the date of the Sale of Minority Interests, the Special Unit Holder did not receive any incentive fees from the Company.
In connection with the Sale of Minority Interests, as of June 9, 2023, the Special Unit Holder became an indirect subsidiary of the Company, though the Special Unit Holder continues to have a contractual obligation to pay any such incentive fees to affiliates of the Former Sponsor, if ever earned.
Investments in Joint Ventures
Solstice, the manager of the Winterfell portfolio, is a joint venture between affiliates of ISL, which owns 80.0%, and the Company, which owns 20.0%. For the nine months ended September 30, 2023, the Company recognized property management fee expense of $5.1 million payable to Solstice related to the Winterfell portfolio.
In June 2023, the Company completed the Sale of Minority Interests, involving the sale of its minority interests in the Diversified US/UK and Eclipse Portfolios, together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates. Refer to Note 4, “Investments in Unconsolidated Ventures” for further discussion of the Sale of Minority Interests.



22
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
7. Equity-Based Compensation
The Company adopted a long-term incentive plan, as amended (the “Plan”), which it may use to attract and retain qualified officers, directors, employees and consultants, as well as an independent directors compensation plan, which is a component of the Plan. Under the Plan, 2.0 million shares of restricted common stock were eligible to be issued for any equity-based awards granted under the Plan.
Pursuant to the Plan, as of September 30, 2023, the Company’s independent directors were granted a total of 159,932 shares of restricted common stock and 203,742 restricted stock units totaling $1.3 million and $0.7 million, respectively, based on the share price on the date of each grant.
The restricted common stock and restricted stock units granted generally vest quarterly over two years in equal installments and will become fully vested on the earlier occurrence of: (i) the termination of the independent director’s service as a director due to his or her death or disability; or (ii) a change in control of the Company. The restricted stock units are convertible, on a one-for-one basis, into shares of the Company’s common stock upon the earlier occurrence of: (i) the termination of the independent director’s service as a director; or (ii) a change in control of the Company.
The Company recognized equity-based compensation expense of $56,250 and $56,875 for the three months ended September 30, 2023 and 2022, respectively, and $170,000 and $150,042 for the nine months ended September 30, 2023 and 2022, respectively. Equity-based compensation expense is recorded in general and administrative expenses in the consolidated statements of operations.
Unrecognized expense related to unvested restricted stock units totaled $296,250 and $211,250 as of September 30, 2023 and December 31, 2022, respectively. Unvested restricted stock units totaled 94,853 and 54,114 as of September 30, 2023 and December 31, 2022, respectively. As of December 31, 2022, the Company’s shares of restricted common stock were fully vested.
8. Stockholders’ Equity
Common Stock
The Company stopped accepting subscriptions for its Offering on December 17, 2015 and all of the shares initially registered for its Offering were issued on or before January 19, 2016. The Company issued 173.4 million shares of common stock generating gross proceeds of $1.7 billion, excluding proceeds from the DRP.
Distribution Reinvestment Plan
The Company adopted the DRP through which common stockholders were able to elect to reinvest an amount equal to the distributions declared on their shares in additional shares of the Company’s common stock in lieu of receiving cash distributions. Since inception, the Company issued 25.7 million shares of common stock, generating gross offering proceeds of $232.6 million pursuant to the DRP. No selling commissions or dealer manager fees were paid on shares issued pursuant to the DRP. In April 2022, the Company’s board of directors elected to end the DRP, effective April 30, 2022.
Distributions
Effective February 1, 2019, the Company’s board of directors determined to stop recurring distributions in order to preserve capital and liquidity.
On April 20, 2022, the Company’s board of directors declared a special distribution of $0.50 per share (the “Special Distribution”) for each stockholder of record on May 2, 2022 totaling approximately $97.0 million.
In order to continue to qualify as a REIT, the Company must distribute annually dividends equal to at least 90% of its REIT taxable income (with certain adjustments). The Company did not have REIT taxable income for its taxable year ending December 31, 2022, therefore, it was not required to make distributions to its stockholders in 2022 to qualify as a REIT. The Company’s most recently filed tax return is for the year ended December 31, 2022 and includes a net operating loss carry-forward of $248.5 million.
Share Repurchase Program
The Company adopted the share repurchase program (the “Share Repurchase Program”) that enabled stockholders to sell their shares to the Company in limited circumstances and could be amended, suspended, or terminated at any time. The Company



23
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
previously funded repurchase requests with cash on hand, borrowings or other available capital. In April 2020, the Company’s board of directors determined to suspend all repurchases under the Share Repurchase Program effective April 30, 2020 in order to preserve capital and liquidity and does not currently anticipate resuming the Share Repurchase Program.
Retirement of Shares
In connection with the Sale of Minority Interests, the Company acquired 9.7 million shares of its common stock in exchange for its minority interests in the Diversified US/UK and Eclipse Portfolios from its Former Sponsor, who is affiliated with the majority partner of each joint venture. Upon completion of the Sale of Minority Interests, the Company retired all of the shares of common stock acquired.
To account for the acquisition and retirement of the common stock, the Company estimated the value of its minority interests in the Diversified US/UK and Eclipse Portfolios based on a variety of factors, including historical and projected revenues, market lease rates, the partners’ respective rights under the joint venture agreements, independent third-party appraisals obtained by the joint ventures and other factors deemed relevant. The Company determined the estimated value of minority interests to be approximately $12.5 million at the time of transaction. The estimated value, together with the $1.1 million of cash consideration, net of closing costs, is presented on the consolidated statements of equity as retirement of common stock.
9. Non-controlling Interests
Operating Partnership
Non-controlling interests included the aggregate limited partnership interests in the Operating Partnership held by limited partners, other than the Company. Income (loss) attributable to the non-controlling interests was based on the limited partners’ ownership percentage of the Operating Partnership. As a result of the Sale of Minority Interests, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, is 100.0% as of September 30, 2023. Income (loss) allocated to the Operating Partnership non-controlling interests for the period prior to June 9, 2023 were de minimis.
Other
Other non-controlling interests represent third-party equity interests in ventures that are consolidated with the Company’s financial statements. Net loss attributable to the other non-controlling interests was $0.2 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively, and $1.5 million and $0.3 million for the nine months ended September 30, 2023 and 2022, respectively.
10.    Fair Value
Fair Value Measurement
The fair value of financial instruments is categorized based on the priority of the inputs to the valuation technique and categorized into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:
Level 1.Quoted prices for identical assets or liabilities in an active market.
Level 2.Financial assets and liabilities whose values are based on the following:
a)Quoted prices for similar assets or liabilities in active markets.
b)Quoted prices for identical or similar assets or liabilities in non-active markets.
c)Pricing models whose inputs are observable for substantially the full term of the asset or liability.
d)Pricing models whose inputs are derived principally from or corroborated by observable market data for substantially the full term of the asset or liability.



24
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Level 3.Prices or valuation techniques based on inputs that are both unobservable and significant to the overall fair value measurement.
Derivative Instruments
Derivative instruments consist of interest rate contracts and foreign exchange contracts that are generally traded over-the-counter, and are valued using a third-party service provider. Quotations on over-the-counter derivatives are not adjusted and are generally valued using observable inputs such as contractual cash flows, yield curve, foreign currency rates and credit spreads, and are classified as Level 2 of the fair value hierarchy. Although credit valuation adjustments, such as the risk of default, rely on Level 3 inputs, these inputs are not significant to the overall valuation of its derivatives. As a result, derivative valuations in their entirety are classified as Level 2 of the fair value hierarchy.
Fair Value Hierarchy
Financial assets recorded at fair value on a recurring basis are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The following table presents financial assets that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 by level within the fair value hierarchy (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Level 1Level 2Level 3Level 1Level 2Level 3
Financial assets:
Derivative assets - interest rate caps
$— $820 $— $— $652 $— 
Investment in Espresso joint venture(1)
— — 3,075 — — — 
_______________________________________
(1)The Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. As of December 31, 2022, the investment was accounted for under the equity method.
Derivative Assets - Interest Rate Caps
The Company’s interest rate caps fair values are determined using models developed by the respective counterparty that use the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The floating interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities.
Investment in Espresso Joint Venture
The Company’s assessment of fair value for its unconsolidated investment in the Espresso joint venture took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses.
Fair Value of Financial Instruments
U.S. GAAP requires disclosure of fair value about all financial instruments. The following disclosure of estimated fair value of financial instruments was determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessary to interpret market data and develop estimated fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize on disposition of the financial instruments. The use of different market assumptions and/or estimation methodologies may have a material effect on estimated fair value.
The following table presents the principal amount, carrying value and fair value of certain financial assets and liabilities (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Principal AmountCarrying ValueFair ValuePrincipal AmountCarrying ValueFair Value
Financial liabilities:(1)
Mortgage notes payable, net$908,287 $901,610 $842,325 $922,355 $912,248 $882,754 
_______________________________________
(1)The fair value of other financial instruments not included in this table is estimated to approximate their carrying value.



25
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Disclosure about fair value of financial instruments is based on pertinent information available to management as of the reporting date. Although management is not aware of any factors that would significantly affect fair value, such amounts have not been comprehensively revalued for purposes of these consolidated financial statements since that date and current estimates of fair value may differ significantly from the amounts presented herein.
Mortgage Notes Payable
The Company primarily uses rates currently available with similar terms and remaining maturities to estimate fair value. These measurements are determined using comparable U.S. Treasury and SOFR rates as of the end of the reporting period. These fair value measurements are based on observable inputs, and as such, are classified as Level 2 of the fair value hierarchy.
Nonrecurring Fair Values
The Company measures fair value of certain assets on a nonrecurring basis when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Adjustments to fair value generally result from the application of lower of amortized cost or fair value accounting for assets held for sale or otherwise, write-down of asset values due to impairment.
The following table summarizes the fair value and impairment losses of Level 3 assets which have been measured at fair value on a nonrecurring basis at the time of impairment during the periods presented (dollars in thousands):
Nine Months EndedYear Ended
September 30, 2023 (Unaudited)December 31, 2022
Fair ValueImpairment LossesFair ValueImpairment Losses
Operating real estate, net(1)
$41,496 $38,694 $80,931 $30,900 
Investments in unconsolidated ventures3,075 4,728 28,442 13,419 
_______________________________________
(1)During the year ended December 31, 2022, the Company recorded impairment losses totaling $1.0 million for property damage sustained by facilities in its Winterfell and Avamere portfolios. The fair value and impairment losses of these facilities are excluded from the table.
Operating Real Estate, Net
Operating real estate that is impaired is carried at fair value at the time of impairment. Impairment was driven by various factors that impacted undiscounted future net cash flows, including declines in operating performance, market growth assumptions and expected margins to be generated by the properties. Fair value of impaired operating real estate was estimated based upon various approaches including discounted cash flow analysis using terminal capitalization rates ranging from 6.00% to 8.50% and discount rates ranging from 8.5% to 10.5%, third party appraisals and offer prices.
Investments in Unconsolidated Ventures
In June 2023, the Company recorded impairment on its investment in the Espresso joint venture, which totaled $4.7 million and reduced the carrying value of its investment to $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.
During the year ended December 31, 2022, the Company recorded impairment on its investment in the Diversified US/UK joint venture, which totaled $13.4 million and reduced the carrying value of its investment to $28.4 million as of December 31, 2022. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s post-COVID-19 underperformance, rising interest rates and the joint venture’s ability to continue to service debt collateralized by substantially all of its domestically-located healthcare real estate. Fair value of the joint venture’s underlying operating real estate was estimated based upon various approaches including discounted cash flow analysis, using terminal capitalization rates ranging from 6.6% to 12.5% and discount rates ranging from 8.8% to 16.0%, and offer prices.



26
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
11. Segment Reporting
The Company conducts its business through the following segments, which are based on how management reviews and manages its business.
•Direct Investments - Operating - Properties operated pursuant to management agreements with healthcare managers.
•Direct Investments - Net Lease - Properties operated under net leases with an operator.
•Unconsolidated Investments - Joint ventures, including properties operated under net leases with operators or pursuant to management agreements with healthcare managers, in which the Company owns a minority interest.
•Corporate - The corporate segment includes corporate level asset management fees - related party and general and administrative expenses.
The Company primarily generates rental and resident fee income from its direct investments. Additionally, the Company reports its proportionate interest of revenues and expenses from unconsolidated investments through equity in earnings (losses) of unconsolidated ventures.
The following tables present segment reporting (dollars in thousands):
Direct Investments
Three Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$837 $51,459 $— $1,078 $53,374 
Property operating expenses— (36,890)— — (36,890)
Interest expense(883)(13,367)— — (14,250)
Transaction costs— — (358)— (358)
General and administrative expenses— (30)— (2,891)(2,921)
Depreciation and amortization(729)(9,119)— — (9,848)
Gain (loss) on investments and other— (311)(36)— (347)
Equity in earnings (losses) of unconsolidated ventures— — (127)— (127)
Income tax expense— (17)— — (17)
Net income (loss)$(775)$(8,275)$(521)$(1,813)$(11,384)
Direct Investments
Three Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$724 $46,715 $— $300 $47,739 
Property operating expenses— (35,134)— — (35,134)
Interest expense(907)(10,107)— — (11,014)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (2,428)(2,428)
General and administrative expenses— (8)— (2,851)(2,859)
Depreciation and amortization(870)(8,772)— — (9,642)
Impairment loss(18,500)— — — (18,500)
Gain (loss) on investments and other— 325 — — 325 
Equity in earnings (losses) of unconsolidated ventures— — 2,872 — 2,872 
Income tax expense— (15)— — (15)
Net income (loss)$(19,553)$(6,996)$2,872 $(5,836)$(29,513)



27
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
Direct Investments
Nine Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,178 $150,374 $— $2,893 $154,445 
Property operating expenses— (106,993)— — (106,993)
Interest expense(2,639)(34,504)— — (37,143)
Transaction costs— — (358)(97)(455)
General and administrative expenses— (555)— (9,869)(10,424)
Depreciation and amortization(2,187)(27,118)— — (29,305)
Impairment loss— (38,694)(4,728)— (43,422)
Other income, net— 202 — — 202 
Gain (loss) on investments and other— (28)(4,634)— (4,662)
Equity in earnings (losses) of unconsolidated ventures— — (6,595)— (6,595)
Income tax expense— (43)— — (43)
Net income (loss)$(3,648)$(57,359)$(16,315)$(7,073)$(84,395)
Direct Investments
Nine Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,220 $134,768 $— $457 $136,445 
Property operating expenses(35)(101,223)— — (101,258)
Interest expense(2,708)(29,169)— — (31,877)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (7,532)(7,532)
General and administrative expenses— (24)— (10,276)(10,300)
Depreciation and amortization(2,601)(26,504)— — (29,105)
Impairment loss(18,500)(13,002)— — (31,502)
Other income, net— 77 — — 77 
Gain (loss) on investments and other(206)620 246 — 660 
Equity in earnings (losses) of unconsolidated ventures— — 39,427 — 39,427 
Income tax expense— (45)— — (45)
Net income (loss)$(22,830)$(34,502)$39,673 $(18,208)$(35,867)

The following table presents total assets by segment (dollars in thousands):
Direct Investments
Total Assets:Net LeaseOperatingUnconsolidated Investments
Corporate(1)
Total
September 30, 2023 (Unaudited)
$80,782 $847,401 $128,026 $79,707 $1,135,916 
December 31, 202283,435 884,137 176,502 93,761 1,237,835 
______________________________________
(1)Represents primarily corporate cash and cash equivalents balances.



28
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
The following table presents the operators and managers of the Company’s properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):
As of September 30, 2023Nine Months Ended September 30, 2023
Operator / ManagerProperties Under Management
Units Under Management(1)
Property and Other Revenues(2)
% of Total Property and Other Revenues
Solstice Senior Living(3)
32 3,969 $94,469 61.2 %
Watermark Retirement Communities14 1,782 35,967 23.2 %
Avamere Health Services5 453 16,266 10.5 %
Integral Senior Living1 40 3,672 2.4 %
Arcadia Management(4)
4 572 1,178 0.8 %
Other(5)
— — 2,893 1.9 %
Total56 6,816 $154,445 100.0 %
______________________________________
(1)Represents rooms for ALFs, ILFs and MCFs, based on predominant type.
(2)Includes rental income received from the Company’s net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from the Company’s ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.
(3)Solstice is a joint venture of which affiliates of ISL own 80%.
(4)During the nine months ended September 30, 2023, the Company recorded rental income to the extent payments were received.
(5)Consists primarily of interest income earned on corporate-level cash and cash equivalents.
12. Commitments and Contingencies
As of September 30, 2023, the Company believes there are no material unrecorded contingencies that would affect its results of operations, cash flows or financial position.
Litigation and Claims
The Company may be involved in various litigation matters arising in the ordinary course of its business. Although the Company is unable to predict with certainty the eventual outcome of any litigation, any current legal proceedings are not expected to have a material adverse effect on its financial position or results of operations.
The Company’s operators and managers may be involved in various litigation matters arising in the ordinary course of their business. The unfavorable resolution of any such actions, investigations or claims could, individually or in the aggregate, materially adversely affect such operators’ or managers’ liquidity, financial condition or results of operations and their ability to satisfy their respective obligations to the Company, which, in turn, could have a material adverse effect on the Company.
As of September 30, 2023, the Company has an accrued reserve of $0.6 million, inclusive of legal fees, relating to a resolution of claims against a manager of one of the Company’s direct operating investments, for which the Company has indemnification obligations under the management agreement.
Environmental Matters
The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its consolidated financial position, results of operations or cash flows. Further, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that it believes would require additional disclosure or the recording of a loss contingency.



29
NORTHSTAR HEALTHCARE INCOME, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Unaudited)
General Uninsured Losses
The Company obtains various types of insurance to mitigate the impact of professional liability, property, business interruption, liability, flood, windstorm, earthquake, environmental and terrorism related losses. The Company attempts to obtain appropriate policy terms, conditions, limits and deductibles considering the relative risk of loss, the cost of such coverage and current industry practice. Disruptions in insurance markets may increase the costs of coverage and result in the Company retaining more risk, to the extent it is more commercially reasonable to do so. In addition, there are also certain types of extraordinary losses, such as those due to acts of war or other events, that may be either uninsurable or not economically insurable.
Other
Other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business, as well as commitments to fund capital expenditures for certain net lease properties. These commitments do not have a required minimum funding and are limited by agreed upon maximum annual funding amounts.
13.    Subsequent Events
The following is a discussion of material events which have occurred subsequent to September 30, 2023 through the issuance of the consolidated financial statements.
Rochester Receivership
As a result of the payment default in July 2023 of the Rochester Sub-Portfolio Loan, on October 25, 2023, the lender filed a complaint seeking the appointment of a receiver and foreclosure on the underlying properties and to enforce its rights in its collateral under the loan documents and, on October 30, 2023, the properties underlying the Rochester Sub-Portfolio Loan were placed into a receivership. The receiver now has effective control of the properties and the Company is working with the lender and the receiver to facilitate an orderly transition of the operations, and eventually ownership, of the properties.
Trilogy Option Agreement
On November 3, 2023, the Company entered into an agreement to sell all of its ownership interests in Trilogy REIT Holdings, LLC (the “Trilogy Joint Venture”), which indirectly owns 123 integrated senior health campuses, to American Healthcare REIT, Inc. or its affiliates (“AHR”), the majority partner of the Trilogy Joint Venture. Under the agreement, AHR has the right to purchase the Company’s ownership interests in the Trilogy Joint Venture at any time prior to September 30, 2025, assuming AHR exercises all of its extension options and subject to satisfaction of certain closing conditions, for a purchase price ranging from $240.5 million to up to $260 million depending upon the purchase price consideration and timing of the closing. A minimum of 10% of the purchase price consideration must be paid in cash, with the balance payable in either cash or new Series A Cumulative Convertible Preferred Stock to be issued by AHR in connection with the closing. The portion of the purchase price consideration paid in cash may be subject to a 7.5% or 5% discount, respectively, if the transaction closes prior to March 31, 2024 or December 31, 2024, respectively. In addition, the Company may be entitled to a supplemental cash payment of $25,600 per day for the period between July 1, 2023 until the closing date, for up to approximately $21 million, if the Trilogy Joint Venture does not distribute an equivalent amount to the Company during the interim period. AHR may terminate the agreement at any time, subject to payment of a termination fee equal to: (i) if terminated prior to the initial outside date, September 30, 2024, $3.9 million or, if a “Qualifying IPO” (i.e., an underwritten public offering of AHR’s common stock resulting in at least $200 million of net proceeds) has occurred, $7.8 million, (ii) if extended and terminated prior March 31, 2025, $11.7 million and (iii) if further extended and terminated prior to September 30, 2025, $15.6 million. There can be no assurance that AHR will consummate the purchase of the Company’s interests on these terms or at all.



30
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included in Part I, Item 1. “Financial Statements” and the risk factors in Part II, Item 1A. “Risk Factors.” References to “we,” “us,” “our,” or “NorthStar Healthcare” refer to NorthStar Healthcare Income, Inc. and its subsidiaries unless the context specifically requires otherwise.
Overview
We own a diversified portfolio of seniors housing properties, including independent living facilities, or ILFs, assisted living facilities, or ALFs, and memory care facilities, or MCFs, located throughout the United States. In addition, we have investments through non-controlling interests in joint ventures in a broader spectrum of healthcare real estate, including seniors housing properties, as well as, skilled nursing facilities, or SNFs, and ancillary services businesses, located throughout the United States.
We were formed in October 2010 as a Maryland corporation and commenced operations in February 2013. We elected to be taxed as a REIT under the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code, commencing with the taxable year ended December 31, 2013. We conduct our operations so as to continue to qualify as a REIT for U.S. federal income tax purposes.
We raised $2.0 billion in total gross proceeds from the sale of shares of our common stock in our continuous, public offerings, including $232.6 million pursuant to our distribution reinvestment plan, or our DRP, collectively referred to as our Offering.
The Internalization
From inception through October 21, 2022, we were externally managed by CNI NSHC Advisors, LLC or its predecessor, or the Former Advisor, an affiliate of NRF Holdco, LLC, or the Former Sponsor. The Former Advisor was responsible for managing our operations, subject to the supervision of our board of directors, pursuant to an advisory agreement. On October 21, 2022, we completed the internalization of our management function, or the Internalization. In connection with the Internalization, we agreed with the Former Advisor to terminate the advisory agreement and arranged for the Former Advisor to continue to provide certain services for a transition period.
Our Strategy
Our primary objective is to maximize value and generate liquidity for shareholders. The key elements of our strategy include:
•Grow the Operating Income Generated by Our Portfolio. Through active portfolio management, we will continue to review and implement operating strategies and initiatives that address factors impacting the industry, including inflation and other economic conditions, to enhance the performance of our existing investment portfolio.
•Deploy Strategic Capital Expenditures. We will continue to invest capital into our investments in order to maintain market position, functional and operating standards, and improve occupancy and resident rates, in an effort to enhance the overall value of our assets.
•Pursue Disposition Opportunities that Maximize Value. We will pursue dispositions of assets and portfolios where we believe the disposition will achieve a desired return and generate value for shareholders.
Market Update
Current market conditions impacting property-level performance are generally favorable. Industry occupancy continues to grow, with an industry average of 84.4% for the third quarter of 2023, up 80 basis points from the previous quarter, but still remains below the pre-pandemic average of 87.1% in March 2020 (source: NIC MAP Vision 3Q2023 Market Fundamentals Report). The 80+ population, a key demographic for senior housing, is expected to grow by 24% through 2028 (source: Organization for Economic Cooperation and Development as of November 2023), and new supply and new construction remain low compared to historical levels, resulting in a demand and supply environment that should contribute to overall industry occupancy and revenue growth. We have made significant capital improvements to many of our properties, which along with these positive dynamics, has contributed to the strong 29.3% growth in revenues, net of property expenses, for the nine months ended September 30, 2023 compared to the same period last year in our directly owned portfolio. Although we continue to face higher labor costs and operating expenses due to inflation, overall we remain optimistic that revenue growth will exceed expense growth, resulting in continued improved net operating income growth.
By contrast, current market conditions affecting transactions, including asset sales, are challenging. The current state of the public and private capital markets have been affected by a general tightening of availability of credit (including the price, terms



31
and conditions under which financing can be obtained), rising interest rates and a general decrease in liquidity in the healthcare lending markets, which has resulted in higher capitalization rates, adversely impacting property values and limiting transaction activity. The senior housing and care transaction volume totaled $700 million during the third quarter of 2023, the lowest quarterly level in ten years according to McKnights Senior Living. Although opportunities may exist to dispose of assets in the current market environment and there are certain scenarios where a sale can generate acceptable market returns for shareholders, many opportunities in the current market would require us to take significant discounts to our view of value.
Liquidity Update
We have not announced or adopted a plan for liquidation and are not required to liquidate by any specified date. We do not have a stated term for a liquidity event, as we believe setting a finite date for a possible, but uncertain future liquidity transaction may result in actions that are not necessarily in the best interest or within the expectations of our stockholders. However, our board of directors, through a special committee formed in August 2020, has evaluated a broad range of transactions, including restructurings, dispositions of particular assets and the company as a whole and the internalization of management, among others. Although this review process did not result in any opportunities to effect a liquidity event for stockholders at an acceptable value at that time, the board of directors has implemented steps to better position us for a future liquidity event. First, our current focus is on growing the net operating income of our existing direct investments, including through selectively investing capital into certain properties in order to achieve a better return upon the sale of those properties. If market conditions improve, we will then proceed with a general plan to sell assets over the next 2-3 years, while also exploring potential merger transactions in which the whole company would be acquired. In addition, the board of directors believes that the decision to internalize management in 2022, and the ability to more closely align management’s incentives with this strategy, will give us the best chance of success.
Based on the current forecasted cash flow of our investments and cash needs to operate the business, we do not anticipate paying recurring dividends in the near future. Although we have more than $98.7 million of unrestricted cash as of November 9, 2023, we require capital to fund operations, capital expenditures, including those invested to improve performance, and other important business uses, as well as to fund our debt service obligations and potentially to refinance indebtedness. Current cash flow generated by operations is not sufficient to cover all of these obligations. If we do not have sufficient capital available to fund our obligations, we may be unable to position properties to maximize value or meet debt service obligations. Instead, the board of directors will evaluate special distributions in connection with any future sales and other realizations of investments on a case-by-case basis based on, among other factors, current and projected liquidity needs.
In light of the foregoing, we do not currently anticipate resuming the share repurchase program, or the Share Repurchase Program. If we have sufficient capital available, at this stage in our life cycle, we believe that returning capital to stockholders through special distributions, rather than repurchases, is a better use of that capital.
Business Update
•On November 9, 2023, upon the recommendation of the audit committee of the board of directors, or the Audit Committee, the board of directors, including all of its independent directors, approved and established an estimated value per share of our common stock of $2.64. Refer to Part II, Item 5. “Other Items” for additional information.
Transaction and Financing Activities
•In November 2023, we entered into an agreement to sell all of our ownership interests in Trilogy REIT Holdings, LLC, or the Trilogy Joint Venture, which indirectly owns 123 integrated senior health campuses, to American Healthcare REIT, Inc. or its affiliates, or AHR, the majority partner of the Trilogy Joint Venture. AHR has the right to purchase our ownership interests in the Trilogy Joint Venture at any time prior to September 30, 2025, assuming AHR exercises all of its extension options and subject to satisfaction of certain closing conditions, ranging from $240.5 million to up to $260 million depending upon the purchase price consideration and timing of the closing. A minimum of 10% of the purchase price consideration must be paid in cash, with the balance payable in either cash or new Series A Cumulative Convertible Preferred Stock to be issued by AHR in connection with the closing. The portion of the purchase price consideration paid in cash may be subject to a 7.5% or 5% discount, respectively, if the transaction closes prior to March 31, 2024 or December 31, 2024, respectively. In addition, we may be entitled to a supplemental cash payment of $25,600 per day for the period between July 1, 2023 until the closing date, for up to approximately $21 million, reduced by any distributions received from the Trilogy Joint Venture by us during the interim period. AHR may terminate the agreement at any time, subject to payment of a termination fee equal to: (i) if terminated prior to the initial outside date, September 30, 2024, $3.9 million or, if a “Qualifying IPO” (i.e., an underwritten public offering of AHR’s common stock resulting in at least $200 million of net proceeds) has occurred prior to the termination, $7.8 million, (ii) if extended and terminated prior March 31, 2025, $11.7 million and (iii) if further extended and terminated prior to



32
September 30, 2025, $15.6 million. Although there can be no assurance that AHR will consummate the purchase of our interests in the Trilogy Joint Venture on these terms, or at all, we believe that this proposed transaction presents an attractive opportunity for us to execute on our disposition strategy, particularly for this minority position in a joint venture.
•In October 2023, as a result of the payment default in July 2023 on seven cross-defaulted and cross-collateralized mortgage notes with an aggregate principal amount outstanding of $99.8 million, or the Rochester Sub-Portfolio Loan, secured by seven healthcare real estate properties, or the Rochester Sub-Portfolio, the lender filed a complaint seeking the appointment of a receiver and foreclosure on the underlying properties and to enforce its rights in its collateral under the loan documents and, on October 30, 2023, the properties underlying the Rochester Sub-Portfolio Loan were placed into a receivership. The receiver now has effective control of the properties and we are working with the lender and the receiver to facilitate an orderly transition of the operations, and eventually ownership, of the properties. The transition of these properties is expected to have a positive impact on our cash flows and will not have a negative impact on value since the balance of debt is believed to exceed the value of the properties.
•In July 2023, we exercised our option to extend the maturity date of a mortgage note payable collateralized by a property within the Rochester portfolio from August 2023 to August 2024 and made a $0.3 million principal repayment toward the outstanding principal balance.
•In June 2023, we sold our minority interests in the Healthcare GA Holdings, General Partnership, which indirectly owned 48 care homes across the United Kingdom, or the Diversified US/UK Portfolio, and the Eclipse Health, General Partnership, which indirectly owned 34 seniors housing facilities, or the Eclipse Portfolio, together with $1.1 million in cash, to our Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the equity held by the Former Sponsor and its affiliates, including 9,709,553 shares of our common stock, 100 common units in the Operating Partnership and 100 special units in the Operating Partnership, or the Sale of Minority Interests. Upon completion of the Sale of Minority Interests, we retired all of the shares of our common stock acquired. With this Sale of Minority Interests, we were able to strategically exit two minority positions in joint ventures experiencing significant distress, where we had limited ability to control outcomes and a lack of alignment with the majority partner, through a transaction that we believe creates additional value for our remaining shareholders.
•In April 2023, the Espresso joint venture completed the sale of 10 properties, the first of two scheduled sale closings for its remaining sub-portfolio, generating net proceeds, of which our proportionate share totaled $17.3 million. The transaction was structured such that the second closing sales price approximates the outstanding debt on the remaining properties and, as such, is not forecasted to generate net proceeds. The second sale closing is scheduled to close during the fourth quarter of 2023, though there can be no assurance that the transaction will close on this timeframe or at all.
Operating Performance
Our occupancy has recovered to pre-pandemic levels, driven by supply-demand fundamentals in the industry overall and specifically by our investment of capital to enhance our facilities, which has led to increases in revenues. However, operating costs remained elevated as a result of macroeconomic trends, including increases in labor costs and historically low unemployment, inflation and rising interest rates, as well as increased health and safety measures. Increased labor costs and a shortage of available skilled and unskilled workers has, and may continue to increase the cost of staffing at our facilities. We have offset increased labor and inflation with increased rates charged to residents, but continuing to do so may result in a decline in occupancy and revenues. Increases in interest rates may help ease inflation and our operating costs, but have increased our debt service obligations on our variable rate debt and may create the possibility of slowing economic growth.
The following is a summary of the performance of our investment segments for the three months ended September 30, 2023 as compared to the three months ended June 30, 2023. For additional information on financial results, refer to “—Results of Operations.”
Direct Investments - Operating
The average quarterly occupancy of our facilities improved 1.4% to 86.5% for the third quarter of 2023, while the quarterly occupancy for the seniors housing industry averaged 84.4% for the same period. The average industry occupancy remains 2.7% below its pre-pandemic level of 87.1% in the first quarter of 2020 (source: The National Investment Centers for Seniors Housing & Care Map Top 31 Primary Metropolitan Markets).



33
A summary of average occupancy of our direct operating investments by property manager is as follows:
Average Monthly OccupancyAverage Quarterly Occupancy
ManagerSeptember 2023June 2023Variance Q3 2023Q2 2023Variance
Solstice Senior Living89.1 %87.6 %1.5 %88.7 %87.4 %1.3 %
Watermark Retirement Communities81.4 %79.3 %2.1 %80.8 %78.9 %1.9 %
Avamere Health Services90.8 %88.1 %2.7 %90.3 %88.7 %1.6 %
Integral Senior Living83.2 %86.9 %(3.7)%85.0 %84.5 %0.5 %
Direct Investments - Operating87.0 %85.2 %1.8 %86.5 %85.1 %1.4 %
The following table is a summary of the operating performance at our direct operating investments for the three months ended September 30, 2023 and June 30, 2023 (dollars in thousands):
Three Months EndedIncrease (Decrease)
September 30, 2023June 30, 2023Amount%
Property revenues
Resident fee income$11,966 $11,839 $127 1.1 %
Rental income39,493 38,227 1,266 3.3 %
Total property revenues51,459 50,066 1,393 2.8 %
Property operating expenses
Salaries and wages16,897 16,561 336 2.0 %
Utilities 3,429 2,694 735 27.3 %
Food and beverage2,748 2,649 99 3.7 %
Repairs and maintenance3,700 3,627 73 2.0 %
Property taxes2,848 2,880 (32)(1.1)%
Property management fee2,989 2,499 490 19.6 %
All other expenses4,279 4,116 163 4.0 %
Total property operating expenses36,890 35,026 1,864 5.3 %
Total property revenues, net of property operating expenses$14,569 $15,040 $(471)(3.1)%
Overall, property revenues, net of property operating expenses, decreased by $0.5 million for the three months ended September 30, 2023 as compared to the prior quarter. Property operating expenses increased by $1.9 million due to higher utility costs, salaries, and additional management fees accrued at our Winterfell portfolio due to exceeding performance targets for the nine months ended September 30, 2023, per the terms of our management agreements. Rental and resident fee income increased by $1.4 million as a result of improved occupancy and increases in market rates for new residents and in-place rates for existing residents across our direct operating investments.
Despite overall improved operating performance at our direct operating investments, certain properties continue to struggle with occupancy, rate growth and controlling expenses. In particular, the Rochester Sub-Portfolio has generated negative cash flow of approximately $3.2 million after capital expenditure and debt service payments remitted during the nine months ended September 30, 2023. We elected to default on our debt service payments on the Rochester Sub-Portfolio Loan in July 2023 because we do not expect the portfolio to generate sufficient cash flow to cover debt service obligations for an extended period of time and ultimately do not believe the portfolio will be able to generate sufficient sales proceeds in order to repay its cross-collateralized debt outstanding at maturity. Refer to “—Transaction and Financing Activities” for further information.
Direct Investments - Net Lease
Beginning in February 2021, the operator of the four net lease properties in our Arbors portfolio has been unable to satisfy its obligations under its leases. In accordance with a forbearance and modification agreement entered into in March 2023, or the Forbearance Agreement, the operator remits rent based on the properties’ available cash after satisfying property-level expenses.
During the three months ended September 30, 2023, we recognized rental income from our Arbors portfolio to the extent excess cash flow was received, which totaled $0.8 million as compared to $0.3 million recognized during the three months ended June 30, 2023.



34
The operator of our net lease properties continues to be impacted by sub-optimal occupancy levels and elevated operating expenses, which has resulted in limited cash flow generated by properties. As a result, during the nine months ended September 30, 2023 we have utilized cash reserves of approximately $2.8 million to fund debt service payments, including principal amortization. Average quarterly occupancy improved 0.8% to 73.8% during the three months ended September 30, 2023 from 73.0% during the three months ended June 30, 2023, but we continue to monitor the portfolio for occupancy and revenue growth and evaluate the potential options for this portfolio.
Unconsolidated Investments
We own minority, non-controlling interests in joint ventures, which own investments in real estate properties. During the three months ended September 30, 2023, we did not receive any distributions from our unconsolidated investments as compared to $21.8 million during the three months ended June 30, 2023, which consisted primarily of excess cash flow and sub-portfolio sales proceeds distributed from the Espresso joint venture, of which our proportionate share totaled $2.2 million and $17.3 million, respectively. In addition, we received a quarterly distribution from the Trilogy joint venture, of which our proportionate share totaled $2.3 million during the three months ended June 30, 2023.
The following is a summary of operations and performance for our unconsolidated investments, excluding sold investments, for the three months ended September 30, 2023:
Trilogy
While continuing to improve from pandemic-era lows, the occupancy of the joint venture's facilities remains below historical levels, which has impacted operating revenues. Operating expenses continue to be impacted by inflationary pressures, most significantly labor-related costs, however, the joint venture has recognized COVID-19 provider relief grant income, which has partially offset the elevated expenses. In addition, the joint venture has incurred higher interest expense on its floating rate debt outstanding due to rising market interest rates, which has limited cash available to be distributed.
Espresso
The joint venture received full contractual rent from the net lease operators of its remaining portfolio. The sale of the remaining portfolio is scheduled to close during the fourth quarter of 2023. Refer to “—Transaction and Financing Activities” for additional information.
Our Investments
Our investments are categorized as follows:
•Direct Investments - Operating - Properties operated pursuant to management agreements with managers, in which we own a controlling interest.
•Direct Investments - Net Lease - Properties operated under net leases with an operator, in which we own a controlling interest.
•Unconsolidated Investments - Joint ventures, which include properties operated under net leases with an operator or pursuant to management agreements with managers, in which we own a minority, non-controlling interest.
Our direct investments are in seniors housing facilities, which include ILFs, ALFs and MCFs, as described in further detail below. Revenues generated by seniors housing facilities typically come from private pay sources, including private insurance, and to a much lesser extent government reimbursement programs, such as Medicaid.
•Independent living facilities. ILFs are properties with central dining facilities that provide services that include security, housekeeping, nutrition and limited laundry services. ILFs are designed specifically for independent seniors who are able to live on their own, but desire the security and conveniences of community living. ILFs typically offer several services covered under a regular monthly fee.
•Assisted living facilities. ALFs provide services that include minimal assistance for activities in daily living and permit residents to maintain some of their privacy and independence as they do not require constant supervision and assistance. Services may be bundled within one monthly fee or based on the care needs of the resident and usually include three meals per day in a central dining room, daily housekeeping, laundry, medical reminders and 24-hour availability of assistance with the activities of daily living, such as eating, dressing and bathing. ALFs typically are comprised of studios, one and two bedroom suites equipped with private bathrooms and efficiency kitchens.



35
•Memory care facilities. MCFs offer specialized options for seniors with Alzheimer’s disease and other forms of dementia. These facilities offer dedicated care and specialized programming for various conditions relating to memory loss in a secured environment. Residents require a higher level of care and more assistance with activities of daily living than in ALFs. Therefore, these facilities have staff available 24 hours a day to respond to the unique needs of their residents.
Through our unconsolidated investments, we have additional investments in seniors housing facilities, as well as in additional types of healthcare real estate, including the following:
•Integrated Senior Health Campuses. Provide a range of services, such as those described for ILFs, ALFs, MCFs, SNFs, in an integrated campus.
•Skilled Nursing Facilities. SNFs provide services that include daily nursing, therapeutic rehabilitation, social services, housekeeping, nutrition and administrative services for individuals requiring certain assistance for activities in daily living. A typical SNF includes mostly one and two bed units, each equipped with a private or shared bathroom and community dining facilities. Revenues generated from SNFs typically come from government reimbursement programs, including Medicare and Medicaid, as well as private pay sources, including private insurance.
For financial information regarding our reportable segments, refer to Note 11, “Segment Reporting” in our accompanying consolidated financial statements included in Part I, Item 1. “Financial Statements.”
The following table presents a summary of investments as of September 30, 2023 (dollars in thousands):
Properties(1)
Investment Type / Portfolio
Amount(2)
ILFALFMCFSNFIntegrated CampusTotalPrimary LocationsOwnership
Interest
Direct Investments - Operating
Winterfell$737,058 32————3212 U.S. States100.0%
Rochester149,204 73———10New York97.0%
Avamere94,246 —5———5Washington/Oregon100.0%
Aqua83,684 211——4Texas/Ohio97.0%
Oak Cottage18,695 ——1——1California 100.0%
Subtotal$1,082,887 4192——52
Direct Investments -
Net Lease
Arbors$103,915 —4———4New York100.0%
Total Direct Investments $1,186,802 41132——56
Unconsolidated Investments
Trilogy(3)
$124,670 ————1231234 U.S. States 23.4%
Espresso3,075 ——23—23Ohio/Michigan36.7%
Solstice(4)
281 ——————20.0%
Total Unconsolidated Investments$128,026 ———23123146
Total Investments$1,314,828 4113223123202
_______________________________________
(1)Classification based on predominant services provided, but may include other services.
(2)For direct investments, amount represents operating real estate, before accumulated depreciation as presented in our consolidated financial statements as of September 30, 2023. For unconsolidated investments, amount represents the carrying value of our investments in unconsolidated ventures as presented in our consolidated financial statements as of September 30, 2023. For additional information, refer to “Note 3, Operating Real Estate” and “Note 4, Investments in Unconsolidated Ventures” of Part I, Item 1. “Financial Statements.”
(3)Property count includes properties owned and leased by the joint venture and excludes its institutional pharmacy and therapy businesses.
(4)Represents our investment in Solstice Senior Living, LLC, or Solstice, the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC, or ISL, a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and us, who owns 20.0%.



36
The following presents the properties of our direct and unconsolidated investments by property type and geographic location based on our proportionate share of cost as of September 30, 2023:
Real Estate Equity by Property Type(1)
Real Estate Equity by Geographic Location
prop type 2.jpg
geo 2.jpg
_______________________________________
(1)Classification based on predominant services provided, but may include other services.

The following table presents the operators and managers of our direct investments (dollars in thousands):
As of September 30, 2023Nine Months Ended September 30, 2023
Operator / ManagerProperties Under Management
Units Under Management(1)
Property and Other Revenues(2)
% of Total Property and Other Revenues
Solstice Senior Living(3)
32 3,969 $94,469 61.2 %
Watermark Retirement Communities14 1,782 35,967 23.2 %
Avamere Health Services5 453 16,266 10.5 %
Integral Senior Living1 40 3,672 2.4 %
Arcadia Management(4)
4 572 1,178 0.8 %
Other(5)
— — 2,893 1.9 %
Total56 6,816 $154,445 100.0 %
_______________________________________
(1)Represents rooms for ALFs, ILFs and MCFs, based on predominant type.
(2)Includes rental income received from our net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from our ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.
(3)Solstice is a joint venture of which affiliates of ISL own 80%.
(4)During the nine months ended September 30, 2023, we recorded rental income to the extent payments were received.
(5)Consists primarily of interest income earned on corporate-level cash and cash equivalents.

Direct Investments - Operating
We generate revenues from resident fees and rental income through our operating properties. Resident fee income is recorded by our ALFs and MCFs when services are rendered and includes resident room and care charges and other resident charges, and rental income is generated from our ILFs.
Our operating properties allow us to participate in the risks and rewards of the operations of the facilities as compared to receiving only contractual rent under a net lease. We engage independent managers to operate these facilities pursuant to management agreements, including procuring supplies, hiring and training all employees, entering into all third-party contracts for the benefit of the property, including resident/patient agreements, complying with laws and regulations, including but not limited to healthcare laws, and providing resident care and services, in exchange for a management fee. As a result, we must rely on our managers’ personnel, expertise, technical resources and information systems, risk management processes, proprietary information, good faith and judgment to manage our operating properties efficiently and effectively. We also rely on our managers to set appropriate resident fees, to provide accurate property-level financial results in a timely manner and otherwise



37
operate our seniors housing facilities in compliance with the terms of our management agreements and all applicable laws and regulations.
Our management agreements generally provide for monthly management fees which are calculated based on various performance measures, including revenue, net operating income and other objective financial metrics. We are also required to reimburse our managers for expenses incurred in the operation of the properties, as well as to indemnify our managers in connection with potential claims and liabilities arising out of the operation of the properties. Our management agreements are terminable after a stated term with certain renewal rights, though we have the ability to terminate earlier upon certain events with or without the payment of a fee.
Watermark Retirement Communities and Solstice, together with their affiliates, manage substantially all of our operating properties. As of September 30, 2023, Watermark and Solstice or their respective affiliates collectively managed 46 of our seniors housing facilities pursuant to management agreements. For the nine months ended September 30, 2023, properties managed by Watermark and Solstice represented 23.2% and 61.2% of our total property and other revenues, respectively, and 19.6% and 62.1% of our operating real estate, respectively. Through our 20.0% ownership of Solstice, we are entitled to certain rights and minority protections.
The following table presents a summary of the terms of the Watermark and Solstice management agreements:
ManagerPortfolioPropertiesExpiration DateManagement Fees
Solstice Senior LivingWinterfell32 October 2025
•5% of monthly gross revenues, subject to certain exclusions
•7% of actual costs of certain capital projects
•Additional fees if net operating income exceeds annual target
•Additional fees if net operating income long-term growth is achieved
Watermark Retirement Communities(1)
Aqua2 December 2023
•5% of monthly gross revenues, subject to certain exclusions
•Eligible for promote in connection with disposition
Aqua2 February 2024
Rochester10 
August
2024
_______________________________________
(1)Affiliates of Watermark also own a 3% non-controlling interest in the Rochester and Aqua portfolios, which may impact various rights and economics under the management agreements.
Direct Investments - Net Lease
We generate revenues from rental income from net leases to operators through our net lease properties. A net lease will typically provide for fixed rental payments, subject to periodic increases based on certain percentages or the consumer price index, and obligate the operator to pay all property-related expenses, including maintenance, utilities, repairs, taxes, insurance and capital expenditures.
As of September 30, 2023, we had four ALF properties operated by Arcadia Management under net leases. These leases obligate Arcadia to pay a fixed rental amount and pay all property-level expenses, with a lease term that expires in August 2029. However, Arcadia has been unable to satisfy its obligations under its leases since February 2021, and instead remits rent and pays property-level expenses based on its available cash. On March 27, 2023, we entered into the Forbearance Agreement, with Arcadia, pursuant to which we are entitled to receive all cash flow in excess of permitted expenses, and are required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. As a result, we participate in the risks and rewards of this portfolio similar to our operating properties. We also agreed to make available funds for capital improvements in order to stabilize and drive improved performance in this portfolio. If Arcadia performs under the Forbearance Agreement, it will be entitled to forgiveness of accrued and unpaid rent during the forbearance period and a potential incentive fee tied to disposition of the portfolio above a certain value.



38
Unconsolidated Investments
For investments accounted for under the equity method, we report our proportionate interest of revenues and expenses from our unconsolidated joint ventures through equity in earnings (losses) of unconsolidated ventures on our consolidated statements of operations. For investments accounted for under the fair value option method, we will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations. As of September 30, 2023, our unconsolidated investment portfolios are as follows:
•Trilogy. Portfolio of Integrated Senior Health Campuses located in the Midwest and operated pursuant to management agreements with Trilogy Health Services. The portfolio includes ancillary services businesses, including a therapy business and a pharmacy business. AHR and management of Trilogy own the remaining 76.6% of this portfolio.
•Espresso. The joint venture is in the process of completing the second and final sale of its remaining net lease portfolio consisting of 23 SNFs located in Ohio and Michigan. An affiliate of Formation acts as the general partner and manager of this investment. Formation and Safanad Management Limited own the remaining 63.3% of this portfolio.
•Solstice. Operator platform joint venture established to manage the operations of the Winterfell portfolio. An affiliate of ISL owns the remaining 80.0%.
In connection with the Sale of Minority Interests, we sold our minority, non-controlling interests in the Diversified US/UK portfolio and Eclipse portfolios. Refer to “—Transaction and Financing Activities” for additional information.
Portfolio Management
The portfolio management process for our investments includes oversight by our executive and asset management teams, regular management meetings and an operating results review process. These processes are designed to evaluate and proactively identify asset-specific issues and trends on a portfolio-wide, sub-portfolio or asset type basis. The teams work in conjunction with our managers and operators to create tailored action plans to address issues identified.
Our executive and asset management teams are experienced and use many methods to actively manage our investments to enhance or preserve our income, value and capital and mitigate risk. Our teams seek to identify opportunities for our investments that may involve replacing or renovating facilities in our portfolio which, in turn, would allow us to improve occupancy and resident rates and enhance the overall value of our assets. To manage risk, our teams engage in frequent review and dialogue with operators/managers/third party advisors and periodic inspections of our owned properties. In addition, our teams consider the impact of regulatory changes on the performance of our portfolio.
Our teams will continue to monitor the performance of, and actively manage, all of our investments. However, there can be no assurance that our investments will continue to perform in accordance with our expectations.
Critical Accounting Policies and Estimates
Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, which requires the use of estimates and assumptions that involve the exercise of judgment and that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. 
Certain accounting policies are considered to be critical accounting policies. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require management’s subjective and complex judgments, and for which the impact of changes in estimates and assumptions could have a material effect on our financial statements. We believe that all of the decisions and assessments upon which our financial statements are based were reasonable at the time made, based upon information available to us at that time.
For a summary of our accounting policies, refer to Note 2, “Summary of Significant Accounting Policies” in our accompanying consolidated financial statements included in Part I, Item 1. “Financial Statements.”
We believe impairment to be a critical accounting estimate based on the nature of our operations and/or require significant management judgment and assumptions. Our investments are reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of our investments may be impaired or that carrying value may not be recoverable. In conducting these reviews, we consider macroeconomic factors, including healthcare sector conditions, together with asset and market specific circumstances, among other factors. To the extent an impairment has occurred, the loss will be measured as compared to the carrying amount of the investment. Fair values can be estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization and discount rates or



39
sales comparison approach, using what other purchasers and sellers in the market have agreed to as price for comparable properties.
Impairment
At this time, it is difficult to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. As the future impact will depend on many factors beyond our control and knowledge, the resulting effect on impairment of our operating real estate and investments in unconsolidated ventures may materially differ from our current expectations and further impairment charges may be recorded in the future.
Direct Operating Investments
During the nine months ended September 30, 2023, we recorded impairment losses on our operating real estate totaling $38.7 million, including impairment losses of $38.6 million for five facilities within the Rochester portfolio as a result of shortened hold period assumptions due to the facilities defaulting on their loan payments in July 2023. On October 30, 2023, the properties underlying the Rochester Sub-Portfolio Loan were placed into a receivership. The receiver now has effective control of the properties and we are working with the lender and the receiver to facilitate an orderly transition of the operations, and eventually ownership, of the properties. Refer to “—Transaction and Financing Activities” for additional discussion. Additionally, we recorded impairment losses totaling $0.1 million for a land parcel within the Rochester Portfolio as a result of lower estimated market value.
Accumulated impairment losses totaled $220.2 million for operating real estate that we continue to hold as of September 30, 2023. Refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and 2021 for additional information regarding impairment recorded in prior years.
Unconsolidated Investments
During the nine months ended September 30, 2023, we recorded an impairment on our investment in the Espresso joint venture totaling $4.7 million, which reduced the carrying value of our investment to $3.1 million. Our assessment for the recoverability of our investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. Upon impairing our investment, we elected the fair value option method to account for our investment in the Espresso joint venture on June 30, 2023.
The joint ventures underlying our unconsolidated ventures assess and record impairment and reserves on their respective real estate portfolios, goodwill, and other assets, and we recognize our proportionate share through equity in earnings (losses). In May 2023, prior to the Sale of Minority Interests, the underlying Diversified US/UK joint venture recorded impairment losses on its UK Portfolio, due to, among other things, an extended period contemplated for the UK Portfolio to reach stabilization. Our proportionate share of the impairment losses recorded by the Diversified US/UK joint venture totaled $11.4 million.



40
Results of Operations
Comparison of the Three Months Ended September 30, 2023 to September 30, 2022 (dollars in thousands):
Three Months Ended September 30,Increase (Decrease)
20232022Amount%
Property and other revenues
Resident fee income$11,966 $11,274 $692 6.1 %
Rental income40,330 36,165 4,165 11.5 %
Other revenue1,078 300 778 259.3 %
Total property and other revenues53,374 47,739 5,635 11.8 %
Expenses
Property operating expenses36,890 35,134 1,756 5.0 %
Interest expense14,250 11,014 3,236 29.4 %
Transaction costs358 857 (499)(58.2)%
Asset management fees - related party— 2,428 (2,428)(100.0)%
General and administrative expenses2,921 2,859 62 2.2 %
Depreciation and amortization9,848 9,642 206 2.1 %
Impairment loss— 18,500 (18,500)(100.0)%
Total expenses64,267 80,434 (16,167)(20.1)%
Gain (loss) on investments and other(347)325 (672)(206.8)%
Equity in earnings (losses) of unconsolidated ventures(127)2,872 (2,999)(104.4)%
Income tax expense(17)(15)(2)13.3 %
Net income (loss)$(11,384)$(29,513)$18,129 (61.4)%
Total Property and Other Revenues
The following table presents total property and other revenues generated by our direct investments (dollars in thousands):
Three Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$11,966 $11,274 $692 6.1 %
ILF properties34,644 30,855 3,789 12.3 %
Net lease properties837 724 113 15.6 %
Rochester Sub-Portfolio (in loan default)4,849 4,586 263 5.7 %
Other revenue1,078 300 778 259.3 %
Total property and other revenues$53,374 $47,739 $5,635 11.8 %
Overall, total property and other revenues increased $5.6 million during the three months ended September 30, 2023. Revenues generated by our operating properties increased as a result of improved occupancy and higher market rates for new residents and in-place rates for existing residents. Other revenue consists of interest earned on cash and cash equivalents, which increased during the three months ended September 30, 2023 as a result of higher market interest rates.
Property Operating Expenses
The following table presents property operating expenses incurred by our direct investments (dollars in thousands):
Three Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$9,387 $9,069 $318 3.5 %
ILF properties23,504 21,790 1,714 7.9 %
Rochester Sub-Portfolio (in loan default)3,999 4,275 (276)(6.5)%
Total property operating expenses$36,890 $35,134 $1,756 5.0 %
Overall, total operating expenses increased $1.8 million, primarily due to an increase in management fees at our Winterfell portfolio as a result of revenue growth and additional fees for exceeding performance targets per the terms of the management agreements. In addition, inflationary pressures significantly impacted all variable operating costs, most notably wages and benefits, repairs and maintenance, and insurance costs.



41
Interest Expense
The following table presents interest expense incurred on our borrowings (dollars in thousands):
Three Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$1,315 $1,310 $5 0.4 %
ILF properties7,482 7,583 (101)(1.3)%
Net lease properties883 907 (24)(2.6)%
Rochester Sub-Portfolio (in loan default)4,570 1,214 3,356 276.4 %
Total interest expense$14,250 $11,014 $3,236 29.4 %
Interest expense increased $3.2 million as a result of higher interest expense on our floating rate debt and default interest and prepayment penalties accrued due to Rochester Sub-Portfolio Loan default and acceleration in July 2023. We do not anticipate remitting payment for debt service obligations due under the Rochester Sub-Portfolio Loan.
Transaction Costs
Transaction costs for the three months ended September 30, 2023 consisted of legal and professional fees incurred for investment activity. Transaction costs for the three months ended September 30, 2022 consisted of legal and professional fees incurred to complete the Internalization.
Asset Management Fees - Related Party & General and Administrative Expenses
The advisory agreement with our Former Advisor was terminated on October 21, 2022. As a result, no asset management fees were incurred during 2023 as compared to $2.4 million incurred during the three months ended September 30, 2022.
Under our new internalized structure, we directly incur and pay all general and administrative expenses, including personnel costs related to our executive officers, which were not allocable under the former advisory agreement. General and administrative expenses were comparable for the three months ended September 30, 2023 and 2022.
Combining asset management fees and general and administrative expenses, $2.4 million of cost savings were realized under the internalized structure during the three months ended September 30, 2023 as compared to the three months ended September 30, 2022.
Depreciation and Amortization
The following table presents depreciation and amortization recognized on our direct investments (dollars in thousands):
Three Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$1,652 $1,581 $71 4.5 %
ILF properties6,439 5,900 539 9.1 %
Net lease properties729 870 (141)(16.2)%
Rochester Sub-Portfolio (in loan default)1,028 1,291 (263)(20.4)%
Total depreciation and amortization$9,848 $9,642 $206 2.1 %
Depreciation and amortization expense increased $0.2 million as a result of additional capital expenditures, primarily at our Winterfell portfolio. The increase was partially offset by lower depreciation for our Rochester Sub-Portfolio due to impairments recognized during the three months ended June 30, 2023, which reduced building depreciation expense for the three months ended September 30, 2023.
Impairment Loss
During the three months ended September 30, 2023, we did not record any impairment losses on our investments. During the three months ended September 30, 2022, impairment losses on operating real estate totaled $18.5 million for facilities within our Arbors net lease portfolio.



42
Gain (Loss) on Investments and Other
During the three months ended September 30, 2023, we recorded losses on the change in value of our mortgage note payable interest rate caps totaling $0.3 million as compared to losses totaling $0.3 million recognized during the three months ended September 30, 2022.
Equity in Earnings (Losses) of Unconsolidated Ventures
The following table presents the results of our unconsolidated ventures (dollars in thousands):
Three Months Ended September 30,
202320222023202220232022
PortfolioEquity in Earnings (Losses)
FFO and MFFO adjustments(1)
Equity in Earnings, after FFO and MFFO adjustmentsIncrease (Decrease)
Trilogy$(146)$6,052 $4,460 $(753)$4,314 $5,299 $(985)(18.6)%
Espresso— (242)— 1,617 — 1,375 (1,375)(100.0)%
Solstice19 17 — — 19 17 2 11.8 %
Subtotal(127)5,827 4,460 864 4,333 6,691 (2,358)(35.2)%
Investments sold — (2,955)— 3,434 — 479 (479)(100.0)%
Total$(127)$2,872 $4,460 $4,298 $4,333 $7,170 $(2,837)(39.6)%
_______________________________________
(1)Represents our proportionate share of revenues and expenses excluded from the calculation of FFO and MFFO for unconsolidated investments. Refer to “—Non-GAAP Financial Measures” for additional discussion.
Excluding the investments in unconsolidated ventures sold, equity in earnings decreased by $6.0 million primarily due to the Trilogy joint venture recognizing a gain upon acquiring the remaining ownership interest of an investment portfolio during the three months ended September 30, 2022.
Excluding the investments in unconsolidated ventures sold, equity in earnings, after FFO and MFFO adjustments, decreased $2.4 million. The Espresso joint venture has sold properties, which has resulted in lower rental income recognized and as of June 30, 2023, we elected to account for the Espresso joint venture under the fair value option, resulting in no equity in earnings recorded during the three months ended September 30, 2023. In addition, higher interest expense on floating rate debt in the Trilogy joint venture has offset operational improvements in the joint venture, resulting in lower cash flows generated.
Comparison of the Nine Months Ended September 30, 2023 to September 30, 2022 (dollars in thousands):
Nine Months Ended September 30,Increase (Decrease)
20232022Amount%
Property and other revenues
Resident fee income$35,655 $32,987 $2,668 8.1 %
Rental income115,897 103,001 12,896 12.5 %
Other revenue2,893 457 2,436 533.0 %
Total property and other revenues154,445 136,445 18,000 13.2 %
Expenses
Property operating expenses106,993 101,258 5,735 5.7 %
Interest expense37,143 31,877 5,266 16.5 %
Transaction costs455 857 (402)(46.9)%
Asset management fees - related party— 7,532 (7,532)(100.0)%
General and administrative expenses10,424 10,300 124 1.2 %
Depreciation and amortization29,305 29,105 200 0.7 %
Impairment loss43,422 31,502 11,920 37.8 %
Total expenses227,742 212,431 15,311 7.2 %
Other income, net202 77 125 162.3 %
Gain (loss) on investments and other(4,662)660 (5,322)(806.4)%
Equity in earnings (losses) of unconsolidated ventures(6,595)39,427 (46,022)(116.7)%
Income tax expense(43)(45)2 (4.4)%
Net income (loss)$(84,395)$(35,867)$(48,528)135.3 %



43
Total Property and Other Revenues
The following table presents total property and other revenues (dollars in thousands):
Nine Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$35,655 $32,987 $2,668 8.1 %
ILF properties100,583 88,146 12,437 14.1 %
Net lease properties1,178 1,220 (42)(3.4)%
Rochester Sub-Portfolio (in loan default)14,136 13,635 501 3.7 %
Other revenue 2,893 457 2,436 533.0 %
Total property and other revenues$154,445 $136,445 $18,000 13.2 %
Overall, total property and other revenues increased $18.0 million during the nine months ended September 30, 2023. Revenues generated by our operating properties increased as a result of improved occupancy and higher market rates for new residents and in-place rates for existing residents. Other revenue consists of interest earned on cash and cash equivalents, which increased during the nine months ended September 30, 2023 as a result of higher market interest rates.
Property Operating Expenses
The following table presents property operating expenses incurred by our direct investments (dollars in thousands):
Nine Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$26,920 $24,937 $1,983 8.0 %
ILF properties67,849 63,431 4,418 7.0 %
Net lease properties— 35 (35)(100.0)%
Rochester Sub-Portfolio (in loan default)12,224 12,855 (631)(4.9)%
Total property operating expenses$106,993 $101,258 $5,735 5.7 %
Overall, total operating expenses increased $5.7 million, primarily due to inflationary pressures significantly impacting all variable operating costs, most notably wages and benefits, repairs and maintenance, insurance, utilities and food and beverage costs. In addition, management fees at our Winterfell portfolio increased as a result of revenue growth and additional fees for exceeding performance targets per the terms of the management agreements.
Interest Expense
The following table presents interest expense incurred on our borrowings (dollars in thousands):
Nine Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$3,937 $3,855 $82 2.1 %
ILF properties22,342 22,603 (261)(1.2)%
Net lease properties2,639 2,708 (69)(2.5)%
Rochester Sub-Portfolio (in loan default)8,225 2,711 5,514 203.4 %
Total interest expense$37,143 $31,877 $5,266 16.5 %
Interest expense increased $5.3 million as a result of higher interest expense on our floating rate debt and default interest and prepayment penalties accrued due to Rochester Sub-Portfolio Loan default and acceleration in July 2023. We do not anticipate remitting payment for debt service obligations due under the Rochester Sub-Portfolio Loan. The increase was partially offset by a decrease in the average mortgage notes principal balances as compared to September 30, 2022 due to continued principal amortization.
Transaction Costs
Transaction costs for the nine months ended September 30, 2023 consisted primarily of legal and professional fees incurred for investment activity and costs incurred in connection with the Internalization and the transition of services and systems previously provided by the Former Advisor.



44
Transaction costs for the nine months ended September 30, 2022 consisted of legal and professional fees incurred to complete the Internalization.
Asset Management Fees - Related Party & General and Administrative Expenses
The advisory agreement with our Former Advisor was terminated on October 21, 2022. As result, no asset management fees were incurred during 2023 as compared to $7.5 million incurred during the nine months ended September 30, 2022.
Under our new internalized structure, we directly incur and pay all general and administrative expenses, including personnel costs related to our executive officers, which were not allocable under the former advisory agreement. General and administrative expenses were comparable for the nine months ended September 30, 2023 and 2022.
Combining asset management fees and general and administrative expenses, $7.4 million of cost savings were realized under the internalized structure during the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022.
Depreciation and Amortization
The following table presents depreciation and amortization recognized on our direct investments (dollars in thousands):
Nine Months Ended September 30,Increase (Decrease)
20232022Amount%
ALF/MCF properties$4,930 $4,703 $227 4.8 %
ILF properties18,539 17,828 711 4.0 %
Net lease properties2,187 2,601 (414)(15.9)%
Rochester Sub-Portfolio (in loan default)3,649 3,973 (324)(8.2)%
Total depreciation and amortization$29,305 $29,105 $200 0.7 %
Depreciation and amortization expense increased at our ALFs, MCFs and ILFs, primarily as a result of capital improvements during 2023. The increase was partially offset by decreased depreciation primarily as a result of impairments recognized at our net lease properties and our Rochester Sub-Portfolio during the year ended December 31, 2022 and three months ended June 30, 2023, respectively, which reduced building depreciation expense for the nine months ended September 30, 2023.
Impairment Loss
During the nine months ended September 30, 2023, impairment losses on operating real estate totaled $38.7 million and impairment losses recorded on unconsolidated ventures investments totaled $4.7 million. Refer to “—Impairment” for additional discussion.
During the nine months ended September 30, 2022, impairment losses on operating real estate totaled $31.5 million, consisting of $18.5 million, $8.5 million and $3.9 million for facilities in Arbors, Winterfell and Rochester portfolios, respectively. In addition, we recorded $0.6 million of impairment losses for property damage sustained by facilities within our Winterfell portfolio.
Other Income, Net
During the nine months ended September 30, 2023, other income, net consisted primarily of capital expenditure reimbursements from the state of Oregon’s Long-Term Care Capital Improvement and Emergency Preparedness Program received and recognized by facilities within our Avamere portfolio.
During the nine months ended September 30, 2022, other income, net consisted of COVID-19 testing reimbursements received and recognized by our Avamere portfolio.
Gain (Loss) on Investments and Other
In connection with the Sale of Minority Interests, we realized a loss totaling $1.3 million, representing the difference between the fair value and carrying value of our investments in the Diversified US/UK and Eclipse joint ventures, which was the consideration exchanged in the transaction for the acquisition of our common stock. In addition, as a result of the Sale of Minority Interests, we reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK portfolio, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other. Refer to “—Transaction and Financing Activities” for additional discussion.



45
During the nine months ended September 30, 2022, we recognized gains on mortgage interest rate caps, a discounted financing payoff and a distribution that exceeded our carrying value for an unconsolidated investment. Gains were partially offset by losses recognized on investment activity.
Equity in Earnings (Losses) of Unconsolidated Ventures
The following table presents the results of our unconsolidated ventures (dollars in thousands):
Nine Months Ended September 30,
202320222023202220232022
PortfolioEquity in Earnings (Losses)
FFO and MFFO adjustments(1)
Equity in Earnings, after FFO and MFFO adjustmentsIncrease (Decrease)
Trilogy$454 $10,757 $13,448 $7,415 $13,902 $18,172 $(4,270)(23.5)%
Espresso9,228 33,711 (8,283)(28,121)945 5,590 (4,645)(83.1)%
Solstice(41)(41)— — (41)(41)— — %
Subtotal9,641 44,427 5,165 (20,706)14,806 23,721 (8,915)(37.6)%
Investments sold(16,236)(5,000)15,087 9,379 (1,149)4,379 (5,528)(126.2)%
Total$(6,595)$39,427 $20,252 $(11,327)$13,657 $28,100 $(14,443)(51.4)%
_______________________________________
(1)Represents our proportionate share of revenues and expenses excluded from the calculation of FFO and MFFO for unconsolidated investments. Refer to “—Non-GAAP Financial Measures” for additional discussion.
Excluding the investments in unconsolidated ventures sold, equity in earnings (losses) decreased $34.8 million primarily due to prior period gains on sales exceeding gains recognized during the nine months ended September 30, 2023 by the Espresso joint venture. In addition, the Trilogy joint venture recognized a gain upon acquiring the remaining ownership interest of an investment portfolio during nine months ended September 30, 2022.
Excluding the investments in unconsolidated ventures sold, equity in earnings (losses), after FFO and MFFO adjustments, decreased $8.9 million. The Espresso joint venture has sold properties, which has resulted in lower rental income recognized during the nine months ended September 30, 2023 and as of June 30, 2023, we elected to account for the Espresso joint venture under the fair value option, resulting in no equity in earnings recorded during the three months ended September 30, 2023. In addition, higher interest expense on floating rate debt in the Trilogy joint venture has offset operational improvements in the joint venture, resulting in lower cash flows generated.
Non-GAAP Financial Measures
Funds from Operations and Modified Funds from Operations
We believe that Funds from Operations, or FFO, and Modified Funds from Operations, or MFFO, are additional appropriate measures of the operating performance of a REIT and of us in particular. We compute FFO in accordance with the standards established by the National Association of Real Estate Investment Trusts, or NAREIT, as net income (loss) (computed in accordance with U.S. GAAP), excluding gains (losses) from sales of depreciable property, the cumulative effect of changes in accounting principles, real estate-related depreciation and amortization, impairment on depreciable property owned directly or indirectly and after adjustments for unconsolidated ventures.
Due to certain of the unique features of publicly-registered, non-traded REITs, the Institute for Portfolio Alternatives, or IPA, an industry trade group, standardized a performance measure known as MFFO and recommends the use of MFFO for such REITs. Management believes MFFO is a useful performance measure to evaluate our business and further believes it is important to disclose MFFO in order to be consistent with the IPA recommendation and other non-traded REITs. Neither the U.S. Securities and Exchange Commission, or SEC, nor any other regulatory body has approved the acceptability of the adjustments that we use to calculate MFFO. In the future, the SEC or another regulatory body may decide to standardize permitted adjustments across the non-listed REIT industry and we may need to adjust our calculation and characterization of MFFO.
We define MFFO in accordance with the concepts established by the IPA. Our computation of MFFO may not be comparable to other REITs that do not calculate MFFO using the same method MFFO is calculated using FFO. FFO, as defined by NAREIT, is a computation made by analysts and investors to measure a real estate company’s operating performance. The IPA’s definition of MFFO excludes from FFO the following items:
•acquisition fees and expenses;



46
•non-cash amounts related to straight-line rent and the amortization of above or below market and in-place intangible lease assets and liabilities (which are adjusted in order to reflect such payments from an accrual basis of accounting under U.S. GAAP to a cash basis of accounting);
•amortization of a premium and accretion of a discount on debt investments;
•non-recurring impairment of real estate-related investments that meet the specified criteria identified in the rules and regulations of the SEC;
•realized gains (losses) from the early extinguishment of debt;
•realized gains (losses) on the extinguishment or sales of hedges, foreign exchange, securities and other derivative holdings except where the trading of such instruments is a fundamental attribute of our business;
•unrealized gains (losses) from fair value adjustments on real estate securities, including CMBS and other securities, interest rate swaps and other derivatives not deemed hedges and foreign exchange holdings;
•unrealized gains (losses) from the consolidation from, or deconsolidation to, equity accounting;
•adjustments related to contingent purchase price obligations; and
•adjustments for consolidated and unconsolidated partnerships and joint ventures calculated to reflect MFFO on the same basis as above.
We believe that MFFO is a useful non-GAAP measure for non-traded REITs. It is helpful to management and stockholders in assessing our future operating performance upon completion of our organization and offering, and acquisition and development stages. However, MFFO may not be a useful measure of our operating performance or as a comparable measure to other typical non-traded REITs if we do not continue to operate in a similar manner to other non-traded REITs, including if we determined not to pursue an exit strategy.
MFFO does have certain limitations. For instance, realized gains (losses) from acquisitions and dispositions and other adjustments listed above are not reported in MFFO, even though such realized gains (losses) and other adjustments could affect our operating performance and cash available for distribution. Any mark-to-market or fair value adjustments may be based on many factors, including current operational or individual property issues or general market or overall industry conditions. Investors should note that while impairment charges are excluded from the calculation of MFFO, investors are cautioned that due to the fact that impairments are based on estimated future undiscounted cash flow and the relatively limited term of a non-traded REIT’s anticipated operations, it could be difficult to recover any impairment charges through operational net revenues or cash flow prior to any liquidity event. In addition, MFFO is not a useful measure in evaluating net asset value, since impairment is taken into account in determining net asset value but not in determining MFFO.
Neither FFO nor MFFO is equivalent to net income (loss) or cash flow provided by operating activities determined in accordance with U.S. GAAP and should not be construed to be more relevant or accurate than the U.S. GAAP methodology in evaluating our operating performance. Neither FFO nor MFFO is necessarily indicative of cash flow available to fund our cash needs including our ability to make distributions to our stockholders. FFO and MFFO do not represent amounts available for management’s discretionary use because of needed capital replacement or expansion, debt service obligations or other commitments or uncertainties. Furthermore, neither FFO nor MFFO should be considered as an alternative to net income (loss) as an indicator of our operating performance.



47
The following table presents a reconciliation of net income (loss) attributable to common stockholders to FFO and MFFO attributable to common stockholders (dollars in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Funds from operations:
Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders$(11,218)$(29,440)$(82,925)$(35,569)
Adjustments:
Depreciation and amortization9,848 9,642 29,305 29,105 
Depreciation and amortization related to non-controlling interests(67)(71)(214)(215)
Depreciation and amortization related to unconsolidated ventures4,137 7,290 14,328 21,386 
(Gain) loss from sales of property— — (136)425 
Gain (loss) from sales of property related to non-controlling interests— — 4 (6)
(Gain) loss from sales of property related to unconsolidated ventures— (505)(7,894)(44,407)
Impairment losses of depreciable real estate— 18,500 38,694 31,502 
Impairment loss on real estate related to non-controlling interests— — (1,161)(117)
Impairment losses of depreciable real estate held by unconsolidated ventures— 38 7,682 58 
Funds from operations attributable to NorthStar Healthcare Income, Inc. common stockholders$2,700 $5,454 $(2,317)$2,162 
Modified funds from operations:
Funds from operations attributable to NorthStar Healthcare Income, Inc. common stockholders$2,700 $5,454 $(2,317)$2,162 
Adjustments:
Transaction costs358 857 455 857 
Amortization of premiums, discounts and fees on investments and borrowings1,513 983 3,507 2,927 
(Gain) loss on investments and other347 (325)4,798 (1,085)
Adjustments related to unconsolidated ventures(1)
323 (2,525)6,136 11,636 
Adjustments related to non-controlling interests(27)7 (28)11 
Impairment of real estate related investment— — 4,728 — 
Modified funds from operations attributable to NorthStar Healthcare Income, Inc. common stockholders$5,214 $4,451 $17,279 $16,508 
_______________________________________
(1)Primarily represents our proportionate share of liability extinguishment gains, loan loss reserves, transaction costs and amortization of above/below market debt adjustments, straight-line rent adjustments, impairment of goodwill, debt extinguishment losses and deferred financing costs, incurred through our investments in unconsolidated ventures.
Liquidity and Capital Resources
Our current principal liquidity needs are to fund: (i) operating expenses, including corporate general and administrative expenses; (ii) principal and interest payments on our borrowings and other commitments; and (iii) capital expenditures, including capital calls in connection with our unconsolidated joint venture investments.
Our current primary sources of liquidity include the following: (i) cash on hand; (ii) proceeds from full or partial realization of investments; (iii) cash flow generated by our investments, both from our operating activities and distributions from our unconsolidated joint ventures; and (iv) secured or unsecured financings from banks and other lenders.
As of November 9, 2023, we had approximately $98.7 million of unrestricted cash and currently believe that our capital resources are sufficient to meet our capital needs for the following 12 months.
Cash From Operations
We primarily generate cash flow from operations through net operating income from our operating properties and rental income from our net lease properties. In addition, we receive distributions from our investments in unconsolidated ventures. Net cash provided by operating activities was $13.1 million for the nine months ended September 30, 2023.
A substantial majority of our direct investments are operating properties whereby we are directly exposed to various operational risks. While our direct investments have not experienced any significant issues collecting rents or other fees from residents, cash flow has continued to be negatively impacted by rate pressures, cost inflation, rising interest rates and other economic market



48
conditions. We expect that these factors will continue to materially impact our revenues, expenses and cash flow generated by the communities of our direct investments.
We have a significant unconsolidated investment in the Trilogy Joint Venture, where we have no control over the timing of distributions, if any. The Trilogy Joint Venture has been similarly impacted as our direct investments by inflation, rising interest rates and other economic market conditions, and, as a result, does not expect to make further distributions in 2023 and may continue to limit distributions to preserve liquidity in the future.
Borrowings
We typically have financed our investments with medium to long-term, non-recourse mortgage loans, though our borrowing levels and terms vary depending upon the nature of the assets and the related financing.
During the nine months ended September 30, 2023, we paid $43.7 million in recurring principal and interest payments on borrowings. Excluding the Rochester Sub-Portfolio Loan, we had $808.5 million of consolidated asset-level borrowings outstanding as of September 30, 2023. Fixed-rate borrowings totaled $779.4 million with interest rates ranging from 3.00% to 4.66%. Excluding the Rochester Sub-Portfolio Loan, floating-rate borrowings totaled $29.1 million and are subject to fluctuating Secured Overnight Financing Rate, or SOFR. As of September 30, 2023, excluding the Rochester Sub-Portfolio Loan, effective interest rates on floating rate debt ranged from 8.11% to 8.26%.
As the impact of inflation, rising interest rates, risk of recession and other economic market conditions continue to influence our investments’ performance and market values, our ability to service or refinance our borrowings may be negatively impacted, including $586.8 million of borrowings collateralized by our Winterfell portfolio that mature in June 2025.
Our charter limits us from incurring borrowings that would exceed 300.0% of our net assets. We cannot exceed this limit unless any excess in borrowing over such level is approved by a majority of our independent directors. We would need to disclose any such approval to our stockholders in our next quarterly report along with the justification for such excess. An approximation of this leverage limitation, excluding indirect leverage held through our unconsolidated joint venture investments and any securitized mortgage obligations to third parties, is 75.0% of our assets, other than intangibles, before deducting loan loss reserves, other non-cash reserves and depreciation. As of September 30, 2023, our leverage was 55.5% of our assets, other than intangibles, before deducting non-cash reserves and depreciation. As of September 30, 2023, indirect leverage on assets, other than intangibles, before deducting non-cash reserves and depreciation, held through our unconsolidated joint ventures was 57.7%.
For additional information regarding our borrowings, including principal repayments, timing of maturities and loans currently in default, refer to Note 5, “Borrowings” in our accompanying consolidated financial statements included in Part I, Item 1. “Financial Statements.”
Capital Expenditures Activities
We are responsible for capital expenditures for our operating properties and may also fund capital expenditures for our net lease properties. We continue to invest cash from reserves and asset sales proceeds into our direct investments in order to maintain market position, functional and operating standards, increase operating income, achieve property stabilization and enhance the overall value of our assets. However, there can be no assurance that these initiatives will achieve these intended results.
The following table presents cash used for capital expenditures at our direct investments (dollars in thousands):
Nine Months Ended September 30,
202320222023 vs. 2022 Change
ALF/MCF properties$2,066 $1,993 $73 
ILF properties 26,359 15,609 10,750 
Net lease properties — 322 (322)
Total capital expenditures$28,425 $17,924 $10,501 
Realization and Disposition of Investments
We will pursue dispositions of assets and portfolios where we believe the disposition will achieve a desired return, improve our liquidity position and generate value for shareholders.
We have made significant investments through unconsolidated joint ventures with third parties, which we have limited ability to influence material decisions, including the disposition of assets. Refer to “—Market Update” and “—Business Update” for further information regarding dispositions.



49
Distributions
To continue to qualify as a REIT, we are required to distribute annually dividends equal to at least 90% of our taxable income, subject to certain adjustments, to stockholders. We have generated net operating losses for tax purposes and, accordingly, are currently not required to make distributions to our stockholders to qualify as a REIT. Refer to “—Distributions Declared and Paid” and “—Liquidity Update” for further information regarding our distributions.
Repurchases
We adopted a Share Repurchase Program effective August 7, 2012, which enabled stockholders to sell their shares to us in limited circumstances and could be amended, suspended, or terminated at any time. On April 7, 2020, our board of directors suspended all repurchases under our existing Share Repurchase Program effective April 30, 2020 in order to preserve capital and liquidity. We do not currently anticipate resuming the Share Repurchase Program. If we have sufficient capital available, at this stage in our life cycle, we believe that returning capital to stockholders through special distributions, rather than repurchases, is a better use of that capital.
Other Commitments
On October 21, 2022, we terminated the advisory agreement and completed the Internalization. Prior to the termination of the advisory agreement, we reimbursed the Former Advisor for direct and indirect operating costs in connection with services provided to us. Under our new internalized structure, we will directly incur and pay all general and administrative costs.

Cash Flows
The following presents a summary of our consolidated statements of cash flows (dollars in thousands):
Nine Months Ended September 30,
Cash flows provided by (used in):202320222023 vs. 2022 Change
Operating activities$13,066 $(13,604)$26,670 
Investing activities(14,295)24,249 (38,544)
Financing activities(15,464)(113,901)98,437 
Net increase (decrease) in cash, cash equivalents and restricted cash$(16,693)$(103,256)$86,563 
Operating Activities
Net cash provided by operating activities totaled $13.1 million for the nine months ended September 30, 2023 as compared to $13.6 million net cash used in operating activities for the nine months ended September 30, 2022. The change in cash flow from operating activities was a result of distributions received from our unconsolidated investment in the Espresso joint venture, $10.6 million of which has been classified as operating cash flows. Additionally, increases in rates and occupancy at our direct operating investments, resulted in higher rent and resident fees collected during the nine months ended September 30, 2023 and lower reimbursement payments made to our Former Advisor increased cash flow from operations.
Investing Activities
Our cash flows from investing activities are primarily proceeds from investment dispositions, net of any capital expenditures. We continue to invest capital into our operating portfolios in order to maintain market position and enhance overall asset value. Net cash used in investing activities totaled $14.3 million for the nine months ended September 30, 2023 as compared to $24.2 million net cash provided by investing activities for the nine months ended September 30, 2022. Cash flows used in investing activities for the nine months ended September 30, 2023 consisted of capital expenditures for our direct investments, partially offset by distributions received from our Espresso and Trilogy unconsolidated investments classified as investing cash flows, which totaled $8.8 million and $4.7 million, respectively. Cash flows provided by investing activities for the nine months ended September 30, 2022 consisted of distributions received from our unconsolidated investments, which totaled $42.2 million, less capital expenditures for our direct investments.
Financing Activities
Cash flows used in financing activities totaled $15.5 million for the nine months ended September 30, 2023 compared to $113.9 million for the nine months ended September 30, 2022. For the nine months ended September 30, 2023, net cash flows used in financing activities were primarily recurring principal amortization on our mortgage notes. For the nine months ended September 30, 2022, net cash flows used in financing activities were primarily attributable to the special distribution our board of



50
directors declared of $0.50 per share for each stockholder of record on May 2, 2022, or the Special Distribution, which was paid in cash on or around May 5, 2022 and totaled approximately $97.0 million. In addition, the repayment of the financing on Oak Cottage and recurring principal amortization on our mortgage notes contributed to cash flows used in financing activities.
Off-Balance Sheet Arrangements
As of September 30, 2023, we are not dependent on the use of any off-balance sheet financing arrangements for liquidity. We have made investments in unconsolidated ventures. Refer to Note 4, “Investments in Unconsolidated Ventures” in Part I, Item 1. “Financial Statements” for a discussion of such unconsolidated ventures in our consolidated financial statements. In each case, our exposure to loss is limited to the carrying value of our investment.
Distributions Declared and Paid
From inception through September 30, 2023, we declared $530.9 million in distributions, inclusive of the Special Distribution, and generated cumulative FFO of $107.0 million. From the date of our first investment on April 5, 2013 through December 31, 2017, we declared an annualized distribution amount of $0.675 per share of our common stock. From January 1, 2018 through January 31, 2019, we declared an annualized distribution amount of $0.3375 per share of our common stock. Effective February 1, 2019, our board of directors stopped recurring distributions in order to preserve capital and liquidity. On April 20, 2022, our board of directors declared the Special Distribution of $0.50 per share for each stockholder of record on May 2, 2022 totaling approximately $97.0 million. While we do not anticipate recurring dividends in the near future, in light of the cash flow generated by our investments as compared to our capital expenditure needs and debt service obligations, our management and board of directors will evaluate special distributions in connection with asset sales and other realizations of our investments on a case-by-case basis based on, among other factors, current and projected liquidity needs, opportunities for investment in our assets (such as capital expenditure and de-levering opportunities) and other strategic initiatives.
To the extent distributions are paid from sources other than FFO, the ownership interest of our public stockholders may be diluted. Future distributions declared and paid may exceed FFO and cash flow provided by operations. FFO, as defined, may not reflect actual cash available for distributions.
Related Party Arrangements
Former Advisor
In connection with the Internalization, the advisory agreement was terminated on October 21, 2022. Prior to the Internalization, the Former Advisor was responsible for managing our affairs on a day-to-day basis and for identifying, acquiring, originating and asset managing investments on our behalf. For such services, to the extent permitted by law and regulations, the Former Advisor received fees and reimbursements from us. Pursuant to the advisory agreement, the Former Advisor could defer or waive fees in its discretion.
Transition Services
In connection with the Internalization, on October 21, 2022, we, the Operating Partnership and the Former Advisor entered into a Transition Services Agreement, or TSA, to facilitate an orderly transition of the management of our operations. The TSA, as amended on March 22, 2023, provides for, among other things, the Former Advisor to provide certain services, including primarily technology and insurance, for a transition period of up to six months following the Internalization, with legal, treasury and accounts payable services to continue until we terminate these services or in other specified circumstances in accordance with the TSA. We will reimburse the Former Advisor for costs to provide the services, including the allocated cost of employee wages and compensation and actually incurred out-of-pocket expenses.
Summary of Fees and Reimbursements
The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):
Reimbursements to Former Advisor EntitiesDue to Related Party as of December 31, 2022Nine Months Ended September 30, 2023
Due to Related Party as of September 30, 2023 (Unaudited)
Financial Statement LocationIncurredPaid
   Operating costsGeneral and administrative expenses/Transaction costs$469 $520 
(1)
$(697)$292 
_____________________________________
(1)Represents costs incurred under the TSA during the nine months ended September 30, 2023.



51
Incentive Fee
The Special Unit Holder, an affiliate of the Former Advisor, was entitled to receive distributions equal to 15.0% of our net cash flows, whether from continuing operations, repayment of loans, disposition of assets or otherwise, but only after stockholders have received, in the aggregate, cumulative distributions equal to their invested capital plus a 6.75% cumulative, non-compounded annual pre-tax return on such invested capital. From inception through the Sale of Minority Interests, the Special Unit Holder did not receive any incentive fees.
In connection with the Sale of Minority Interests, as of June 9, 2023, the Special Unit Holder became an indirect subsidiary of us, though the Special Unit Holder continues to have a contractual obligation to pay any such incentive fees to affiliates of the Former Sponsor, if ever earned.
Investments in Joint Ventures
Solstice, the manager of the Winterfell portfolio, is a joint venture between affiliates of ISL, who own 80.0%, and us, who owns 20.0%. For the nine months ended September 30, 2023, we recognized property management fee expense of $5.1 million payable to Solstice related to the Winterfell portfolio.
In June 2023, we completed the Sale of Minority Interests, involving the sale of our minority interests in the Diversified US/UK Portfolio and Eclipse Portfolio, together with $1.1 million in cash, to our Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of our equity securities held by the Former Sponsor and its affiliates. Refer to “—Transaction and Financing Activities” for further discussion of the Sale of Minority Interests.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
The principal market risks affecting us are interest rate risk, inflation risk and credit risk. These risks are dependent on various factors beyond our control, including monetary and fiscal policies, domestic and international economic conditions and political considerations. Our market risk sensitive assets, liabilities and related derivative positions (if any) are held for investment and not for trading purposes.
Interest Rate Risk
Changes in interest rates may affect our net income as a result of changes in interest expense incurred in connection with floating-rate borrowings used to finance our equity investments. As of September 30, 2023, 14.2% of our total borrowings were floating-rate liabilities, which are related to mortgage notes payable of our direct operating investments.
Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings, prepayment penalties and cash flows and to lower overall borrowing costs by borrowing primarily at fixed rates. When borrowing at variable rates, we seek the lowest margins available and evaluate hedging opportunities. For our floating-rate borrowings we have entered into interest rate caps that involve the receipt of variable amounts from a counterparty if interest rates rise above the strike rate on the contract in exchange for an up-front premium.
The interest rate on our floating-rate liabilities is a fixed spread over an index such as SOFR and typically reprices every 30 days. As of September 30, 2023, a hypothetical 100 basis point increase in interest rates would not impact net annual interest expense due to the interest rate caps in place.
Inflation Risk
Many of our costs are subject to inflationary pressures. These include labor, repairs and maintenance, food costs, utilities, insurance and other operating costs. Higher rates of inflation affecting the economy may substantially affect the operating margins of our investments. While our managers have an ability to partially offset cost inflation by increasing the rates charged to residents, this ability is often limited by competitive conditions and timing may lag behind cost volatility. Therefore, there can be no assurance that cost increases can be offset by increased rates charged to residents in real time or that increased rates will not result in occupancy declines.
Credit Risk
We are subject to the credit risk of the operators of our healthcare properties. The operator of our four net lease properties failed to remit contractual monthly rent obligations and it is not probable that these obligations will be satisfied in the foreseeable future.



52
Risk Concentration
The following table presents the operators and managers of our properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):
As of September 30, 2023Nine Months Ended September 30, 2023
Operator / ManagerProperties Under Management
Units Under Management(1)
Property and Other Revenues(2)
% of Total Property and Other Revenues
Solstice Senior Living(3)
32 3,969 $94,469 61.2 %
Watermark Retirement Communities14 1,782 35,967 23.2 %
Avamere Health Services5 453 16,266 10.5 %
Integral Senior Living1 40 3,672 2.4 %
Arcadia Management(4)
4 572 1,178 0.8 %
Other(5)
— — 2,893 1.9 %
Total56 6,816 $154,445 100.0 %
_______________________________________
(1)Represents rooms for ALFs, ILFs and MCFs, based on predominant type.
(2)Includes rental income received from our net lease properties, as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from our ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.
(3)Solstice is a joint venture of which affiliates of ISL own 80%.
(4)During the nine months ended September 30, 2023, we recorded rental income to the extent payments were received.
(5)Consists primarily of interest income earned on corporate-level cash and cash equivalents.
Watermark Retirement Communities and Solstice, together with their affiliates, manage substantially all of our operating properties. As a result, we are dependent upon their personnel, expertise, technical resources and information systems, proprietary information, good faith and judgment to manage our properties efficiently and effectively. Through our 20.0% ownership of Solstice, we are entitled to certain rights and minority protections. As Solstice is a joint venture formed exclusively to operate the Winterfell portfolio, Solstice has generated, and may generate, operating losses if our Winterfell portfolio experiences declines in occupancy and operating revenues.
Item 4. Controls and Procedures
Internal Control over Financial Reporting
Changes in Internal Control over Financial Reporting.
There have not been any changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the most recent fiscal quarter that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Disclosure Controls and Procedures
Our management established and maintains disclosure controls and procedures that are designed to ensure that material information relating to us and our subsidiaries required to be disclosed in reports that are filed or submitted under the Securities Exchange Act of 1934, as amended, or Exchange Act, are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
As of the end of the period covered by this report, management conducted an evaluation as required under Rules 13a-15(b) and 15d-15(b) under the Exchange Act, under the supervision and with the participation of the Company’s Chief Executive Officer and Chief Financial Officer of the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act).
Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures are effective. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that it will detect or uncover failures to disclose material information otherwise required to be set forth in the Company’s periodic reports. Our internal control framework, which includes controls over financial reporting and disclosure, continues to operate effectively.



53
Part II—Other Information
Item 1. Legal Proceedings
We may be involved in various litigation matters arising in the ordinary course of our business. Although we are unable to predict with certainty the eventual outcome of any litigation, in the opinion of management, any current legal proceedings are not expected to have a material adverse effect on our financial position or results of operations.
Item 1A. Risk Factors
If we pay distributions from sources other than our cash flow provided by operations, we will have less cash available for investments and your overall return may be reduced.
Our organizational documents permit us to pay distributions from any source, including offering proceeds, borrowings or sales of assets or we may make distributions in the form of taxable stock dividends. We have not established a limit on the amount of proceeds we may use to fund distributions. We have funded distributions in the past in excess of our cash flow from operations and may continue to do so in the future. If we pay distributions from sources other than our cash flow provided by operations, our book value may be negatively impacted and stockholders’ overall return may be reduced. In April 2022, our board of directors declared a special distribution to stockholders, of which approximately $97.0 million was paid in cash in May 2022, using proceeds from asset sales and not cash flow provided by operations. We did not declare any distributions during the nine months ended September 30, 2023.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
We adopted a Share Repurchase Program in 2012, which enabled shareholders to sell their shares to us in limited circumstances and could be amended, suspended and terminated by our board of directors at any time in their sole discretion (subject to certain notice requirements set forth in the Share Repurchase Program). On April 7, 2020, in accordance with the terms of our Share Repurchase Program, our board of directors suspended all repurchases under the Share Repurchase Program effective April 30, 2020 in order to preserve capital and liquidity and does not currently anticipate resuming the Share Repurchase Program.
Unregistered Sales of Equity Securities
We did not issue any shares of common stock during the nine months ended September 30, 2023.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Securities Trading Plans of Directors and Executive Officers
During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408.
Determination of Estimated Value Per Share
Overview
On November 9, 2023, upon the recommendation of the Audit Committee of the Board of NorthStar Healthcare Income, Inc., the Board, including all of its independent directors, approved and established an estimated value per share of NorthStar Healthcare’s common stock of $2.64. The estimated value per share is based upon the estimated value of NorthStar Healthcare’s assets less the estimated value of NorthStar Healthcare’s liabilities as of June 30, 2023, divided by the number of shares of NorthStar Healthcare’s common stock outstanding as of June 30, 2023. The information used to generate the estimated value per share, including market information, investment- and property-level data and other information provided by third parties, was the most recent information practically available as of June 30, 2023.



54
Process
The estimated value per share was calculated with the assistance of NorthStar Healthcare’s management team and Kroll, LLC, or Kroll, an experienced third-party independent valuation and consulting firm engaged by NorthStar Healthcare to perform an appraisal and valuation of its assets and liabilities. The engagement of Kroll was approved by the Board, including all of its independent directors. Kroll has extensive experience in conducting asset valuations, including appraisals of properties similar to those owned by NorthStar Healthcare. While NorthStar Healthcare has engaged or may engage Kroll in the future for services of various kinds, NorthStar Healthcare believes that there are no material conflicts of interest with respect to its engagement of Kroll.
The Audit Committee recommended and the Board established the estimated value per share as of June 30, 2023 based upon the analyses and reports provided by Kroll and NorthStar Healthcare’s management team. In arriving at its recommendation, the Audit Committee relied in part on valuation and appraisal methodologies that Kroll and NorthStar Healthcare’s management team believe are standard and acceptable in the real estate and non-listed REIT industries for the types of assets and liabilities held by NorthStar Healthcare. The process for estimating the value of NorthStar Healthcare’s assets and liabilities was performed in accordance with the provisions of the Institute for Portfolio Alternatives Practice Guideline 2013-01, Valuations of Publicly Registered Non-Listed REITs. NorthStar Healthcare believes that the valuation was developed in a manner reasonably designed to ensure its reliability.
On November 9, 2023, Kroll delivered its report related to the valuation and appraisal of NorthStar Healthcare’s assets and liabilities as of June 30, 2023, reflecting an estimated range of values for NorthStar Healthcare’s real estate properties, or the Healthcare Properties, including 56 consolidated Healthcare Properties, 6 of which have excess land and undeveloped land parcels, collectively the Direct Investments, and interests in 121 Healthcare Properties, two ancillary businesses and related assets and liabilities held through two unconsolidated joint ventures, collectively the Unconsolidated Investments, in each case less the fair value of outstanding borrowings on the Healthcare Properties, or the Healthcare Borrowings, as well as one unconsolidated joint venture investment in a senior housing management company, or the Management Company Investment. The Direct Investments, Unconsolidated Investments and Management Company Investment are collectively referred to herein as the “Investments”.
The Board currently expects that NorthStar Healthcare’s next estimated value per share will be based upon its assets and liabilities as of June 30, 2024, and that such value will be included in a report filed with the SEC. NorthStar Healthcare intends to publish estimated values per share annually, although NorthStar Healthcare may determine to publish such revised values more frequently.
Valuation Methodology
To estimate the range of value of the Healthcare Properties, Kroll conducted an appraisal for the Healthcare Properties performed in accordance with the Uniform Standards of Professional Appraisal Practice of the Appraisal Foundation and with an effective valuation date of June 30, 2023. Kroll’s appraisals were certified by an appraiser licensed in the state in which the Healthcare Properties were located. In determining the value of each Healthcare Property, Kroll utilized all information that they deemed relevant, including information from NorthStar Healthcare’s management team, and its own data sources, including trends in capitalization rates, leasing rates and other economic factors. In conducting its appraisals of the Healthcare Properties, other than for the undeveloped land parcels and any excess land associated with the Healthcare Properties, Kroll utilized both the direct capitalization approach and discounted cash flow, or the DCF, approach to value Healthcare Properties.
In the direct capitalization approach, a market capitalization rate is applied to the estimated forward-year annual stabilized net operating income. In the DCF approach, a market terminal capitalization and discount rate are utilized to derive a value indication from the estimated forward multi-year annual net operating income. Kroll placed primary emphasis on the direct capitalization approach for the Healthcare Properties with stable and long-term income streams. The DCF was completed as a secondary, confirmatory approach. Kroll placed primary emphasis on the DCF approach for the Healthcare Properties that are not stabilized. Kroll believes the two methodologies are the most appropriate for valuing assets similar to those owned by NorthStar Healthcare. In selecting each capitalization rate range for the direct capitalization or DCF approach, Kroll took into account, among other factors, prevailing capitalization rates in the healthcare property sector, the property’s location, age and condition, the property’s operating trends and lease coverage ratios, if applicable, and other unique property factors. As applicable, Kroll adjusted the capitalized value range of each investment it appraised for any excess land, deferred maintenance or other anticipated property capital expenditures, lease-up costs and other adjustments as appropriate to estimate the “as-is” value range of each of the Healthcare Properties it appraised. For the Healthcare Properties with excess land and undeveloped land parcels, Kroll valued the land by utilizing a comparable sales analysis, where land sales or listings in the market were analyzed and a market-based value indication per square foot or acre was derived and applied to the land parcel to determine the parcel’s estimated market value.



55
After establishing an estimated value range for each Healthcare Property, Kroll then added or subtracted, as appropriate, the estimated fair value of Healthcare Borrowings after factoring in any adjustments for above- or below-market in-place financing, as deemed applicable. Kroll estimated the fair value range of the long-term liabilities by discounting the stream of expected interest and principal payments for each liability by an interest rate range that Kroll estimated a current market participant would require for instruments with similar collateral and duration assuming an orderly market environment, taking into account factors such as remaining loan term, loan-to-value ratio, collateral type, debt service coverage, security position and other factors deemed relevant. In the aggregate, the estimated market adjustment to our proportionate share of the outstanding principal balance of the Healthcare Borrowings totaled $96.9 million, which reduced the liabilities to fair value.
For both the Direct Investments where there is a minority joint venture partner and the Unconsolidated Investments, Kroll adjusted the values of the Healthcare Properties, net of Healthcare Borrowings, and any other balance sheet assets and liabilities, for NorthStar Healthcare’s allocable ownership interest.
The Management Company Investment is a property management venture that as of June 30, 2023 manages solely NorthStar Healthcare’s 32-property independent living portfolio, or the Winterfell Portfolio. To estimate the value of the Management Company Investment, Kroll reviewed the joint venture agreement, historical revenues and earnings before interest, taxes, depreciation and amortization, or EBITDA, for the Management Company Investment, historical and budgeted property operating revenues for the Winterfell Portfolio, the estimated property revenue utilized in the appraisal for the Winterfell Portfolio, and revenue and EBITDA valuation metrics associated with real estate management companies. Based on the above, Kroll determined an appropriate range of revenue and EBITDA multiples for the Management Company Investment to determine a value range for the Management Company Investment. Kroll then applied the terms of the joint venture agreement, including any distribution priorities, to its Management Company Investment value estimate to establish the value range of NorthStar Healthcare’s interest in the Management Company Investment. In addition, Kroll utilized a similar valuation approach to establish an estimated range of value for the Unconsolidated Ventures’ ancillary businesses.
The following summarizes the key assumptions that were used in the DCF, direct capitalization, and Revenue and EBITDA valuation multiple analyses to arrive at the value of the Direct Investments, Unconsolidated Investments and Management Company Investment:
Range
Weighted Average(1)
MinimumMaximum
Healthcare Properties
Discount Rate7.50 %12.25 %8.95 %
Terminal Capitalization Rate6.25 %11.00 %7.51 %
Direct Capitalization Rate6.00 %10.75 %7.26 %
Property Management & Ancillary Businesses
Revenue Valuation Multiple1.10x1.30x1.20x
Healthcare Borrowings
Discount Rate3.04 %8.17 %5.89 %
_______________________________________
(1)Weighted averages are calculated using the applicable ownership percentage for each Healthcare Property and Healthcare Borrowing. Healthcare Properties’ property types for Direct Investments include independent living, assisted living & memory care facilities. In addition to the same property types owned by the Direct Investments, the Unconsolidated Investments also own skilled nursing facilities, which have been ascribed higher capitalization and discount rates relative to the other property types.
The fair value of NorthStar Healthcare’s cash, other tangible assets and liabilities was estimated by NorthStar Healthcare’s management team to approximate carrying value as of June 30, 2023 and Kroll relied upon and utilized such amounts in its determination of the estimated value range per share.
Estimated Value Per Share
Based on the above valuations and estimates and subject to the assumptions and limiting conditions contained in its report, Kroll estimated the net asset value range per fully diluted common share outstanding of NorthStar Healthcare as of June 30, 2023 from $2.30 to $2.98 per share. Based on its review of the Kroll report and the analysis of NorthStar Healthcare’s management team, the Audit Committee recommended and the Board approved an estimated value per share of $2.64 as of June 30, 2023.
The table below illustrates a breakdown of NorthStar Healthcare’s estimated value per share as of June 30, 2023 ($ in thousands, except per share values):



56
Estimated ValueEstimated Value Per Share
Healthcare Properties, net Healthcare Borrowings, at ownership share$387,184 $2.08 
Cash and other tangible assets124,711 0.67 
Other liabilities(21,993)(0.12)
Estimated net asset value as of June 30, 2023$489,902 $2.64 
Estimated enterprise value per shareNone assumed
Shares outstanding (in thousands)185,712 
As previously described, the estimated value per share recommended by the Audit Committee and approved by the Board does not reflect NorthStar Healthcare’s “enterprise value,” which may be affected by:
•the characteristics of NorthStar Healthcare’s working capital, leverage and other financial structures where some buyers may ascribe different values;
•investments through joint ventures, where NorthStar Healthcare owns a non-controlling interest and may have limited decision making authority, as some buyers may pay less for these types of investments;
•disposition and other expenses that would be necessary to realize the value;
•NorthStar Healthcare’s general and administrative expenses, including the costs to retain its management team; and
•the potential difference in per share value if NorthStar Healthcare were to list its shares of common stock on a national securities exchange.
On November 9, 2023, Kroll delivered its valuation report to the Audit Committee. The Audit Committee was given an opportunity to confer with Kroll and NorthStar Healthcare’s management team regarding the methodologies and assumptions used therein, and determined to recommend to the Board the estimated value per share of NorthStar Healthcare’s common stock.
The Board is ultimately and solely responsible for the establishment of the estimated value per share of NorthStar Healthcare’s common stock. In arriving at its determination of the estimated value per share, the Board considered all information provided in light of its own familiarity with NorthStar Healthcare’s assets and unanimously approved the estimated value recommended by the Audit Committee.
Sensitivity Analysis
Changes to the key assumptions used to arrive at the estimated value per share, including the capitalization rates and discount rates used to value the Healthcare Properties and Healthcare Borrowings, would have a significant impact on the underlying value of NorthStar Healthcare’s assets. The following table presents the impact on the estimated value per share of NorthStar Healthcare’s common stock resulting from a 5.0% increase and decrease to both (1) the capitalization and discount rates used to value the Healthcare Properties and (2) the discount rates used to value the Healthcare Borrowings:
Sensitized Range of Value
LowEstimated ValueHigh
Estimated Net Asset Value Per Share$2.09$2.64$3.02
Healthcare Properties:
Weighted Average Capitalization Rate7.62%7.26%6.90%
Weighted Average Discount Rate9.34%8.95%8.47%
Healthcare Borrowings:
Weighted Average Discount Rate5.60%5.89%6.19%
The above sensitivity analysis differs from the methodology employed by Kroll to generate the range of estimated per share values in its report. The sensitivity analysis above assumes a 5.0% increase and decrease to the underlying valuation assumptions, which generally differs from the adjustments to the valuation assumptions employed by Kroll in its valuation report.
Limitations and Risks
As with any valuation methodology, the methodologies used to determine the estimated value per share are based upon a number of estimates and assumptions that may prove later to be inaccurate or incomplete. Further, different market participants using different assumptions and estimates could derive different estimated values.
Although the Board relied on estimated value ranges of NorthStar Healthcare’s assets and liabilities in establishing the estimated value per share, the estimated value per share may bear no relationship to NorthStar Healthcare’s book or asset value. In



57
addition, the estimated value per share may not represent the price at which the shares of NorthStar Healthcare’s common stock would trade on a national securities exchange, the amount realized in a sale, merger or liquidation of NorthStar Healthcare or the amount a stockholder would realize in a private sale of shares.
The estimated value of NorthStar Healthcare’s assets and liabilities is as of a specific date and such value is expected to fluctuate over time in response to future events, including but not limited to, the lasting effects of the COVID-19 pandemic, inflationary pressures on operating expenses, changes to commercial real estate values, particularly healthcare-related commercial real estate, developments related to individual assets, changes in market interest rates for commercial real estate debt and its impact on transaction executions, including, in particular, the current interest rate environment, changes in capitalization rates, rental and growth rates, changes in laws or regulations impacting the healthcare industry, demographic changes, returns on competing investments, changes in administrative expenses and other costs, the amount of distributions on NorthStar Healthcare’s common stock, repurchases of NorthStar Healthcare’s common stock, changes in the number of shares of NorthStar Healthcare’s common stock outstanding, local and national economic factors and the factors specified in Part I, Item 1A. of NorthStar Healthcare’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and Part II, Item IA. of NorthStar Healthcare's Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 under the heading "Risk Factors". There is no assurance that the methodologies used to establish the estimated value per share would be acceptable to the Financial Industry Regulatory Authority, Inc. or in compliance with guidelines pursuant to the Employee Retirement Income Security Act of 1974 with respect to their reporting requirements.



58
EXHIBIT INDEX
Exhibit
Number		Description of Exhibit
3.1
3.2
3.3
4.1
10.1
31.1*
31.2**
32.1**
32.2*
101.INS*XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
    
______________________________________________________
*    Filed herewith
**    Furnished herewith
^ Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
^^ Certain schedules and similar attachments have been omitted in reliance on Item 601(a)(5) of Regulation S-K. The Company will provide, on a supplemental basis, a copy of any omitted schedule or attachment to the SEC or its staff upon request.




59
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 

NorthStar Healthcare Income, Inc.
 
Date:
November 13, 2023
By:/s/ KENDALL K. YOUNG
Name:
Kendall K. Young
Title:Chief Executive Officer, President and Director
By:/s/ NICHOLAS R. BALZO
Name:Nicholas R. Balzo
Title:Chief Financial Officer and Treasurer






60
 EX-31.1 2 nshi09302023exhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
17 CFR 240.13a-14(a)/15(d)-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kendall K. Young, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of NorthStar Healthcare Income, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 By: /s/ KENDALL K. YOUNG 
  Name:Kendall K. Young 
  Title:Chief Executive Officer, President and Director 
  Date:November 13, 2023 

 EX-31.2 3 nshi09302023exhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO
17 CFR 240.13a-14(a)/15(d)-14(a),
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Nicholas R. Balzo, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of NorthStar Healthcare Income, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

     
 By:/s/ NICHOLAS R. BALZO 
  Name:Nicholas R. Balzo 
  Title:  Chief Financial Officer and Treasurer 
  Date:November 13, 2023 

 EX-32.1 4 nshi09302023exhibit321.htm EX-32.1 Document

Exhibit 32.1
 
CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of NorthStar Healthcare Income, Inc. (the “Company”) for the three months ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Kendall K. Young, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By: /s/ KENDALL K. YOUNG
Kendall K. Young
Chief Executive Officer, President and Director
Date: November 13, 2023
This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
 
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-32.2 5 nshi09302023exhibit322.htm EX-32.2 Document

Exhibit 32.2
 
CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of NorthStar Healthcare Income, Inc. (the “Company”) for the three months ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Nicholas R. Balzo, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
By: /s/ NICHOLAS R. BALZO
Nicholas R. Balzo
Chief Financial Officer and Treasurer
Date:November 13, 2023

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
 
A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 6 nshi-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business and Organization link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Operating Real Estate link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Investments in Unconsolidated Ventures link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Borrowings link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Related Party Arrangements link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Non-controlling Interests link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Fair Value link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Operating Real Estate (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Investments in Unconsolidated Ventures (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Borrowings (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Related Party Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Fair Value (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Operating Real Estate - Identifiable Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Operating Real Estate - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Investments in Unconsolidated Ventures - Changes in Carrying Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Investments in Unconsolidated Ventures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Borrowings - Schedule of Borrowings (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Borrowings - Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Related Party Arrangements - Transition Services (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Related Party Arrangements - Summary of Fees and Reimbursements (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Related Party Arrangements - Incentive Fee (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Related Party Arrangements - Investments in Joint Ventures (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Equity-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Stockholders' Equity - Distributions (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stockholders' Equity - Retirement of Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Non-controlling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Fair Value - Nonrecurring Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Fair Value - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Segment Reporting - Segment Statement of Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Segment Reporting - Schedule of Properties (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Subsequent Events - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 nshi-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 nshi-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 nshi-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities [Axis] Consolidated Entities [Axis] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Net (income) loss attributable to non-controlling interests Net income (loss) attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Deferred Costs Deferred Charges, Policy [Policy Text Block] Pay vs Performance Disclosure [Line Items] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Impaired Long-Lived Assets Held and Used, Asset Name [Domain] Statistical Measurement [Domain] Statistical Measurement [Domain] Operating Direct Investments - Operating [Member] Direct Investments - Operating Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Unvested shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Borrowings Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] March 31, 2024 March 31, 2024 [Member] March 31, 2024 Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Related Party Transition Services Agreement Related Party Transition Services Agreement [Member] Related Party Transition Services Agreement Investments in Unconsolidated Ventures Equity Method Investments and Joint Ventures [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Restatement Determination Date: Restatement Determination Date [Axis] Units Under Management Number of Units in Real Estate Property Investment, Name [Axis] Investment, Name [Axis] Commitments and contingencies (Note 12) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Construction in progress Construction in Progress, Gross Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Equity Equity [Text Block] Termination Scenario [Axis] Termination Scenario [Axis] Termination Scenario Limited partnership interest in operating partnership Ownership interest in operating partnership Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Subtotal Real Estate Investment Property, at Cost Acquisition Fees and Expenses Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block] Ownership [Axis] Ownership [Axis] Independent Directors Director [Member] Lessee Accounting Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Qualifying IPO Has Occurred Qualifying IPO of $200 Million Has Occurred [Member] Qualifying IPO of $200 Million Has Occurred Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and December 31, 2022 Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Distributions paid on common stock Payments of Ordinary Dividends, Common Stock Related party transaction, term of agreement Related Party Transaction, Term Of Agreement Related Party Transaction, Term Of Agreement Net income (loss) per share of common stock, diluted (in dollars per share) Earnings Per Share, Diluted PEO Total Compensation Amount PEO Total Compensation Amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Land Land Foreign Currency Foreign Currency [Abstract] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Proceeds from divestiture of equity method investment, supplemental cash payment, maximum Proceeds From Divestiture Of Equity Method Investment, Supplemental Cash Payment Proceeds From Divestiture Of Equity Method Investment, Supplemental Cash Payment Building and Building Improvements Building and Building Improvements [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Net Income (Loss) Net Income (Loss) Special Unit Holder Special Units Holder [Member] Represents information pertaining to the enitity which is the holder of a separate class of non-controlling interests in the registrant. Proceeds from divestiture of equity method investment, supplemental cash payment Proceeds From Divestiture Of Equity Method Investment, Supplemental Daily Cash Payment Proceeds From Divestiture Of Equity Method Investment, Supplemental Daily Cash Payment Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Paid Operating Costs Paid [Member] Operating Costs Paid 2025 Finance Lease, Liability, to be Paid, Year Two Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Frisco, TX Frisco, TX [Member] Frisco [Member] Reconciliation of Cash, Cash Equivalents and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Number of triple net lease portfolios Number of Triple Net Lease Portfolios Number of Triple Net Lease Portfolios Amortization of below market debt Amortization of Debt Discount (Premium) Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Facility Facility [Member] Facility NorthStar Healthcare Income, Inc. Stockholders’ Equity Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Advisor Advisor of the Registrant [Member] Represents information pertaining to the advisor (external manager) of the registrant. Receivables Increase (Decrease) in Receivables Property operating expenses Property operating expenses Cost of Goods and Services Sold Related party transaction, amounts of transaction Related Party Transaction, Amounts of Transaction Executive Category: Executive Category [Axis] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Former Sponsor and Affiliates Former Sponsor and Affiliates [Member] Former Sponsor and Affiliates Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Impaired Long-Lived Assets Held and Used by Type [Axis] Impaired Long-Lived Assets Held and Used by Type [Axis] Schedule of Operating Real Estate Estimated Useful Life Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Credit Losses on Receivables Credit Loss, Financial Instrument [Policy Text Block] Investment Type [Axis] Investment Type [Axis] Eclipse Eclipse Joint Venture [Member] Eclipse Joint Venture [Member] 2025 Long-Term Debt, Maturity, Year Two Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Forecast Forecast [Member] October 1 through December 31, 2023 Long-Term Debt, Maturity, Remainder of Fiscal Year Distributions declared per share of common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Measurement Frequency [Axis] Measurement Frequency [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Amortization expense for in-place leases and deferred costs Amortization of Deferred Costs and Intangible Assets Amortization of Deferred Costs and Intangible Assets Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Disposal group, not discontinued operation, termination fee Disposal Group, Including Discontinued Operation, Termination Fee Disposal Group, Including Discontinued Operation, Termination Fee Financial assets: Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Summary of Borrowings Schedule of Long-Term Debt Instruments [Table Text Block] Schedule of Real Estate Properties [Table] Schedule of Real Estate Properties [Table] Net Lease Direct Investments - Net Lease [Member] Direct Investments - Net Lease Equity Method Investments Equity Method Investments [Table Text Block] Mortgages Mortgage notes payable, net Mortgages [Member] Cash, Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Policy [Policy Text Block] December 31, 2024 December 31, 2024 [Member] December 31, 2024 Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Total property and other revenues Revenues Incentive Fee Incentive Fees [Member] Incentive Fees [Member] Property and other revenues Operating Income (Loss) [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Fair Value Notes Payable, Fair Value Disclosure Transaction costs Transaction costs Business Combination, Acquisition Related Costs Award Type [Axis] Award Type [Axis] Number of shares granted to independent directors (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Interest expense Interest expense Interest Expense Unrecognized equity-based compensation Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Accrued capital expenditures Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Derivative Derivative [Abstract] Trading Arrangement: Trading Arrangement [Axis] Related Party Arrangements Related Party Transactions Disclosure [Text Block] Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Property and other revenues Rental and Resident Fee Income Rental and Resident Fee Income Incentive fee distributions, minimum non-compounded annual pre-tax return on invested capital Incentive Fee, Non-Compounded Annual Pre-tax Return on Invested Capital, Minimum Incentive Fee, Non-Compounded Annual Pre-tax Return on Invested Capital, Minimum General and administrative expenses/ Transaction costs General And Administrative Expenses And Transaction Costs [Member] General And Administrative Expenses And Transaction Costs Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Schedule of Operating Real Estate Schedule of Real Estate Investments [Table Text Block] Schedule of Real Estate Investments [Table Text Block] Entity File Number Entity File Number Discount rate Measurement Input, Discount Rate [Member] Terminated Prior To September 30, 2025 Terminated Prior To September 30, 2025 [Member] Terminated Prior To September 30, 2025 2026 Long-Term Debt, Maturity, Year Three Voting Interest Entities Voting Interest Entity [Policy Text Block] Disclosure of accounting policy for voting interest entities. Real Estate [Abstract] Real Estate [Abstract] Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Intangible assets, net Finite-Lived Intangible Assets, Net Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Other liabilities Increase (Decrease) in Other Operating Liabilities Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash Distribution Proceeds From Equity Method Investment, Distribution, Operating And Investing Activities Proceeds From Equity Method Investment, Distribution, Operating And Investing Activities Cash, cash equivalents and restricted cash-beginning of period Cash, cash equivalents and restricted cash-end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Less: Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Asset Class [Axis] Asset Class [Axis] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities Non-Recourse Nonrecourse [Member] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Common stock, shares issued (in shares) Beginning Balance (in shares) Ending Balance (in shares) Common Stock, Shares, Issued Operating Real Estate Real Estate Owned [Policy Text Block] Disclosure of accounting policy related to real estate owned. Carrying Value Total Long-Term Debt 2027 Long-Term Debt, Maturity, Year Four Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Employee Stock Option Employee Stock Option [Member] Northstar Healthcare Income Operating Partnership, LP Northstar Healthcare Income Operating Partnership, LP [Member] Northstar Healthcare Income Operating Partnership, LP [Member] Non-controlling Interests Noncontrolling Interest Disclosure [Text Block] Total expenses Costs and Expenses Maximum Maximum [Member] Comprehensive income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Schedule of the Fees and Reimbursements Incurred to the Advisor and Dealer Manager Schedule of Related Party Transactions [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Financial liabilities Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract] 2026 Finance Lease, Liability, to be Paid, Year Three Subsequent Event [Table] Subsequent Event [Table] Avamere Health Services Avamere Health Services [Member] Avamere Health Services [Member] Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Noncontrolling interest, ownership percentage by parent (as a percentage) Subsidiary, Ownership Percentage, Parent Equity method investment, realized gain on disposal Equity Method Investment, Realized Gain (Loss) on Disposal Basis of Accounting Basis of Accounting, Policy [Policy Text Block] 2024 Finance Lease, Liability, to be Paid, Year One Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Subsequent event Subsequent Event [Member] Share-based payment of advisor asset management fees Stock Redeemed or Called During Period, Value, Payment of Advisor Asset Management Fees Stock Redeemed or Called During Period, Value, Payment of Advisor Asset Management Fees Equity method investment, fair value Equity Method Investments, Fair Value Disclosure Operating loss carryforwards Operating Loss Carryforwards Customer Concentration Risk Customer Concentration Risk [Member] Real Estate [Table] Real Estate [Table] Schedule of Intangible Assets, Net Schedule of Finite-Lived Intangible Assets [Table Text Block] Variable Rate [Axis] Variable Rate [Axis] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Resident fee income Revenue from Contract with Customer, Including Assessed Tax Number of shares issued (in shares) Stock Issued During Period, Shares, New Issues Expenses Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Related Party [Domain] Related Party, Type [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Operating Segments Operating Segments [Member] Real Estate [Line Items] Real Estate [Line Items] Income Taxes Income Tax Disclosure [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Distributions to non-controlling interests Payments to Noncontrolling Interests Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Less: Accumulated depreciation Real Estate Investment Property, Accumulated Depreciation Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) Carrying value Investment in Espresso joint venture Equity Method Investments Thereafter Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, After Year Four Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, After Year Four Statistical Measurement [Axis] Statistical Measurement [Axis] Operating Real Estate Real Estate Disclosure [Text Block] Financial Statement Location [Axis] Financial Statement Location [Axis] Information by location in the financial statement. Non-controlling interest investment in operating partnership Proceeds from (Payments to) Noncontrolling Interests Non-controlling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Impairment Losses Impairment of Real Estate Total Shareholder Return Amount Total Shareholder Return Amount Acquisition and retirement of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Identified Intangibles Goodwill and Intangible Assets, Policy [Policy Text Block] Share-based payment of advisor assets management fees (in shares) Stock Redeemed or Called During Period, Shares, Payment of Advisor Asset Management Fees Stock Redeemed or Called During Period, Shares, Payment of Advisor Asset Management Fees Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Total Company’s Stockholders’ Equity Parent [Member] Segments [Domain] Segments [Domain] Number of senior care homes owned Number Of Senior Care Homes Owned Number Of Senior Care Homes Owned Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Equity-based compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Consolidation Items [Domain] Consolidation Items [Domain] Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name 2025 Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Two Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Two Arbors Portfolio Arbors Portfolio [Member] Arbors Portfolio [Member] Capital expenditures for operating real estate Payments to Improve Real Estate Payments to Improve Real Estate Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Frisco, TX Non-recourse, February 2026 Frisco, TX Non-recourse, February 2026 [Member] Frisco, TX Non-recourse [Member] Exchange of ownership interests in unconsolidated ventures for common stock Noncash or Part Noncash Divestiture, Amount of Consideration Received Property and Other Revenues Noninterest Income Related Party Transaction, Due to Related Parties [Roll Forward] Related Party Transaction, Due to Related Parties [Roll Forward] Related Party Transaction, Due to Related Parties [Roll Forward] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Impairment on Operating Real Estate and Investments in Unconsolidated Ventures Loans and Leases Receivable Allowance for Loan Losses and Impairment on Investments [Policy Text Block] Disclosure of accounting policy for credit losses and impairment on investments. Derivative Instruments Derivatives, Policy [Policy Text Block] Total minimum lease payments Finance Lease, Liability, to be Paid Integral Senior Living Integral [Member] Integral [Member] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Disposal Group Name [Domain] Disposal Group Name [Domain] Distributions declared Dividends PEO PEO [Member] Mortgage notes payable, net Carrying Value Notes Payable Payments for divestiture of interest in joint venture Payments For Divestiture Of Interest In Joint Venture Payments For Divestiture Of Interest In Joint Venture Thereafter Finance Lease, Liability, To Be Paid, after Year Four Finance Lease, Liability, To Be Paid, after Year Four Escrow deposits payable Advance Payments by Borrowers for Taxes and Insurance Asset Class [Domain] Asset Class [Domain] Payments of finance lease obligations Finance Lease, Payments Finance Lease, Payments Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share 2024 Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year One Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year One Sale of Stock [Axis] Sale of Stock [Axis] Finance Lease Liability Finance Lease, Liability [Abstract] Class of Stock [Domain] Class of Stock [Domain] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Disposal group, not discontinued operation, discount on purchase consideration paid in cash Disposal Group, Including Discontinued Operation, Discount On Purchase Consideration Paid In Cash Disposal Group, Including Discontinued Operation, Discount On Purchase Consideration Paid In Cash Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders Net Income (Loss) Available to Common Stockholders, Basic Debt Instrument [Axis] Debt Instrument [Axis] Disposal Closing Date [Domain] Disposal Closing Date [Domain] Disposal Closing Date [Domain] Name of Property [Domain] Name of Property [Domain] Retirement of common stock (Note 8) Stock Repurchased and Retired During Period, Value Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Measurement Input Type [Domain] Measurement Input Type [Domain] October 1 through December 31, 2023 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Impairment on Operating Real Estate and Investments in Unconsolidated Ventures Real Estate Investments, Net [Abstract] Buildings and improvements Investment Building and Building Improvements Schedule of Principal on Borrowings based on Final Maturity Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Consideration received Disposal Group, Including Discontinued Operation, Consideration Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] October 1 through December 31, 2023 Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Title of Individual [Axis] Title of Individual [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Related Party Transaction [Domain] Related Party Transaction [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Terminated Prior To March 31, 2025 Terminated Prior To March 31, 2025 [Member] Terminated Prior To March 31, 2025 Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.01 par value, 400,000,000 shares authorized, 185,712,103 and 195,421,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued General and administrative expenses General and administrative expenses General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Proceeds from rents received Proceeds from Rents Received Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Payments under finance leases Finance Lease, Principal Payments Issuance of common stock as payment for asset management fees Issuance of Stock and Warrants for Services or Claims Schedule of Future Minimum Lease Payments for Capital Leases Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Impairment loss Impairment loss Asset Impairment Charges Receivables, net Accounts Receivable, after Allowance for Credit Loss Restricted cash Restricted cash Restricted Cash All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Interest Rate Cap Interest Rate Cap [Member] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Due to related party Other liabilities Due to related party, beginning balance Due to related party, ending balance Other Liabilities Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Shares repurchased during period (in shares) Stock Repurchased During Period, Shares Winterfell Portfolio Winterfell Portfolio [Member] Winterfell Portfolio [Member] PEO Name PEO Name % of Total Property and Other Revenues Concentration Risk, Percentage Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Rochester, NY Non-recourse, July 2023 Rochester, NY Non-recourse, July 2023 [Member] Rochester, NY Non-recourse, August 2027 [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Tenant improvements Tenant Improvements Building Building [Member] Rochester Portfolio Rochester Portfolio [Member] Rochester Portfolio Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Trilogy The Trilogy Joint Venture [Member] The Trilogy Joint Venture [Member] 2027 Finance Lease, Liability, to be Paid, Year Four Espresso Joint Venture Espresso Espresso Joint Venture [Member] Espresso Joint Venture [Member] Rochester NY Nonrecourse August 2024 Rochester NY Nonrecourse August 2024 [Member] Rochester NY Nonrecourse August 2024 Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock [Axis] Class of Stock [Axis] One-Month LIBOR Floating Rate Debt, One-Month LIBOR [Member] Floating Rate Debt, One-Month LIBOR [Member] Accumulated impairment Real Estate Owned, Valuation Allowance, Component Investments in Unconsolidated Ventures Equity Method Investments and Joint Ventures Disclosure [Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Nonrecurring Fair Value, Nonrecurring [Member] Corporate Corporate, Non-Segment [Member] Watermark Retirement Communities Watermark Retirement Communities [Member] Watermark Retirement Communities [Member] Business and Organization Nature of Operations [Text Block] Depreciation and amortization Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Common unit, outstanding (in shares) Common Unit, Outstanding Disposal Closing Date [Axis] Disposal Closing Date [Axis] Disposal Closing Date Furniture, fixtures and equipment Furniture and Fixtures [Member] Fixed interest rate Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total NorthStar Healthcare Income, Inc. stockholders’ equity Equity, Attributable to Parent Consolidation Items [Axis] Consolidation Items [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Restricted stock Restricted Stock [Member] Schedule Of Share-Based Compensation Arrangements By Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments related to investment in unconsolidated venture Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] 2027 Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Four Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Four Tangible asset impairment charges Tangible Asset Impairment Charges Capitalized acquisition costs Equity Method Investments, Capitalized Acquisition Costs Equity Method Investments, Capitalized Acquisition Costs Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Disposal Group Classification [Domain] Disposal Group Classification [Domain] Deferred tax asset Deferred Tax Assets, Gross Increase (Decrease) in Stockholder's Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Number of debt instruments Debt Instrument, Number of Instruments Defaulted Debt Instrument, Number of Instruments Defaulted Document Fiscal Period Focus Document Fiscal Period Focus Restricted common shares grant vesting period Share Based Compensation Arrangements by Share Based Payment Award, Period of Cumulative Performance Goals Considered under Plan Represents the period established by the Committee for achieving cumulative performance hurdles or target stock prices under the incentive compensation plan. Special distribution (dollars per share) Dividends Payable, Amount Per Share Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Amortization of equity-based compensation Share-Based Payment Arrangement, Noncash Expense Selling commissions or dealer manager fees paid Sales Commissions and Fees Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Terminal capitalization rate Terminal Capitalization Rate [Member] Terminal Capitalization Rate [Member] Investments in unconsolidated ventures Corporate Joint Venture [Member] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] Discounted cash flow method Valuation Technique, Discounted Cash Flow [Member] Ownership interest (as a percentage) Ownership interest (as a percentage) Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Total equity Beginning Balance Ending Balance Equity, Including Portion Attributable to Noncontrolling Interest Non-controlling interests - distributions Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Diversified US/UK and Eclipse Diversified US/UK and Eclipse [Member] Diversified US/UK and Eclipse Equity-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Dividend Reinvestment Plan Dividend Reinvestment Plan [Member] Dividend Reinvestment Plan [Member] Minimum Minimum [Member] Operating real estate, net Real Estate Investments, Net Land improvements Land Improvements [Member] Distributions from unconsolidated ventures Proceeds from Equity Method Investment, Distribution Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Properties Under Management Number of Real Estate Properties Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Disposal Group Classification [Axis] Disposal Group Classification [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] In-place lease value Leases, Acquired-in-Place [Member] Mortgages and other notes payable Mortgages And Other Notes Payable [Member] Mortgages And Other Notes Payable Nonrelated Party Nonrelated Party [Member] Other revenue Other Operating Income Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Liabilities Liabilities [Abstract] Net income (loss) Net income (loss) Net income (loss) Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Sales of other assets Payments for (Proceeds from) Other Investing Activities Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and equity Liabilities and Equity Number of facilities impaired Number Of Facilities Impaired Number Of Facilities Impaired Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Net income (loss) per share of common stock, basic (in dollars per share) Earnings Per Share, Basic Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Land Parcel Land Parcel [Member] Land Parcel Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Incentive fee distributions, percent of net cash flows Incentive Fee, Percentage Incentive Fee, Percentage Reconciliation of Cash, Cash Equivalents and Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Summary of Segment Reporting Schedule of Segment Reporting Information, by Segment [Table Text Block] Related Party Related Party [Member] Real Estate Investment Real Estate Investment [Member] Asset management fees - related party Asset management fees - related party Costs and Expenses, Related Party Cash paid for income taxes Income Taxes Paid Principles of Consolidation Consolidation, Policy [Policy Text Block] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Operating real estate, net Real Estate Investment Property, Net Termination Date Trading Arrangement Termination Date Furniture, fixtures and equipment Furniture and Fixtures, Gross Common stock, shares authorized (in shares) Common Stock, Shares Authorized Termination Scenario [Domain] Termination Scenario [Domain] Termination Scenario [Domain] Contributions from non-controlling interests Proceeds from Noncontrolling Interests Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity method investee, cash consideration Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions Land improvements Land Improvements Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Principal Amount Long-Term Debt, Gross Terminated Prior To Initial Outside Date Terminated Prior To Initial Outside Date [Member] Terminated Prior To Initial Outside Date Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Operating real estate, net Operating Real Estate, Net [Member] Operating Real Estate, Net [Member] Title of Individual [Domain] Title of Individual [Domain] Milford, OH Milford, OH [Member] Milford, OH Compensation Amount Outstanding Recovery Compensation Amount Dividends payable Dividends Payable Summary of Assets by Segment Reconciliation of Assets from Segment to Consolidated [Table Text Block] Comprehensive (income) loss attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Gain (loss) on investments and other (Gain) loss on investments and other Gain (Loss) on Investments Change in allowance for uncollectible accounts Accounts Receivable, Credit Loss Expense (Reversal) Derivative asset Derivative asset - interest rate caps Derivative Asset Subsequent Event Type [Axis] Subsequent Event Type [Axis] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Investments in unconsolidated ventures Real Estate Investments, Unconsolidated Real Estate and Other Joint Ventures Financing Receivable, after Allowance for Credit Loss Financing Receivable, after Allowance for Credit Loss [Abstract] Variable Interest Entities Variable Interest Entity, Measure of Activity [Abstract] Other Other Properties [Member] Other Properties Milford, OH Non-recourse, September 2026 Milford, OH Non-recourse, September 2026 [Member] Milford, OH Non-recourse [Member] Present value of minimum lease payments Finance Lease, Liability Income Taxes Income Tax, Policy [Policy Text Block] Investments in Unconsolidated Ventures Equity Method Investments [Policy Text Block] Insider Trading Arrangements [Line Items] Allowance for credit losses on receivables Accounts Receivable, Allowance for Credit Loss Schedule of Real Estate Properties Schedule of Real Estate Properties [Table Text Block] Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Distributions from unconsolidated ventures Proceeds from Equity Method Investment, Distribution, Return of Capital Avamere Portfolio Avamere Portfolio [Member] Avamere Portfolio [Member] 2024 Long-Term Debt, Maturity, Year One Related Party [Axis] Related Party, Type [Axis] Trilogy, Espresso, Solstice Trilogy, Espresso, Solstice [Member] Eclipse, Envoy, Diversified US/UK, Espresso, Trilogy [Member] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Other assets Other Assets Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Total Total Properties [Member] Total Properties Other assets Increase (Decrease) in Other Operating Assets Adjustment to Compensation, Amount Adjustment to Compensation Amount Disposal group, not discontinued operation, percentage of consideration paid in cash Disposal Group, Including Discontinued Operation, Percentage Of Consideration Paid In Cash Disposal Group, Including Discontinued Operation, Percentage Of Consideration Paid In Cash Non-controlling interests Equity, Attributable to Noncontrolling Interest Total Deferred Costs and Finite-Lived Intangible Assets, Net Deferred Costs and Finite-Lived Intangible Assets, Net Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Disposal Group Name [Axis] Disposal Group Name [Axis] Weighted average interest rate (percent) Finance Lease, Weighted Average Discount Rate, Percent Entity Central Index Key Entity Central Index Key Loss contingency accrual Loss Contingency Accrual Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Derivative, gain (loss) on derivative, net Derivative, Gain (Loss) on Derivative, Net Equity-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] In-place lease value Finite-Lived Intangible Assets, Gross Income tax expense Income tax expense Income Tax Expense (Benefit) Impairment recognized Equity Method Investment, Other than Temporary Impairment Finance leases for equipment Finance Lease, Right-of-Use Asset, after Accumulated Amortization Sales of real estate Proceeds From Sale Of Real Estate, Investing Proceeds From Sale Of Real Estate, Investing Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Fair Value Fair Value Disclosures [Text Block] Payment of deferred financing costs Payments of Financing Costs Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense [Table Text Block] Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Reclassification of accumulated other comprehensive loss Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax 2026 Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Three Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Three Net proceeds from issuance of common stock Value of common stock issued Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Diversified US/UK Diversified US/UK [Member] Griffin-American Joint Venture [Member] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Arcadia Management Arcadia [Member] Arcadia [Member] Repayments of mortgage notes Repayments of Notes Payable Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Retirement of common stock (in shares) Stock Repurchased and Retired During Period, Shares Basis spread on variable interest rate Debt Instrument, Basis Spread on Variable Rate Estimated useful life (in years) Property, Plant and Equipment, Useful Life Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Financial Statement Location [Domain] Financial Statement Location [Domain] Information by location in the financial statement. Remaining lease term (years) Finance Lease, Weighted Average Remaining Lease Term Weighted average number of shares of common stock outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Assets acquired under capital lease obligations Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Less: Amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Variable lease revenues Operating Lease, Variable Lease Income Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Equity in earnings (losses) of unconsolidated ventures Equity in (earnings) losses of unconsolidated ventures Income (Loss) from Equity Method Investments Cover [Abstract] Other income (loss) Other Income (Expense) [Abstract] Other Income (Expense) [Abstract] Subsequent Events Subsequent Events [Text Block] Amortization of equity-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of deferred financing costs Amortization of Debt Issuance Costs Non-NEOs Non-NEOs [Member] Segment Reporting Segment Reporting Disclosure [Text Block] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Rochester, NY Rochester, NY [Member] Rochester, NY [Member] Days notice required for lease termination Lease, Terms, Days Notice Required For Termination Lease, Terms, Days Notice Required For Termination Income (loss) before equity in earnings (losses) of unconsolidated ventures and income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Non-PEO NEO Non-PEO NEO [Member] Total Equity Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Rochester, NY Non-recourse, February 2025 Rochester, NY Non-recourse, February 2025 [Member] Rochester, NY Non-recourse, February 2025 [Member] Incurred Operating Costs Incurred [Member] Operating Costs Incurred Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Scenario [Axis] Scenario [Axis] Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average number of shares of common stock outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Number of healthcare real estate properties Number of Healthcare Real Estate Properties Number of Healthcare Real Estate Properties Solstice Solstice Senior Living Solstice Senior Living LLC [Member] Solstice Senior Living LLC [Member] Non-controlling interests - contributions Noncontrolling Interest, Increase from Business Combination Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Identified Intangibles Intangible Assets, Net (Including Goodwill) [Abstract] Revenue Recognition Revenue Recognition [Abstract] Escrow deposits payable Increase (Decrease) in Escrow Payable Increase (Decrease) in Escrow Payable Aggregate value for restricted common shares granted to independent directors Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Consolidated Entities [Domain] Consolidated Entities [Domain] Measurement input (percentage) Real Estate, Measurement Input Real Estate, Measurement Input Rental income Operating Lease, Lease Income Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Due to related party Increase (Decrease) in Due to Related Parties Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax [Abstract] Scenario [Domain] Scenario [Domain] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Unconsolidated Investments Unconsolidated Investments Segment [Member] Unconsolidated Investments Segment [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Real Estate Properties [Line Items] Real Estate Properties [Line Items] Name of Property [Axis] Name of Property [Axis] Equity Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Non-controlling Interests Noncontrolling Interest [Member] EX-101.PRE 10 nshi-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 nshi-20230930_g1.jpg begin 644 nshi-20230930_g1.jpg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nshi-20230930_g2.jpg begin 644 nshi-20230930_g2.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover Page - shares
 9 Months Ended
Sep. 30, 2023
Nov. 13, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 000-55190  
Entity Registrant Name NORTHSTAR HEALTHCARE INCOME, INC.  
Entity Incorporation, State or Country Code MD  
Entity Tax Identification Number 27-3663988  
Entity Address, Address Line One 16 East 34th Street  
Entity Address, Address Line Two 18th Floor  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 929  
Local Phone Number 777-3135  
Title of 12(b) Security Common stock, par value $0.01 per share  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   185,712,103
Entity Central Index Key 0001503707  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Assets    
Cash and cash equivalents $ 87,581 $ 103,926
Restricted cash 11,386 11,734
Operating real estate, net 894,245 933,002
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) 128,026 176,502
Receivables, net 2,253 2,815
Intangible assets, net 2,000 2,253
Other assets 10,425 7,603
Total assets [1] 1,135,916 1,237,835
Liabilities    
Mortgage notes payable, net 901,610 912,248
Escrow deposits payable 1,023 993
Accounts payable and accrued expenses 23,967 21,034
Total liabilities [1] 928,484 936,763
Commitments and contingencies (Note 12)
NorthStar Healthcare Income, Inc. Stockholders’ Equity    
Preferred stock, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September 30, 2023 and December 31, 2022 0 0
Common stock, $0.01 par value, 400,000,000 shares authorized, 185,712,103 and 195,421,656 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively 1,857 1,954
Additional paid-in capital 1,716,701 1,729,589
Retained earnings (accumulated deficit) (1,511,765) (1,428,840)
Accumulated other comprehensive income (loss) 0 (3,679)
Total NorthStar Healthcare Income, Inc. stockholders’ equity 206,793 299,024
Non-controlling interests 639 2,048
Total equity 207,432 301,072
Total liabilities and equity 1,135,916 1,237,835
Related Party    
Liabilities    
Due to related party 292 469
Other liabilities 292 469
Nonrelated Party    
Liabilities    
Due to related party 1,592 2,019
Other liabilities $ 1,592 $ 2,019
[1] ncludes $174.4 million and $180.2 million of assets and liabilities, respectively, of certain VIEs that are consolidated by the Operating Partnership. Refer to Note 2, “Summary of Significant Accounting Policies.”
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Equity method investment, fair value $ 3,075  
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 50,000,000 50,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 400,000,000 400,000,000
Common stock, shares issued (in shares) 185,712,103 195,421,656
Common stock, shares outstanding (in shares) 185,712,103 195,421,656
Total assets [1] $ 1,135,916 $ 1,237,835
Liabilities [1] 928,484 $ 936,763
Northstar Healthcare Income Operating Partnership, LP | Primary Beneficiary    
Total assets 174,400  
Liabilities $ 180,200  
[1] ncludes $174.4 million and $180.2 million of assets and liabilities, respectively, of certain VIEs that are consolidated by the Operating Partnership. Refer to Note 2, “Summary of Significant Accounting Policies.”
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Property and other revenues        
Resident fee income $ 11,966,000 $ 11,274,000 $ 35,655,000 $ 32,987,000
Rental income 40,330,000 36,165,000 115,897,000 103,001,000
Other revenue 1,078,000 300,000 2,893,000 457,000
Total property and other revenues 53,374,000 47,739,000 154,445,000 136,445,000
Expenses        
Property operating expenses 36,890,000 35,134,000 106,993,000 101,258,000
Interest expense 14,250,000 11,014,000 37,143,000 31,877,000
Transaction costs 358,000 857,000 455,000 857,000
Asset management fees - related party 0 2,428,000 0 7,532,000
General and administrative expenses 2,921,000 2,859,000 10,424,000 10,300,000
Depreciation and amortization 9,848,000 9,642,000 29,305,000 29,105,000
Impairment loss 0 18,500,000 43,422,000 31,502,000
Total expenses 64,267,000 80,434,000 227,742,000 212,431,000
Other income (loss)        
Other income, net 0 0 202,000 77,000
Gain (loss) on investments and other (347,000) 325,000 (4,662,000) 660,000
Income (loss) before equity in earnings (losses) of unconsolidated ventures and income tax expense (11,240,000) (32,370,000) (77,757,000) (75,249,000)
Equity in earnings (losses) of unconsolidated ventures (127,000) 2,872,000 (6,595,000) 39,427,000
Income tax expense (17,000) (15,000) (43,000) (45,000)
Net income (loss) (11,384,000) (29,513,000) (84,395,000) (35,867,000)
Net (income) loss attributable to non-controlling interests 166,000 73,000 1,470,000 298,000
Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders (11,218,000) (29,440,000) (82,925,000) (35,569,000)
Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders $ (11,218,000) $ (29,440,000) $ (82,925,000) $ (35,569,000)
Net income (loss) per share of common stock, basic (in dollars per share) [1] $ (0.06) $ (0.15) $ (0.43) $ (0.18)
Net income (loss) per share of common stock, diluted (in dollars per share) [1] $ (0.06) $ (0.15) $ (0.43) $ (0.18)
Weighted average number of shares of common stock outstanding, basic (in shares) [1] 185,712,103 194,670,948 191,367,117 194,032,819
Weighted average number of shares of common stock outstanding, diluted (in shares) [1] 185,712,103 194,670,948 191,367,117 194,032,819
Distributions declared per share of common stock (in dollars per share) $ 0 $ 0 $ 0 $ 0.50
[1] The Company issued 203,742 and 116,712 restricted stock units as of September 30, 2023 and September 30, 2022, respectively. The restricted stock units have been excluded from the diluted earnings per share calculation as their impact is anti-dilutive due to the net loss generated during the three and nine months ended September 30, 2023 and 2022.
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - shares
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Number of shares granted to independent directors (in shares) 203,742 116,712
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ (11,384) $ (29,513) $ (84,395) $ (35,867)
Other comprehensive income (loss)        
Foreign currency translation adjustments related to investment in unconsolidated venture 0 (1,664) 3,679 (4,602)
Total other comprehensive income (loss) 0 (1,664) 3,679 (4,602)
Comprehensive income (loss) (11,384) (31,177) (80,716) (40,469)
Comprehensive (income) loss attributable to non-controlling interests 166 73 1,470 298
Comprehensive income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders $ (11,218) $ (31,104) $ (79,246) $ (40,171)
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Total Company’s Stockholders’ Equity
Common Stock
Additional Paid-in Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Income (Loss)
Non-controlling Interests
Beginning Balance (in shares) at Dec. 31, 2021     193,121,000        
Beginning Balance at Dec. 31, 2021 $ 446,818 $ 444,475 $ 1,930 $ 1,720,719 $ (1,277,688) $ (486) $ 2,343
Increase (Decrease) in Stockholder's Equity              
Share-based payment of advisor assets management fees (in shares)     698,000        
Share-based payment of advisor asset management fees 2,729 2,729 $ 7 2,722      
Amortization of equity-based compensation 15 15   15      
Non-controlling interests - contributions 64           64
Non-controlling interests - distributions (53)           (53)
Other comprehensive income (loss) (568) (568)       (568)  
Net income (loss) (12,981) (12,936)     (12,936)   (45)
Ending Balance (in shares) at Mar. 31, 2022     193,819,000        
Ending Balance at Mar. 31, 2022 436,024 433,715 $ 1,937 1,723,456 (1,290,624) (1,054) 2,309
Beginning Balance (in shares) at Dec. 31, 2021     193,121,000        
Beginning Balance at Dec. 31, 2021 446,818 444,475 $ 1,930 1,720,719 (1,277,688) (486) 2,343
Increase (Decrease) in Stockholder's Equity              
Other comprehensive income (loss) (4,602)            
Net income (loss) (35,867)            
Ending Balance (in shares) at Sep. 30, 2022     195,079,000        
Ending Balance at Sep. 30, 2022 317,057 314,937 $ 1,951 1,728,383 (1,410,309) (5,088) 2,120
Beginning Balance (in shares) at Mar. 31, 2022     193,819,000        
Beginning Balance at Mar. 31, 2022 436,024 433,715 $ 1,937 1,723,456 (1,290,624) (1,054) 2,309
Increase (Decrease) in Stockholder's Equity              
Share-based payment of advisor assets management fees (in shares)     637,000        
Share-based payment of advisor asset management fees 2,515 2,515 $ 8 2,507      
Amortization of equity-based compensation 13 13   13      
Non-controlling interests - contributions 113           113
Non-controlling interests - distributions (61)           (61)
Distributions declared (97,052)            
Other comprehensive income (loss) (2,370) (2,370)       (2,370)  
Net income (loss) 6,627 6,807     6,807   (180)
Ending Balance (in shares) at Jun. 30, 2022     194,456,000        
Ending Balance at Jun. 30, 2022 345,809 343,628 $ 1,945 1,725,976 (1,380,869) (3,424) 2,181
Increase (Decrease) in Stockholder's Equity              
Share-based payment of advisor assets management fees (in shares)     623,000        
Share-based payment of advisor asset management fees 2,413 2,413 $ 6 2,407      
Non-controlling interests - contributions 86           86
Non-controlling interests - distributions (74)           (74)
Other comprehensive income (loss) (1,664) (1,664)       (1,664)  
Net income (loss) (29,513) (29,440)     (29,440)   (73)
Ending Balance (in shares) at Sep. 30, 2022     195,079,000        
Ending Balance at Sep. 30, 2022 $ 317,057 314,937 $ 1,951 1,728,383 (1,410,309) (5,088) 2,120
Beginning Balance (in shares) at Dec. 31, 2022 195,421,656   195,422,000        
Beginning Balance at Dec. 31, 2022 $ 301,072 299,024 $ 1,954 1,729,589 (1,428,840) (3,679) 2,048
Increase (Decrease) in Stockholder's Equity              
Non-controlling interests - contributions 45           45
Non-controlling interests - distributions (22)           (22)
Other comprehensive income (loss) 1,248 1,248       1,248  
Net income (loss) (13,997) (13,926)     (13,926)   (71)
Ending Balance (in shares) at Mar. 31, 2023     195,422,000        
Ending Balance at Mar. 31, 2023 $ 288,346 286,346 $ 1,954 1,729,589 (1,442,766) (2,431) 2,000
Beginning Balance (in shares) at Dec. 31, 2022 195,421,656   195,422,000        
Beginning Balance at Dec. 31, 2022 $ 301,072 299,024 $ 1,954 1,729,589 (1,428,840) (3,679) 2,048
Increase (Decrease) in Stockholder's Equity              
Other comprehensive income (loss) 3,679            
Net income (loss) $ (84,395)            
Ending Balance (in shares) at Sep. 30, 2023 185,712,103   185,712,000        
Ending Balance at Sep. 30, 2023 $ 207,432 206,793 $ 1,857 1,716,701 (1,511,765) 0 639
Beginning Balance (in shares) at Mar. 31, 2023     195,422,000        
Beginning Balance at Mar. 31, 2023 288,346 286,346 $ 1,954 1,729,589 (1,442,766) (2,431) 2,000
Increase (Decrease) in Stockholder's Equity              
Non-controlling interests - contributions 55           55
Non-controlling interests - distributions (33)           (33)
Retirement of common stock (in shares)     (9,710,000)        
Retirement of common stock (Note 8) (13,399) (13,399) $ (97) (13,302)      
Other comprehensive income (loss) (844) (844)       (844)  
Reclassification of accumulated other comprehensive loss [1] 3,275 3,275       3,275  
Net income (loss) (59,014) (57,781)     (57,781)   (1,233)
Ending Balance (in shares) at Jun. 30, 2023     185,712,000        
Ending Balance at Jun. 30, 2023 218,386 217,597 $ 1,857 1,716,287 (1,500,547) 0 789
Increase (Decrease) in Stockholder's Equity              
Amortization of equity-based compensation 414 414   414      
Non-controlling interests - contributions 44           44
Non-controlling interests - distributions (28)           (28)
Other comprehensive income (loss) 0            
Reclassification of accumulated other comprehensive loss 3,300            
Net income (loss) $ (11,384) (11,218)     (11,218)   (166)
Ending Balance (in shares) at Sep. 30, 2023 185,712,103   185,712,000        
Ending Balance at Sep. 30, 2023 $ 207,432 $ 206,793 $ 1,857 $ 1,716,701 $ (1,511,765) $ 0 $ 639
[1] The Company reclassified the accumulated other comprehensive loss related to foreign currency adjustments for an unconsolidated venture ownership interest that was sold during the three months ended June 30, 2023. The accumulated balance was reclassified to gain (loss) on investments and other on the consolidated statements of operations.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net income (loss) $ (84,395) $ (35,867)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Equity in (earnings) losses of unconsolidated ventures 6,595 (39,427)
Depreciation and amortization 29,305 29,105
Impairment loss 43,422 31,502
Amortization of below market debt 2,487 2,428
Amortization of deferred financing costs 988 475
Amortization of equity-based compensation 170 150
(Gain) loss on investments and other 4,662 (660)
Change in allowance for uncollectible accounts 360 326
Issuance of common stock as payment for asset management fees 0 7,532
Distributions from unconsolidated ventures 10,640 0
Changes in assets and liabilities:    
Receivables 203 (114)
Other assets (3,786) 3,583
Due to related party (177) (3,868)
Escrow deposits payable 30 256
Accounts payable and accrued expenses 2,640 (8,727)
Other liabilities (78) (298)
Net cash provided by (used in) operating activities 13,066 (13,604)
Cash flows from investing activities:    
Capital expenditures for operating real estate (28,425) (17,924)
Sales of real estate 135 0
Distributions from unconsolidated ventures 13,472 42,173
Sales of other assets 523 0
Net cash provided by (used in) investing activities (14,295) 24,249
Cash flows from financing activities:    
Repayments of mortgage notes (14,066) (16,514)
Payment of deferred financing costs (48) 0
Payments under finance leases (96) (36)
Acquisition and retirement of common stock (1,315) (408)
Distributions paid on common stock 0 (97,018)
Contributions from non-controlling interests 144 263
Distributions to non-controlling interests (83) (188)
Net cash provided by (used in) financing activities (15,464) (113,901)
Net increase (decrease) in cash, cash equivalents and restricted cash (16,693) (103,256)
Cash, cash equivalents and restricted cash-beginning of period 115,660 210,938
Cash, cash equivalents and restricted cash-end of period 98,967 107,682
Supplemental disclosure of cash flow information:    
Cash paid for interest 29,666 28,625
Cash paid for income taxes 61 41
Supplemental disclosure of non-cash investing and financing activities:    
Accrued capital expenditures 540 2,561
Exchange of ownership interests in unconsolidated ventures for common stock 13,399 0
Assets acquired under capital lease obligations $ 25 $ 0
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Business and Organization
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business and Organization Business and Organization
NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), owns a diversified portfolio of seniors housing properties, including independent living facilities (“ILF”), assisted living (“ALF”) and memory care facilities (“MCF”) located throughout the United States. In addition, the Company also has investments through non-controlling interests in joint ventures in a broader spectrum of healthcare real estate, including seniors housing properties, as well as skilled nursing (“SNF”) and ancillary services businesses, located throughout the United States.
The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company has conducted its operations, and intends to do so in the future, so as to continue to qualify as a REIT for U.S. federal income tax purposes.
Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”), which became indirect subsidiaries of the Company on June 9, 2023. NorthStar Healthcare Income Advisor, LLC invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which were collectively recorded as non-controlling interests on the accompanying consolidated balance sheets prior to June 9, 2023. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of September 30, 2023, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, was 100.0%.
The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.
The Company raised $2.0 billion in total gross proceeds from the sale of shares of common stock in its continuous, public offerings (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”).
The Internalization
From inception through October 21, 2022, the Company was externally managed by CNI NSHC Advisors, LLC or its predecessor (the “Former Advisor”), an affiliate of NRF Holdco, LLC (the “Former Sponsor”). The Former Advisor was responsible for managing the Company’s operations, subject to the supervision of the Company’s board of directors, pursuant to an advisory agreement. On October 21, 2022, the Company completed the internalization of the Company’s management function (the “Internalization”). In connection with the Internalization, the Company agreed with the Former Advisor to terminate the advisory agreement and arranged for the Former Advisor to continue to provide certain services for a transition period.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Accounting
The accompanying consolidated financial statements and related notes of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures normally included in the consolidated financial statements prepared under U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 27, 2023.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company, the Operating Partnership and their consolidated subsidiaries. The Company consolidates entities in which it has a controlling financial interest by first considering if an entity meets the definition of a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary or if the Company has the power to control an entity through majority voting interest or other arrangements. All significant intercompany balances are eliminated in consolidation.
Variable Interest Entities
A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. A VIE is defined as an entity in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The determination of whether an entity is a VIE includes both a qualitative and quantitative analysis. The Company bases its qualitative analysis on its review of the design of the entity, its organizational structure including decision-making ability and relevant financial agreements and the quantitative analysis on the forecasted cash flow of the entity. The Company reassesses its initial evaluation of an entity as a VIE upon the occurrence of certain reconsideration events.
A VIE must be consolidated only by its primary beneficiary, which is defined as the party who, along with its affiliates and agents, has both the: (i) power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The Company determines whether it is the primary beneficiary of a VIE by considering qualitative and quantitative factors, including, but not limited to: which activities most significantly impact the VIE’s economic performance and which party controls such activities; the amount and characteristics of its investment; the obligation or likelihood for the Company or other interests to provide financial support; consideration of the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders and the similarity with and significance to the business activities of the Company and the other interests. The Company reassesses its determination of whether it is the primary beneficiary of a VIE each reporting period. Judgments related to these determinations include estimates about the current and future fair value and performance of investments held by these VIEs and general market conditions.
The Company evaluates its investments and financings, including investments in unconsolidated ventures and securitization financing transactions to determine whether each investment or financing is a VIE. The Company analyzes new investments and financings, as well as reconsideration events for existing investments and financings, which vary depending on type of investment or financing.
As of September 30, 2023, the Company has identified certain consolidated and unconsolidated VIEs. Assets of each of the VIEs, may only be used to settle obligations of the respective VIE. Creditors of each of the VIEs have no recourse to the general credit of the Company.
Consolidated VIEs
The most significant VIEs of the Company are certain entities that are consolidated by the Operating Partnership. These entities are VIEs because of non-controlling interests owned by third parties, which do not have substantive kick-out or participating rights. Included in operating real estate, net and mortgage notes payable, net on the Company’s consolidated balance sheet as of September 30, 2023 is $170.1 million and $172.0 million, respectively, related to such consolidated VIEs.
Unconsolidated VIEs
As of September 30, 2023, the Company identified unconsolidated VIEs related to its investments in unconsolidated ventures with a carrying value of $128.0 million. The Company’s maximum exposure to loss as of September 30, 2023 would not exceed the carrying value of its investment in the VIEs. The Company determined that it is not the primary beneficiary of these VIEs and, accordingly, they are not consolidated in the Company’s financial statements as of September 30, 2023. The Company did not provide financial support to its unconsolidated VIEs during the nine months ended September 30, 2023. As of September 30, 2023, there were no explicit arrangements or implicit variable interests that could require the Company to provide financial support to its unconsolidated VIEs.
Voting Interest Entities
A voting interest entity is an entity in which the total equity investment at risk is sufficient to enable it to finance its activities independently and the equity holders have the power to direct the activities of the entity that most significantly impact its
economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity. The usual condition for a controlling financial interest in a voting interest entity is ownership of a majority voting interest. If the Company has a majority voting interest in a voting interest entity, the entity will generally be consolidated. The Company does not consolidate a voting interest entity if there are substantive participating rights by other parties and/or kick-out rights by a single party or through a simple majority vote.
The Company performs on-going reassessments of whether entities previously evaluated under the voting interest framework have become VIEs, based on certain events, and therefore subject to the VIE consolidation framework.
Investments in Unconsolidated Ventures
A non-controlling, unconsolidated ownership interest in an entity may be accounted for using the equity method or the Company may elect the fair value option.
The Company will account for an investment under the equity method of accounting if it has the ability to exercise significant influence over the operating and financial policies of an entity, but does not have a controlling financial interest. Under the equity method, the investment is adjusted each period for capital contributions and distributions and its share of the entity’s net income (loss). Capital contributions, distributions and net income (loss) of such entities are recorded in accordance with the terms of the governing documents. An allocation of net income (loss) may differ from the stated ownership percentage interest in such entity as a result of preferred returns and allocation formulas, if any, as described in such governing documents. Equity method investments are recognized using a cost accumulation model, in which the investment is recognized based on the cost to the investor, which includes acquisition fees. The Company records as an expense certain acquisition costs and fees associated with consolidated investments deemed to be business combinations and capitalizes these costs for investments deemed to be acquisitions of an asset, including an equity method investment.
The Company may elect the fair value option of accounting for an investment that would otherwise be accounted for under the equity method. The fair value option election allows an entity to make an irrevocable election of fair value for certain financial assets and liabilities on an instrument-by-instrument basis at the initial or subsequent measurement. The decision to elect the fair value option must be applied to an entire instrument and is irrevocable once elected. Under the fair value option, the Company records its share of the changes to fair value of the investment and any unrealized gains and losses.
On June 30, 2023, the Company elected the fair value option method to account for its investment in the Espresso joint venture, which is included in investments in unconsolidated ventures on the consolidated balance sheets. The fair value election was made based on the Company’s assessment that the expected return of investment was lower than the Company’s carrying value of its investment in the Espresso joint venture, which resulted in an impairment of $4.7 million and reduced the carrying value of its investment to recoverable fair value of $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. The Company will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations. During the three months ended September 30, 2023, the Company did not record any changes to the fair value of its investment in the Espresso joint venture. Refer to Note 4 “Investment in Unconsolidated Ventures” and Note 10 “Fair Value” for further discussion.
Non-controlling Interests
A non-controlling interest in a consolidated subsidiary is defined as the portion of the equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company. A non-controlling interest is required to be presented as a separate component of equity on the consolidated balance sheets and presented separately as net income (loss) and comprehensive income (loss) attributable to controlling and non-controlling interests. An allocation to a non-controlling interest may differ from the stated ownership percentage interest in such entity as a result of a preferred return and allocation formula, if any, as described in such governing documents.
Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments with an original maturity date of three months or less to be cash equivalents. Cash, including amounts restricted, may at times exceed the Federal Deposit Insurance Corporation deposit insurance limit of $250,000 per institution. The Company mitigates credit risk by placing cash and cash equivalents with major financial institutions and money market funds invested in short-term U.S. government securities. To date, the Company has not experienced any losses on cash and cash equivalents.
Restricted cash consists of amounts related to operating real estate (escrows for taxes, insurance, capital expenditures, security deposits received from residents and payments required under certain lease agreements) and other escrows required by lenders of the Company’s borrowings.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):
September 30, 2023 (Unaudited)
December 31, 2022
Cash and cash equivalents$87,581 $103,926 
Restricted cash11,386 11,734 
Total cash, cash equivalents and restricted cash$98,967 $115,660 
Operating Real Estate
Operating real estate is carried at historical cost less accumulated depreciation. Major replacements and betterments which improve or extend the life of the asset are capitalized and depreciated over their useful life. Ordinary repairs and maintenance are expensed as incurred. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:
Category:Term:
Building
30 to 50 years
Building improvementsLesser of the useful life or remaining life of the building
Land improvements
9 to 15 years
Tenant improvementsLesser of the useful life or remaining term of the lease
Furniture, fixtures and equipment
5 to 14 years
Construction costs incurred in connection with the Company’s investments are capitalized and included in operating real estate, net on the consolidated balance sheets. Construction in progress is not depreciated until the asset is available for its intended use.
Lessee Accounting
A leasing arrangement, a right to control the use of an identified asset for a period of time in exchange for consideration, is classified by the lessee either as a finance lease, which represents a financed purchase of the leased asset, or as an operating lease. For leases with terms greater than 12 months, a lease asset and a lease liability are recognized on the balance sheet at commencement date based on the present value of lease payments over the lease term.
Lease renewal or termination options are included in the lease asset and lease liability only if it is reasonably certain that the option to extend would be exercised or the option to terminate would not be exercised. As the implicit rate in most leases are not readily determinable, the Company’s incremental borrowing rate for each lease at commencement date is used to determine the present value of lease payments. Consideration is given to the Company’s recent debt financing transactions, as well as publicly available data for instruments with similar characteristics, adjusted for the respective lease term, when estimating incremental borrowing rates.
Lease expense is recognized over the lease term based on an effective interest method for finance leases and on a straight-line basis for operating leases.
Right of Use (“ROU”) - Finance Assets
The Company has entered into finance leases for equipment which are included in operating real estate, net on the Company’s consolidated balance sheets. As of September 30, 2023, furniture, fixtures and equipment under finance leases totaled $0.3 million. The leased equipment is amortized on a straight-line basis. Payments for finance leases totaled $0.1 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively.
The following table presents the future minimum lease payments under finance leases and the present value of the minimum lease payments, which are included in other liabilities on the Company’s consolidated balance sheets (dollars in thousands):
October 1 through December 31, 2023$18 
Years Ending December 31:
202469 
202538 
202633 
202718 
Thereafter10 
Total minimum lease payments$186 
Less: Amount representing interest(27)
Present value of minimum lease payments$159 
The weighted average interest rate related to the finance lease obligations is 6.8% with a weighted average lease term of 3.4 years.
As of September 30, 2023, there were no leases that had yet to commence which would create significant rights and obligations to the Company as lessee.
Intangible Assets and Deferred Costs
Deferred Costs
Deferred costs consist of deferred financing costs. Deferred financing costs represent commitment fees, legal and other third-party costs associated with obtaining financing. These costs are recorded against the carrying value of such financing and are amortized to interest expense over the term of the financing using the effective interest method. Unamortized deferred financing costs are expensed to gain (loss) on investments and other, when the associated borrowing is repaid before maturity. Costs incurred in seeking financing transactions which do not close are expensed in the period in which it is determined that the financing will not occur.
Identified Intangibles
The Company records acquired identified intangibles, such as the value of in-place leases and other intangibles, based on estimated fair value at the acquisition date. The value allocated to the identified intangibles is amortized over the remaining lease term. In-place leases are amortized into depreciation and amortization expense.
Impairment analysis for identified intangible assets is performed in connection with the impairment assessment of the related operating real estate. An impairment establishes a new basis for the identified intangible asset and any impairment loss recognized is not subject to subsequent reversal. Refer to “—Impairment on Operating Real Estate and Investments in Unconsolidated Ventures” for additional information.
Identified intangible assets are recorded in intangible assets, net on the consolidated balance sheets. Intangible assets relate to the Company’s in-place lease values for the Company’s four net lease properties. The following table presents intangible assets, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
In-place lease value$120,149 $120,149 
Less: Accumulated amortization(118,149)(117,896)
Intangible assets, net$2,000 $2,253 
The Company recorded $0.1 million and $0.3 million of amortization expense for in-place leases for the three and nine months ended September 30, 2023 and 2022, respectively.
The following table presents future amortization of in-place lease value (dollars in thousands):
October 1 through December 31, 2023$84 
Years Ending December 31:
2024337 
2025337 
2026337 
2027337 
Thereafter568 
Total$2,000 
Derivative Instruments
The Company uses derivative instruments to manage its interest rate risk. The Company’s derivative instruments are recorded at fair value. The accounting for changes in fair value of derivatives depends upon whether or not the Company has elected to designate the derivative in a hedging relationship and the derivative qualifies for hedge accounting. Under hedge accounting, changes in fair value for derivatives are recorded through other comprehensive income. When hedge accounting is not elected, changes in fair value for derivatives are recorded through the income statement.
The Company has interest rate caps that have not been designated for hedge accounting. The fair value of the Company's interest rate caps totaled $0.8 million and $0.7 million as of September 30, 2023 and December 31, 2022, respectively, and are included in other assets on the consolidated balance sheets. Changes in fair value of derivatives have been recorded in gain (loss) on investments and other in the consolidated statements of operations. The Company recognized losses totaling $0.3 million and $0.5 million for the three and nine months ended September 30, 2023, respectively, and gains totaling $0.3 million and $0.6 million for the three and nine months ended September 30, 2022, respectively.
Revenue Recognition
Operating Real Estate
Rental income from operating real estate is derived from leasing of space to operators and residents, including rent received from the Company’s net lease properties and rent, ancillary service fees and other related revenue earned from ILF residents. Rental income recognition commences when the operator takes legal possession of the leased space and the leased space is substantially ready for its intended use. The leases are for fixed terms of varying length and generally provide for rentals and expense reimbursements to be paid in monthly installments. Rental income from leases, which includes community and move-in fees, is recognized over the term of the respective leases. ILF resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice.
The Company also generates revenue from operating healthcare properties. Revenue related to operating healthcare properties includes resident room and care charges, ancillary fees and other resident service charges. Rent is charged and revenue is recognized when such services are provided, generally defined per the resident agreement as of the date upon which a resident occupies a room or uses the services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Revenue derived from our ALFs and MCFs is recorded in resident fee income in the consolidated statements of operations.
Revenue from operators and residents is recognized at lease commencement only to the extent collection is expected to be probable. This assessment is based on several qualitative and quantitative factors, including and as appropriate, the payment history, ability to satisfy its lease obligations, the value of the underlying collateral or deposit, if any, and current economic conditions. If collection is assessed to not be probable, thereafter lease income recognized is limited to amounts collected, with the reversal of any revenue recognized to date in excess of amounts received. If collection is subsequently reassessed to be probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable.
The operator of the Company’s four net lease properties failed to remit contractual monthly rent obligations and the Company deemed it not probable that these obligations will be satisfied in the foreseeable future. On March 27, 2023, the Company entered into a lease forbearance and modification agreement (the “Forbearance Agreement”) with the existing operator, pursuant to which, among other things, the Company will be entitled to receive all cash flow in excess of permitted expenses, and be required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. For the three and nine months ended September 30, 2023, the Company received excess cash flow of $0.8 million and $1.2 million, respectively, which was recorded as rental income.
For the three months ended September 30, 2023 and 2022, total property and other revenues includes variable lease revenue of $3.6 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, total property and other revenue includes variable lease revenue of $10.7 million and $9.2 million, respectively. Variable lease revenue includes ancillary services provided to operator/residents, as well as non-recurring services and fees at the Company’s operating facilities.
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures
At this time, it is difficult for the Company to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. The future economic effects will depend on many factors beyond the Company’s control and knowledge. The resulting effect on impairment of the Company's real estate held for investment and held for sale and investments in unconsolidated ventures may materially differ from the Company's current expectations and further impairment charges may be recorded in future periods.
Operating Real Estate
The Company’s real estate portfolio is reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of its operating real estate may be impaired or that its carrying value may not be recoverable. A property’s value is considered impaired if the Company’s estimate of the aggregate expected future undiscounted cash flow generated by the property is less than the carrying value. In conducting this review, the Company considers U.S. macroeconomic factors, real estate and healthcare sector conditions, together with asset specific and other factors. To the extent an impairment has occurred, the loss is measured as the excess of the carrying value of the property over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
Real estate held for sale is stated at the lower of its carrying amount or estimated fair value less disposal cost, with any write-down to disposal cost recorded as an impairment loss. For any increase in fair value less disposal cost subsequent to classification as held for sale, the impairment may be reversed, but only up to the amount of cumulative loss previously recognized.
The Company considered the potential impact of the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions on the future net operating income of its healthcare real estate held for investment as an indicator of impairment. Fair values were estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization rates.
During the nine months ended September 30, 2023, the Company recorded impairment losses on its operating real estate totaling $38.7 million, including impairment losses of $38.6 million for five facilities within the Rochester portfolio as a result of revised holding period assumptions. Additionally, the Company recorded impairment losses totaling $0.1 million for a land parcel within the Rochester portfolio as a result of lower estimated market value.
During the nine months ended September 30, 2022, the Company recorded impairment losses on its operating real estate totaling $31.5 million. The Company recorded impairment losses of $18.5 million, $8.5 million, and $3.9 million for facilities in its Arbors, Winterfell and Rochester portfolios, respectively, as a result of declining operating margins and lower projected future cash flows. In addition, the Company recorded impairment losses totaling $0.6 million for property damage sustained by facilities in its Winterfell portfolio.
Investments in Unconsolidated Ventures
The Company reviews its investments in unconsolidated ventures on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value may be impaired or that its carrying value may not be recoverable. An investment is considered impaired if the projected net recoverable amount over the expected holding period is less than the carrying value. In conducting this review, the Company considers global macroeconomic factors, including real estate sector conditions, together with investment specific and other factors. To the extent an impairment has occurred on the Company’s investment in unconsolidated ventures, and is considered to be other than temporary, the loss is measured as the excess of the carrying value of the investment over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
During the nine months ended September 30, 2023, the Company recorded an impairment on its investment in the Espresso joint venture totaling $4.7 million, which reduced the carrying value of its investment to $3.1 million. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. During the nine months ended September 30, 2022, there was no impairment recorded on any of the Company’s investments in unconsolidated ventures.
The joint ventures underlying the Company’s unconsolidated ventures assess and record impairment and reserves on their respective real estate portfolios, goodwill, and other assets, and the Company recognizes its proportionate share through equity in earnings (losses). In May 2023, prior to the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”), the Diversified US/UK joint venture recorded impairment losses on its remaining properties, 48 care homes located in the United Kingdom (the “UK Portfolio”), due to, among other things, the extended period contemplated for the UK Portfolio to reach stabilization. The Company’s proportionate share of the impairment losses recorded by the Diversified US/UK portfolio totaled $11.4 million. The Company’s proportionate share of impairment and reserves recognized by the underlying joint ventures of its unconsolidated ventures during the nine months ended September 30, 2022 was de minimis.
Credit Losses on Receivables
The current expected credit loss model, in estimating expected credit losses over the life of a financial instrument at the time of origination or acquisition, considers historical loss experiences, current conditions and the effects of reasonable and supportable expectations of changes in future macroeconomic conditions. The Company assesses the estimate of expected credit losses on a quarterly basis or more frequently as necessary. The Company considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts.
The Company measures expected credit losses of receivables on a collective basis when similar risk characteristics exist. If the Company determines that a particular receivable does not share risk characteristics with its other receivables, the Company evaluates the receivable for expected credit losses on an individual basis.
When developing an estimate of expected credit losses on receivables, the Company considers available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both relating to past events, current conditions, and reasonable and supportable forecasts. The Company considers relevant qualitative and quantitative factors that relate to the environment in which the Company operates and are specific to the borrower.
Further, the fair value of the collateral, less estimated costs to sell, may be used when determining the allowance for credit losses for a receivable for which the repayment is expected to be provided substantially through the sale of the collateral when the borrower is experiencing financial difficulty.
As of September 30, 2023, the Company has not recorded an allowance for credit losses on its receivables.
Acquisition Fees and Expenses
The Company recorded an expense for certain acquisition costs and fees associated with transactions deemed to be business combinations in which it consolidated the asset and capitalized these costs for transactions deemed to be acquisitions of an asset, including an equity investment.
Equity-Based Compensation
The Company accounts for equity-based compensation awards using the fair value method, which requires an estimate of fair value of the award at the time of grant. All fixed equity-based awards to directors, which have no vesting conditions other than
time of service, are amortized to compensation expense over the awards’ vesting period on a straight-line basis. Equity-based compensation is classified within general and administrative expenses in the consolidated statements of operations.
Income Taxes
The Company elected to be taxed as a REIT and to comply with the related provisions of the Internal Revenue Code beginning in its taxable year ended December 31, 2013. Accordingly, the Company will generally not be subject to U.S. federal income tax to the extent of its distributions to stockholders as long as certain asset, gross income and share ownership tests are met. To maintain its qualification as a REIT, the Company must annually distribute dividends equal to at least 90.0% of its REIT taxable income (with certain adjustments) to its stockholders and meet certain other requirements. The Company believes that all of the criteria to maintain the Company’s REIT qualification have been met for the applicable periods, but there can be no assurance that these criteria will continue to be met in subsequent periods. If the Company were to fail to meet these requirements, it would be subject to U.S. federal income tax and potential interest and penalties, which could have a material adverse impact on its results of operations and amounts available for distributions to its stockholders. The Company’s accounting policy with respect to interest and penalties is to classify these amounts as a component of income tax expense, where applicable. The Company has assessed its tax positions for all open tax years, which include 2018 to 2022, and concluded there were no material uncertainties to be recognized.
The Company may also be subject to certain state, local and franchise taxes. Under certain circumstances, federal income and excise taxes may be due on its undistributed taxable income.
The Company made a joint election to treat certain subsidiaries as taxable REIT subsidiaries (“TRS”) which may be subject to U.S. federal, state and local income taxes. In general, a TRS of the Company may perform services for managers/operators/residents of the Company, hold assets that the Company cannot hold directly and may engage in any real estate or non-real estate related business.
Certain subsidiaries of the Company are subject to taxation by federal and state authorities for the periods presented. Income taxes are accounted for by the asset/liability approach in accordance with U.S. GAAP. Deferred taxes, if any, represent the expected future tax consequences when the reported amounts of assets and liabilities are recovered or paid. Such amounts arise from differences between the financial reporting and tax bases of assets and liabilities and are adjusted for changes in tax laws and tax rates in the period which such changes are enacted. A provision for income tax represents the total of income taxes paid or payable for the current period, plus the change in deferred taxes. Current and deferred taxes are provided on the portion of earnings (losses) recognized by the Company with respect to its interest in the TRS. Deferred income tax assets and liabilities are calculated based on temporary differences between the Company’s U.S. GAAP consolidated financial statements and the federal and state income tax basis of assets and liabilities as of the consolidated balance sheet date. The Company evaluates the realizability of its deferred tax assets (e.g., net operating loss and capital loss carryforwards) and recognizes a valuation allowance if, based on the available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. When evaluating the realizability of its deferred tax assets, the Company considers estimates of expected future taxable income, existing and projected book/tax differences, tax planning strategies available and the general and industry specific economic outlook. This realizability analysis is inherently subjective, as it requires the Company to forecast its business and general economic environment in future periods. Changes in estimate of deferred tax asset realizability, if any, are included in provision for income tax benefit (expense) in the consolidated statements of operations. The Company has a deferred tax asset, which as of September 30, 2023 totaled $15.9 million and continues to have a full valuation allowance recognized, as there are no changes in the facts and circumstances to indicate that the Company should release the valuation allowance.
The Company recorded an income tax expense of approximately $17,000 and $43,000 for the three and nine months ended September 30, 2023, respectively. The Company recorded an income tax expense of approximately $15,000 and $45,000 for the three and nine months ended September 30, 2022, respectively.
Comprehensive Income (Loss)
The Company reports consolidated comprehensive income (loss) in separate statements following the consolidated statements of operations. Comprehensive income (loss) is defined as the change in equity resulting from net income (loss) and other comprehensive income (loss) (“OCI”). The only component of OCI for the Company was foreign currency translation adjustments related to its investment in an unconsolidated venture.
Foreign Currency
Assets and liabilities denominated in a foreign currency for which the functional currency is a foreign currency are translated using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are translated into U.S. dollars using the average currency exchange rate in effect during the period. The resulting foreign currency translation adjustment is recorded as a component of accumulated OCI in the consolidated statements of equity.
Assets and liabilities denominated in a foreign currency for which the functional currency is the U.S. dollar are remeasured using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are remeasured into U.S. dollars using the average currency exchange rate in effect during the period.
For the period December 31, 2022 through June 9, 2023, the Company had exposure to foreign currency through an investment in an unconsolidated venture, the effects of which were recorded as a component of accumulated OCI in the consolidated statements of equity and in equity in earnings (losses) in the consolidated statements of operations. As a result of the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”) in June 2023, the Company is no longer exposed to foreign currency as of September 30, 2023. The Company reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK joint venture, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other on the consolidated statements of operations.
Recent Accounting Pronouncements
Accounting Standards Adopted in 2023
In March 2020, the FASB issued an amendment to the reference rate reform standard, which provides the option for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on contract modifications and hedge accounting. An example of such reform is the market transition from the London Interbank Offered Rate (“LIBOR”) to alternative reference rates. Entities that make this optional expedient election would not have to remeasure the contracts at the modification date or reassess the accounting treatment if certain criteria are met and would continue applying hedge accounting for relationships affected by reference rate reform. In December 2022, the FASB extended the date for which this guidance can be applied from December 31, 2022 to December 31, 2024. The Company did not make the optional election of the aforementioned accounting standards.
Future Application of Accounting Standards
None.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Real Estate
 9 Months Ended
Sep. 30, 2023
Real Estate [Abstract]  
Operating Real Estate Operating Real Estate
The following table presents operating real estate, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Land$121,424 $121,518 
Land improvements19,913 18,945 
Buildings and improvements932,261 957,924 
Tenant improvements372 372 
Construction in progress8,956 6,736 
Furniture, fixtures and equipment103,876 91,058 
Subtotal$1,186,802 $1,196,553 
Less: Accumulated depreciation(292,557)(263,551)
Operating real estate, net$894,245 $933,002 
For the three and nine months ended September 30, 2023, depreciation expense was $9.8 million and $29.1 million, respectively. For the three and nine months ended September 30, 2022, depreciation expense was $9.6 million and $28.9 million, respectively.
Within the table above, operating real estate has been reduced by accumulated impairment losses of $220.2 million and $181.5 million as of September 30, 2023 and December 31, 2022, respectively. Impairment losses on the Company’s operating real estate totaled $38.7 million and $31.5 million for the nine months ended September 30, 2023 and 2022, respectively, and are
recorded in impairment losses on the consolidated statements of operations. Refer to Note 2, “Summary of Significant Accounting Policies” for further discussion.
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in Unconsolidated Ventures
 9 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Investments in Unconsolidated Ventures Investments in Unconsolidated Ventures
The Company’s investments in unconsolidated ventures are accounted for under the equity method or fair value option. The following table presents the Company’s investments in unconsolidated ventures (dollars in thousands):
Carrying Value
PortfolioAcquisition DateOwnershipSeptember 30, 2023 (Unaudited)December 31, 2022
Trilogy(1)
Dec-201523.4 %$124,670 $128,884 
Espresso(2)
Jul-201536.7 %3,075 18,019 
Solstice(3)
Jul-201720.0 %281 323 
Investments sold(4)
— 29,276 
Investments in Unconsolidated Ventures$128,026 $176,502 
_______________________________________
(1)The carrying value for the Company’s investment in the Trilogy joint venture includes $9.8 million of capitalized acquisition costs.
(2)In June 2023, the Company recorded an impairment of $4.7 million to reflect the fair value of its investment in the Espresso joint venture, based on the estimated cash distributions to be received from the joint venture. Based on the Company’s assessment, it elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.
(3)Represents the Company’s investment in Solstice Senior Living, LLC (“Solstice”), the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC (“ISL”), a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and the Company, which owns 20.0%.
(4)In June 2023, the Company sold its ownership interests in the Diversified US/UK and Eclipse joint ventures.
Sale of Minority Interests
In June 2023, the Company sold its 14% interest in Healthcare GA Holdings, General Partnership, which indirectly owned 48 care homes across the United Kingdom (the “Diversified US/UK Portfolio”), and its 6% interest in Eclipse Health, General Partnership, which indirectly owned 34 seniors housing facilities (the “Eclipse Portfolio”), together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates, including 9,709,553 shares of common stock of the Company, 100 common units in the Operating Partnership and 100 special units in the Operating Partnership (the “Sale of Minority Interests”).
The following table presents the results of the Company’s investment in unconsolidated ventures (dollars in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
PortfolioEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash Distribution
Trilogy$(146)$— $6,052 $2,300 $454 $4,668 $10,757 $6,900 
Espresso(1)
— — (242)1,375 9,228 19,444 33,711 32,363 
Solstice19 — 17 — (41)— (41)— 
Investments sold(2)
— — (2,955)358 (16,236)— (5,000)2,910 
Total$(127)$— $2,872 $4,033 $(6,595)$24,112 $39,427 $42,173 
_______________________________________
(1)The Espresso joint venture recognized net gains related to sub-portfolio sales, of which the Company’s proportionate share totaled $9.2 million and $32.0 million for the nine months ended September 30, 2023 and 2022, respectively. The Company was distributed its proportionate share of the net proceeds generated from the sales during the nine months ended September 30, 2023 and 2022, totaling $17.3 million and $27.4 million, respectively.
(2)In May 2023, the Diversified US/UK joint venture recognized impairment, of which the Company’s proportionate share totaled $11.4 million and is included in equity in earnings (losses) for the nine months ended September 30, 2023.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Borrowings Borrowings
The following table presents the Company’s mortgage notes payable (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Recourse vs. Non-Recourse(1)
Initial
Maturity
Contractual
Interest Rate(2)
Principal
Amount(3)
Carrying
Value(3)
Principal
Amount(3)
Carrying
Value(3)
Aqua Portfolio
Frisco, TX(4)
Non-recourseFeb 20263.0%$26,000 $25,660 $26,000 $25,560 
Milford, OHNon-recourseSep 2026
SOFR + 2.79%
18,212 18,036 18,336 18,126 
Rochester Portfolio
Rochester, NYNon-recourseFeb 20254.25%17,657 17,629 18,206 18,165 
Rochester, NY(5)
Non-recourseJul 2023
SOFR + 2.45%
99,786 99,787 100,651 100,042 
Rochester, NYNon-recourseAug 2024
SOFR + 2.93%
10,922 10,891 11,336 11,315 
Arbors Portfolio(6)
Various locationsNon-recourseFeb 20253.99%81,912 81,680 83,423 83,051 
Winterfell Portfolio(7)
Various locationsNon-recourseJun 20254.17%586,773 581,157 596,408 588,306 
Avamere Portfolio(8)
Various locationsNon-recourseFeb 20274.66%67,025 66,770 67,995 67,683 
Mortgage notes payable, net$908,287 $901,610 $922,355 $912,248 
_______________________________________
(1)Subject to non-recourse carve-outs.
(2)Floating-rate borrowings total $128.9 million of principal outstanding and reference one-month SOFR as of September 30, 2023.
(3)The difference between principal amount and carrying value of mortgage notes payable is attributable to deferred financing costs, net for all borrowings, other than the Winterfell portfolio which is attributable to below market debt intangibles.
(4)The mortgage note carries a fixed interest rate of 3.0% through February 2024, followed by one-month adjusted SOFR, plus 2.80% through the initial maturity date of February 2026.
(5)Composed of seven individual mortgage notes payable (the “Rochester Sub-Portfolio Loan”) secured by seven healthcare real estate properties (the “Rochester Sub-Portfolio”), cross-collateralized and subject to cross-default. In July 2023, the Company elected not to pay debt service on the Rochester Sub-Portfolio Loan, which resulted in a default notice accelerating the maturity of the loan from its original terms of August 2027.
(6)Composed of four individual mortgage notes payable secured by four healthcare real estate properties, cross-collateralized and subject to cross-default.
(7)Composed of 32 individual mortgage notes payable secured by 32 healthcare real estate properties, cross-collateralized and subject to cross-default.
(8)Composed of five individual mortgage notes payable secured by five healthcare real estate properties, cross-collateralized and subject to cross-default.
The following table presents future scheduled principal payments on mortgage notes payable based on initial maturity as of September 30, 2023 (dollars in thousands):
October 1 through December 31, 2023$104,238 
Years Ending December 31:
202428,761 
2025667,741 
202645,151 
202762,396 
Total$908,287 
Beginning in February 2021, the operator of the four net lease properties in the Arbors portfolio was unable to satisfy its obligations under its leases and began remitting rent based on its available cash after satisfying property-level expenses, which resulted in a default under the mortgage notes collateralized by the properties. On March 27, 2023, with consent of the lender, the Company entered into a Forbearance Agreement relating to these defaults. During the nine months ended September 30, 2023, the Company remitted contractual debt service and is in compliance with the other contractual terms under the mortgage notes collateralized by the properties.
In July 2023, the Company elected not to pay July debt service on the Rochester Sub-Portfolio Loan in light of the continued negative cash flow generated by the Rochester Sub-Portfolio. The Rochester Sub-Portfolio Loan is non-recourse to the Company, subject to limited customary exceptions.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related Party Arrangements Related Party Arrangements
Former Advisor
In connection with the Internalization, the advisory agreement was terminated on October 21, 2022. Prior to the Internalization, the Former Advisor was responsible for managing the Company’s affairs on a day-to-day basis and for identifying, acquiring, originating and asset managing investments on behalf of the Company. For such services, to the extent permitted by law and regulations, the Former Advisor received fees and reimbursements from the Company. Pursuant to the advisory agreement, the Former Advisor could defer or waive fees in its discretion.
Transition Services
In connection with the Internalization, on October 21, 2022, the Company, the Operating Partnership and the Former Advisor entered into a Transition Services Agreement (the “TSA”) to facilitate an orderly transition of the Company’s management of its operations. The TSA, as amended on March 22, 2023, provides for, among other things, the Former Advisor to provide certain services, including primarily technology and insurance, for a transition period of up to six months following the Internalization, with legal, treasury and accounts payable services to continue until the Company terminates these services or in other specified circumstances in accordance with the TSA. The Company will reimburse the Former Advisor for costs to provide the services, including the allocated cost of employee wages and compensation and incurred out-of-pocket expenses.
Summary of Fees and Reimbursements
The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):
Reimbursements to Former Advisor EntitiesDue to Related Party as of December 31, 2022Nine Months Ended September 30, 2023
Due to Related Party as of September 30, 2023 (Unaudited)
Financial Statement LocationIncurredPaid
   Operating costsGeneral and administrative expenses/ Transaction costs$469 $520 
(1)
$(697)$292 
_______________________________________
(1)Represents costs incurred under the TSA during the nine months ended September 30, 2023.
Incentive Fee
The Special Unit Holder, formerly an affiliate of the Former Advisor, was entitled to receive distributions equal to 15.0% of net cash flows of the Company, whether from continuing operations, repayment of loans, disposition of assets or otherwise, but only after stockholders have received, in the aggregate, cumulative distributions equal to their invested capital plus a 6.75% cumulative, non-compounded annual pre-tax return on such invested capital. From inception through the date of the Sale of Minority Interests, the Special Unit Holder did not receive any incentive fees from the Company.
In connection with the Sale of Minority Interests, as of June 9, 2023, the Special Unit Holder became an indirect subsidiary of the Company, though the Special Unit Holder continues to have a contractual obligation to pay any such incentive fees to affiliates of the Former Sponsor, if ever earned.
Investments in Joint Ventures
Solstice, the manager of the Winterfell portfolio, is a joint venture between affiliates of ISL, which owns 80.0%, and the Company, which owns 20.0%. For the nine months ended September 30, 2023, the Company recognized property management fee expense of $5.1 million payable to Solstice related to the Winterfell portfolio.
In June 2023, the Company completed the Sale of Minority Interests, involving the sale of its minority interests in the Diversified US/UK and Eclipse Portfolios, together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates. Refer to Note 4, “Investments in Unconsolidated Ventures” for further discussion of the Sale of Minority Interests.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Equity-Based Compensation Equity-Based Compensation
The Company adopted a long-term incentive plan, as amended (the “Plan”), which it may use to attract and retain qualified officers, directors, employees and consultants, as well as an independent directors compensation plan, which is a component of the Plan. Under the Plan, 2.0 million shares of restricted common stock were eligible to be issued for any equity-based awards granted under the Plan.
Pursuant to the Plan, as of September 30, 2023, the Company’s independent directors were granted a total of 159,932 shares of restricted common stock and 203,742 restricted stock units totaling $1.3 million and $0.7 million, respectively, based on the share price on the date of each grant.
The restricted common stock and restricted stock units granted generally vest quarterly over two years in equal installments and will become fully vested on the earlier occurrence of: (i) the termination of the independent director’s service as a director due to his or her death or disability; or (ii) a change in control of the Company. The restricted stock units are convertible, on a one-for-one basis, into shares of the Company’s common stock upon the earlier occurrence of: (i) the termination of the independent director’s service as a director; or (ii) a change in control of the Company.
The Company recognized equity-based compensation expense of $56,250 and $56,875 for the three months ended September 30, 2023 and 2022, respectively, and $170,000 and $150,042 for the nine months ended September 30, 2023 and 2022, respectively. Equity-based compensation expense is recorded in general and administrative expenses in the consolidated statements of operations.
Unrecognized expense related to unvested restricted stock units totaled $296,250 and $211,250 as of September 30, 2023 and December 31, 2022, respectively. Unvested restricted stock units totaled 94,853 and 54,114 as of September 30, 2023 and December 31, 2022, respectively. As of December 31, 2022, the Company’s shares of restricted common stock were fully vested.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Equity Stockholders’ Equity
Common Stock
The Company stopped accepting subscriptions for its Offering on December 17, 2015 and all of the shares initially registered for its Offering were issued on or before January 19, 2016. The Company issued 173.4 million shares of common stock generating gross proceeds of $1.7 billion, excluding proceeds from the DRP.
Distribution Reinvestment Plan
The Company adopted the DRP through which common stockholders were able to elect to reinvest an amount equal to the distributions declared on their shares in additional shares of the Company’s common stock in lieu of receiving cash distributions. Since inception, the Company issued 25.7 million shares of common stock, generating gross offering proceeds of $232.6 million pursuant to the DRP. No selling commissions or dealer manager fees were paid on shares issued pursuant to the DRP. In April 2022, the Company’s board of directors elected to end the DRP, effective April 30, 2022.
Distributions
Effective February 1, 2019, the Company’s board of directors determined to stop recurring distributions in order to preserve capital and liquidity.
On April 20, 2022, the Company’s board of directors declared a special distribution of $0.50 per share (the “Special Distribution”) for each stockholder of record on May 2, 2022 totaling approximately $97.0 million.
In order to continue to qualify as a REIT, the Company must distribute annually dividends equal to at least 90% of its REIT taxable income (with certain adjustments). The Company did not have REIT taxable income for its taxable year ending December 31, 2022, therefore, it was not required to make distributions to its stockholders in 2022 to qualify as a REIT. The Company’s most recently filed tax return is for the year ended December 31, 2022 and includes a net operating loss carry-forward of $248.5 million.
Share Repurchase Program
The Company adopted the share repurchase program (the “Share Repurchase Program”) that enabled stockholders to sell their shares to the Company in limited circumstances and could be amended, suspended, or terminated at any time. The Company
previously funded repurchase requests with cash on hand, borrowings or other available capital. In April 2020, the Company’s board of directors determined to suspend all repurchases under the Share Repurchase Program effective April 30, 2020 in order to preserve capital and liquidity and does not currently anticipate resuming the Share Repurchase Program.
Retirement of Shares
In connection with the Sale of Minority Interests, the Company acquired 9.7 million shares of its common stock in exchange for its minority interests in the Diversified US/UK and Eclipse Portfolios from its Former Sponsor, who is affiliated with the majority partner of each joint venture. Upon completion of the Sale of Minority Interests, the Company retired all of the shares of common stock acquired.
To account for the acquisition and retirement of the common stock, the Company estimated the value of its minority interests in the Diversified US/UK and Eclipse Portfolios based on a variety of factors, including historical and projected revenues, market lease rates, the partners’ respective rights under the joint venture agreements, independent third-party appraisals obtained by the joint ventures and other factors deemed relevant. The Company determined the estimated value of minority interests to be approximately $12.5 million at the time of transaction. The estimated value, together with the $1.1 million of cash consideration, net of closing costs, is presented on the consolidated statements of equity as retirement of common stock.
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Non-controlling Interests Non-controlling Interests
Operating Partnership
Non-controlling interests included the aggregate limited partnership interests in the Operating Partnership held by limited partners, other than the Company. Income (loss) attributable to the non-controlling interests was based on the limited partners’ ownership percentage of the Operating Partnership. As a result of the Sale of Minority Interests, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, is 100.0% as of September 30, 2023. Income (loss) allocated to the Operating Partnership non-controlling interests for the period prior to June 9, 2023 were de minimis.
Other
Other non-controlling interests represent third-party equity interests in ventures that are consolidated with the Company’s financial statements. Net loss attributable to the other non-controlling interests was $0.2 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively, and $1.5 million and $0.3 million for the nine months ended September 30, 2023 and 2022, respectively.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Fair Value
Fair Value Measurement
The fair value of financial instruments is categorized based on the priority of the inputs to the valuation technique and categorized into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:
Level 1.Quoted prices for identical assets or liabilities in an active market.
Level 2.Financial assets and liabilities whose values are based on the following:
a)Quoted prices for similar assets or liabilities in active markets.
b)Quoted prices for identical or similar assets or liabilities in non-active markets.
c)Pricing models whose inputs are observable for substantially the full term of the asset or liability.
d)Pricing models whose inputs are derived principally from or corroborated by observable market data for substantially the full term of the asset or liability.
Level 3.Prices or valuation techniques based on inputs that are both unobservable and significant to the overall fair value measurement.
Derivative Instruments
Derivative instruments consist of interest rate contracts and foreign exchange contracts that are generally traded over-the-counter, and are valued using a third-party service provider. Quotations on over-the-counter derivatives are not adjusted and are generally valued using observable inputs such as contractual cash flows, yield curve, foreign currency rates and credit spreads, and are classified as Level 2 of the fair value hierarchy. Although credit valuation adjustments, such as the risk of default, rely on Level 3 inputs, these inputs are not significant to the overall valuation of its derivatives. As a result, derivative valuations in their entirety are classified as Level 2 of the fair value hierarchy.
Fair Value Hierarchy
Financial assets recorded at fair value on a recurring basis are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The following table presents financial assets that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 by level within the fair value hierarchy (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Level 1Level 2Level 3Level 1Level 2Level 3
Financial assets:
Derivative assets - interest rate caps
$— $820 $— $— $652 $— 
Investment in Espresso joint venture(1)
— — 3,075 — — — 
_______________________________________
(1)The Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. As of December 31, 2022, the investment was accounted for under the equity method.
Derivative Assets - Interest Rate Caps
The Company’s interest rate caps fair values are determined using models developed by the respective counterparty that use the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The floating interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities.
Investment in Espresso Joint Venture
The Company’s assessment of fair value for its unconsolidated investment in the Espresso joint venture took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses.
Fair Value of Financial Instruments
U.S. GAAP requires disclosure of fair value about all financial instruments. The following disclosure of estimated fair value of financial instruments was determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessary to interpret market data and develop estimated fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize on disposition of the financial instruments. The use of different market assumptions and/or estimation methodologies may have a material effect on estimated fair value.
The following table presents the principal amount, carrying value and fair value of certain financial assets and liabilities (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Principal AmountCarrying ValueFair ValuePrincipal AmountCarrying ValueFair Value
Financial liabilities:(1)
Mortgage notes payable, net$908,287 $901,610 $842,325 $922,355 $912,248 $882,754 
_______________________________________
(1)The fair value of other financial instruments not included in this table is estimated to approximate their carrying value.
Disclosure about fair value of financial instruments is based on pertinent information available to management as of the reporting date. Although management is not aware of any factors that would significantly affect fair value, such amounts have not been comprehensively revalued for purposes of these consolidated financial statements since that date and current estimates of fair value may differ significantly from the amounts presented herein.
Mortgage Notes Payable
The Company primarily uses rates currently available with similar terms and remaining maturities to estimate fair value. These measurements are determined using comparable U.S. Treasury and SOFR rates as of the end of the reporting period. These fair value measurements are based on observable inputs, and as such, are classified as Level 2 of the fair value hierarchy.
Nonrecurring Fair Values
The Company measures fair value of certain assets on a nonrecurring basis when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Adjustments to fair value generally result from the application of lower of amortized cost or fair value accounting for assets held for sale or otherwise, write-down of asset values due to impairment.
The following table summarizes the fair value and impairment losses of Level 3 assets which have been measured at fair value on a nonrecurring basis at the time of impairment during the periods presented (dollars in thousands):
Nine Months EndedYear Ended
September 30, 2023 (Unaudited)December 31, 2022
Fair ValueImpairment LossesFair ValueImpairment Losses
Operating real estate, net(1)
$41,496 $38,694 $80,931 $30,900 
Investments in unconsolidated ventures3,075 4,728 28,442 13,419 
_______________________________________
(1)During the year ended December 31, 2022, the Company recorded impairment losses totaling $1.0 million for property damage sustained by facilities in its Winterfell and Avamere portfolios. The fair value and impairment losses of these facilities are excluded from the table.
Operating Real Estate, Net
Operating real estate that is impaired is carried at fair value at the time of impairment. Impairment was driven by various factors that impacted undiscounted future net cash flows, including declines in operating performance, market growth assumptions and expected margins to be generated by the properties. Fair value of impaired operating real estate was estimated based upon various approaches including discounted cash flow analysis using terminal capitalization rates ranging from 6.00% to 8.50% and discount rates ranging from 8.5% to 10.5%, third party appraisals and offer prices.
Investments in Unconsolidated Ventures
In June 2023, the Company recorded impairment on its investment in the Espresso joint venture, which totaled $4.7 million and reduced the carrying value of its investment to $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.
During the year ended December 31, 2022, the Company recorded impairment on its investment in the Diversified US/UK joint venture, which totaled $13.4 million and reduced the carrying value of its investment to $28.4 million as of December 31, 2022. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s post-COVID-19 underperformance, rising interest rates and the joint venture’s ability to continue to service debt collateralized by substantially all of its domestically-located healthcare real estate. Fair value of the joint venture’s underlying operating real estate was estimated based upon various approaches including discounted cash flow analysis, using terminal capitalization rates ranging from 6.6% to 12.5% and discount rates ranging from 8.8% to 16.0%, and offer prices.
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company conducts its business through the following segments, which are based on how management reviews and manages its business.
•Direct Investments - Operating - Properties operated pursuant to management agreements with healthcare managers.
•Direct Investments - Net Lease - Properties operated under net leases with an operator.
•Unconsolidated Investments - Joint ventures, including properties operated under net leases with operators or pursuant to management agreements with healthcare managers, in which the Company owns a minority interest.
•Corporate - The corporate segment includes corporate level asset management fees - related party and general and administrative expenses.
The Company primarily generates rental and resident fee income from its direct investments. Additionally, the Company reports its proportionate interest of revenues and expenses from unconsolidated investments through equity in earnings (losses) of unconsolidated ventures.
The following tables present segment reporting (dollars in thousands):
Direct Investments
Three Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$837 $51,459 $— $1,078 $53,374 
Property operating expenses— (36,890)— — (36,890)
Interest expense(883)(13,367)— — (14,250)
Transaction costs— — (358)— (358)
General and administrative expenses— (30)— (2,891)(2,921)
Depreciation and amortization(729)(9,119)— — (9,848)
Gain (loss) on investments and other— (311)(36)— (347)
Equity in earnings (losses) of unconsolidated ventures— — (127)— (127)
Income tax expense— (17)— — (17)
Net income (loss)$(775)$(8,275)$(521)$(1,813)$(11,384)
Direct Investments
Three Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$724 $46,715 $— $300 $47,739 
Property operating expenses— (35,134)— — (35,134)
Interest expense(907)(10,107)— — (11,014)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (2,428)(2,428)
General and administrative expenses— (8)— (2,851)(2,859)
Depreciation and amortization(870)(8,772)— — (9,642)
Impairment loss(18,500)— — — (18,500)
Gain (loss) on investments and other— 325 — — 325 
Equity in earnings (losses) of unconsolidated ventures— — 2,872 — 2,872 
Income tax expense— (15)— — (15)
Net income (loss)$(19,553)$(6,996)$2,872 $(5,836)$(29,513)
Direct Investments
Nine Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,178 $150,374 $— $2,893 $154,445 
Property operating expenses— (106,993)— — (106,993)
Interest expense(2,639)(34,504)— — (37,143)
Transaction costs— — (358)(97)(455)
General and administrative expenses— (555)— (9,869)(10,424)
Depreciation and amortization(2,187)(27,118)— — (29,305)
Impairment loss— (38,694)(4,728)— (43,422)
Other income, net— 202 — — 202 
Gain (loss) on investments and other— (28)(4,634)— (4,662)
Equity in earnings (losses) of unconsolidated ventures— — (6,595)— (6,595)
Income tax expense— (43)— — (43)
Net income (loss)$(3,648)$(57,359)$(16,315)$(7,073)$(84,395)
Direct Investments
Nine Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,220 $134,768 $— $457 $136,445 
Property operating expenses(35)(101,223)— — (101,258)
Interest expense(2,708)(29,169)— — (31,877)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (7,532)(7,532)
General and administrative expenses— (24)— (10,276)(10,300)
Depreciation and amortization(2,601)(26,504)— — (29,105)
Impairment loss(18,500)(13,002)— — (31,502)
Other income, net— 77 — — 77 
Gain (loss) on investments and other(206)620 246 — 660 
Equity in earnings (losses) of unconsolidated ventures— — 39,427 — 39,427 
Income tax expense— (45)— — (45)
Net income (loss)$(22,830)$(34,502)$39,673 $(18,208)$(35,867)

The following table presents total assets by segment (dollars in thousands):
Direct Investments
Total Assets:Net LeaseOperatingUnconsolidated Investments
Corporate(1)
Total
September 30, 2023 (Unaudited)
$80,782 $847,401 $128,026 $79,707 $1,135,916 
December 31, 202283,435 884,137 176,502 93,761 1,237,835 
______________________________________
(1)Represents primarily corporate cash and cash equivalents balances.
The following table presents the operators and managers of the Company’s properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):
As of September 30, 2023Nine Months Ended September 30, 2023
Operator / ManagerProperties Under Management
Units Under Management(1)
Property and Other Revenues(2)
% of Total Property and Other Revenues
Solstice Senior Living(3)
32 3,969 $94,469 61.2 %
Watermark Retirement Communities14 1,782 35,967 23.2 %
Avamere Health Services5 453 16,266 10.5 %
Integral Senior Living1 40 3,672 2.4 %
Arcadia Management(4)
4 572 1,178 0.8 %
Other(5)
— — 2,893 1.9 %
Total56 6,816 $154,445 100.0 %
______________________________________
(1)Represents rooms for ALFs, ILFs and MCFs, based on predominant type.
(2)Includes rental income received from the Company’s net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from the Company’s ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.
(3)Solstice is a joint venture of which affiliates of ISL own 80%.
(4)During the nine months ended September 30, 2023, the Company recorded rental income to the extent payments were received.
(5)Consists primarily of interest income earned on corporate-level cash and cash equivalents.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
As of September 30, 2023, the Company believes there are no material unrecorded contingencies that would affect its results of operations, cash flows or financial position.
Litigation and Claims
The Company may be involved in various litigation matters arising in the ordinary course of its business. Although the Company is unable to predict with certainty the eventual outcome of any litigation, any current legal proceedings are not expected to have a material adverse effect on its financial position or results of operations.
The Company’s operators and managers may be involved in various litigation matters arising in the ordinary course of their business. The unfavorable resolution of any such actions, investigations or claims could, individually or in the aggregate, materially adversely affect such operators’ or managers’ liquidity, financial condition or results of operations and their ability to satisfy their respective obligations to the Company, which, in turn, could have a material adverse effect on the Company.
As of September 30, 2023, the Company has an accrued reserve of $0.6 million, inclusive of legal fees, relating to a resolution of claims against a manager of one of the Company’s direct operating investments, for which the Company has indemnification obligations under the management agreement.
Environmental Matters
The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its consolidated financial position, results of operations or cash flows. Further, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that it believes would require additional disclosure or the recording of a loss contingency.
General Uninsured Losses
The Company obtains various types of insurance to mitigate the impact of professional liability, property, business interruption, liability, flood, windstorm, earthquake, environmental and terrorism related losses. The Company attempts to obtain appropriate policy terms, conditions, limits and deductibles considering the relative risk of loss, the cost of such coverage and current industry practice. Disruptions in insurance markets may increase the costs of coverage and result in the Company retaining more risk, to the extent it is more commercially reasonable to do so. In addition, there are also certain types of extraordinary losses, such as those due to acts of war or other events, that may be either uninsurable or not economically insurable.
Other
Other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business, as well as commitments to fund capital expenditures for certain net lease properties. These commitments do not have a required minimum funding and are limited by agreed upon maximum annual funding amounts.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The following is a discussion of material events which have occurred subsequent to September 30, 2023 through the issuance of the consolidated financial statements.
Rochester Receivership
As a result of the payment default in July 2023 of the Rochester Sub-Portfolio Loan, on October 25, 2023, the lender filed a complaint seeking the appointment of a receiver and foreclosure on the underlying properties and to enforce its rights in its collateral under the loan documents and, on October 30, 2023, the properties underlying the Rochester Sub-Portfolio Loan were placed into a receivership. The receiver now has effective control of the properties and the Company is working with the lender and the receiver to facilitate an orderly transition of the operations, and eventually ownership, of the properties.
Trilogy Option Agreement
On November 3, 2023, the Company entered into an agreement to sell all of its ownership interests in Trilogy REIT Holdings, LLC (the “Trilogy Joint Venture”), which indirectly owns 123 integrated senior health campuses, to American Healthcare REIT, Inc. or its affiliates (“AHR”), the majority partner of the Trilogy Joint Venture. Under the agreement, AHR has the right to purchase the Company’s ownership interests in the Trilogy Joint Venture at any time prior to September 30, 2025, assuming AHR exercises all of its extension options and subject to satisfaction of certain closing conditions, for a purchase price ranging from $240.5 million to up to $260 million depending upon the purchase price consideration and timing of the closing. A minimum of 10% of the purchase price consideration must be paid in cash, with the balance payable in either cash or new Series A Cumulative Convertible Preferred Stock to be issued by AHR in connection with the closing. The portion of the purchase price consideration paid in cash may be subject to a 7.5% or 5% discount, respectively, if the transaction closes prior to March 31, 2024 or December 31, 2024, respectively. In addition, the Company may be entitled to a supplemental cash payment of $25,600 per day for the period between July 1, 2023 until the closing date, for up to approximately $21 million, if the Trilogy Joint Venture does not distribute an equivalent amount to the Company during the interim period. AHR may terminate the agreement at any time, subject to payment of a termination fee equal to: (i) if terminated prior to the initial outside date, September 30, 2024, $3.9 million or, if a “Qualifying IPO” (i.e., an underwritten public offering of AHR’s common stock resulting in at least $200 million of net proceeds) has occurred, $7.8 million, (ii) if extended and terminated prior March 31, 2025, $11.7 million and (iii) if further extended and terminated prior to September 30, 2025, $15.6 million. There can be no assurance that AHR will consummate the purchase of the Company’s interests on these terms or at all.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of Accounting
Basis of Accounting
The accompanying consolidated financial statements and related notes of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures normally included in the consolidated financial statements prepared under U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 27, 2023.
Principles of Consolidation
Principles of Consolidation
The consolidated financial statements include the accounts of the Company, the Operating Partnership and their consolidated subsidiaries. The Company consolidates entities in which it has a controlling financial interest by first considering if an entity meets the definition of a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary or if the Company has the power to control an entity through majority voting interest or other arrangements. All significant intercompany balances are eliminated in consolidation.
Variable Interest Entities
Variable Interest Entities
A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. A VIE is defined as an entity in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The determination of whether an entity is a VIE includes both a qualitative and quantitative analysis. The Company bases its qualitative analysis on its review of the design of the entity, its organizational structure including decision-making ability and relevant financial agreements and the quantitative analysis on the forecasted cash flow of the entity. The Company reassesses its initial evaluation of an entity as a VIE upon the occurrence of certain reconsideration events.
A VIE must be consolidated only by its primary beneficiary, which is defined as the party who, along with its affiliates and agents, has both the: (i) power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The Company determines whether it is the primary beneficiary of a VIE by considering qualitative and quantitative factors, including, but not limited to: which activities most significantly impact the VIE’s economic performance and which party controls such activities; the amount and characteristics of its investment; the obligation or likelihood for the Company or other interests to provide financial support; consideration of the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders and the similarity with and significance to the business activities of the Company and the other interests. The Company reassesses its determination of whether it is the primary beneficiary of a VIE each reporting period. Judgments related to these determinations include estimates about the current and future fair value and performance of investments held by these VIEs and general market conditions.
The Company evaluates its investments and financings, including investments in unconsolidated ventures and securitization financing transactions to determine whether each investment or financing is a VIE. The Company analyzes new investments and financings, as well as reconsideration events for existing investments and financings, which vary depending on type of investment or financing.
As of September 30, 2023, the Company has identified certain consolidated and unconsolidated VIEs. Assets of each of the VIEs, may only be used to settle obligations of the respective VIE. Creditors of each of the VIEs have no recourse to the general credit of the Company.
Consolidated VIEs
The most significant VIEs of the Company are certain entities that are consolidated by the Operating Partnership. These entities are VIEs because of non-controlling interests owned by third parties, which do not have substantive kick-out or participating rights. Included in operating real estate, net and mortgage notes payable, net on the Company’s consolidated balance sheet as of September 30, 2023 is $170.1 million and $172.0 million, respectively, related to such consolidated VIEs.
Unconsolidated VIEs
As of September 30, 2023, the Company identified unconsolidated VIEs related to its investments in unconsolidated ventures with a carrying value of $128.0 million. The Company’s maximum exposure to loss as of September 30, 2023 would not exceed the carrying value of its investment in the VIEs. The Company determined that it is not the primary beneficiary of these VIEs and, accordingly, they are not consolidated in the Company’s financial statements as of September 30, 2023. The Company did not provide financial support to its unconsolidated VIEs during the nine months ended September 30, 2023. As of September 30, 2023, there were no explicit arrangements or implicit variable interests that could require the Company to provide financial support to its unconsolidated VIEs.
Voting Interest Entities
Voting Interest Entities
A voting interest entity is an entity in which the total equity investment at risk is sufficient to enable it to finance its activities independently and the equity holders have the power to direct the activities of the entity that most significantly impact its
economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity. The usual condition for a controlling financial interest in a voting interest entity is ownership of a majority voting interest. If the Company has a majority voting interest in a voting interest entity, the entity will generally be consolidated. The Company does not consolidate a voting interest entity if there are substantive participating rights by other parties and/or kick-out rights by a single party or through a simple majority vote.
The Company performs on-going reassessments of whether entities previously evaluated under the voting interest framework have become VIEs, based on certain events, and therefore subject to the VIE consolidation framework.
Investments in Unconsolidated Ventures
Investments in Unconsolidated Ventures
A non-controlling, unconsolidated ownership interest in an entity may be accounted for using the equity method or the Company may elect the fair value option.
The Company will account for an investment under the equity method of accounting if it has the ability to exercise significant influence over the operating and financial policies of an entity, but does not have a controlling financial interest. Under the equity method, the investment is adjusted each period for capital contributions and distributions and its share of the entity’s net income (loss). Capital contributions, distributions and net income (loss) of such entities are recorded in accordance with the terms of the governing documents. An allocation of net income (loss) may differ from the stated ownership percentage interest in such entity as a result of preferred returns and allocation formulas, if any, as described in such governing documents. Equity method investments are recognized using a cost accumulation model, in which the investment is recognized based on the cost to the investor, which includes acquisition fees. The Company records as an expense certain acquisition costs and fees associated with consolidated investments deemed to be business combinations and capitalizes these costs for investments deemed to be acquisitions of an asset, including an equity method investment.
The Company may elect the fair value option of accounting for an investment that would otherwise be accounted for under the equity method. The fair value option election allows an entity to make an irrevocable election of fair value for certain financial assets and liabilities on an instrument-by-instrument basis at the initial or subsequent measurement. The decision to elect the fair value option must be applied to an entire instrument and is irrevocable once elected. Under the fair value option, the Company records its share of the changes to fair value of the investment and any unrealized gains and losses.
On June 30, 2023, the Company elected the fair value option method to account for its investment in the Espresso joint venture, which is included in investments in unconsolidated ventures on the consolidated balance sheets. The fair value election was made based on the Company’s assessment that the expected return of investment was lower than the Company’s carrying value of its investment in the Espresso joint venture, which resulted in an impairment of $4.7 million and reduced the carrying value of its investment to recoverable fair value of $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. The Company will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations.
Non-controlling Interests
Non-controlling Interests
A non-controlling interest in a consolidated subsidiary is defined as the portion of the equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company. A non-controlling interest is required to be presented as a separate component of equity on the consolidated balance sheets and presented separately as net income (loss) and comprehensive income (loss) attributable to controlling and non-controlling interests. An allocation to a non-controlling interest may differ from the stated ownership percentage interest in such entity as a result of a preferred return and allocation formula, if any, as described in such governing documents.
Estimates
Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.
Cash, Cash Equivalents and Restricted Cash
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly-liquid investments with an original maturity date of three months or less to be cash equivalents. Cash, including amounts restricted, may at times exceed the Federal Deposit Insurance Corporation deposit insurance limit of $250,000 per institution. The Company mitigates credit risk by placing cash and cash equivalents with major financial institutions and money market funds invested in short-term U.S. government securities. To date, the Company has not experienced any losses on cash and cash equivalents.
Restricted cash consists of amounts related to operating real estate (escrows for taxes, insurance, capital expenditures, security deposits received from residents and payments required under certain lease agreements) and other escrows required by lenders of the Company’s borrowings.
Operating Real Estate
Operating Real Estate
Operating real estate is carried at historical cost less accumulated depreciation. Major replacements and betterments which improve or extend the life of the asset are capitalized and depreciated over their useful life. Ordinary repairs and maintenance are expensed as incurred. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:
Category:Term:
Building
30 to 50 years
Building improvementsLesser of the useful life or remaining life of the building
Land improvements
9 to 15 years
Tenant improvementsLesser of the useful life or remaining term of the lease
Furniture, fixtures and equipment
5 to 14 years
Construction costs incurred in connection with the Company’s investments are capitalized and included in operating real estate, net on the consolidated balance sheets. Construction in progress is not depreciated until the asset is available for its intended use.
Lessee Accounting
Lessee Accounting
A leasing arrangement, a right to control the use of an identified asset for a period of time in exchange for consideration, is classified by the lessee either as a finance lease, which represents a financed purchase of the leased asset, or as an operating lease. For leases with terms greater than 12 months, a lease asset and a lease liability are recognized on the balance sheet at commencement date based on the present value of lease payments over the lease term.
Lease renewal or termination options are included in the lease asset and lease liability only if it is reasonably certain that the option to extend would be exercised or the option to terminate would not be exercised. As the implicit rate in most leases are not readily determinable, the Company’s incremental borrowing rate for each lease at commencement date is used to determine the present value of lease payments. Consideration is given to the Company’s recent debt financing transactions, as well as publicly available data for instruments with similar characteristics, adjusted for the respective lease term, when estimating incremental borrowing rates.
Lease expense is recognized over the lease term based on an effective interest method for finance leases and on a straight-line basis for operating leases.
Right of Use (“ROU”) - Finance AssetsThe Company has entered into finance leases for equipment which are included in operating real estate, net on the Company’s consolidated balance sheets.
Deferred Costs
Deferred Costs
Deferred costs consist of deferred financing costs. Deferred financing costs represent commitment fees, legal and other third-party costs associated with obtaining financing. These costs are recorded against the carrying value of such financing and are amortized to interest expense over the term of the financing using the effective interest method. Unamortized deferred financing costs are expensed to gain (loss) on investments and other, when the associated borrowing is repaid before maturity. Costs incurred in seeking financing transactions which do not close are expensed in the period in which it is determined that the financing will not occur.
Identified Intangibles
Identified Intangibles
The Company records acquired identified intangibles, such as the value of in-place leases and other intangibles, based on estimated fair value at the acquisition date. The value allocated to the identified intangibles is amortized over the remaining lease term. In-place leases are amortized into depreciation and amortization expense.
Impairment analysis for identified intangible assets is performed in connection with the impairment assessment of the related operating real estate. An impairment establishes a new basis for the identified intangible asset and any impairment loss recognized is not subject to subsequent reversal. Refer to “—Impairment on Operating Real Estate and Investments in Unconsolidated Ventures” for additional information.
Identified intangible assets are recorded in intangible assets, net on the consolidated balance sheets.
Derivative Instruments Derivative Instruments The Company uses derivative instruments to manage its interest rate risk. The Company’s derivative instruments are recorded at fair value. The accounting for changes in fair value of derivatives depends upon whether or not the Company has elected to designate the derivative in a hedging relationship and the derivative qualifies for hedge accounting. Under hedge accounting, changes in fair value for derivatives are recorded through other comprehensive income. When hedge accounting is not elected, changes in fair value for derivatives are recorded through the income statement.
Revenue Recognition
Revenue Recognition
Operating Real Estate
Rental income from operating real estate is derived from leasing of space to operators and residents, including rent received from the Company’s net lease properties and rent, ancillary service fees and other related revenue earned from ILF residents. Rental income recognition commences when the operator takes legal possession of the leased space and the leased space is substantially ready for its intended use. The leases are for fixed terms of varying length and generally provide for rentals and expense reimbursements to be paid in monthly installments. Rental income from leases, which includes community and move-in fees, is recognized over the term of the respective leases. ILF resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice.
The Company also generates revenue from operating healthcare properties. Revenue related to operating healthcare properties includes resident room and care charges, ancillary fees and other resident service charges. Rent is charged and revenue is recognized when such services are provided, generally defined per the resident agreement as of the date upon which a resident occupies a room or uses the services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Revenue derived from our ALFs and MCFs is recorded in resident fee income in the consolidated statements of operations.
Revenue from operators and residents is recognized at lease commencement only to the extent collection is expected to be probable. This assessment is based on several qualitative and quantitative factors, including and as appropriate, the payment history, ability to satisfy its lease obligations, the value of the underlying collateral or deposit, if any, and current economic conditions. If collection is assessed to not be probable, thereafter lease income recognized is limited to amounts collected, with the reversal of any revenue recognized to date in excess of amounts received. If collection is subsequently reassessed to be probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable.
The operator of the Company’s four net lease properties failed to remit contractual monthly rent obligations and the Company deemed it not probable that these obligations will be satisfied in the foreseeable future. On March 27, 2023, the Company entered into a lease forbearance and modification agreement (the “Forbearance Agreement”) with the existing operator, pursuant to which, among other things, the Company will be entitled to receive all cash flow in excess of permitted expenses, and be required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. For the three and nine months ended September 30, 2023, the Company received excess cash flow of $0.8 million and $1.2 million, respectively, which was recorded as rental income.
For the three months ended September 30, 2023 and 2022, total property and other revenues includes variable lease revenue of $3.6 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, total property and other revenue includes variable lease revenue of $10.7 million and $9.2 million, respectively. Variable lease revenue includes ancillary services provided to operator/residents, as well as non-recurring services and fees at the Company’s operating facilities.
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures
At this time, it is difficult for the Company to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. The future economic effects will depend on many factors beyond the Company’s control and knowledge. The resulting effect on impairment of the Company's real estate held for investment and held for sale and investments in unconsolidated ventures may materially differ from the Company's current expectations and further impairment charges may be recorded in future periods.
Operating Real Estate
The Company’s real estate portfolio is reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of its operating real estate may be impaired or that its carrying value may not be recoverable. A property’s value is considered impaired if the Company’s estimate of the aggregate expected future undiscounted cash flow generated by the property is less than the carrying value. In conducting this review, the Company considers U.S. macroeconomic factors, real estate and healthcare sector conditions, together with asset specific and other factors. To the extent an impairment has occurred, the loss is measured as the excess of the carrying value of the property over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
Real estate held for sale is stated at the lower of its carrying amount or estimated fair value less disposal cost, with any write-down to disposal cost recorded as an impairment loss. For any increase in fair value less disposal cost subsequent to classification as held for sale, the impairment may be reversed, but only up to the amount of cumulative loss previously recognized.
The Company considered the potential impact of the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions on the future net operating income of its healthcare real estate held for investment as an indicator of impairment. Fair values were estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization rates.
Investments in Unconsolidated Ventures
The Company reviews its investments in unconsolidated ventures on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value may be impaired or that its carrying value may not be recoverable. An investment is considered impaired if the projected net recoverable amount over the expected holding period is less than the carrying value. In conducting this review, the Company considers global macroeconomic factors, including real estate sector conditions, together with investment specific and other factors. To the extent an impairment has occurred on the Company’s investment in unconsolidated ventures, and is considered to be other than temporary, the loss is measured as the excess of the carrying value of the investment over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.
Credit Losses on Receivables
Credit Losses on Receivables
The current expected credit loss model, in estimating expected credit losses over the life of a financial instrument at the time of origination or acquisition, considers historical loss experiences, current conditions and the effects of reasonable and supportable expectations of changes in future macroeconomic conditions. The Company assesses the estimate of expected credit losses on a quarterly basis or more frequently as necessary. The Company considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts.
The Company measures expected credit losses of receivables on a collective basis when similar risk characteristics exist. If the Company determines that a particular receivable does not share risk characteristics with its other receivables, the Company evaluates the receivable for expected credit losses on an individual basis.
When developing an estimate of expected credit losses on receivables, the Company considers available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both relating to past events, current conditions, and reasonable and supportable forecasts. The Company considers relevant qualitative and quantitative factors that relate to the environment in which the Company operates and are specific to the borrower.
Further, the fair value of the collateral, less estimated costs to sell, may be used when determining the allowance for credit losses for a receivable for which the repayment is expected to be provided substantially through the sale of the collateral when the borrower is experiencing financial difficulty.
Acquisition Fees and Expenses Acquisition Fees and ExpensesThe Company recorded an expense for certain acquisition costs and fees associated with transactions deemed to be business combinations in which it consolidated the asset and capitalized these costs for transactions deemed to be acquisitions of an asset, including an equity investment.
Equity-Based Compensation
Equity-Based Compensation
The Company accounts for equity-based compensation awards using the fair value method, which requires an estimate of fair value of the award at the time of grant. All fixed equity-based awards to directors, which have no vesting conditions other than
time of service, are amortized to compensation expense over the awards’ vesting period on a straight-line basis. Equity-based compensation is classified within general and administrative expenses in the consolidated statements of operations.
Income Taxes
Income Taxes
The Company elected to be taxed as a REIT and to comply with the related provisions of the Internal Revenue Code beginning in its taxable year ended December 31, 2013. Accordingly, the Company will generally not be subject to U.S. federal income tax to the extent of its distributions to stockholders as long as certain asset, gross income and share ownership tests are met. To maintain its qualification as a REIT, the Company must annually distribute dividends equal to at least 90.0% of its REIT taxable income (with certain adjustments) to its stockholders and meet certain other requirements. The Company believes that all of the criteria to maintain the Company’s REIT qualification have been met for the applicable periods, but there can be no assurance that these criteria will continue to be met in subsequent periods. If the Company were to fail to meet these requirements, it would be subject to U.S. federal income tax and potential interest and penalties, which could have a material adverse impact on its results of operations and amounts available for distributions to its stockholders. The Company’s accounting policy with respect to interest and penalties is to classify these amounts as a component of income tax expense, where applicable. The Company has assessed its tax positions for all open tax years, which include 2018 to 2022, and concluded there were no material uncertainties to be recognized.
The Company may also be subject to certain state, local and franchise taxes. Under certain circumstances, federal income and excise taxes may be due on its undistributed taxable income.
The Company made a joint election to treat certain subsidiaries as taxable REIT subsidiaries (“TRS”) which may be subject to U.S. federal, state and local income taxes. In general, a TRS of the Company may perform services for managers/operators/residents of the Company, hold assets that the Company cannot hold directly and may engage in any real estate or non-real estate related business.
Certain subsidiaries of the Company are subject to taxation by federal and state authorities for the periods presented. Income taxes are accounted for by the asset/liability approach in accordance with U.S. GAAP. Deferred taxes, if any, represent the expected future tax consequences when the reported amounts of assets and liabilities are recovered or paid. Such amounts arise from differences between the financial reporting and tax bases of assets and liabilities and are adjusted for changes in tax laws and tax rates in the period which such changes are enacted. A provision for income tax represents the total of income taxes paid or payable for the current period, plus the change in deferred taxes. Current and deferred taxes are provided on the portion of earnings (losses) recognized by the Company with respect to its interest in the TRS. Deferred income tax assets and liabilities are calculated based on temporary differences between the Company’s U.S. GAAP consolidated financial statements and the federal and state income tax basis of assets and liabilities as of the consolidated balance sheet date. The Company evaluates the realizability of its deferred tax assets (e.g., net operating loss and capital loss carryforwards) and recognizes a valuation allowance if, based on the available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. When evaluating the realizability of its deferred tax assets, the Company considers estimates of expected future taxable income, existing and projected book/tax differences, tax planning strategies available and the general and industry specific economic outlook. This realizability analysis is inherently subjective, as it requires the Company to forecast its business and general economic environment in future periods. Changes in estimate of deferred tax asset realizability, if any, are included in provision for income tax benefit (expense) in the consolidated statements of operations.
Comprehensive Income (Loss) Comprehensive Income (Loss) The Company reports consolidated comprehensive income (loss) in separate statements following the consolidated statements of operations. Comprehensive income (loss) is defined as the change in equity resulting from net income (loss) and other comprehensive income (loss) (“OCI”). The only component of OCI for the Company was foreign currency translation adjustments related to its investment in an unconsolidated venture.
Foreign Currency
Foreign Currency
Assets and liabilities denominated in a foreign currency for which the functional currency is a foreign currency are translated using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are translated into U.S. dollars using the average currency exchange rate in effect during the period. The resulting foreign currency translation adjustment is recorded as a component of accumulated OCI in the consolidated statements of equity.
Assets and liabilities denominated in a foreign currency for which the functional currency is the U.S. dollar are remeasured using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are remeasured into U.S. dollars using the average currency exchange rate in effect during the period.
For the period December 31, 2022 through June 9, 2023, the Company had exposure to foreign currency through an investment in an unconsolidated venture, the effects of which were recorded as a component of accumulated OCI in the consolidated statements of equity and in equity in earnings (losses) in the consolidated statements of operations. As a result of the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”) in June 2023, the Company is no longer exposed to foreign currency as of September 30, 2023. The Company reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK joint venture, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other on the consolidated statements of operations.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Accounting Standards Adopted in 2023
In March 2020, the FASB issued an amendment to the reference rate reform standard, which provides the option for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on contract modifications and hedge accounting. An example of such reform is the market transition from the London Interbank Offered Rate (“LIBOR”) to alternative reference rates. Entities that make this optional expedient election would not have to remeasure the contracts at the modification date or reassess the accounting treatment if certain criteria are met and would continue applying hedge accounting for relationships affected by reference rate reform. In December 2022, the FASB extended the date for which this guidance can be applied from December 31, 2022 to December 31, 2024. The Company did not make the optional election of the aforementioned accounting standards.
Future Application of Accounting Standards
None.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):
September 30, 2023 (Unaudited)
December 31, 2022
Cash and cash equivalents$87,581 $103,926 
Restricted cash11,386 11,734 
Total cash, cash equivalents and restricted cash$98,967 $115,660 
Reconciliation of Cash, Cash Equivalents and Restricted Cash
The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):
September 30, 2023 (Unaudited)
December 31, 2022
Cash and cash equivalents$87,581 $103,926 
Restricted cash11,386 11,734 
Total cash, cash equivalents and restricted cash$98,967 $115,660 
Schedule of Operating Real Estate Estimated Useful Life Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:
Category:Term:
Building
30 to 50 years
Building improvementsLesser of the useful life or remaining life of the building
Land improvements
9 to 15 years
Tenant improvementsLesser of the useful life or remaining term of the lease
Furniture, fixtures and equipment
5 to 14 years
Schedule of Future Minimum Lease Payments for Capital Leases
The following table presents the future minimum lease payments under finance leases and the present value of the minimum lease payments, which are included in other liabilities on the Company’s consolidated balance sheets (dollars in thousands):
October 1 through December 31, 2023$18 
Years Ending December 31:
202469 
202538 
202633 
202718 
Thereafter10 
Total minimum lease payments$186 
Less: Amount representing interest(27)
Present value of minimum lease payments$159 
Schedule of Intangible Assets, Net The following table presents intangible assets, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
In-place lease value$120,149 $120,149 
Less: Accumulated amortization(118,149)(117,896)
Intangible assets, net$2,000 $2,253 
Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense
The following table presents future amortization of in-place lease value (dollars in thousands):
October 1 through December 31, 2023$84 
Years Ending December 31:
2024337 
2025337 
2026337 
2027337 
Thereafter568 
Total$2,000 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Real Estate (Tables)
 9 Months Ended
Sep. 30, 2023
Real Estate [Abstract]  
Schedule of Operating Real Estate
The following table presents operating real estate, net (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Land$121,424 $121,518 
Land improvements19,913 18,945 
Buildings and improvements932,261 957,924 
Tenant improvements372 372 
Construction in progress8,956 6,736 
Furniture, fixtures and equipment103,876 91,058 
Subtotal$1,186,802 $1,196,553 
Less: Accumulated depreciation(292,557)(263,551)
Operating real estate, net$894,245 $933,002 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in Unconsolidated Ventures (Tables)
 9 Months Ended
Sep. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]  
Equity Method Investments The following table presents the Company’s investments in unconsolidated ventures (dollars in thousands):
Carrying Value
PortfolioAcquisition DateOwnershipSeptember 30, 2023 (Unaudited)December 31, 2022
Trilogy(1)
Dec-201523.4 %$124,670 $128,884 
Espresso(2)
Jul-201536.7 %3,075 18,019 
Solstice(3)
Jul-201720.0 %281 323 
Investments sold(4)
— 29,276 
Investments in Unconsolidated Ventures$128,026 $176,502 
_______________________________________
(1)The carrying value for the Company’s investment in the Trilogy joint venture includes $9.8 million of capitalized acquisition costs.
(2)In June 2023, the Company recorded an impairment of $4.7 million to reflect the fair value of its investment in the Espresso joint venture, based on the estimated cash distributions to be received from the joint venture. Based on the Company’s assessment, it elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.
(3)Represents the Company’s investment in Solstice Senior Living, LLC (“Solstice”), the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC (“ISL”), a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and the Company, which owns 20.0%.
(4)In June 2023, the Company sold its ownership interests in the Diversified US/UK and Eclipse joint ventures.
The following table presents the results of the Company’s investment in unconsolidated ventures (dollars in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
PortfolioEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash DistributionEquity in Earnings (Losses)Cash Distribution
Trilogy$(146)$— $6,052 $2,300 $454 $4,668 $10,757 $6,900 
Espresso(1)
— — (242)1,375 9,228 19,444 33,711 32,363 
Solstice19 — 17 — (41)— (41)— 
Investments sold(2)
— — (2,955)358 (16,236)— (5,000)2,910 
Total$(127)$— $2,872 $4,033 $(6,595)$24,112 $39,427 $42,173 
_______________________________________
(1)The Espresso joint venture recognized net gains related to sub-portfolio sales, of which the Company’s proportionate share totaled $9.2 million and $32.0 million for the nine months ended September 30, 2023 and 2022, respectively. The Company was distributed its proportionate share of the net proceeds generated from the sales during the nine months ended September 30, 2023 and 2022, totaling $17.3 million and $27.4 million, respectively.
(2)In May 2023, the Diversified US/UK joint venture recognized impairment, of which the Company’s proportionate share totaled $11.4 million and is included in equity in earnings (losses) for the nine months ended September 30, 2023.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings (Tables)
 9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Summary of Borrowings
The following table presents the Company’s mortgage notes payable (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Recourse vs. Non-Recourse(1)
Initial
Maturity
Contractual
Interest Rate(2)
Principal
Amount(3)
Carrying
Value(3)
Principal
Amount(3)
Carrying
Value(3)
Aqua Portfolio
Frisco, TX(4)
Non-recourseFeb 20263.0%$26,000 $25,660 $26,000 $25,560 
Milford, OHNon-recourseSep 2026
SOFR + 2.79%
18,212 18,036 18,336 18,126 
Rochester Portfolio
Rochester, NYNon-recourseFeb 20254.25%17,657 17,629 18,206 18,165 
Rochester, NY(5)
Non-recourseJul 2023
SOFR + 2.45%
99,786 99,787 100,651 100,042 
Rochester, NYNon-recourseAug 2024
SOFR + 2.93%
10,922 10,891 11,336 11,315 
Arbors Portfolio(6)
Various locationsNon-recourseFeb 20253.99%81,912 81,680 83,423 83,051 
Winterfell Portfolio(7)
Various locationsNon-recourseJun 20254.17%586,773 581,157 596,408 588,306 
Avamere Portfolio(8)
Various locationsNon-recourseFeb 20274.66%67,025 66,770 67,995 67,683 
Mortgage notes payable, net$908,287 $901,610 $922,355 $912,248 
_______________________________________
(1)Subject to non-recourse carve-outs.
(2)Floating-rate borrowings total $128.9 million of principal outstanding and reference one-month SOFR as of September 30, 2023.
(3)The difference between principal amount and carrying value of mortgage notes payable is attributable to deferred financing costs, net for all borrowings, other than the Winterfell portfolio which is attributable to below market debt intangibles.
(4)The mortgage note carries a fixed interest rate of 3.0% through February 2024, followed by one-month adjusted SOFR, plus 2.80% through the initial maturity date of February 2026.
(5)Composed of seven individual mortgage notes payable (the “Rochester Sub-Portfolio Loan”) secured by seven healthcare real estate properties (the “Rochester Sub-Portfolio”), cross-collateralized and subject to cross-default. In July 2023, the Company elected not to pay debt service on the Rochester Sub-Portfolio Loan, which resulted in a default notice accelerating the maturity of the loan from its original terms of August 2027.
(6)Composed of four individual mortgage notes payable secured by four healthcare real estate properties, cross-collateralized and subject to cross-default.
(7)Composed of 32 individual mortgage notes payable secured by 32 healthcare real estate properties, cross-collateralized and subject to cross-default.
(8)Composed of five individual mortgage notes payable secured by five healthcare real estate properties, cross-collateralized and subject to cross-default.
Schedule of Principal on Borrowings based on Final Maturity
The following table presents future scheduled principal payments on mortgage notes payable based on initial maturity as of September 30, 2023 (dollars in thousands):
October 1 through December 31, 2023$104,238 
Years Ending December 31:
202428,761 
2025667,741 
202645,151 
202762,396 
Total$908,287 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements (Tables)
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Schedule of the Fees and Reimbursements Incurred to the Advisor and Dealer Manager
The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):
Reimbursements to Former Advisor EntitiesDue to Related Party as of December 31, 2022Nine Months Ended September 30, 2023
Due to Related Party as of September 30, 2023 (Unaudited)
Financial Statement LocationIncurredPaid
   Operating costsGeneral and administrative expenses/ Transaction costs$469 $520 
(1)
$(697)$292 
_______________________________________
(1)Represents costs incurred under the TSA during the nine months ended September 30, 2023.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities The following table presents financial assets that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 by level within the fair value hierarchy (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Level 1Level 2Level 3Level 1Level 2Level 3
Financial assets:
Derivative assets - interest rate caps
$— $820 $— $— $652 $— 
Investment in Espresso joint venture(1)
— — 3,075 — — — 
_______________________________________
(1)The Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. As of December 31, 2022, the investment was accounted for under the equity method.
The following table presents the principal amount, carrying value and fair value of certain financial assets and liabilities (dollars in thousands):
September 30, 2023 (Unaudited)December 31, 2022
Principal AmountCarrying ValueFair ValuePrincipal AmountCarrying ValueFair Value
Financial liabilities:(1)
Mortgage notes payable, net$908,287 $901,610 $842,325 $922,355 $912,248 $882,754 
_______________________________________
(1)The fair value of other financial instruments not included in this table is estimated to approximate their carrying value.
The following table summarizes the fair value and impairment losses of Level 3 assets which have been measured at fair value on a nonrecurring basis at the time of impairment during the periods presented (dollars in thousands):
Nine Months EndedYear Ended
September 30, 2023 (Unaudited)December 31, 2022
Fair ValueImpairment LossesFair ValueImpairment Losses
Operating real estate, net(1)
$41,496 $38,694 $80,931 $30,900 
Investments in unconsolidated ventures3,075 4,728 28,442 13,419 
_______________________________________
(1)During the year ended December 31, 2022, the Company recorded impairment losses totaling $1.0 million for property damage sustained by facilities in its Winterfell and Avamere portfolios. The fair value and impairment losses of these facilities are excluded from the table.
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2023
Segment Reporting [Abstract]  
Summary of Segment Reporting
The following tables present segment reporting (dollars in thousands):
Direct Investments
Three Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$837 $51,459 $— $1,078 $53,374 
Property operating expenses— (36,890)— — (36,890)
Interest expense(883)(13,367)— — (14,250)
Transaction costs— — (358)— (358)
General and administrative expenses— (30)— (2,891)(2,921)
Depreciation and amortization(729)(9,119)— — (9,848)
Gain (loss) on investments and other— (311)(36)— (347)
Equity in earnings (losses) of unconsolidated ventures— — (127)— (127)
Income tax expense— (17)— — (17)
Net income (loss)$(775)$(8,275)$(521)$(1,813)$(11,384)
Direct Investments
Three Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$724 $46,715 $— $300 $47,739 
Property operating expenses— (35,134)— — (35,134)
Interest expense(907)(10,107)— — (11,014)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (2,428)(2,428)
General and administrative expenses— (8)— (2,851)(2,859)
Depreciation and amortization(870)(8,772)— — (9,642)
Impairment loss(18,500)— — — (18,500)
Gain (loss) on investments and other— 325 — — 325 
Equity in earnings (losses) of unconsolidated ventures— — 2,872 — 2,872 
Income tax expense— (15)— — (15)
Net income (loss)$(19,553)$(6,996)$2,872 $(5,836)$(29,513)
Direct Investments
Nine Months Ended September 30, 2023Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,178 $150,374 $— $2,893 $154,445 
Property operating expenses— (106,993)— — (106,993)
Interest expense(2,639)(34,504)— — (37,143)
Transaction costs— — (358)(97)(455)
General and administrative expenses— (555)— (9,869)(10,424)
Depreciation and amortization(2,187)(27,118)— — (29,305)
Impairment loss— (38,694)(4,728)— (43,422)
Other income, net— 202 — — 202 
Gain (loss) on investments and other— (28)(4,634)— (4,662)
Equity in earnings (losses) of unconsolidated ventures— — (6,595)— (6,595)
Income tax expense— (43)— — (43)
Net income (loss)$(3,648)$(57,359)$(16,315)$(7,073)$(84,395)
Direct Investments
Nine Months Ended September 30, 2022Net LeaseOperatingUnconsolidated InvestmentsCorporateTotal
Property and other revenues$1,220 $134,768 $— $457 $136,445 
Property operating expenses(35)(101,223)— — (101,258)
Interest expense(2,708)(29,169)— — (31,877)
Transaction costs— — — (857)(857)
Asset management fees - related party— — — (7,532)(7,532)
General and administrative expenses— (24)— (10,276)(10,300)
Depreciation and amortization(2,601)(26,504)— — (29,105)
Impairment loss(18,500)(13,002)— — (31,502)
Other income, net— 77 — — 77 
Gain (loss) on investments and other(206)620 246 — 660 
Equity in earnings (losses) of unconsolidated ventures— — 39,427 — 39,427 
Income tax expense— (45)— — (45)
Net income (loss)$(22,830)$(34,502)$39,673 $(18,208)$(35,867)
Summary of Assets by Segment
The following table presents total assets by segment (dollars in thousands):
Direct Investments
Total Assets:Net LeaseOperatingUnconsolidated Investments
Corporate(1)
Total
September 30, 2023 (Unaudited)
$80,782 $847,401 $128,026 $79,707 $1,135,916 
December 31, 202283,435 884,137 176,502 93,761 1,237,835 
______________________________________
(1)Represents primarily corporate cash and cash equivalents balances.
Schedule of Real Estate Properties
The following table presents the operators and managers of the Company’s properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):
As of September 30, 2023Nine Months Ended September 30, 2023
Operator / ManagerProperties Under Management
Units Under Management(1)
Property and Other Revenues(2)
% of Total Property and Other Revenues
Solstice Senior Living(3)
32 3,969 $94,469 61.2 %
Watermark Retirement Communities14 1,782 35,967 23.2 %
Avamere Health Services5 453 16,266 10.5 %
Integral Senior Living1 40 3,672 2.4 %
Arcadia Management(4)
4 572 1,178 0.8 %
Other(5)
— — 2,893 1.9 %
Total56 6,816 $154,445 100.0 %
______________________________________
(1)Represents rooms for ALFs, ILFs and MCFs, based on predominant type.
(2)Includes rental income received from the Company’s net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from the Company’s ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.
(3)Solstice is a joint venture of which affiliates of ISL own 80%.
(4)During the nine months ended September 30, 2023, the Company recorded rental income to the extent payments were received.
(5)Consists primarily of interest income earned on corporate-level cash and cash equivalents.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Business and Organization (Details) - USD ($)
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Class of Stock [Line Items]    
Common stock, shares authorized (in shares) 400,000,000 400,000,000
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 50,000,000 50,000,000
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Net proceeds from issuance of common stock $ 2,000,000,000  
Dividend Reinvestment Plan    
Class of Stock [Line Items]    
Net proceeds from issuance of common stock $ 232,600,000  
Primary Beneficiary | Northstar Healthcare Income Operating Partnership, LP    
Class of Stock [Line Items]    
Limited partnership interest in operating partnership 100.00%  
Advisor    
Class of Stock [Line Items]    
Non-controlling interest investment in operating partnership $ 1,000  
Special Unit Holder    
Class of Stock [Line Items]    
Non-controlling interest investment in operating partnership $ 1,000  
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Narrative (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
home
May 31, 2023
home
Sep. 30, 2023
USD ($)
day
property
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
facility
day
property
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Variable Interest Entities                  
Operating real estate, net     $ 894,245,000       $ 894,245,000   $ 933,002,000
Mortgage notes payable, net     901,610,000       901,610,000   912,248,000
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)     $ 128,026,000       $ 128,026,000   $ 176,502,000
Impairment recognized               $ 0  
Finance Lease Liability                  
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]     Operating real estate, net       Operating real estate, net   Operating real estate, net
Finance leases for equipment     $ 300,000       $ 300,000    
Payments of finance lease obligations             $ 100,000 $ 400,000  
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]     Other liabilities   Other liabilities   Other liabilities Other liabilities  
Weighted average interest rate (percent)     6.80%       6.80%    
Remaining lease term (years)     3 years 4 months 24 days       3 years 4 months 24 days    
Identified Intangibles                  
Number of triple net lease portfolios | property     4       4    
Amortization expense for in-place leases and deferred costs     $ 100,000   $ 300,000   $ 100,000 $ 300,000  
Derivative                  
Derivative, gain (loss) on derivative, net     $ 300,000   (300,000)   $ 500,000 (600,000)  
Revenue Recognition                  
Days notice required for lease termination | day     30       30    
Proceeds from rents received     $ 800,000       $ 1,200,000    
Variable lease revenues     3,600,000   2,100,000   10,700,000 9,200,000  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses             $ 38,700,000    
Number of facilities impaired | facility             5    
Tangible asset impairment charges                 $ 1,000,000
Impairment recognized               0  
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)     128,026,000       $ 128,026,000   176,502,000
Financing Receivable, after Allowance for Credit Loss                  
Allowance for credit losses on receivables     0       0    
Income Taxes                  
Deferred tax asset     15,900,000       15,900,000    
Income tax expense     17,000   $ 15,000   43,000 45,000  
Foreign Currency                  
Reclassification of accumulated other comprehensive loss     3,300,000 $ 3,275,000 [1]          
Espresso Joint Venture                  
Variable Interest Entities                  
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) $ 3,100,000   3,075,000 3,100,000   $ 3,100,000 3,075,000   18,019,000
Impairment recognized 4,700,000         4,700,000 4,700,000    
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment recognized 4,700,000         4,700,000 4,700,000    
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) $ 3,100,000   3,075,000 $ 3,100,000   $ 3,100,000 3,075,000   18,019,000
Diversified US/UK                  
Variable Interest Entities                  
Impairment recognized             11,400,000    
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses                 13,400,000
Impairment recognized             11,400,000    
Number of senior care homes owned | home 48 48              
Arbors Portfolio                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses               18,500,000  
Winterfell Portfolio                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses               8,500,000  
Tangible asset impairment charges               600,000  
Rochester Portfolio                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses               3,900,000  
Rochester Portfolio | Facility                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses             38,600,000    
Rochester Portfolio | Land Parcel                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses             100,000    
Operating real estate, net                  
Impairment on Operating Real Estate and Investments in Unconsolidated Ventures                  
Impairment Losses             38,700,000 $ 31,500,000  
Primary Beneficiary                  
Variable Interest Entities                  
Operating real estate, net     170,100,000       170,100,000    
Mortgage notes payable, net     172,000,000       172,000,000    
Interest Rate Cap                  
Derivative                  
Derivative asset     $ 800,000       $ 800,000   $ 700,000
[1] The Company reclassified the accumulated other comprehensive loss related to foreign currency adjustments for an unconsolidated venture ownership interest that was sold during the three months ended June 30, 2023. The accumulated balance was reclassified to gain (loss) on investments and other on the consolidated statements of operations.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash and cash equivalents $ 87,581 $ 103,926    
Restricted cash 11,386 11,734    
Total cash, cash equivalents and restricted cash $ 98,967 $ 115,660 $ 107,682 $ 210,938
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Estimated Useful Lives (Details)
Sep. 30, 2023
Building | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 30 years
Building | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 50 years
Land improvements | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 9 years
Land improvements | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 15 years
Furniture, fixtures and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 5 years
Furniture, fixtures and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (in years) 14 years
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Accounting Policies [Abstract]  
October 1 through December 31, 2023 $ 18
2024 69
2025 38
2026 33
2027 18
Thereafter 10
Total minimum lease payments 186
Less: Amount representing interest (27)
Present value of minimum lease payments $ 159
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Less: Accumulated amortization $ (118,149) $ (117,896)
Intangible assets, net 2,000 2,253
In-place lease value    
Finite-Lived Intangible Assets [Line Items]    
In-place lease value $ 120,149 $ 120,149
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Accounting Policies [Abstract]  
October 1 through December 31, 2023 $ 84
2024 337
2025 337
2026 337
2027 337
Thereafter 568
Total $ 2,000
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Real Estate - Identifiable Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Real Estate [Abstract]    
Land $ 121,424 $ 121,518
Land improvements 19,913 18,945
Buildings and improvements 932,261 957,924
Tenant improvements 372 372
Construction in progress 8,956 6,736
Furniture, fixtures and equipment 103,876 91,058
Subtotal 1,186,802 1,196,553
Less: Accumulated depreciation (292,557) (263,551)
Operating real estate, net $ 894,245 $ 933,002
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Operating Real Estate - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Real Estate [Line Items]          
Depreciation $ 9.8 $ 9.6 $ 29.1 $ 28.9  
Impairment Losses     38.7    
Building and Building Improvements          
Real Estate [Line Items]          
Accumulated impairment $ 220.2   $ 220.2   $ 181.5
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in Unconsolidated Ventures - Changes in Carrying Value (Details) - USD ($)
 1 Months Ended 6 Months Ended 9 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]          
Carrying value     $ 128,026,000   $ 176,502,000
Impairment recognized       $ 0  
Trilogy, Espresso, Solstice          
Schedule of Equity Method Investments [Line Items]          
Carrying value     $ 0   29,276,000
Trilogy          
Schedule of Equity Method Investments [Line Items]          
Ownership interest (as a percentage)     23.40%    
Carrying value     $ 124,670,000   128,884,000
Capitalized acquisition costs     $ 9,800,000   9,800,000
Espresso          
Schedule of Equity Method Investments [Line Items]          
Ownership interest (as a percentage)     36.70%    
Carrying value $ 3,100,000 $ 3,100,000 $ 3,075,000   18,019,000
Impairment recognized $ 4,700,000 $ 4,700,000 $ 4,700,000    
Solstice          
Schedule of Equity Method Investments [Line Items]          
Ownership interest (as a percentage)     20.00%    
Carrying value     $ 281,000   $ 323,000
Solstice          
Schedule of Equity Method Investments [Line Items]          
Noncontrolling interest, ownership percentage by parent (as a percentage)     80.00%    
Winterfell Portfolio | Solstice          
Schedule of Equity Method Investments [Line Items]          
Ownership interest (as a percentage)     20.00%    
Winterfell Portfolio | Solstice          
Schedule of Equity Method Investments [Line Items]          
Noncontrolling interest, ownership percentage by parent (as a percentage)     80.00%    
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in Unconsolidated Ventures - Narrative (Details)
$ in Millions
 1 Months Ended
Jun. 30, 2023
USD ($)
facility
home
May 31, 2023
home
Sep. 30, 2023
shares
Dec. 31, 2022
shares
Schedule of Equity Method Investments [Line Items]        
Common stock, shares outstanding (in shares)     185,712,103 195,421,656
Preferred stock, shares outstanding (in shares)     0 0
Former Sponsor and Affiliates        
Schedule of Equity Method Investments [Line Items]        
Payments for divestiture of interest in joint venture | $ $ 1.1      
Common stock, shares outstanding (in shares)     9,709,553  
Common unit, outstanding (in shares)     100  
Preferred stock, shares outstanding (in shares)     100  
Eclipse        
Schedule of Equity Method Investments [Line Items]        
Ownership interest (as a percentage)     6.00%  
Number of senior care homes owned | facility 34      
Diversified US/UK        
Schedule of Equity Method Investments [Line Items]        
Ownership interest (as a percentage)     14.00%  
Number of senior care homes owned | home 48 48    
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Schedule of Equity Method Investments [Line Items]            
Equity in earnings (losses) of unconsolidated ventures   $ (127,000) $ 2,872,000   $ (6,595,000) $ 39,427,000
Cash Distribution   0 4,033,000   24,112,000 42,173,000
Distributions from unconsolidated ventures         10,640,000 0
Impairment recognized           0
Trilogy            
Schedule of Equity Method Investments [Line Items]            
Equity in earnings (losses) of unconsolidated ventures   (146,000) 6,052,000   454,000 10,757,000
Cash Distribution   0 2,300,000   4,668,000 6,900,000
Espresso Joint Venture            
Schedule of Equity Method Investments [Line Items]            
Equity in earnings (losses) of unconsolidated ventures   0 (242,000)   9,228,000 33,711,000
Cash Distribution   0 1,375,000   19,444,000 32,363,000
Equity method investment, realized gain on disposal         9,200,000 32,000,000
Distributions from unconsolidated ventures         17,300,000 27,400,000
Impairment recognized $ 4,700,000     $ 4,700,000 4,700,000  
Solstice            
Schedule of Equity Method Investments [Line Items]            
Equity in earnings (losses) of unconsolidated ventures   19,000 17,000   (41,000) (41,000)
Cash Distribution   0 0   0 0
Trilogy, Espresso, Solstice            
Schedule of Equity Method Investments [Line Items]            
Equity in earnings (losses) of unconsolidated ventures   0 (2,955,000)   (16,236,000) (5,000,000)
Cash Distribution   $ 0 $ 358,000   0 $ 2,910,000
Diversified US/UK            
Schedule of Equity Method Investments [Line Items]            
Impairment recognized         $ 11,400,000  
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings - Schedule of Borrowings (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
property
debt_instrument
Dec. 31, 2022
USD ($)
Debt Instrument [Line Items]    
Carrying Value $ 908,287  
Winterfell Portfolio    
Debt Instrument [Line Items]    
Number of healthcare real estate properties | property 32  
Mortgages and other notes payable    
Debt Instrument [Line Items]    
Principal Amount $ 908,287 $ 922,355
Carrying Value 901,610 912,248
Mortgages    
Debt Instrument [Line Items]    
Principal Amount $ 908,287 922,355
Mortgages | Rochester, NY    
Debt Instrument [Line Items]    
Number of debt instruments | debt_instrument 7  
Number of healthcare real estate properties | property 7  
Mortgages | Arbors Portfolio    
Debt Instrument [Line Items]    
Number of debt instruments | debt_instrument 4  
Number of healthcare real estate properties | property 4  
Mortgages | Winterfell Portfolio    
Debt Instrument [Line Items]    
Number of debt instruments | debt_instrument 32  
Mortgages | Avamere Portfolio    
Debt Instrument [Line Items]    
Number of debt instruments | debt_instrument 5  
Number of healthcare real estate properties | property 5  
Mortgages | Frisco, TX Non-recourse, February 2026 | Frisco, TX    
Debt Instrument [Line Items]    
Fixed interest rate 3.00%  
Principal Amount $ 26,000 26,000
Carrying Value $ 25,660 25,560
Mortgages | Frisco, TX Non-recourse, February 2026 | Frisco, TX | Secured Overnight Financing Rate (SOFR)    
Debt Instrument [Line Items]    
Basis spread on variable interest rate 2.80%  
Mortgages | Milford, OH Non-recourse, September 2026 | Milford, OH    
Debt Instrument [Line Items]    
Principal Amount $ 18,212 18,336
Carrying Value $ 18,036 18,126
Mortgages | Milford, OH Non-recourse, September 2026 | Milford, OH | Secured Overnight Financing Rate (SOFR)    
Debt Instrument [Line Items]    
Basis spread on variable interest rate 2.79%  
Mortgages | Rochester, NY Non-recourse, February 2025 | Rochester, NY    
Debt Instrument [Line Items]    
Fixed interest rate 4.25%  
Principal Amount $ 17,657 18,206
Carrying Value 17,629 18,165
Mortgages | Rochester, NY Non-recourse, July 2023 | Rochester, NY    
Debt Instrument [Line Items]    
Principal Amount 99,786 100,651
Carrying Value $ 99,787 100,042
Mortgages | Rochester, NY Non-recourse, July 2023 | Rochester, NY | Secured Overnight Financing Rate (SOFR)    
Debt Instrument [Line Items]    
Basis spread on variable interest rate 2.45%  
Mortgages | Rochester NY Nonrecourse August 2024 | Rochester, NY    
Debt Instrument [Line Items]    
Principal Amount $ 10,922 11,336
Carrying Value $ 10,891 11,315
Mortgages | Rochester NY Nonrecourse August 2024 | Rochester, NY | Secured Overnight Financing Rate (SOFR)    
Debt Instrument [Line Items]    
Basis spread on variable interest rate 2.93%  
Mortgages | Non-Recourse | Arbors Portfolio    
Debt Instrument [Line Items]    
Fixed interest rate 3.99%  
Principal Amount $ 81,912 83,423
Carrying Value $ 81,680 83,051
Mortgages | Non-Recourse | Winterfell Portfolio    
Debt Instrument [Line Items]    
Fixed interest rate 4.17%  
Principal Amount $ 586,773 596,408
Carrying Value $ 581,157 588,306
Mortgages | Non-Recourse | Avamere Portfolio    
Debt Instrument [Line Items]    
Fixed interest rate 4.66%  
Principal Amount $ 67,025 67,995
Carrying Value 66,770 $ 67,683
Mortgages | One-Month LIBOR    
Debt Instrument [Line Items]    
Principal Amount $ 128,900  
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Borrowings - Maturity Schedule (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Debt Disclosure [Abstract]  
October 1 through December 31, 2023 $ 104,238
2024 28,761
2025 667,741
2026 45,151
2027 62,396
Total $ 908,287
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements - Transition Services (Details)
Mar. 22, 2023
Related Party Transition Services Agreement  
Related Party Transaction [Line Items]  
Related party transaction, term of agreement 6 months
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements - Summary of Fees and Reimbursements (Details) - Advisor - General and administrative expenses/ Transaction costs
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
Related Party Transaction, Due to Related Parties [Roll Forward]  
Due to related party, beginning balance $ 469
Due to related party, ending balance 292
Incurred  
Related Party Transaction, Due to Related Parties [Roll Forward]  
Related party transaction, amounts of transaction 520
Paid  
Related Party Transaction, Due to Related Parties [Roll Forward]  
Related party transaction, amounts of transaction $ (697)
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements - Incentive Fee (Details) - Related Party - Incentive Fee
 9 Months Ended
Sep. 30, 2023
Related Party Transaction [Line Items]  
Incentive fee distributions, percent of net cash flows 15.00%
Incentive fee distributions, minimum non-compounded annual pre-tax return on invested capital 6.75%
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Related Party Arrangements - Investments in Joint Ventures (Details) - USD ($)
$ in Millions
 1 Months Ended 9 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Former Sponsor and Affiliates    
Related Party Transaction [Line Items]    
Payments for divestiture of interest in joint venture $ 1.1  
Solstice    
Related Party Transaction [Line Items]    
Noncontrolling interest, ownership percentage by parent (as a percentage)   80.00%
Eclipse    
Related Party Transaction [Line Items]    
Ownership interest (as a percentage)   6.00%
Diversified US/UK    
Related Party Transaction [Line Items]    
Ownership interest (as a percentage)   14.00%
Solstice    
Related Party Transaction [Line Items]    
Ownership interest (as a percentage)   20.00%
Winterfell Portfolio | Solstice    
Related Party Transaction [Line Items]    
Noncontrolling interest, ownership percentage by parent (as a percentage)   80.00%
Winterfell Portfolio | Solstice    
Related Party Transaction [Line Items]    
Ownership interest (as a percentage)   20.00%
Related party transaction, amounts of transaction   $ 5.1
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Equity-Based Compensation (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Equity-based compensation              
Number of shares granted to independent directors (in shares) 203,742 116,712          
Equity-based compensation expense     $ 56,250 $ 56,875 $ 170,000 $ 150,042  
Unrecognized equity-based compensation $ 296,250   $ 296,250   $ 296,250   $ 211,250
Restricted stock              
Equity-based compensation              
Number of shares authorized (in shares) 2,000,000   2,000,000   2,000,000    
Restricted common shares grant vesting period         2 years    
Restricted Stock Units (RSUs)              
Equity-based compensation              
Restricted common shares grant vesting period         2 years    
Unvested shares (in shares) 94,853   94,853   94,853   54,114
Independent Directors | Restricted stock              
Equity-based compensation              
Number of shares granted to independent directors (in shares)         159,932    
Aggregate value for restricted common shares granted to independent directors $ 1,300,000   $ 1,300,000   $ 1,300,000    
Independent Directors | Restricted Stock Units (RSUs)              
Equity-based compensation              
Number of shares granted to independent directors (in shares)         203,742    
Aggregate value for restricted common shares granted to independent directors $ 700,000   $ 700,000   $ 700,000    
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details) - USD ($)
shares in Millions
 1 Months Ended 9 Months Ended 90 Months Ended
Jan. 19, 2016
Sep. 30, 2023
Jun. 30, 2023
Class of Stock [Line Items]      
Value of common stock issued   $ 2,000,000,000  
Dividend Reinvestment Plan      
Class of Stock [Line Items]      
Selling commissions or dealer manager fees paid   $ 0  
Common Stock      
Class of Stock [Line Items]      
Number of shares issued (in shares) 173.4    
Value of common stock issued $ 1,700,000,000    
Common Stock | Dividend Reinvestment Plan      
Class of Stock [Line Items]      
Number of shares issued (in shares)     25.7
Value of common stock issued     $ 232,600,000
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Distributions (Details) - USD ($)
$ / shares in Units, $ in Millions
Dec. 31, 2022
May 02, 2022
Equity [Abstract]    
Special distribution (dollars per share)   $ 0.50
Dividends payable   $ 97.0
Operating loss carryforwards $ 248.5  
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Equity - Retirement of Shares (Details) - USD ($)
$ in Thousands, shares in Millions
 9 Months Ended
Jun. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]      
Shares repurchased during period (in shares) 9.7    
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)   $ 128,026 $ 176,502
Diversified US/UK and Eclipse      
Schedule of Equity Method Investments [Line Items]      
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)   12,500  
Equity method investee, cash consideration   $ 1,100  
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Non-controlling Interests (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Noncontrolling Interest [Line Items]        
Net income (loss) attributable to non-controlling interests $ (166) $ (73) $ (1,470) $ (298)
Primary Beneficiary | Northstar Healthcare Income Operating Partnership, LP        
Noncontrolling Interest [Line Items]        
Ownership interest in operating partnership     100.00%  
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Financial assets:      
Investment in Espresso joint venture $ 128,026   $ 176,502
Financial liabilities      
Carrying Value 901,610   912,248
Espresso Joint Venture      
Financial assets:      
Investment in Espresso joint venture 3,075 $ 3,100 18,019
Interest Rate Cap      
Financial assets:      
Derivative asset - interest rate caps 800   700
Level 1 | Espresso Joint Venture      
Financial assets:      
Investment in Espresso joint venture 0   0
Level 1 | Interest Rate Cap      
Financial assets:      
Derivative asset - interest rate caps 0   0
Level 2 | Espresso Joint Venture      
Financial assets:      
Investment in Espresso joint venture 0   0
Level 2 | Interest Rate Cap      
Financial assets:      
Derivative asset - interest rate caps 820   652
Level 3 | Espresso Joint Venture      
Financial assets:      
Investment in Espresso joint venture 3,075   0
Level 3 | Interest Rate Cap      
Financial assets:      
Derivative asset - interest rate caps 0   0
Mortgage notes payable, net      
Financial liabilities      
Principal Amount 908,287   922,355
Carrying Value 901,610   912,248
Fair Value $ 842,325   $ 882,754
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Nonrecurring Fair Value (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Operating real estate, net $ 894,245   $ 933,002
Impairment Losses 38,700    
Tangible asset impairment charges     1,000
Operating real estate, net      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Impairment Losses 38,700 $ 31,500  
Nonrecurring | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Operating real estate, net 41,496   80,931
Investments in unconsolidated ventures 3,075   28,442
Nonrecurring | Level 3 | Operating real estate, net      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Impairment Losses 38,694   30,900
Nonrecurring | Level 3 | Investments in unconsolidated ventures      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Impairment Losses $ 4,728   $ 13,419
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value - Narrative (Details) - USD ($)
 1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Impairment Losses     $ 38,700,000    
Impairment recognized       $ 0  
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023)     128,026,000   $ 176,502,000
Diversified US/UK          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Impairment Losses         13,400,000
Capitalized acquisition costs         28,400,000
Impairment recognized     11,400,000    
Espresso Joint Venture          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Impairment recognized $ 4,700,000 $ 4,700,000 4,700,000    
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) 3,100,000 3,100,000 $ 3,075,000   $ 18,019,000
Eclipse          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Investments in unconsolidated ventures ($3,075 held at fair value as of September 30, 2023) $ 3,100,000 $ 3,100,000      
Discounted cash flow method | Minimum | Real Estate Investment | Terminal capitalization rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     6.00%    
Discounted cash flow method | Minimum | Real Estate Investment | Discount rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     8.50%    
Discounted cash flow method | Minimum | Investments in unconsolidated ventures | Terminal capitalization rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     6.60%    
Discounted cash flow method | Minimum | Investments in unconsolidated ventures | Discount rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     8.80%    
Discounted cash flow method | Maximum | Real Estate Investment | Terminal capitalization rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     8.50%    
Discounted cash flow method | Maximum | Real Estate Investment | Discount rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     10.50%    
Discounted cash flow method | Maximum | Investments in unconsolidated ventures | Terminal capitalization rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     12.50%    
Discounted cash flow method | Maximum | Investments in unconsolidated ventures | Discount rate | Nonrecurring          
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]          
Measurement input (percentage)     16.00%    
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Segment Statement of Operations (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Segment Reporting Information [Line Items]                
Property and other revenues $ 53,374,000     $ 47,739,000     $ 154,445,000 $ 136,445,000
Property operating expenses (36,890,000)     (35,134,000)     (106,993,000) (101,258,000)
Interest expense (14,250,000)     (11,014,000)     (37,143,000) (31,877,000)
Transaction costs (358,000)     (857,000)     (455,000) (857,000)
Asset management fees - related party 0     (2,428,000)     0 (7,532,000)
General and administrative expenses (2,921,000)     (2,859,000)     (10,424,000) (10,300,000)
Depreciation and amortization (9,848,000)     (9,642,000)     (29,305,000) (29,105,000)
Impairment loss 0     (18,500,000)     (43,422,000) (31,502,000)
Other income, net 0     0     202,000 77,000
Gain (loss) on investments and other (347,000)     325,000     (4,662,000) 660,000
Equity in earnings (losses) of unconsolidated ventures (127,000)     2,872,000     (6,595,000) 39,427,000
Income tax expense (17,000)     (15,000)     (43,000) (45,000)
Net income (loss) (11,384,000) $ (59,014,000) $ (13,997,000) (29,513,000) $ 6,627,000 $ (12,981,000) (84,395,000) (35,867,000)
Corporate                
Segment Reporting Information [Line Items]                
Property and other revenues 1,078,000     300,000     2,893,000 457,000
Property operating expenses 0     0     0 0
Interest expense 0     0     0 0
Transaction costs 0     (857,000)     (97,000) (857,000)
Asset management fees - related party       (2,428,000)       (7,532,000)
General and administrative expenses (2,891,000)     (2,851,000)     (9,869,000) (10,276,000)
Depreciation and amortization 0     0     0 0
Impairment loss       0     0 0
Other income, net             0 0
Gain (loss) on investments and other 0     0     0 0
Equity in earnings (losses) of unconsolidated ventures 0     0     0 0
Income tax expense 0     0     0 0
Net income (loss) (1,813,000)     (5,836,000)     (7,073,000) (18,208,000)
Net Lease | Operating Segments                
Segment Reporting Information [Line Items]                
Property and other revenues 837,000     724,000     1,178,000 1,220,000
Property operating expenses 0     0     0 (35,000)
Interest expense (883,000)     (907,000)     (2,639,000) (2,708,000)
Transaction costs 0     0     0 0
Asset management fees - related party       0       0
General and administrative expenses 0     0     0 0
Depreciation and amortization (729,000)     (870,000)     (2,187,000) (2,601,000)
Impairment loss       (18,500,000)     0 (18,500,000)
Other income, net             0 0
Gain (loss) on investments and other 0     0     0 (206,000)
Equity in earnings (losses) of unconsolidated ventures 0     0     0 0
Income tax expense 0     0     0 0
Net income (loss) (775,000)     (19,553,000)     (3,648,000) (22,830,000)
Operating | Operating Segments                
Segment Reporting Information [Line Items]                
Property and other revenues 51,459,000     46,715,000     150,374,000 134,768,000
Property operating expenses (36,890,000)     (35,134,000)     (106,993,000) (101,223,000)
Interest expense (13,367,000)     (10,107,000)     (34,504,000) (29,169,000)
Transaction costs 0     0     0 0
Asset management fees - related party       0       0
General and administrative expenses (30,000)     (8,000)     (555,000) (24,000)
Depreciation and amortization (9,119,000)     (8,772,000)     (27,118,000) (26,504,000)
Impairment loss       0     (38,694,000) (13,002,000)
Other income, net             202,000 77,000
Gain (loss) on investments and other (311,000)     325,000     (28,000) 620,000
Equity in earnings (losses) of unconsolidated ventures 0     0     0 0
Income tax expense (17,000)     (15,000)     (43,000) (45,000)
Net income (loss) (8,275,000)     (6,996,000)     (57,359,000) (34,502,000)
Unconsolidated Investments | Operating Segments                
Segment Reporting Information [Line Items]                
Property and other revenues 0     0     0 0
Property operating expenses 0     0     0 0
Interest expense 0     0     0 0
Transaction costs (358,000)     0     (358,000) 0
Asset management fees - related party       0       0
General and administrative expenses 0     0     0 0
Depreciation and amortization 0     0     0 0
Impairment loss       0     (4,728,000) 0
Other income, net             0 0
Gain (loss) on investments and other (36,000)     0     (4,634,000) 246,000
Equity in earnings (losses) of unconsolidated ventures (127,000)     2,872,000     (6,595,000) 39,427,000
Income tax expense 0     0     0 0
Net income (loss) $ (521,000)     $ 2,872,000     $ (16,315,000) $ 39,673,000
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Summary of Assets by Segment (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Total assets [1] $ 1,135,916 $ 1,237,835
Corporate    
Segment Reporting Information [Line Items]    
Total assets 79,707 93,761
Net Lease | Operating Segments    
Segment Reporting Information [Line Items]    
Total assets 80,782 83,435
Operating | Operating Segments    
Segment Reporting Information [Line Items]    
Total assets 847,401 884,137
Unconsolidated Investments | Operating Segments    
Segment Reporting Information [Line Items]    
Total assets $ 128,026 $ 176,502
[1] ncludes $174.4 million and $180.2 million of assets and liabilities, respectively, of certain VIEs that are consolidated by the Operating Partnership. Refer to Note 2, “Summary of Significant Accounting Policies.”
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting - Schedule of Properties (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
property
unit
Real Estate Properties [Line Items]  
Properties Under Management | property 56
Units Under Management | unit 6,816
Property and Other Revenues | $ $ 154,445
Total | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 100.00%
Solstice Senior Living  
Real Estate Properties [Line Items]  
Properties Under Management | property 32
Units Under Management | unit 3,969
Property and Other Revenues | $ $ 94,469
Solstice Senior Living | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 61.20%
Watermark Retirement Communities  
Real Estate Properties [Line Items]  
Properties Under Management | property 14
Units Under Management | unit 1,782
Property and Other Revenues | $ $ 35,967
Watermark Retirement Communities | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 23.20%
Avamere Health Services  
Real Estate Properties [Line Items]  
Properties Under Management | property 5
Units Under Management | unit 453
Property and Other Revenues | $ $ 16,266
Avamere Health Services | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 10.50%
Integral Senior Living  
Real Estate Properties [Line Items]  
Properties Under Management | property 1
Units Under Management | unit 40
Property and Other Revenues | $ $ 3,672
Integral Senior Living | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 2.40%
Arcadia Management  
Real Estate Properties [Line Items]  
Properties Under Management | property 4
Units Under Management | unit 572
Property and Other Revenues | $ $ 1,178
Arcadia Management | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 0.80%
Other  
Real Estate Properties [Line Items]  
Properties Under Management | property 0
Units Under Management | unit 0
Property and Other Revenues | $ $ 2,893
Other | Revenue | Customer Concentration Risk  
Real Estate Properties [Line Items]  
% of Total Property and Other Revenues 1.90%
Solstice Senior Living  
Real Estate Properties [Line Items]  
Noncontrolling interest, ownership percentage by parent (as a percentage) 80.00%
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Narrative (Details)
$ in Millions
Sep. 30, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Loss contingency accrual $ 0.6
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events - Narrative (Details) - Subsequent event - Trilogy - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Forecast
$ in Millions
 12 Months Ended
Dec. 31, 2024
USD ($)
campus
uSDollarsPerDay
Subsequent Event [Line Items]  
Number of senior care homes owned | campus 123
Disposal group, not discontinued operation, percentage of consideration paid in cash 10.00%
Proceeds from divestiture of equity method investment, supplemental cash payment | uSDollarsPerDay 25,600
Proceeds from divestiture of equity method investment, supplemental cash payment, maximum $ 21.0
Terminated Prior To Initial Outside Date  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, termination fee 3.9
Qualifying IPO Has Occurred  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, termination fee 7.8
Terminated Prior To March 31, 2025  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, termination fee 11.7
Terminated Prior To September 30, 2025  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, termination fee $ 15.6
March 31, 2024  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, discount on purchase consideration paid in cash 7.50%
December 31, 2024  
Subsequent Event [Line Items]  
Disposal group, not discontinued operation, discount on purchase consideration paid in cash 5.00%
Minimum  
Subsequent Event [Line Items]  
Consideration received $ 240.5
Maximum  
Subsequent Event [Line Items]  
Consideration received $ 260.0
XML 74 nshi-20230930_htm.xml IDEA: XBRL DOCUMENT 0001503707 2023-01-01 2023-09-30 0001503707 2023-11-13 0001503707 2023-09-30 0001503707 2022-12-31 0001503707 us-gaap:RelatedPartyMember 2023-09-30 0001503707 us-gaap:RelatedPartyMember 2022-12-31 0001503707 us-gaap:NonrelatedPartyMember 2023-09-30 0001503707 us-gaap:NonrelatedPartyMember 2022-12-31 0001503707 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nshi:NorthstarHealthcareIncomeOperatingPartnershipLPMember 2023-09-30 0001503707 2023-07-01 2023-09-30 0001503707 2022-07-01 2022-09-30 0001503707 2022-01-01 2022-09-30 0001503707 2023-09-30 2023-09-30 0001503707 2022-09-30 2022-09-30 0001503707 us-gaap:CommonStockMember 2021-12-31 0001503707 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001503707 us-gaap:RetainedEarningsMember 2021-12-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001503707 us-gaap:ParentMember 2021-12-31 0001503707 us-gaap:NoncontrollingInterestMember 2021-12-31 0001503707 2021-12-31 0001503707 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001503707 us-gaap:ParentMember 2022-01-01 2022-03-31 0001503707 2022-01-01 2022-03-31 0001503707 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001503707 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001503707 us-gaap:CommonStockMember 2022-03-31 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001503707 us-gaap:RetainedEarningsMember 2022-03-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001503707 us-gaap:ParentMember 2022-03-31 0001503707 us-gaap:NoncontrollingInterestMember 2022-03-31 0001503707 2022-03-31 0001503707 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001503707 us-gaap:ParentMember 2022-04-01 2022-06-30 0001503707 2022-04-01 2022-06-30 0001503707 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001503707 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001503707 us-gaap:CommonStockMember 2022-06-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001503707 us-gaap:RetainedEarningsMember 2022-06-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001503707 us-gaap:ParentMember 2022-06-30 0001503707 us-gaap:NoncontrollingInterestMember 2022-06-30 0001503707 2022-06-30 0001503707 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001503707 us-gaap:ParentMember 2022-07-01 2022-09-30 0001503707 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001503707 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001503707 us-gaap:CommonStockMember 2022-09-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001503707 us-gaap:RetainedEarningsMember 2022-09-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001503707 us-gaap:ParentMember 2022-09-30 0001503707 us-gaap:NoncontrollingInterestMember 2022-09-30 0001503707 2022-09-30 0001503707 us-gaap:CommonStockMember 2022-12-31 0001503707 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001503707 us-gaap:RetainedEarningsMember 2022-12-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001503707 us-gaap:ParentMember 2022-12-31 0001503707 us-gaap:NoncontrollingInterestMember 2022-12-31 0001503707 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001503707 2023-01-01 2023-03-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001503707 us-gaap:ParentMember 2023-01-01 2023-03-31 0001503707 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001503707 us-gaap:CommonStockMember 2023-03-31 0001503707 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001503707 us-gaap:RetainedEarningsMember 2023-03-31 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001503707 us-gaap:ParentMember 2023-03-31 0001503707 us-gaap:NoncontrollingInterestMember 2023-03-31 0001503707 2023-03-31 0001503707 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001503707 2023-04-01 2023-06-30 0001503707 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001503707 us-gaap:ParentMember 2023-04-01 2023-06-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001503707 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001503707 us-gaap:CommonStockMember 2023-06-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001503707 us-gaap:RetainedEarningsMember 2023-06-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001503707 us-gaap:ParentMember 2023-06-30 0001503707 us-gaap:NoncontrollingInterestMember 2023-06-30 0001503707 2023-06-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001503707 us-gaap:ParentMember 2023-07-01 2023-09-30 0001503707 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001503707 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001503707 us-gaap:CommonStockMember 2023-09-30 0001503707 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001503707 us-gaap:RetainedEarningsMember 2023-09-30 0001503707 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001503707 us-gaap:ParentMember 2023-09-30 0001503707 us-gaap:NoncontrollingInterestMember 2023-09-30 0001503707 nshi:AdvisoroftheRegistrantMember 2023-01-01 2023-09-30 0001503707 nshi:SpecialUnitsHolderMember 2023-01-01 2023-09-30 0001503707 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember nshi:NorthstarHealthcareIncomeOperatingPartnershipLPMember 2023-01-01 2023-09-30 0001503707 nshi:DividendReinvestmentPlanMember 2023-01-01 2023-09-30 0001503707 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-09-30 0001503707 nshi:EspressoJointVentureMember 2023-01-01 2023-06-30 0001503707 nshi:EspressoJointVentureMember 2023-06-30 0001503707 srt:MinimumMember us-gaap:BuildingMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:BuildingMember 2023-09-30 0001503707 srt:MinimumMember us-gaap:LandImprovementsMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:LandImprovementsMember 2023-09-30 0001503707 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2023-09-30 0001503707 us-gaap:LeasesAcquiredInPlaceMember 2023-09-30 0001503707 us-gaap:LeasesAcquiredInPlaceMember 2022-12-31 0001503707 us-gaap:InterestRateCapMember 2023-09-30 0001503707 us-gaap:InterestRateCapMember 2022-12-31 0001503707 nshi:OperatingRealEstateNetMember 2023-01-01 2023-09-30 0001503707 nshi:RochesterPortfolioMember nshi:FacilityMember 2023-01-01 2023-09-30 0001503707 nshi:RochesterPortfolioMember nshi:LandParcelMember 2023-01-01 2023-09-30 0001503707 nshi:OperatingRealEstateNetMember 2022-01-01 2022-09-30 0001503707 nshi:ArborsPortfolioMember 2022-01-01 2022-09-30 0001503707 nshi:WinterfellPortfolioMember 2022-01-01 2022-09-30 0001503707 nshi:RochesterPortfolioMember 2022-01-01 2022-09-30 0001503707 nshi:EspressoJointVentureMember 2023-01-01 2023-09-30 0001503707 nshi:EspressoJointVentureMember 2023-09-30 0001503707 nshi:DiversifiedUSUKMember 2023-05-01 2023-05-31 0001503707 nshi:DiversifiedUSUKMember 2023-01-01 2023-09-30 0001503707 us-gaap:BuildingAndBuildingImprovementsMember 2023-09-30 0001503707 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0001503707 nshi:TheTrilogyJointVentureMember 2023-09-30 0001503707 nshi:TheTrilogyJointVentureMember 2022-12-31 0001503707 nshi:EspressoJointVentureMember 2022-12-31 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2022-12-31 0001503707 nshi:TrilogyEspressoSolsticeMember 2023-09-30 0001503707 nshi:TrilogyEspressoSolsticeMember 2022-12-31 0001503707 nshi:EspressoJointVentureMember 2023-06-01 2023-06-30 0001503707 nshi:SolsticeSeniorLivingLLCMember nshi:WinterfellPortfolioMember 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember nshi:WinterfellPortfolioMember 2023-09-30 0001503707 nshi:DiversifiedUSUKMember 2023-09-30 0001503707 nshi:DiversifiedUSUKMember 2023-06-01 2023-06-30 0001503707 nshi:EclipseJointVentureMember 2023-09-30 0001503707 nshi:EclipseJointVentureMember 2023-06-01 2023-06-30 0001503707 nshi:FormerSponsorAndAffiliatesMember 2023-06-01 2023-06-30 0001503707 nshi:FormerSponsorAndAffiliatesMember 2023-09-30 0001503707 nshi:TheTrilogyJointVentureMember 2023-07-01 2023-09-30 0001503707 nshi:TheTrilogyJointVentureMember 2022-07-01 2022-09-30 0001503707 nshi:TheTrilogyJointVentureMember 2023-01-01 2023-09-30 0001503707 nshi:TheTrilogyJointVentureMember 2022-01-01 2022-09-30 0001503707 nshi:EspressoJointVentureMember 2023-07-01 2023-09-30 0001503707 nshi:EspressoJointVentureMember 2022-07-01 2022-09-30 0001503707 nshi:EspressoJointVentureMember 2022-01-01 2022-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-07-01 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2022-07-01 2022-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-01-01 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2022-01-01 2022-09-30 0001503707 nshi:TrilogyEspressoSolsticeMember 2023-07-01 2023-09-30 0001503707 nshi:TrilogyEspressoSolsticeMember 2022-07-01 2022-09-30 0001503707 nshi:TrilogyEspressoSolsticeMember 2023-01-01 2023-09-30 0001503707 nshi:TrilogyEspressoSolsticeMember 2022-01-01 2022-09-30 0001503707 nshi:FriscoTXMember nshi:FriscoTXNonRecourseFebruary2026Member us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:FriscoTXMember nshi:FriscoTXNonRecourseFebruary2026Member us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:MilfordOHMember nshi:MilfordOHNonRecourseSeptember2026Member us-gaap:MortgagesMember nshi:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001503707 nshi:MilfordOHMember nshi:MilfordOHNonRecourseSeptember2026Member us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:MilfordOHMember nshi:MilfordOHNonRecourseSeptember2026Member us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonrecourseFebruary2025Member us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonrecourseFebruary2025Member us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonRecourseJuly2023Member us-gaap:MortgagesMember nshi:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonRecourseJuly2023Member us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonRecourseJuly2023Member us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonrecourseAugust2024Member us-gaap:MortgagesMember nshi:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonrecourseAugust2024Member us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:RochesterNYMember nshi:RochesterNYNonrecourseAugust2024Member us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:ArborsPortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:ArborsPortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:WinterfellPortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:WinterfellPortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:AvamerePortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:AvamerePortfolioMember us-gaap:NonrecourseMember us-gaap:MortgagesMember 2022-12-31 0001503707 nshi:MortgagesAndOtherNotesPayableMember 2023-09-30 0001503707 nshi:MortgagesAndOtherNotesPayableMember 2022-12-31 0001503707 nshi:FloatingRateDebtOneMonthLIBORMember us-gaap:MortgagesMember 2023-09-30 0001503707 nshi:FriscoTXMember nshi:FriscoTXNonRecourseFebruary2026Member us-gaap:MortgagesMember nshi:SecuredOvernightFinancingRateSOFRMember 2023-01-01 2023-09-30 0001503707 nshi:RochesterNYMember us-gaap:MortgagesMember 2023-01-01 2023-09-30 0001503707 nshi:ArborsPortfolioMember us-gaap:MortgagesMember 2023-01-01 2023-09-30 0001503707 nshi:WinterfellPortfolioMember us-gaap:MortgagesMember 2023-01-01 2023-09-30 0001503707 nshi:WinterfellPortfolioMember 2023-01-01 2023-09-30 0001503707 nshi:AvamerePortfolioMember us-gaap:MortgagesMember 2023-01-01 2023-09-30 0001503707 nshi:RelatedPartyTransitionServicesAgreementMember 2023-03-22 2023-03-22 0001503707 nshi:AdvisoroftheRegistrantMember nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMember 2022-12-31 0001503707 nshi:OperatingCostsIncurredMember nshi:AdvisoroftheRegistrantMember nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMember 2023-01-01 2023-09-30 0001503707 nshi:OperatingCostsPaidMember nshi:AdvisoroftheRegistrantMember nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMember 2023-01-01 2023-09-30 0001503707 nshi:AdvisoroftheRegistrantMember nshi:GeneralAndAdministrativeExpensesAndTransactionCostsMember 2023-09-30 0001503707 nshi:IncentiveFeesMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember nshi:WinterfellPortfolioMember 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember nshi:WinterfellPortfolioMember 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember nshi:WinterfellPortfolioMember 2023-01-01 2023-09-30 0001503707 us-gaap:RestrictedStockMember 2023-09-30 0001503707 srt:DirectorMember us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001503707 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001503707 srt:DirectorMember us-gaap:RestrictedStockMember 2023-09-30 0001503707 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001503707 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001503707 us-gaap:RestrictedStockMember 2023-01-01 2023-09-30 0001503707 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0001503707 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001503707 us-gaap:CommonStockMember 2015-12-17 2016-01-19 0001503707 nshi:DividendReinvestmentPlanMember us-gaap:CommonStockMember 2015-12-17 2023-06-30 0001503707 nshi:DividendReinvestmentPlanMember 2023-01-01 2023-09-30 0001503707 2022-05-02 0001503707 2023-06-30 2023-06-30 0001503707 nshi:DiversifiedUSUKAndEclipseMember 2023-09-30 0001503707 nshi:DiversifiedUSUKAndEclipseMember 2023-01-01 2023-09-30 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001503707 us-gaap:InterestRateCapMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel1Member 2023-09-30 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel2Member 2023-09-30 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel3Member 2023-09-30 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel1Member 2022-12-31 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel2Member 2022-12-31 0001503707 nshi:EspressoJointVentureMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001503707 us-gaap:MortgagesMember 2023-09-30 0001503707 us-gaap:MortgagesMember 2022-12-31 0001503707 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-09-30 0001503707 nshi:OperatingRealEstateNetMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-01-01 2023-09-30 0001503707 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2022-12-31 0001503707 nshi:OperatingRealEstateNetMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2022-01-01 2022-12-31 0001503707 us-gaap:CorporateJointVentureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2023-01-01 2023-09-30 0001503707 us-gaap:CorporateJointVentureMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember 2022-01-01 2022-12-31 0001503707 2022-01-01 2022-12-31 0001503707 srt:MinimumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:RealEstateInvestmentMember nshi:TerminalCapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:RealEstateInvestmentMember nshi:TerminalCapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MinimumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:RealEstateInvestmentMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:RealEstateInvestmentMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 nshi:EclipseJointVentureMember 2023-06-30 0001503707 nshi:DiversifiedUSUKMember 2022-01-01 2022-12-31 0001503707 nshi:DiversifiedUSUKMember 2022-12-31 0001503707 srt:MinimumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:CorporateJointVentureMember nshi:TerminalCapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:CorporateJointVentureMember nshi:TerminalCapitalizationRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MinimumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:CorporateJointVentureMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 srt:MaximumMember us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:CorporateJointVentureMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2023-07-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2023-07-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2023-07-01 2023-09-30 0001503707 us-gaap:CorporateNonSegmentMember 2023-07-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2022-07-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2022-07-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2022-07-01 2022-09-30 0001503707 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2023-01-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2023-01-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2023-01-01 2023-09-30 0001503707 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2022-01-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2022-01-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2022-01-01 2022-09-30 0001503707 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2023-09-30 0001503707 us-gaap:CorporateNonSegmentMember 2023-09-30 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsNetLeaseMember 2022-12-31 0001503707 us-gaap:OperatingSegmentsMember nshi:DirectInvestmentsOperatingMember 2022-12-31 0001503707 us-gaap:OperatingSegmentsMember nshi:UnconsolidatedInvestmentsSegmentMember 2022-12-31 0001503707 us-gaap:CorporateNonSegmentMember 2022-12-31 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-01-01 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:WatermarkRetirementCommunitiesMember 2023-09-30 0001503707 nshi:WatermarkRetirementCommunitiesMember 2023-01-01 2023-09-30 0001503707 nshi:WatermarkRetirementCommunitiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:AvamereHealthServicesMember 2023-09-30 0001503707 nshi:AvamereHealthServicesMember 2023-01-01 2023-09-30 0001503707 nshi:AvamereHealthServicesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:IntegralMember 2023-09-30 0001503707 nshi:IntegralMember 2023-01-01 2023-09-30 0001503707 nshi:IntegralMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:ArcadiaMember 2023-09-30 0001503707 nshi:ArcadiaMember 2023-01-01 2023-09-30 0001503707 nshi:ArcadiaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:OtherPropertiesMember 2023-09-30 0001503707 nshi:OtherPropertiesMember 2023-01-01 2023-09-30 0001503707 nshi:OtherPropertiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:TotalPropertiesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001503707 nshi:SolsticeSeniorLivingLLCMember 2023-09-30 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember 2024-01-01 2024-12-31 0001503707 srt:MinimumMember srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember 2024-12-31 0001503707 srt:MaximumMember srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:March312024Member 2024-01-01 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:December312024Member 2024-01-01 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:TerminatedPriorToInitialOutsideDateMember 2024-01-01 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:QualifyingIPOOf200MillionHasOccurredMember 2024-01-01 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:TerminatedPriorToMarch312025Member 2024-01-01 2024-12-31 0001503707 srt:ScenarioForecastMember us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember nshi:TheTrilogyJointVentureMember us-gaap:SubsequentEventMember nshi:TerminatedPriorToSeptember302025Member 2024-01-01 2024-12-31 shares iso4217:USD iso4217:USD shares pure nshi:property nshi:day nshi:facility nshi:home nshi:debt_instrument nshi:unit nshi:campus nshi:uSDollarsPerDay 0001503707 --12-31 false 2023 Q3 http://fasb.org/us-gaap/2023#RealEstateInvestmentPropertyNet http://fasb.org/us-gaap/2023#RealEstateInvestmentPropertyNet http://fasb.org/us-gaap/2023#OtherLiabilities http://fasb.org/us-gaap/2023#OtherLiabilities 0 10-Q true 2023-09-30 false 000-55190 NORTHSTAR HEALTHCARE INCOME, INC. MD 27-3663988 16 East 34th Street 18th Floor New York NY 10016 929 777-3135 Common stock, par value $0.01 per share Yes Yes Non-accelerated Filer false false false 185712103 87581000 103926000 11386000 11734000 894245000 933002000 3075000 128026000 176502000 2253000 2815000 2000000 2253000 10425000 7603000 1135916000 1237835000 901610000 912248000 292000 469000 1023000 993000 23967000 21034000 1592000 2019000 928484000 936763000 0.01 0.01 50000000 50000000 0 0 0 0 0 0 0.01 0.01 400000000 400000000 185712103 185712103 195421656 195421656 1857000 1954000 1716701000 1729589000 -1511765000 -1428840000 0 -3679000 206793000 299024000 639000 2048000 207432000 301072000 1135916000 1237835000 174400000 180200000 11966000 11274000 35655000 32987000 40330000 36165000 115897000 103001000 1078000 300000 2893000 457000 53374000 47739000 154445000 136445000 36890000 35134000 106993000 101258000 14250000 11014000 37143000 31877000 358000 857000 455000 857000 0 2428000 0 7532000 2921000 2859000 10424000 10300000 9848000 9642000 29305000 29105000 0 18500000 43422000 31502000 64267000 80434000 227742000 212431000 0 0 202000 77000 -347000 325000 -4662000 660000 -11240000 -32370000 -77757000 -75249000 -127000 2872000 -6595000 39427000 17000 15000 43000 45000 -11384000 -29513000 -84395000 -35867000 -166000 -73000 -1470000 -298000 -11218000 -11218000 -29440000 -29440000 -82925000 -82925000 -35569000 -35569000 -0.06 -0.06 -0.15 -0.15 -0.43 -0.43 -0.18 -0.18 185712103 185712103 194670948 194670948 191367117 191367117 194032819 194032819 0 0 0 0.50 203742 116712 -11384000 -29513000 -84395000 -35867000 0 -1664000 3679000 -4602000 0 -1664000 3679000 -4602000 -11384000 -31177000 -80716000 -40469000 -166000 -73000 -1470000 -298000 -11218000 -31104000 -79246000 -40171000 193121000 1930000 1720719000 -1277688000 -486000 444475000 2343000 446818000 698000 7000 2722000 2729000 2729000 15000 15000 15000 64000 64000 53000 53000 -568000 -568000 -568000 -12936000 -12936000 -45000 -12981000 193819000 1937000 1723456000 -1290624000 -1054000 433715000 2309000 436024000 637000 8000 2507000 2515000 2515000 13000 13000 13000 113000 113000 61000 61000 97052000 97052000 97052000 -2370000 -2370000 -2370000 6807000 6807000 -180000 6627000 194456000 1945000 1725976000 -1380869000 -3424000 343628000 2181000 345809000 623000 6000 2407000 2413000 2413000 86000 86000 74000 74000 -1664000 -1664000 -1664000 -29440000 -29440000 -73000 -29513000 195079000 1951000 1728383000 -1410309000 -5088000 314937000 2120000 317057000 195422000 1954000 1729589000 -1428840000 -3679000 299024000 2048000 301072000 45000 45000 22000 22000 1248000 1248000 1248000 -13926000 -13926000 -71000 -13997000 195422000 1954000 1729589000 -1442766000 -2431000 286346000 2000000 288346000 55000 55000 33000 33000 9710000 97000 13302000 13399000 13399000 -844000 -844000 -844000 -3275000 -3275000 -3275000 -57781000 -57781000 -1233000 -59014000 185712000 1857000 1716287000 -1500547000 0 217597000 789000 218386000 414000 414000 414000 44000 44000 28000 28000 -11218000 -11218000 -166000 -11384000 185712000 1857000 1716701000 -1511765000 0 206793000 639000 207432000 -84395000 -35867000 -6595000 39427000 29305000 29105000 43422000 31502000 2487000 2428000 988000 475000 170000 150000 -4662000 660000 360000 326000 0 7532000 10640000 0 -203000 114000 3786000 -3583000 -177000 -3868000 30000 256000 2640000 -8727000 -78000 -298000 13066000 -13604000 28425000 17924000 135000 0 13472000 42173000 -523000 0 -14295000 24249000 14066000 16514000 48000 0 96000 36000 1315000 408000 0 97018000 144000 263000 83000 188000 -15464000 -113901000 -16693000 -103256000 115660000 210938000 98967000 107682000 29666000 28625000 61000 41000 540000 2561000 13399000 0 25000 0 Business and Organization<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), owns a diversified portfolio of seniors housing properties, including independent living facilities (“ILF”), assisted living (“ALF”) and memory care facilities (“MCF”) located throughout the United States. In addition, the Company also has investments through non-controlling interests in joint ventures in a broader spectrum of healthcare real estate, including seniors housing properties, as well as skilled nursing (“SNF”) and ancillary services businesses, located throughout the United States.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company has conducted its operations, and intends to do so in the future, so as to continue to qualify as a REIT for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”), which became indirect subsidiaries of the Company on June 9, 2023. NorthStar Healthcare Income Advisor, LLC invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which were collectively recorded as non-controlling interests on the accompanying consolidated balance sheets prior to June 9, 2023. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of September 30, 2023, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, was 100.0%.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company raised $2.0 billion in total gross proceeds from the sale of shares of common stock in its continuous, public offerings (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Internalization</span></div>From inception through October 21, 2022, the Company was externally managed by CNI NSHC Advisors, LLC or its predecessor (the “Former Advisor”), an affiliate of NRF Holdco, LLC (the “Former Sponsor”). The Former Advisor was responsible for managing the Company’s operations, subject to the supervision of the Company’s board of directors, pursuant to an advisory agreement. On October 21, 2022, the Company completed the internalization of the Company’s management function (the “Internalization”). In connection with the Internalization, the Company agreed with the Former Advisor to terminate the advisory agreement and arranged for the Former Advisor to continue to provide certain services for a transition period. 1000 1000 1.000 400000000 0.01 50000000 0.01 2000000000 232600000 Summary of Significant Accounting Policies<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Accounting </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and related notes of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures normally included in the consolidated financial statements prepared under U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 27, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company, the Operating Partnership and their consolidated subsidiaries. The Company consolidates entities in which it has a controlling financial interest by first considering if an entity meets the definition of a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary or if the Company has the power to control an entity through majority voting interest or other arrangements. All significant intercompany balances are eliminated in consolidation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. A VIE is defined as an entity in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The determination of whether an entity is a VIE includes both a qualitative and quantitative analysis. The Company bases its qualitative analysis on its review of the design of the entity, its organizational structure including decision-making ability and relevant financial agreements and the quantitative analysis on the forecasted cash flow of the entity. The Company reassesses its initial evaluation of an entity as a VIE upon the occurrence of certain reconsideration events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE must be consolidated only by its primary beneficiary, which is defined as the party who, along with its affiliates and agents, has both the: (i) power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The Company determines whether it is the primary beneficiary of a VIE by considering qualitative and quantitative factors, including, but not limited to: which activities most significantly impact the VIE’s economic performance and which party controls such activities; the amount and characteristics of its investment; the obligation or likelihood for the Company or other interests to provide financial support; consideration of the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders and the similarity with and significance to the business activities of the Company and the other interests. The Company reassesses its determination of whether it is the primary beneficiary of a VIE each reporting period. Judgments related to these determinations include estimates about the current and future fair value and performance of investments held by these VIEs and general market conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its investments and financings, including investments in unconsolidated ventures and securitization financing transactions to determine whether each investment or financing is a VIE. The Company analyzes new investments and financings, as well as reconsideration events for existing investments and financings, which vary depending on type of investment or financing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has identified certain consolidated and unconsolidated VIEs. Assets of each of the VIEs, may only be used to settle obligations of the respective VIE. Creditors of each of the VIEs have no recourse to the general credit of the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated VIEs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant VIEs of the Company are certain entities that are consolidated by the Operating Partnership. These entities are VIEs because of non-controlling interests owned by third parties, which do not have substantive kick-out or participating rights. Included in operating real estate, net and mortgage notes payable, net on the Company’s consolidated balance sheet as of September 30, 2023 is $170.1 million and $172.0 million, respectively, related to such consolidated VIEs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unconsolidated VIEs </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company identified unconsolidated VIEs related to its investments in unconsolidated ventures with a carrying value of $128.0 million. The Company’s maximum exposure to loss as of September 30, 2023 would not exceed the carrying value of its investment in the VIEs. The Company determined that it is not the primary beneficiary of these VIEs and, accordingly, they are not consolidated in the Company’s financial statements as of September 30, 2023. The Company did not provide financial support to its unconsolidated VIEs during the nine months ended September 30, 2023. As of September 30, 2023, there were no explicit arrangements or implicit variable interests that could require the Company to provide financial support to its unconsolidated VIEs. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting Interest Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A voting interest entity is an entity in which the total equity investment at risk is sufficient to enable it to finance its activities independently and the equity holders have the power to direct the activities of the entity that most significantly impact its </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity. The usual condition for a controlling financial interest in a voting interest entity is ownership of a majority voting interest. If the Company has a majority voting interest in a voting interest entity, the entity will generally be consolidated. The Company does not consolidate a voting interest entity if there are substantive participating rights by other parties and/or kick-out rights by a single party or through a simple majority vote.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs on-going reassessments of whether entities previously evaluated under the voting interest framework have become VIEs, based on certain events, and therefore subject to the VIE consolidation framework.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-controlling, unconsolidated ownership interest in an entity may be accounted for using the equity method or the Company may elect the fair value option. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will account for an investment under the equity method of accounting if it has the ability to exercise significant influence over the operating and financial policies of an entity, but does not have a controlling financial interest. Under the equity method, the investment is adjusted each period for capital contributions and distributions and its share of the entity’s net income (loss). Capital contributions, distributions and net income (loss) of such entities are recorded in accordance with the terms of the governing documents. An allocation of net income (loss) may differ from the stated ownership percentage interest in such entity as a result of preferred returns and allocation formulas, if any, as described in such governing documents. Equity method investments are recognized using a cost accumulation model, in which the investment is recognized based on the cost to the investor, which includes acquisition fees. The Company records as an expense certain acquisition costs and fees associated with consolidated investments deemed to be business combinations and capitalizes these costs for investments deemed to be acquisitions of an asset, including an equity method investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect the fair value option of accounting for an investment that would otherwise be accounted for under the equity method. The fair value option election allows an entity to make an irrevocable election of fair value for certain financial assets and liabilities on an instrument-by-instrument basis at the initial or subsequent measurement. The decision to elect the fair value option must be applied to an entire instrument and is irrevocable once elected. Under the fair value option, the Company records its share of the changes to fair value of the investment and any unrealized gains and losses. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, the Company elected the fair value option method to account for its investment in the Espresso joint venture, which is included in investments in unconsolidated ventures on the consolidated balance sheets. The fair value election was made based on the Company’s assessment that the expected return of investment was lower than the Company’s carrying value of its investment in the Espresso joint venture, which resulted in an impairment of $4.7 million and reduced the carrying value of its investment to recoverable fair value of $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. The Company will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations. During the three months ended September 30, 2023, the Company did not record any changes to the fair value of its investment in the Espresso joint venture. Refer to Note 4 “Investment in Unconsolidated Ventures” and Note 10 “Fair Value” for further discussion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-controlling Interests</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-controlling interest in a consolidated subsidiary is defined as the portion of the equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company. A non-controlling interest is required to be presented as a separate component of equity on the consolidated balance sheets and presented separately as net income (loss) and comprehensive income (loss) attributable to controlling and non-controlling interests. An allocation to a non-controlling interest may differ from the stated ownership percentage interest in such entity as a result of a preferred return and allocation formula, if any, as described in such governing documents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments with an original maturity date of three months or less to be cash equivalents. Cash, including amounts restricted, may at times exceed the Federal Deposit Insurance Corporation deposit insurance limit of $250,000 per institution. The Company mitigates credit risk by placing cash and cash equivalents with major financial institutions and money market funds invested in short-term U.S. government securities. To date, the Company has not experienced any losses on cash and cash equivalents.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of amounts related to operating real estate (escrows for taxes, insurance, capital expenditures, security deposits received from residents and payments required under certain lease agreements) and other escrows required by lenders of the Company’s borrowings. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.246%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Real Estate</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating real estate is carried at historical cost less accumulated depreciation. Major replacements and betterments which improve or extend the life of the asset are capitalized and depreciated over their useful life. Ordinary repairs and maintenance are expensed as incurred. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.971%"><tr><td style="width:1.0%"></td><td style="width:31.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Category:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Term:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining life of the building</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining term of the lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 to 14 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction costs incurred in connection with the Company’s investments are capitalized and included in operating real estate, net on the consolidated balance sheets. Construction in progress is not depreciated until the asset is available for its intended use. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A leasing arrangement, a right to control the use of an identified asset for a period of time in exchange for consideration, is classified by the lessee either as a finance lease, which represents a financed purchase of the leased asset, or as an operating lease. For leases with terms greater than 12 months, a lease asset and a lease liability are recognized on the balance sheet at commencement date based on the present value of lease payments over the lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease renewal or termination options are included in the lease asset and lease liability only if it is reasonably certain that the option to extend would be exercised or the option to terminate would not be exercised. As the implicit rate in most leases are not readily determinable, the Company’s incremental borrowing rate for each lease at commencement date is used to determine the present value of lease payments. Consideration is given to the Company’s recent debt financing transactions, as well as publicly available data for instruments with similar characteristics, adjusted for the respective lease term, when estimating incremental borrowing rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense is recognized over the lease term based on an effective interest method for finance leases and on a straight-line basis for operating leases.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Use (“ROU”) - Finance Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into finance leases for equipment which are included in <span style="-sec-ix-hidden:f-507"><span style="-sec-ix-hidden:f-508">operating real estate, net</span></span> on the Company’s consolidated balance sheets. As of September 30, 2023, furniture, fixtures and equipment under finance leases totaled $0.3 million. The leased equipment is amortized on a straight-line basis. Payments for finance leases totaled $0.1 million and $0.4 million for the nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum lease payments under finance leases and the present value of the minimum lease payments, which are included in <span style="-sec-ix-hidden:f-513"><span style="-sec-ix-hidden:f-514">other liabilities</span></span> on the Company’s consolidated balance sheets (dollars in thousands):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.869%"><tr><td style="width:1.0%"></td><td style="width:68.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average interest rate related to the finance lease obligations is 6.8% with a weighted average lease term of 3.4 years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, there were no leases that had yet to commence which would create significant rights and obligations to the Company as lessee.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets and Deferred Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs consist of deferred financing costs. Deferred financing costs represent commitment fees, legal and other third-party costs associated with obtaining financing. These costs are recorded against the carrying value of such financing and are amortized to interest expense over the term of the financing using the effective interest method. Unamortized deferred financing costs are expensed to gain (loss) on investments and other, when the associated borrowing is repaid before maturity. Costs incurred in seeking financing transactions which do not close are expensed in the period in which it is determined that the financing will not occur.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identified Intangibles</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records acquired identified intangibles, such as the value of in-place leases and other intangibles, based on estimated fair value at the acquisition date. The value allocated to the identified intangibles is amortized over the remaining lease term. In-place leases are amortized into depreciation and amortization expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment analysis for identified intangible assets is performed in connection with the impairment assessment of the related operating real estate. An impairment establishes a new basis for the identified intangible asset and any impairment loss recognized is not subject to subsequent reversal. Refer to “—Impairment on Operating Real Estate and Investments in Unconsolidated Ventures” for additional information.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded in intangible assets, net on the consolidated balance sheets. Intangible assets relate to the Company’s in-place lease values for the Company’s four net lease properties. The following table presents intangible assets, net (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.521%"><tr><td style="width:1.0%"></td><td style="width:54.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-place lease value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded $0.1 million and $0.3 million of amortization expense for in-place leases for the three and nine months ended September 30, 2023 and 2022, respectively.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future amortization of in-place lease value (dollars in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.434%"><tr><td style="width:1.0%"></td><td style="width:69.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments to manage its interest rate risk. The Company’s derivative instruments are recorded at fair value. The accounting for changes in fair value of derivatives depends upon whether or not the Company has elected to designate the derivative in a hedging relationship and the derivative qualifies for hedge accounting. Under hedge accounting, changes in fair value for derivatives are recorded through other comprehensive income. When hedge accounting is not elected, changes in fair value for derivatives are recorded through the income statement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has interest rate caps that have not been designated for hedge accounting. The fair value of the Company's interest rate caps totaled $0.8 million and $0.7 million as of September 30, 2023 and December 31, 2022, respectively, and are included in other assets on the consolidated balance sheets. Changes in fair value of derivatives have been recorded in gain (loss) on investments and other in the consolidated statements of operations. The Company recognized losses totaling $0.3 million and $0.5 million for the three and nine months ended September 30, 2023, respectively, and gains totaling $0.3 million and $0.6 million for the three and nine months ended September 30, 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Real Estate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental income from operating real estate is derived from leasing of space to operators and residents, including rent received from the Company’s net lease properties and rent, ancillary service fees and other related revenue earned from ILF residents. Rental income recognition commences when the operator takes legal possession of the leased space and the leased space is substantially ready for its intended use. The leases are for fixed terms of varying length and generally provide for rentals and expense reimbursements to be paid in monthly installments. Rental income from leases, which includes community and move-in fees, is recognized over the term of the respective leases. ILF resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generates revenue from operating healthcare properties. Revenue related to operating healthcare properties includes resident room and care charges, ancillary fees and other resident service charges. Rent is charged and revenue is recognized when such services are provided, generally defined per the resident agreement as of the date upon which a resident occupies a room or uses the services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Revenue derived from our ALFs and MCFs is recorded in resident fee income in the consolidated statements of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from operators and residents is recognized at lease commencement only to the extent collection is expected to be probable. This assessment is based on several qualitative and quantitative factors, including and as appropriate, the payment history, ability to satisfy its lease obligations, the value of the underlying collateral or deposit, if any, and current economic conditions. If collection is assessed to not be probable, thereafter lease income recognized is limited to amounts collected, with the reversal of any revenue recognized to date in excess of amounts received. If collection is subsequently reassessed to be probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operator of the Company’s four net lease properties failed to remit contractual monthly rent obligations and the Company deemed it not probable that these obligations will be satisfied in the foreseeable future. On March 27, 2023, the Company entered into a lease forbearance and modification agreement (the “Forbearance Agreement”) with the existing operator, pursuant to which, among other things, the Company will be entitled to receive all cash flow in excess of permitted expenses, and be required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. For the three and nine months ended September 30, 2023, the Company received excess cash flow of $0.8 million and $1.2 million, respectively, which was recorded as rental income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023 and 2022, total property and other revenues includes variable lease revenue of $3.6 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, total property and other revenue includes variable lease revenue of $10.7 million and $9.2 million, respectively. Variable lease revenue includes ancillary services provided to operator/residents, as well as non-recurring services and fees at the Company’s operating facilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment on Operating Real Estate and Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, it is difficult for the Company to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. The future economic effects will depend on many factors beyond the Company’s control and knowledge. The resulting effect on impairment of the Company's real estate held for investment and held for sale and investments in unconsolidated ventures may materially differ from the Company's current expectations and further impairment charges may be recorded in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Real Estate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate portfolio is reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of its operating real estate may be impaired or that its carrying value may not be recoverable. A property’s value is considered impaired if the Company’s estimate of the aggregate expected future undiscounted cash flow generated by the property is less than the carrying value. In conducting this review, the Company considers U.S. macroeconomic factors, real estate and healthcare sector conditions, together with asset specific and other factors. To the extent an impairment has occurred, the loss is measured as the excess of the carrying value of the property over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate held for sale is stated at the lower of its carrying amount or estimated fair value less disposal cost, with any write-down to disposal cost recorded as an impairment loss. For any increase in fair value less disposal cost subsequent to classification as held for sale, the impairment may be reversed, but only up to the amount of cumulative loss previously recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the potential impact of the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions on the future net operating income of its healthcare real estate held for investment as an indicator of impairment. Fair values were estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded impairment losses on its operating real estate totaling $38.7 million, including impairment losses of $38.6 million for five facilities within the Rochester portfolio as a result of revised holding period assumptions. Additionally, the Company recorded impairment losses totaling $0.1 million for a land parcel within the Rochester portfolio as a result of lower estimated market value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2022, the Company recorded impairment losses on its operating real estate totaling $31.5 million. The Company recorded impairment losses of $18.5 million, $8.5 million, and $3.9 million for facilities in its Arbors, Winterfell and Rochester portfolios, respectively, as a result of declining operating margins and lower projected future cash flows. In addition, the Company recorded impairment losses totaling $0.6 million for property damage sustained by facilities in its Winterfell portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investments in unconsolidated ventures on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value may be impaired or that its carrying value may not be recoverable. An investment is considered impaired if the projected net recoverable amount over the expected holding period is less than the carrying value. In conducting this review, the Company considers global macroeconomic factors, including real estate sector conditions, together with investment specific and other factors. To the extent an impairment has occurred on the Company’s investment in unconsolidated ventures, and is considered to be other than temporary, the loss is measured as the excess of the carrying value of the investment over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2023, the Company recorded an impairment on its investment in the Espresso joint venture totaling $4.7 million, which reduced the carrying value of its investment to $3.1 million. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. During the nine months ended September 30, 2022, there was no impairment recorded on any of the Company’s investments in unconsolidated ventures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The joint ventures underlying the Company’s unconsolidated ventures assess and record impairment and reserves on their respective real estate portfolios, goodwill, and other assets, and the Company recognizes its proportionate share through equity in earnings (losses). In May 2023, prior to the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”), the Diversified US/UK joint venture recorded impairment losses on its remaining properties, 48 care homes located in the United Kingdom (the “UK Portfolio”), due to, among other things, the extended period contemplated for the UK Portfolio to reach stabilization. The Company’s proportionate share of the impairment losses recorded by the Diversified US/UK portfolio totaled $11.4 million. The Company’s proportionate share of impairment and reserves recognized by the underlying joint ventures of its unconsolidated ventures during the nine months ended September 30, 2022 was de minimis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Losses on Receivables</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expected credit loss model, in estimating expected credit losses over the life of a financial instrument at the time of origination or acquisition, considers historical loss experiences, current conditions and the effects of reasonable and supportable expectations of changes in future macroeconomic conditions. The Company assesses the estimate of expected credit losses on a quarterly basis or more frequently as necessary. The Company considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures expected credit losses of receivables on a collective basis when similar risk characteristics exist. If the Company determines that a particular receivable does not share risk characteristics with its other receivables, the Company evaluates the receivable for expected credit losses on an individual basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When developing an estimate of expected credit losses on receivables, the Company considers available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both relating to past events, current conditions, and reasonable and supportable forecasts. The Company considers relevant qualitative and quantitative factors that relate to the environment in which the Company operates and are specific to the borrower. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the fair value of the collateral, less estimated costs to sell, may be used when determining the allowance for credit losses for a receivable for which the repayment is expected to be provided substantially through the sale of the collateral when the borrower is experiencing financial difficulty. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has not recorded an allowance for credit losses on its receivables. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition Fees and Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an expense for certain acquisition costs and fees associated with transactions deemed to be business combinations in which it consolidated the asset and capitalized these costs for transactions deemed to be acquisitions of an asset, including an equity investment. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for equity-based compensation awards using the fair value method, which requires an estimate of fair value of the award at the time of grant. All fixed equity-based awards to directors, which have no vesting conditions other than </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">time of service, are amortized to compensation expense over the awards’ vesting period on a straight-line basis. Equity-based compensation is classified within general and administrative expenses in the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT and to comply with the related provisions of the Internal Revenue Code beginning in its taxable year ended December 31, 2013. Accordingly, the Company will generally not be subject to U.S. federal income tax to the extent of its distributions to stockholders as long as certain asset, gross income and share ownership tests are met. To maintain its qualification as a REIT, the Company must annually distribute dividends equal to at least 90.0% of its REIT taxable income (with certain adjustments) to its stockholders and meet certain other requirements. The Company believes that all of the criteria to maintain the Company’s REIT qualification have been met for the applicable periods, but there can be no assurance that these criteria will continue to be met in subsequent periods. If the Company were to fail to meet these requirements, it would be subject to U.S. federal income tax and potential interest and penalties, which could have a material adverse impact on its results of operations and amounts available for distributions to its stockholders. The Company’s accounting policy with respect to interest and penalties is to classify these amounts as a component of income tax expense, where applicable. The Company has assessed its tax positions for all open tax years, which include 2018 to 2022, and concluded there were no material uncertainties to be recognized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also be subject to certain state, local and franchise taxes. Under certain circumstances, federal income and excise taxes may be due on its undistributed taxable income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made a joint election to treat certain subsidiaries as taxable REIT subsidiaries (“TRS”) which may be subject to U.S. federal, state and local income taxes. In general, a TRS of the Company may perform services for managers/operators/residents of the Company, hold assets that the Company cannot hold directly and may engage in any real estate or non-real estate related business.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of the Company are subject to taxation by federal and state authorities for the periods presented. Income taxes are accounted for by the asset/liability approach in accordance with U.S. GAAP. Deferred taxes, if any, represent the expected future tax consequences when the reported amounts of assets and liabilities are recovered or paid. Such amounts arise from differences between the financial reporting and tax bases of assets and liabilities and are adjusted for changes in tax laws and tax rates in the period which such changes are enacted. A provision for income tax represents the total of income taxes paid or payable for the current period, plus the change in deferred taxes. Current and deferred taxes are provided on the portion of earnings (losses) recognized by the Company with respect to its interest in the TRS. Deferred income tax assets and liabilities are calculated based on temporary differences between the Company’s U.S. GAAP consolidated financial statements and the federal and state income tax basis of assets and liabilities as of the consolidated balance sheet date. The Company evaluates the realizability of its deferred tax assets (e.g., net operating loss and capital loss carryforwards) and recognizes a valuation allowance if, based on the available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. When evaluating the realizability of its deferred tax assets, the Company considers estimates of expected future taxable income, existing and projected book/tax differences, tax planning strategies available and the general and industry specific economic outlook. This realizability analysis is inherently subjective, as it requires the Company to forecast its business and general economic environment in future periods. Changes in estimate of deferred tax asset realizability, if any, are included in provision for income tax benefit (expense) in the consolidated statements of operations. The Company has a deferred tax asset, which as of September 30, 2023 totaled $15.9 million and continues to have a full valuation allowance recognized, as there are no changes in the facts and circumstances to indicate that the Company should release the valuation allowance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded an income tax expense of approximately $17,000 and $43,000 for the three and nine months ended September 30, 2023, respectively. The Company recorded an income tax expense of approximately $15,000 and $45,000 for the three and nine months ended September 30, 2022, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Comprehensive Income (Loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports consolidated comprehensive income (loss) in separate statements following the consolidated statements of operations. Comprehensive income (loss) is defined as the change in equity resulting from net income (loss) and other comprehensive income (loss) (“OCI”). The only component of OCI for the Company was foreign currency translation adjustments related to its investment in an unconsolidated venture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a foreign currency for which the functional currency is a foreign currency are translated using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are translated into U.S. dollars using the average currency exchange rate in effect during the period. The resulting foreign currency translation adjustment is recorded as a component of accumulated OCI in the consolidated statements of equity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a foreign currency for which the functional currency is the U.S. dollar are remeasured using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are remeasured into U.S. dollars using the average currency exchange rate in effect during the period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period December 31, 2022 through June 9, 2023, the Company had exposure to foreign currency through an investment in an unconsolidated venture, the effects of which were recorded as a component of accumulated OCI in the consolidated statements of equity and in equity in earnings (losses) in the consolidated statements of operations. As a result of the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”) in June 2023, the Company is no longer exposed to foreign currency as of September 30, 2023. The Company reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK joint venture, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other on the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Adopted in 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued an amendment to the reference rate reform standard, which provides the option for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on contract modifications and hedge accounting. An example of such reform is the market transition from the London Interbank Offered Rate (“LIBOR”) to alternative reference rates. Entities that make this optional expedient election would not have to remeasure the contracts at the modification date or reassess the accounting treatment if certain criteria are met and would continue applying hedge accounting for relationships affected by reference rate reform. In December 2022, the FASB extended the date for which this guidance can be applied from December 31, 2022 to December 31, 2024. The Company did not make the optional election of the aforementioned accounting standards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Application of Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Accounting </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements and related notes of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial reporting and the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, certain information and note disclosures normally included in the consolidated financial statements prepared under U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows have been included and are of a normal and recurring nature. The operating results presented for interim periods are not necessarily indicative of the results that may be expected for any other interim period or for the entire year. These consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the U.S. Securities and Exchange Commission on March 27, 2023.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Principles of Consolidation</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company, the Operating Partnership and their consolidated subsidiaries. The Company consolidates entities in which it has a controlling financial interest by first considering if an entity meets the definition of a variable interest entity (“VIE”) for which the Company is deemed to be the primary beneficiary or if the Company has the power to control an entity through majority voting interest or other arrangements. All significant intercompany balances are eliminated in consolidation.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that lacks one or more of the characteristics of a voting interest entity. A VIE is defined as an entity in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. The determination of whether an entity is a VIE includes both a qualitative and quantitative analysis. The Company bases its qualitative analysis on its review of the design of the entity, its organizational structure including decision-making ability and relevant financial agreements and the quantitative analysis on the forecasted cash flow of the entity. The Company reassesses its initial evaluation of an entity as a VIE upon the occurrence of certain reconsideration events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE must be consolidated only by its primary beneficiary, which is defined as the party who, along with its affiliates and agents, has both the: (i) power to direct the activities that most significantly impact the VIE’s economic performance; and (ii) obligation to absorb the losses of the VIE or the right to receive the benefits from the VIE, which could be significant to the VIE. The Company determines whether it is the primary beneficiary of a VIE by considering qualitative and quantitative factors, including, but not limited to: which activities most significantly impact the VIE’s economic performance and which party controls such activities; the amount and characteristics of its investment; the obligation or likelihood for the Company or other interests to provide financial support; consideration of the VIE’s purpose and design, including the risks the VIE was designed to create and pass through to its variable interest holders and the similarity with and significance to the business activities of the Company and the other interests. The Company reassesses its determination of whether it is the primary beneficiary of a VIE each reporting period. Judgments related to these determinations include estimates about the current and future fair value and performance of investments held by these VIEs and general market conditions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its investments and financings, including investments in unconsolidated ventures and securitization financing transactions to determine whether each investment or financing is a VIE. The Company analyzes new investments and financings, as well as reconsideration events for existing investments and financings, which vary depending on type of investment or financing. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has identified certain consolidated and unconsolidated VIEs. Assets of each of the VIEs, may only be used to settle obligations of the respective VIE. Creditors of each of the VIEs have no recourse to the general credit of the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidated VIEs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant VIEs of the Company are certain entities that are consolidated by the Operating Partnership. These entities are VIEs because of non-controlling interests owned by third parties, which do not have substantive kick-out or participating rights. Included in operating real estate, net and mortgage notes payable, net on the Company’s consolidated balance sheet as of September 30, 2023 is $170.1 million and $172.0 million, respectively, related to such consolidated VIEs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unconsolidated VIEs </span></div>As of September 30, 2023, the Company identified unconsolidated VIEs related to its investments in unconsolidated ventures with a carrying value of $128.0 million. The Company’s maximum exposure to loss as of September 30, 2023 would not exceed the carrying value of its investment in the VIEs. The Company determined that it is not the primary beneficiary of these VIEs and, accordingly, they are not consolidated in the Company’s financial statements as of September 30, 2023. The Company did not provide financial support to its unconsolidated VIEs during the nine months ended September 30, 2023. As of September 30, 2023, there were no explicit arrangements or implicit variable interests that could require the Company to provide financial support to its unconsolidated VIEs. 170100000 172000000 128000000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting Interest Entities</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A voting interest entity is an entity in which the total equity investment at risk is sufficient to enable it to finance its activities independently and the equity holders have the power to direct the activities of the entity that most significantly impact its </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic performance, the obligation to absorb the losses of the entity and the right to receive the residual returns of the entity. The usual condition for a controlling financial interest in a voting interest entity is ownership of a majority voting interest. If the Company has a majority voting interest in a voting interest entity, the entity will generally be consolidated. The Company does not consolidate a voting interest entity if there are substantive participating rights by other parties and/or kick-out rights by a single party or through a simple majority vote.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performs on-going reassessments of whether entities previously evaluated under the voting interest framework have become VIEs, based on certain events, and therefore subject to the VIE consolidation framework.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-controlling, unconsolidated ownership interest in an entity may be accounted for using the equity method or the Company may elect the fair value option. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will account for an investment under the equity method of accounting if it has the ability to exercise significant influence over the operating and financial policies of an entity, but does not have a controlling financial interest. Under the equity method, the investment is adjusted each period for capital contributions and distributions and its share of the entity’s net income (loss). Capital contributions, distributions and net income (loss) of such entities are recorded in accordance with the terms of the governing documents. An allocation of net income (loss) may differ from the stated ownership percentage interest in such entity as a result of preferred returns and allocation formulas, if any, as described in such governing documents. Equity method investments are recognized using a cost accumulation model, in which the investment is recognized based on the cost to the investor, which includes acquisition fees. The Company records as an expense certain acquisition costs and fees associated with consolidated investments deemed to be business combinations and capitalizes these costs for investments deemed to be acquisitions of an asset, including an equity method investment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect the fair value option of accounting for an investment that would otherwise be accounted for under the equity method. The fair value option election allows an entity to make an irrevocable election of fair value for certain financial assets and liabilities on an instrument-by-instrument basis at the initial or subsequent measurement. The decision to elect the fair value option must be applied to an entire instrument and is irrevocable once elected. Under the fair value option, the Company records its share of the changes to fair value of the investment and any unrealized gains and losses. </span></div>On June 30, 2023, the Company elected the fair value option method to account for its investment in the Espresso joint venture, which is included in investments in unconsolidated ventures on the consolidated balance sheets. The fair value election was made based on the Company’s assessment that the expected return of investment was lower than the Company’s carrying value of its investment in the Espresso joint venture, which resulted in an impairment of $4.7 million and reduced the carrying value of its investment to recoverable fair value of $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s remaining assets and estimated future cash distributions, less transaction and wind down costs. The Company will record any changes to its investment’s fair value in gain (loss) on investments and other in the consolidated statements of operations. 4700000 3100000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-controlling Interests</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-controlling interest in a consolidated subsidiary is defined as the portion of the equity (net assets) in a subsidiary not attributable, directly or indirectly, to the Company. A non-controlling interest is required to be presented as a separate component of equity on the consolidated balance sheets and presented separately as net income (loss) and comprehensive income (loss) attributable to controlling and non-controlling interests. An allocation to a non-controlling interest may differ from the stated ownership percentage interest in such entity as a result of a preferred return and allocation formula, if any, as described in such governing documents.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly-liquid investments with an original maturity date of three months or less to be cash equivalents. Cash, including amounts restricted, may at times exceed the Federal Deposit Insurance Corporation deposit insurance limit of $250,000 per institution. The Company mitigates credit risk by placing cash and cash equivalents with major financial institutions and money market funds invested in short-term U.S. government securities. To date, the Company has not experienced any losses on cash and cash equivalents.</span></div>Restricted cash consists of amounts related to operating real estate (escrows for taxes, insurance, capital expenditures, security deposits received from residents and payments required under certain lease agreements) and other escrows required by lenders of the Company’s borrowings. <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.246%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents, and restricted cash as reported on the consolidated balance sheets to the total of such amounts as reported on the consolidated statements of cash flows (dollars in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.246%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,581 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,926 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,386 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,967 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115,660 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 87581000 103926000 11386000 11734000 98967000 115660000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Real Estate</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating real estate is carried at historical cost less accumulated depreciation. Major replacements and betterments which improve or extend the life of the asset are capitalized and depreciated over their useful life. Ordinary repairs and maintenance are expensed as incurred. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.971%"><tr><td style="width:1.0%"></td><td style="width:31.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Category:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Term:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining life of the building</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining term of the lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 to 14 years</span></div></td></tr></table></div>Construction costs incurred in connection with the Company’s investments are capitalized and included in operating real estate, net on the consolidated balance sheets. Construction in progress is not depreciated until the asset is available for its intended use. Operating real estate is depreciated using the straight-line method over the estimated useful life of the assets, summarized as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.971%"><tr><td style="width:1.0%"></td><td style="width:31.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Category:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Term:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 to 50 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Building improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining life of the building</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 to 15 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lesser of the useful life or remaining term of the lease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 to 14 years</span></div></td></tr></table> P30Y P50Y P9Y P15Y P5Y P14Y <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lessee Accounting</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A leasing arrangement, a right to control the use of an identified asset for a period of time in exchange for consideration, is classified by the lessee either as a finance lease, which represents a financed purchase of the leased asset, or as an operating lease. For leases with terms greater than 12 months, a lease asset and a lease liability are recognized on the balance sheet at commencement date based on the present value of lease payments over the lease term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease renewal or termination options are included in the lease asset and lease liability only if it is reasonably certain that the option to extend would be exercised or the option to terminate would not be exercised. As the implicit rate in most leases are not readily determinable, the Company’s incremental borrowing rate for each lease at commencement date is used to determine the present value of lease payments. Consideration is given to the Company’s recent debt financing transactions, as well as publicly available data for instruments with similar characteristics, adjusted for the respective lease term, when estimating incremental borrowing rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense is recognized over the lease term based on an effective interest method for finance leases and on a straight-line basis for operating leases.</span></div>Right of Use (“ROU”) - Finance AssetsThe Company has entered into finance leases for equipment which are included in <span style="-sec-ix-hidden:f-507"><span style="-sec-ix-hidden:f-508">operating real estate, net</span></span> on the Company’s consolidated balance sheets. 300000 100000 400000 <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum lease payments under finance leases and the present value of the minimum lease payments, which are included in <span style="-sec-ix-hidden:f-513"><span style="-sec-ix-hidden:f-514">other liabilities</span></span> on the Company’s consolidated balance sheets (dollars in thousands):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.869%"><tr><td style="width:1.0%"></td><td style="width:68.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 18000 69000 38000 33000 18000 10000 186000 27000 159000 0.068 P3Y4M24D <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred costs consist of deferred financing costs. Deferred financing costs represent commitment fees, legal and other third-party costs associated with obtaining financing. These costs are recorded against the carrying value of such financing and are amortized to interest expense over the term of the financing using the effective interest method. Unamortized deferred financing costs are expensed to gain (loss) on investments and other, when the associated borrowing is repaid before maturity. Costs incurred in seeking financing transactions which do not close are expensed in the period in which it is determined that the financing will not occur.</span></div> <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Identified Intangibles</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records acquired identified intangibles, such as the value of in-place leases and other intangibles, based on estimated fair value at the acquisition date. The value allocated to the identified intangibles is amortized over the remaining lease term. In-place leases are amortized into depreciation and amortization expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment analysis for identified intangible assets is performed in connection with the impairment assessment of the related operating real estate. An impairment establishes a new basis for the identified intangible asset and any impairment loss recognized is not subject to subsequent reversal. Refer to “—Impairment on Operating Real Estate and Investments in Unconsolidated Ventures” for additional information.</span></div>Identified intangible assets are recorded in intangible assets, net on the consolidated balance sheets. 4 The following table presents intangible assets, net (dollars in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.521%"><tr><td style="width:1.0%"></td><td style="width:54.019%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.035%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-place lease value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(118,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,253 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 120149000 120149000 118149000 117896000 2000000 2253000 100000 100000 300000 300000 <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future amortization of in-place lease value (dollars in thousands):</span></div><div style="margin-bottom:8pt;margin-top:13pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:40.434%"><tr><td style="width:1.0%"></td><td style="width:69.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.499%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">568 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 84000 337000 337000 337000 337000 568000 2000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>The Company uses derivative instruments to manage its interest rate risk. The Company’s derivative instruments are recorded at fair value. The accounting for changes in fair value of derivatives depends upon whether or not the Company has elected to designate the derivative in a hedging relationship and the derivative qualifies for hedge accounting. Under hedge accounting, changes in fair value for derivatives are recorded through other comprehensive income. When hedge accounting is not elected, changes in fair value for derivatives are recorded through the income statement. 800000 700000 300000 500000 -300000 -600000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Real Estate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rental income from operating real estate is derived from leasing of space to operators and residents, including rent received from the Company’s net lease properties and rent, ancillary service fees and other related revenue earned from ILF residents. Rental income recognition commences when the operator takes legal possession of the leased space and the leased space is substantially ready for its intended use. The leases are for fixed terms of varying length and generally provide for rentals and expense reimbursements to be paid in monthly installments. Rental income from leases, which includes community and move-in fees, is recognized over the term of the respective leases. ILF resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generates revenue from operating healthcare properties. Revenue related to operating healthcare properties includes resident room and care charges, ancillary fees and other resident service charges. Rent is charged and revenue is recognized when such services are provided, generally defined per the resident agreement as of the date upon which a resident occupies a room or uses the services. Resident agreements are generally short-term in nature and may allow for termination with 30 days’ notice. Revenue derived from our ALFs and MCFs is recorded in resident fee income in the consolidated statements of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from operators and residents is recognized at lease commencement only to the extent collection is expected to be probable. This assessment is based on several qualitative and quantitative factors, including and as appropriate, the payment history, ability to satisfy its lease obligations, the value of the underlying collateral or deposit, if any, and current economic conditions. If collection is assessed to not be probable, thereafter lease income recognized is limited to amounts collected, with the reversal of any revenue recognized to date in excess of amounts received. If collection is subsequently reassessed to be probable, revenue is adjusted to reflect the amount that would have been recognized had collection always been assessed as probable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operator of the Company’s four net lease properties failed to remit contractual monthly rent obligations and the Company deemed it not probable that these obligations will be satisfied in the foreseeable future. On March 27, 2023, the Company entered into a lease forbearance and modification agreement (the “Forbearance Agreement”) with the existing operator, pursuant to which, among other things, the Company will be entitled to receive all cash flow in excess of permitted expenses, and be required to fund any operating deficits, through 2025, subject to the terms and conditions thereof. For the three and nine months ended September 30, 2023, the Company received excess cash flow of $0.8 million and $1.2 million, respectively, which was recorded as rental income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2023 and 2022, total property and other revenues includes variable lease revenue of $3.6 million and $2.1 million, respectively. For the nine months ended September 30, 2023 and 2022, total property and other revenue includes variable lease revenue of $10.7 million and $9.2 million, respectively. Variable lease revenue includes ancillary services provided to operator/residents, as well as non-recurring services and fees at the Company’s operating facilities.</span></div> 30 30 800000 1200000 3600000 2100000 10700000 9200000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impairment on Operating Real Estate and Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, it is difficult for the Company to assess and estimate the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions. The future economic effects will depend on many factors beyond the Company’s control and knowledge. The resulting effect on impairment of the Company's real estate held for investment and held for sale and investments in unconsolidated ventures may materially differ from the Company's current expectations and further impairment charges may be recorded in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Real Estate</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s real estate portfolio is reviewed on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value of its operating real estate may be impaired or that its carrying value may not be recoverable. A property’s value is considered impaired if the Company’s estimate of the aggregate expected future undiscounted cash flow generated by the property is less than the carrying value. In conducting this review, the Company considers U.S. macroeconomic factors, real estate and healthcare sector conditions, together with asset specific and other factors. To the extent an impairment has occurred, the loss is measured as the excess of the carrying value of the property over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate held for sale is stated at the lower of its carrying amount or estimated fair value less disposal cost, with any write-down to disposal cost recorded as an impairment loss. For any increase in fair value less disposal cost subsequent to classification as held for sale, the impairment may be reversed, but only up to the amount of cumulative loss previously recognized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the potential impact of the lasting effects of the COVID-19 pandemic, inflation, rising interest rates, risk of recession and other economic conditions on the future net operating income of its healthcare real estate held for investment as an indicator of impairment. Fair values were estimated based upon the income capitalization approach, using net operating income for each property and applying indicative capitalization rates.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews its investments in unconsolidated ventures on a quarterly basis, or more frequently as necessary, to assess whether there are any indicators that the value may be impaired or that its carrying value may not be recoverable. An investment is considered impaired if the projected net recoverable amount over the expected holding period is less than the carrying value. In conducting this review, the Company considers global macroeconomic factors, including real estate sector conditions, together with investment specific and other factors. To the extent an impairment has occurred on the Company’s investment in unconsolidated ventures, and is considered to be other than temporary, the loss is measured as the excess of the carrying value of the investment over the estimated fair value and recorded in impairment loss in the consolidated statements of operations.</span></div> 38700000 38600000 5 100000 31500000 18500000 8500000 3900000 600000 4700000 3100000 48 11400000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Credit Losses on Receivables</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current expected credit loss model, in estimating expected credit losses over the life of a financial instrument at the time of origination or acquisition, considers historical loss experiences, current conditions and the effects of reasonable and supportable expectations of changes in future macroeconomic conditions. The Company assesses the estimate of expected credit losses on a quarterly basis or more frequently as necessary. The Company considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures expected credit losses of receivables on a collective basis when similar risk characteristics exist. If the Company determines that a particular receivable does not share risk characteristics with its other receivables, the Company evaluates the receivable for expected credit losses on an individual basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When developing an estimate of expected credit losses on receivables, the Company considers available information relevant to assessing the collectability of cash flows. This information may include internal information, external information, or a combination of both relating to past events, current conditions, and reasonable and supportable forecasts. The Company considers relevant qualitative and quantitative factors that relate to the environment in which the Company operates and are specific to the borrower. </span></div>Further, the fair value of the collateral, less estimated costs to sell, may be used when determining the allowance for credit losses for a receivable for which the repayment is expected to be provided substantially through the sale of the collateral when the borrower is experiencing financial difficulty. 0 Acquisition Fees and ExpensesThe Company recorded an expense for certain acquisition costs and fees associated with transactions deemed to be business combinations in which it consolidated the asset and capitalized these costs for transactions deemed to be acquisitions of an asset, including an equity investment. <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for equity-based compensation awards using the fair value method, which requires an estimate of fair value of the award at the time of grant. All fixed equity-based awards to directors, which have no vesting conditions other than </span></div>time of service, are amortized to compensation expense over the awards’ vesting period on a straight-line basis. Equity-based compensation is classified within general and administrative expenses in the consolidated statements of operations. <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected to be taxed as a REIT and to comply with the related provisions of the Internal Revenue Code beginning in its taxable year ended December 31, 2013. Accordingly, the Company will generally not be subject to U.S. federal income tax to the extent of its distributions to stockholders as long as certain asset, gross income and share ownership tests are met. To maintain its qualification as a REIT, the Company must annually distribute dividends equal to at least 90.0% of its REIT taxable income (with certain adjustments) to its stockholders and meet certain other requirements. The Company believes that all of the criteria to maintain the Company’s REIT qualification have been met for the applicable periods, but there can be no assurance that these criteria will continue to be met in subsequent periods. If the Company were to fail to meet these requirements, it would be subject to U.S. federal income tax and potential interest and penalties, which could have a material adverse impact on its results of operations and amounts available for distributions to its stockholders. The Company’s accounting policy with respect to interest and penalties is to classify these amounts as a component of income tax expense, where applicable. The Company has assessed its tax positions for all open tax years, which include 2018 to 2022, and concluded there were no material uncertainties to be recognized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also be subject to certain state, local and franchise taxes. Under certain circumstances, federal income and excise taxes may be due on its undistributed taxable income. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company made a joint election to treat certain subsidiaries as taxable REIT subsidiaries (“TRS”) which may be subject to U.S. federal, state and local income taxes. In general, a TRS of the Company may perform services for managers/operators/residents of the Company, hold assets that the Company cannot hold directly and may engage in any real estate or non-real estate related business.</span></div>Certain subsidiaries of the Company are subject to taxation by federal and state authorities for the periods presented. Income taxes are accounted for by the asset/liability approach in accordance with U.S. GAAP. Deferred taxes, if any, represent the expected future tax consequences when the reported amounts of assets and liabilities are recovered or paid. Such amounts arise from differences between the financial reporting and tax bases of assets and liabilities and are adjusted for changes in tax laws and tax rates in the period which such changes are enacted. A provision for income tax represents the total of income taxes paid or payable for the current period, plus the change in deferred taxes. Current and deferred taxes are provided on the portion of earnings (losses) recognized by the Company with respect to its interest in the TRS. Deferred income tax assets and liabilities are calculated based on temporary differences between the Company’s U.S. GAAP consolidated financial statements and the federal and state income tax basis of assets and liabilities as of the consolidated balance sheet date. The Company evaluates the realizability of its deferred tax assets (e.g., net operating loss and capital loss carryforwards) and recognizes a valuation allowance if, based on the available evidence, it is more likely than not that some portion or all of its deferred tax assets will not be realized. When evaluating the realizability of its deferred tax assets, the Company considers estimates of expected future taxable income, existing and projected book/tax differences, tax planning strategies available and the general and industry specific economic outlook. This realizability analysis is inherently subjective, as it requires the Company to forecast its business and general economic environment in future periods. Changes in estimate of deferred tax asset realizability, if any, are included in provision for income tax benefit (expense) in the consolidated statements of operations. 15900000 17000 43000 15000 45000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Comprehensive Income (Loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span>The Company reports consolidated comprehensive income (loss) in separate statements following the consolidated statements of operations. Comprehensive income (loss) is defined as the change in equity resulting from net income (loss) and other comprehensive income (loss) (“OCI”). The only component of OCI for the Company was foreign currency translation adjustments related to its investment in an unconsolidated venture. <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a foreign currency for which the functional currency is a foreign currency are translated using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are translated into U.S. dollars using the average currency exchange rate in effect during the period. The resulting foreign currency translation adjustment is recorded as a component of accumulated OCI in the consolidated statements of equity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities denominated in a foreign currency for which the functional currency is the U.S. dollar are remeasured using the currency exchange rate in effect at the end of the period presented and the results of operations for such entities are remeasured into U.S. dollars using the average currency exchange rate in effect during the period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period December 31, 2022 through June 9, 2023, the Company had exposure to foreign currency through an investment in an unconsolidated venture, the effects of which were recorded as a component of accumulated OCI in the consolidated statements of equity and in equity in earnings (losses) in the consolidated statements of operations. As a result of the Sale of Minority Interests (as defined in Note 4, “Investments in Unconsolidated Ventures”) in June 2023, the Company is no longer exposed to foreign currency as of September 30, 2023. The Company reclassified the accumulated foreign currency losses, totaling $3.3 million, related to the Diversified US/UK joint venture, previously recorded through other comprehensive income on the consolidated statements of equity to gain (loss) on investments and other on the consolidated statements of operations.</span></div> -3300000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Adopted in 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued an amendment to the reference rate reform standard, which provides the option for a limited period of time to ease the potential burden in accounting for, or recognizing the effects of, reference rate reform on contract modifications and hedge accounting. An example of such reform is the market transition from the London Interbank Offered Rate (“LIBOR”) to alternative reference rates. Entities that make this optional expedient election would not have to remeasure the contracts at the modification date or reassess the accounting treatment if certain criteria are met and would continue applying hedge accounting for relationships affected by reference rate reform. In December 2022, the FASB extended the date for which this guidance can be applied from December 31, 2022 to December 31, 2024. The Company did not make the optional election of the aforementioned accounting standards.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Application of Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Operating Real Estate<div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents operating real estate, net (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.434%"><tr><td style="width:1.0%"></td><td style="width:49.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">957,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186,802 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(292,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(263,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating real estate, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">933,002 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2023, depreciation expense was $9.8 million and $29.1 million, respectively. For the three and nine months ended September 30, 2022, depreciation expense was $9.6 million and $28.9 million, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the table above, operating real estate has been reduced by accumulated impairment losses of $220.2 million and $181.5 million as of September 30, 2023 and December 31, 2022, respectively. Impairment losses on the Company’s operating real estate totaled $38.7 million and $31.5 million for the nine months ended September 30, 2023 and 2022, respectively, and are </span></div>recorded in impairment losses on the consolidated statements of operations. Refer to Note 2, “Summary of Significant Accounting Policies” for further discussion. <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents operating real estate, net (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.434%"><tr><td style="width:1.0%"></td><td style="width:49.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121,518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932,261 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">957,924 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tenant improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,956 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,736 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture, fixtures and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,876 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91,058 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186,802 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,196,553 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(292,557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(263,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating real estate, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894,245 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">933,002 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 121424000 121518000 19913000 18945000 932261000 957924000 372000 372000 8956000 6736000 103876000 91058000 1186802000 1196553000 292557000 263551000 894245000 933002000 9800000 29100000 9600000 28900000 220200000 181500000 38700000 31500000 Investments in Unconsolidated Ventures<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments in unconsolidated ventures are accounted for under the equity method or fair value option. The following table presents the Company’s investments in unconsolidated ventures (dollars in thousands): </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.579%"><tr><td style="width:1.0%"></td><td style="width:34.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ownership</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trilogy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Espresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in Unconsolidated Ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,502 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The carrying value for the Company’s investment in the Trilogy joint venture includes $9.8 million of capitalized acquisition costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2023, the Company recorded an impairment of $4.7 million to reflect the fair value of its investment in the Espresso joint venture, based on the estimated cash distributions to be received from the joint venture. Based on the Company’s assessment, it elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the Company’s investment in Solstice Senior Living, LLC (“Solstice”), the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC (“ISL”), a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and the Company, which owns 20.0%. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2023, the Company sold its ownership interests in the Diversified US/UK and Eclipse joint ventures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Minority Interests</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company sold its 14% interest in Healthcare GA Holdings, General Partnership, which indirectly owned 48 care homes across the United Kingdom (the “Diversified US/UK Portfolio”), and its 6% interest in Eclipse Health, General Partnership, which indirectly owned 34 seniors housing facilities (the “Eclipse Portfolio”), together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates, including 9,709,553 shares of common stock of the Company, 100 common units in the Operating Partnership and 100 special units in the Operating Partnership (the “Sale of Minority Interests”).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of the Company’s investment in unconsolidated ventures (dollars in thousands): </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.371%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trilogy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Espresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,033 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Espresso joint venture recognized net gains related to sub-portfolio sales, of which the Company’s proportionate share totaled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$9.2 million and $32.0 million for the nine months ended September 30, 2023 and 2022, respectively. The Company was distributed its proportionate share of the net proceeds generated from the sales during the nine months ended September 30, 2023 and 2022, totaling $17.3 million and $27.4 million, respectively.</span></div>(2)In May 2023, the Diversified US/UK joint venture recognized impairment, of which the Company’s proportionate share totaled $11.4 million and is included in equity in earnings (losses) for the nine months ended September 30, 2023. The following table presents the Company’s investments in unconsolidated ventures (dollars in thousands): <div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.579%"><tr><td style="width:1.0%"></td><td style="width:34.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.708%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Acquisition Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ownership</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trilogy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dec-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,884 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Espresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul-2015</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,019 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul-2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Investments in Unconsolidated Ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,026 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,502 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The carrying value for the Company’s investment in the Trilogy joint venture includes $9.8 million of capitalized acquisition costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2023, the Company recorded an impairment of $4.7 million to reflect the fair value of its investment in the Espresso joint venture, based on the estimated cash distributions to be received from the joint venture. Based on the Company’s assessment, it elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents the Company’s investment in Solstice Senior Living, LLC (“Solstice”), the manager of the Winterfell portfolio. Solstice is a joint venture between affiliates of Integral Senior Living, LLC (“ISL”), a management company of ILF, ALF and MCF founded in 2000, which owns 80.0%, and the Company, which owns 20.0%. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">In June 2023, the Company sold its ownership interests in the Diversified US/UK and Eclipse joint ventures.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of the Company’s investment in unconsolidated ventures (dollars in thousands): </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.371%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Portfolio</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity in Earnings (Losses)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Distribution</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trilogy</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,668 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Espresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,711 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,363 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,033 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,112 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,173 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Espresso joint venture recognized net gains related to sub-portfolio sales, of which the Company’s proportionate share totaled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$9.2 million and $32.0 million for the nine months ended September 30, 2023 and 2022, respectively. The Company was distributed its proportionate share of the net proceeds generated from the sales during the nine months ended September 30, 2023 and 2022, totaling $17.3 million and $27.4 million, respectively.</span></div>(2)In May 2023, the Diversified US/UK joint venture recognized impairment, of which the Company’s proportionate share totaled $11.4 million and is included in equity in earnings (losses) for the nine months ended September 30, 2023. 0.234 124670000 128884000 0.367 3075000 18019000 0.200 281000 323000 0 29276000 128026000 176502000 9800000 9800000 4700000 0.800 0.200 0.14 48 0.06 34 1100000 9709553 100 100 -146000 0 6052000 2300000 454000 4668000 10757000 6900000 0 0 -242000 1375000 9228000 19444000 33711000 32363000 19000 0 17000 0 -41000 0 -41000 0 0 0 -2955000 358000 -16236000 0 -5000000 2910000 -127000 0 2872000 4033000 -6595000 24112000 39427000 42173000 9200000 32000000 17300000 27400000 11400000 Borrowings<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s mortgage notes payable (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.463%"><tr><td style="width:1.0%"></td><td style="width:20.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Recourse vs. Non-Recourse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Initial<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Aqua Portfolio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Frisco, TX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milford, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.79% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rochester Portfolio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aug 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.93% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arbors Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Winterfell Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Avamere Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.66%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912,248 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Subject to non-recourse carve-outs. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Floating-rate borrowings total $128.9 million of principal outstanding and reference one-month SOFR as of September 30, 2023.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The difference between principal amount and carrying value of mortgage notes payable is attributable to deferred financing costs, net for all borrowings, other than the Winterfell portfolio which is attributable to below market debt intangibles.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The mortgage note carries a fixed interest rate of 3.0% through February 2024, followed by one-month adjusted SOFR, plus 2.80% through the initial maturity date of February 2026.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of seven individual mortgage notes payable (the “Rochester Sub-Portfolio Loan”) secured by seven healthcare real estate properties (the “Rochester Sub-Portfolio”), cross-collateralized and subject to cross-default. In July 2023, the Company elected not to pay debt service on the Rochester Sub-Portfolio Loan, which resulted in a default notice accelerating the maturity of the loan from its original terms of August 2027. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of four individual mortgage notes payable secured by four healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of 32 individual mortgage notes payable secured by 32 healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of five individual mortgage notes payable secured by five healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future scheduled principal payments on mortgage notes payable based on initial maturity as of September 30, 2023 (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.405%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in February 2021, the operator of the four net lease properties in the Arbors portfolio was unable to satisfy its obligations under its leases and began remitting rent based on its available cash after satisfying property-level expenses, which resulted in a default under the mortgage notes collateralized by the properties. On March 27, 2023, with consent of the lender, the Company entered into a Forbearance Agreement relating to these defaults. During the nine months ended September 30, 2023, the Company remitted contractual debt service and is in compliance with the other contractual terms under the mortgage notes collateralized by the properties. </span></div>In July 2023, the Company elected not to pay July debt service on the Rochester Sub-Portfolio Loan in light of the continued negative cash flow generated by the Rochester Sub-Portfolio. The Rochester Sub-Portfolio Loan is non-recourse to the Company, subject to limited customary exceptions. <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s mortgage notes payable (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.463%"><tr><td style="width:1.0%"></td><td style="width:20.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.439%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Recourse vs. Non-Recourse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Initial<br/>Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal<br/>Amount</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Aqua Portfolio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Frisco, TX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Milford, OH</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sep 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.79% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Rochester Portfolio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,657 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,629 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,165 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jul 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.45%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,787 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,651 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,042 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rochester, NY</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aug 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOFR + 2.93% </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,922 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,315 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Arbors Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.99%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,051 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Winterfell Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jun 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">586,773 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">581,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588,306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Avamere Portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Various locations</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-recourse</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Feb 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.66%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,770 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67,683 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mortgage notes payable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901,610 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922,355 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912,248 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Subject to non-recourse carve-outs. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Floating-rate borrowings total $128.9 million of principal outstanding and reference one-month SOFR as of September 30, 2023.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The difference between principal amount and carrying value of mortgage notes payable is attributable to deferred financing costs, net for all borrowings, other than the Winterfell portfolio which is attributable to below market debt intangibles.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The mortgage note carries a fixed interest rate of 3.0% through February 2024, followed by one-month adjusted SOFR, plus 2.80% through the initial maturity date of February 2026.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of seven individual mortgage notes payable (the “Rochester Sub-Portfolio Loan”) secured by seven healthcare real estate properties (the “Rochester Sub-Portfolio”), cross-collateralized and subject to cross-default. In July 2023, the Company elected not to pay debt service on the Rochester Sub-Portfolio Loan, which resulted in a default notice accelerating the maturity of the loan from its original terms of August 2027. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of four individual mortgage notes payable secured by four healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of 32 individual mortgage notes payable secured by 32 healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Composed of five individual mortgage notes payable secured by five healthcare real estate properties, cross-collateralized and subject to cross-default.</span></div> 0.030 26000000 25660000 26000000 25560000 0.0279 18212000 18036000 18336000 18126000 0.0425 17657000 17629000 18206000 18165000 0.0245 99786000 99787000 100651000 100042000 0.0293 10922000 10891000 11336000 11315000 0.0399 81912000 81680000 83423000 83051000 0.0417 586773000 581157000 596408000 588306000 0.0466 67025000 66770000 67995000 67683000 908287000 901610000 922355000 912248000 128900000 0.030 0.0280 7 7 4 4 32 32 5 5 <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents future scheduled principal payments on mortgage notes payable based on initial maturity as of September 30, 2023 (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:38.405%"><tr><td style="width:1.0%"></td><td style="width:66.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.686%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">October 1 through December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">667,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 104238000 28761000 667741000 45151000 62396000 908287000 Related Party Arrangements<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Former Advisor</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Internalization, the advisory agreement was terminated on October 21, 2022. Prior to the Internalization, the Former Advisor was responsible for managing the Company’s affairs on a day-to-day basis and for identifying, acquiring, originating and asset managing investments on behalf of the Company. For such services, to the extent permitted by law and regulations, the Former Advisor received fees and reimbursements from the Company. Pursuant to the advisory agreement, the Former Advisor could defer or waive fees in its discretion.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transition Services</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Internalization, on October 21, 2022, the Company, the Operating Partnership and the Former Advisor entered into a Transition Services Agreement (the “TSA”) to facilitate an orderly transition of the Company’s management of its operations. The TSA, as amended on March 22, 2023, provides for, among other things, the Former Advisor to provide certain services, including primarily technology and insurance, for a transition period of up to six months following the Internalization, with legal, treasury and accounts payable services to continue until the Company terminates these services or in other specified circumstances in accordance with the TSA. The Company will reimburse the Former Advisor for costs to provide the services, including the allocated cost of employee wages and compensation and incurred out-of-pocket expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Fees and Reimbursements</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.840%"><tr><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.073%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reimbursements to Former Advisor Entities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due to Related Party as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due to Related Party as of September 30, 2023 (Unaudited)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Operating costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses/ Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents costs incurred under the TSA during the nine months ended September 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incentive Fee</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Special Unit Holder, formerly an affiliate of the Former Advisor, was entitled to receive distributions equal to 15.0% of net cash flows of the Company, whether from continuing operations, repayment of loans, disposition of assets or otherwise, but only after stockholders have received, in the aggregate, cumulative distributions equal to their invested capital plus a 6.75% cumulative, non-compounded annual pre-tax return on such invested capital. From inception through the date of the Sale of Minority Interests, the Special Unit Holder did not receive any incentive fees from the Company.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Sale of Minority Interests, as of June 9, 2023, the Special Unit Holder became an indirect subsidiary of the Company, though the Special Unit Holder continues to have a contractual obligation to pay any such incentive fees to affiliates of the Former Sponsor, if ever earned. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments in Joint Ventures</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Solstice, the manager of the Winterfell portfolio, is a joint venture between affiliates of ISL, which owns 80.0%, and the Company, which owns 20.0%. For the nine months ended September 30, 2023, the Company recognized property management fee expense of $5.1 million payable to Solstice related to the Winterfell portfolio.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company completed the Sale of Minority Interests, involving the sale of its minority interests in the Diversified US/UK and Eclipse Portfolios, together with $1.1 million in cash, to its Former Sponsor, who is affiliated with the majority partner of each joint venture, for all of the Company’s equity securities held by the Former Sponsor and its affiliates. Refer to Note 4, “Investments in Unconsolidated Ventures” for further discussion of the Sale of Minority Interests</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</span></div> P6M <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the fees and reimbursements incurred and paid to the Former Advisor (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.840%"><tr><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.073%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reimbursements to Former Advisor Entities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due to Related Party as of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Due to Related Party as of September 30, 2023 (Unaudited)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Operating costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses/ Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(697)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents costs incurred under the TSA during the nine months ended September 30, 2023.</span></div> 469000 520000 -697000 292000 0.150 0.0675 0.800 0.200 5100000 1100000 Equity-Based Compensation<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted a long-term incentive plan, as amended (the “Plan”), which it may use to attract and retain qualified officers, directors, employees and consultants, as well as an independent directors compensation plan, which is a component of the Plan. Under the Plan, 2.0 million shares of restricted common stock were eligible to be issued for any equity-based awards granted under the Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Plan, as of September 30, 2023, the Company’s independent directors were granted a total of 159,932 shares of restricted common stock and 203,742 restricted stock units totaling $1.3 million and $0.7 million, respectively, based on the share price on the date of each grant. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted common stock and restricted stock units granted generally vest quarterly over two years in equal installments and will become fully vested on the earlier occurrence of: (i) the termination of the independent director’s service as a director due to his or her death or disability; or (ii) a change in control of the Company. The restricted stock units are convertible, on a one-for-one basis, into shares of the Company’s common stock upon the earlier occurrence of: (i) the termination of the independent director’s service as a director; or (ii) a change in control of the Company.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity-based compensation expense of $56,250 and $56,875 for the three months ended September 30, 2023 and 2022, respectively, and $170,000 and $150,042 for the nine months ended September 30, 2023 and 2022, respectively. Equity-based compensation expense is recorded in general and administrative expenses in the consolidated statements of operations. </span></div>Unrecognized expense related to unvested restricted stock units totaled $296,250 and $211,250 as of September 30, 2023 and December 31, 2022, respectively. Unvested restricted stock units totaled 94,853 and 54,114 as of September 30, 2023 and December 31, 2022, respectively. As of December 31, 2022, the Company’s shares of restricted common stock were fully vested. 2000000 159932 203742 1300000 700000 P2Y P2Y 56250 56875 170000 150042 296250 211250 94853 54114 Stockholders’ Equity<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company stopped accepting subscriptions for its Offering on December 17, 2015 and all of the shares initially registered for its Offering were issued on or before January 19, 2016. The Company issued 173.4 million shares of common stock generating gross proceeds of $1.7 billion, excluding proceeds from the DRP. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Reinvestment Plan</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the DRP through which common stockholders were able to elect to reinvest an amount equal to the distributions declared on their shares in additional shares of the Company’s common stock in lieu of receiving cash distributions. Since inception, the Company issued 25.7 million shares of common stock, generating gross offering proceeds of $232.6 million pursuant to the DRP. No selling commissions or dealer manager fees were paid on shares issued pursuant to the DRP. In April 2022, the Company’s board of directors elected to end the DRP, effective April 30, 2022. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 1, 2019, the Company’s board of directors determined to stop recurring distributions in order to preserve capital and liquidity. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2022, the Company’s board of directors declared a special distribution of $0.50 per share (the “Special Distribution”) for each stockholder of record on May 2, 2022 totaling approximately $97.0 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to qualify as a REIT, the Company must distribute annually dividends equal to at least 90% of its REIT taxable income (with certain adjustments). The Company did not have REIT taxable income for its taxable year ending December 31, 2022, therefore, it was not required to make distributions to its stockholders in 2022 to qualify as a REIT. The Company’s most recently filed tax return is for the year ended December 31, 2022 and includes a net operating loss carry-forward of $248.5 million. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the share repurchase program (the “Share Repurchase Program”) that enabled stockholders to sell their shares to the Company in limited circumstances and could be amended, suspended, or terminated at any time. The Company </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously funded repurchase requests with cash on hand, borrowings or other available capital. In April 2020, the Company’s board of directors determined to suspend all repurchases under the Share Repurchase Program effective April 30, 2020 in order to preserve capital and liquidity and does not currently anticipate resuming the Share Repurchase Program. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement of Shares </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Sale of Minority Interests, the Company acquired 9.7 million shares of its common stock in exchange for its minority interests in the Diversified US/UK and Eclipse Portfolios from its Former Sponsor, who is affiliated with the majority partner of each joint venture. Upon completion of the Sale of Minority Interests, the Company retired all of the shares of common stock acquired. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To account for the acquisition and retirement of the common stock, the Company estimated the value of its minority interests in the Diversified US/UK and Eclipse Portfolios based on a variety of factors, including historical and projected revenues, market lease rates, the partners’ respective rights under the joint venture agreements, independent third-party appraisals obtained by the joint ventures and other factors deemed relevant. The Company determined the estimated value of minority interests to be approximately $12.5 million at the time of transaction. The estimated value, together with the $1.1 million of cash consideration, net of closing costs, is presented on the consolidated statements of equity as retirement of common stock.</span></div> 173400000 1700000000 25700000 232600000 0 0.50 97000000 248500000 9700000 12500000 1100000 Non-controlling Interests<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Partnership</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interests included the aggregate limited partnership interests in the Operating Partnership held by limited partners, other than the Company. Income (loss) attributable to the non-controlling interests was based on the limited partners’ ownership percentage of the Operating Partnership. As a result of the Sale of Minority Interests, the Company’s limited partnership interest in the Operating Partnership, directly or indirectly, is 100.0% as of September 30, 2023. Income (loss) allocated to the Operating Partnership non-controlling interests for the period prior to June 9, 2023 were de minimis. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div>Other non-controlling interests represent third-party equity interests in ventures that are consolidated with the Company’s financial statements. Net loss attributable to the other non-controlling interests was $0.2 million and $0.1 million for the three months ended September 30, 2023 and 2022, respectively, and $1.5 million and $0.3 million for the nine months ended September 30, 2023 and 2022, respectively. 1.000 -200000 -100000 -1500000 -300000 Fair Value<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Measurement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is categorized based on the priority of the inputs to the valuation technique and categorized into a three-level fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.27pt">Quoted prices for identical assets or liabilities in an active market.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.27pt">Financial assets and liabilities whose values are based on the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Quoted prices for similar assets or liabilities in active markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Quoted prices for identical or similar assets or liabilities in non-active markets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.24pt">Pricing models whose inputs are observable for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:108pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:18.67pt">Pricing models whose inputs are derived principally from or corroborated by observable market data for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:81pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.27pt">Prices or valuation techniques based on inputs that are both unobservable and significant to the overall fair value measurement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments consist of interest rate contracts and foreign exchange contracts that are generally traded over-the-counter, and are valued using a third-party service provider. Quotations on over-the-counter derivatives are not adjusted and are generally valued using observable inputs such as contractual cash flows, yield curve, foreign currency rates and credit spreads, and are classified as Level 2 of the fair value hierarchy. Although credit valuation adjustments, such as the risk of default, rely on Level 3 inputs, these inputs are not significant to the overall valuation of its derivatives. As a result, derivative valuations in their entirety are classified as Level 2 of the fair value hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value Hierarchy</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets recorded at fair value on a recurring basis are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The following table presents financial assets that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 by level within the fair value hierarchy (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.246%"><tr><td style="width:1.0%"></td><td style="width:29.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets - interest rate caps</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investment in Espresso joint venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. As of December 31, 2022, the investment was accounted for under the equity method. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Assets - Interest Rate Caps</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s interest rate caps fair values are determined using models developed by the respective counterparty that use the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps. The floating interest rates used in the calculation of projected receipts on the caps are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Espresso Joint Venture</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s assessment of fair value for its unconsolidated investment in the Espresso joint venture took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. GAAP requires disclosure of fair value about all financial instruments. The following disclosure of estimated fair value of financial instruments was determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessary to interpret market data and develop estimated fair value. Accordingly, the estimates presented herein are not necessarily indicative of the amounts the Company could realize on disposition of the financial instruments. The use of different market assumptions and/or estimation methodologies may have a material effect on estimated fair value.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the principal amount, carrying value and fair value of certain financial assets and liabilities (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.246%"><tr><td style="width:1.0%"></td><td style="width:29.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">842,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912,248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">882,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The fair value of other financial instruments not included in this table is estimated to approximate their carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure about fair value of financial instruments is based on pertinent information available to management as of the reporting date. Although management is not aware of any factors that would significantly affect fair value, such amounts have not been comprehensively revalued for purposes of these consolidated financial statements since that date and current estimates of fair value may differ significantly from the amounts presented herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mortgage Notes Payable</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily uses rates currently available with similar terms and remaining maturities to estimate fair value. These measurements are determined using comparable U.S. Treasury and SOFR rates as of the end of the reporting period. These fair value measurements are based on observable inputs, and as such, are classified as Level 2 of the fair value hierarchy. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nonrecurring Fair Values</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures fair value of certain assets on a nonrecurring basis when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Adjustments to fair value generally result from the application of lower of amortized cost or fair value accounting for assets held for sale or otherwise, write-down of asset values due to impairment. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and impairment losses of Level 3 assets which have been measured at fair value on a nonrecurring basis at the time of impairment during the periods presented (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.594%"><tr><td style="width:1.0%"></td><td style="width:34.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating real estate, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ended December 31, 2022, the Company recorded impairment losses totaling $1.0 million for property damage sustained by facilities in its Winterfell and Avamere portfolios. The fair value and impairment losses of these facilities are excluded from the table.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Real Estate, Net </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating real estate that is impaired is carried at fair value at the time of impairment. Impairment was driven by various factors that impacted undiscounted future net cash flows, including declines in operating performance, market growth assumptions and expected margins to be generated by the properties. Fair value of impaired operating real estate was estimated based upon various approaches including discounted cash flow analysis using terminal capitalization rates ranging from 6.00% to 8.50% and discount rates ranging from 8.5% to 10.5%, third party appraisals and offer prices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments in Unconsolidated Ventures</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the Company recorded impairment on its investment in the Espresso joint venture, which totaled $4.7 million and reduced the carrying value of its investment to $3.1 million as of June 30, 2023. The Company’s assessment for the recoverability of its investment took into consideration the net proceeds that are estimated to be realized from the sales, under contract, of the remaining real estate owned by the joint venture as well as forecasted distributions of available cash, less and wind down and other expenses. Upon impairing its investment, the Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company recorded impairment on its investment in the Diversified US/UK joint venture, which totaled $13.4 million and reduced the carrying value of its investment to $28.4 million as of December 31, 2022. The Company’s assessment for the recoverability of its investment took into consideration the joint venture’s post-COVID-19 underperformance, rising interest rates and the joint venture’s ability to continue to service debt collateralized by substantially all of its domestically-located healthcare real estate. Fair value of the joint venture’s underlying operating real estate was estimated based upon various approaches including discounted cash flow analysis, using terminal capitalization rates ranging from 6.6% to 12.5% and discount rates ranging from 8.8% to 16.0%, and offer prices.</span></div> The following table presents financial assets that were accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022 by level within the fair value hierarchy (dollars in thousands):<div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.246%"><tr><td style="width:1.0%"></td><td style="width:29.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Derivative assets - interest rate caps</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">652 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investment in Espresso joint venture</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The Company elected the fair value option method to account for its investment in the Espresso joint venture on June 30, 2023. As of December 31, 2022, the investment was accounted for under the equity method. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the principal amount, carrying value and fair value of certain financial assets and liabilities (dollars in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.246%"><tr><td style="width:1.0%"></td><td style="width:29.898%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Financial liabilities:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage notes payable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901,610 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">842,325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">922,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">912,248 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">882,754 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The fair value of other financial instruments not included in this table is estimated to approximate their carrying value.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and impairment losses of Level 3 assets which have been measured at fair value on a nonrecurring basis at the time of impairment during the periods presented (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.594%"><tr><td style="width:1.0%"></td><td style="width:34.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023 (Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment Losses</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating real estate, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,931 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,900 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments in unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,442 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ended December 31, 2022, the Company recorded impairment losses totaling $1.0 million for property damage sustained by facilities in its Winterfell and Avamere portfolios. The fair value and impairment losses of these facilities are excluded from the table.</span></div> 0 820000 0 0 652000 0 0 0 3075000 0 0 0 908287000 901610000 842325000 922355000 912248000 882754000 41496000 38694000 80931000 30900000 3075000 4728000 28442000 13419000 1000000 0.0600 0.0850 0.085 0.105 4700000 3100000 13400000 28400000 0.066 0.125 0.088 0.160 Segment Reporting<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business through the following segments, which are based on how management reviews and manages its business. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Direct Investments - Operating</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Properties operated pursuant to management agreements with healthcare managers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Direct Investments - Net Lease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Properties operated under net leases with an operator.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Unconsolidated Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Joint ventures, including properties operated under net leases with operators or pursuant to management agreements with healthcare managers, in which the Company owns a minority interest.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The corporate segment includes corporate level asset management fees - related party and general and administrative expenses.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily generates rental and resident fee income from its direct investments. Additionally, the Company reports its proportionate interest of revenues and expenses from unconsolidated investments through equity in earnings (losses) of unconsolidated ventures.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment reporting (dollars in thousands):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.391%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,275)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,813)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,384)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,996)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,836)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,513)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.391%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,648)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,359)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,315)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,073)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84,395)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101,258)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,830)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,208)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,867)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets by segment (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023 (Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">847,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents primarily corporate cash and cash equivalents balances. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the operators and managers of the Company’s properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.260%"><tr><td style="width:1.0%"></td><td style="width:29.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operator / Manager</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties Under Management</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Under Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property and Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Property and Other Revenues</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice Senior Living</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Watermark Retirement Communities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Avamere Health Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integral Senior Living</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcadia Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,445 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents rooms for ALFs, ILFs and MCFs, based on predominant type.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes rental income received from the Company’s net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from the Company’s ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Solstice is a joint venture of which affiliates of ISL own 80%.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the nine months ended September 30, 2023, the Company recorded rental income to the extent payments were received. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists primarily of interest income earned on corporate-level cash and cash equivalents.</span></div> <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment reporting (dollars in thousands):</span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.391%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,459 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,891)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,921)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(729)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(347)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(775)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,275)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,813)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,384)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">724 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,715 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,739 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,014)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,851)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,859)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,772)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,642)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,996)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,872 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,836)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,513)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.391%"><tr><td style="width:1.0%"></td><td style="width:34.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,374 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,869)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,424)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27,118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,728)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43,422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,648)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,359)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,315)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,073)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84,395)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and other revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134,768 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136,445 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101,223)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101,258)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,877)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(857)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset management fees - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,532)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31,502)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on investments and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in earnings (losses) of unconsolidated ventures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,427 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,830)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34,502)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,673 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,208)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35,867)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 837000 51459000 0 1078000 53374000 0 36890000 0 0 36890000 883000 13367000 0 0 14250000 0 0 358000 0 358000 0 30000 0 2891000 2921000 729000 9119000 0 0 9848000 0 -311000 -36000 0 -347000 0 0 -127000 0 -127000 0 17000 0 0 17000 -775000 -8275000 -521000 -1813000 -11384000 724000 46715000 0 300000 47739000 0 35134000 0 0 35134000 907000 10107000 0 0 11014000 0 0 0 857000 857000 0 0 0 2428000 2428000 0 8000 0 2851000 2859000 870000 8772000 0 0 9642000 18500000 0 0 0 18500000 0 325000 0 0 325000 0 0 2872000 0 2872000 0 15000 0 0 15000 -19553000 -6996000 2872000 -5836000 -29513000 1178000 150374000 0 2893000 154445000 0 106993000 0 0 106993000 2639000 34504000 0 0 37143000 0 0 358000 97000 455000 0 555000 0 9869000 10424000 2187000 27118000 0 0 29305000 0 38694000 4728000 0 43422000 0 202000 0 0 202000 0 -28000 -4634000 0 -4662000 0 0 -6595000 0 -6595000 0 43000 0 0 43000 -3648000 -57359000 -16315000 -7073000 -84395000 1220000 134768000 0 457000 136445000 35000 101223000 0 0 101258000 2708000 29169000 0 0 31877000 0 0 0 857000 857000 0 0 0 7532000 7532000 0 24000 0 10276000 10300000 2601000 26504000 0 0 29105000 18500000 13002000 0 0 31502000 0 77000 0 0 77000 -206000 620000 246000 0 660000 0 0 39427000 0 39427000 0 45000 0 0 45000 -22830000 -34502000 39673000 -18208000 -35867000 <div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets by segment (dollars in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.681%"><tr><td style="width:1.0%"></td><td style="width:34.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Direct Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Lease</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unconsolidated Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2023 (Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,782 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">847,401 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,135,916 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83,435 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">884,137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,237,835 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________________________________</span></div>(1)Represents primarily corporate cash and cash equivalents balances. 80782000 847401000 128026000 79707000 1135916000 83435000 884137000 176502000 93761000 1237835000 <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the operators and managers of the Company’s properties, excluding properties owned through unconsolidated joint ventures (dollars in thousands):</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.260%"><tr><td style="width:1.0%"></td><td style="width:29.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.725%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operator / Manager</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Properties Under Management</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Units Under Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property and Other Revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Total Property and Other Revenues</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solstice Senior Living</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,969 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Watermark Retirement Communities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Avamere Health Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">453 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Integral Senior Living</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,672 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcadia Management</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,178 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,893 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,816 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,445 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">______________________________________</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Represents rooms for ALFs, ILFs and MCFs, based on predominant type.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes rental income received from the Company’s net lease properties as well as rental income, ancillary service fees and other related revenue earned from ILF residents and resident fee income derived from the Company’s ALFs and MCFs, which includes resident room and care charges, ancillary fees and other resident service charges.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Solstice is a joint venture of which affiliates of ISL own 80%.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the nine months ended September 30, 2023, the Company recorded rental income to the extent payments were received. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists primarily of interest income earned on corporate-level cash and cash equivalents.</span></div> 32 3969 94469000 0.612 14 1782 35967000 0.232 5 453 16266000 0.105 1 40 3672000 0.024 4 572 1178000 0.008 0 0 2893000 0.019 56 6816 154445000 1.000 0.80 Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company believes there are no material unrecorded contingencies that would affect its results of operations, cash flows or financial position.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation and Claims</span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be involved in various litigation matters arising in the ordinary course of its business. Although the Company is unable to predict with certainty the eventual outcome of any litigation, any current legal proceedings are not expected to have a material adverse effect on its financial position or results of operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operators and managers may be involved in various litigation matters arising in the ordinary course of their business. The unfavorable resolution of any such actions, investigations or claims could, individually or in the aggregate, materially adversely affect such operators’ or managers’ liquidity, financial condition or results of operations and their ability to satisfy their respective obligations to the Company, which, in turn, could have a material adverse effect on the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company has an accrued reserve of $0.6 million, inclusive of legal fees, relating to a resolution of claims against a manager of one of the Company’s direct operating investments, for which the Company has indemnification obligations under the management agreement. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its consolidated financial position, results of operations or cash flows. Further, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that it believes would require additional disclosure or the recording of a loss contingency.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Uninsured Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company obtains various types of insurance to mitigate the impact of professional liability, property, business interruption, liability, flood, windstorm, earthquake, environmental and terrorism related losses. The Company attempts to obtain appropriate policy terms, conditions, limits and deductibles considering the relative risk of loss, the cost of such coverage and current industry practice. Disruptions in insurance markets may increase the costs of coverage and result in the Company retaining more risk, to the extent it is more commercially reasonable to do so. In addition, there are also certain types of extraordinary losses, such as those due to acts of war or other events, that may be either uninsurable or not economically insurable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other </span></div>Other commitments and contingencies include the usual obligations of real estate owners and operators in the normal course of business, as well as commitments to fund capital expenditures for certain net lease properties. These commitments do not have a required minimum funding and are limited by agreed upon maximum annual funding amounts. 600000 Subsequent Events<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion of material events which have occurred subsequent to September 30, 2023 through the issuance of the consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rochester Receivership</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the payment default in July 2023 of the Rochester Sub-Portfolio Loan, on October 25, 2023, the lender filed a complaint seeking the appointment of a receiver and foreclosure on the underlying properties and to enforce its rights in its collateral under the loan documents and, on October 30, 2023, the properties underlying the Rochester Sub-Portfolio Loan were placed into a receivership. The receiver now has effective control of the properties and the Company is working with the lender and the receiver to facilitate an orderly transition of the operations, and eventually ownership, of the properties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trilogy Option Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2023, the Company entered into an agreement to sell all of its ownership interests in Trilogy REIT Holdings, LLC (the “Trilogy Joint Venture”), which indirectly owns 123 integrated senior health campuses, to American Healthcare REIT, Inc. or its affiliates (“AHR”), the majority partner of the Trilogy Joint Venture. Under the agreement, AHR has the right to purchase the Company’s ownership interests in the Trilogy Joint Venture at any time prior to September 30, 2025, assuming AHR exercises all of its extension options and subject to satisfaction of certain closing conditions, for a purchase price ranging from $240.5 million to up to $260 million depending upon the purchase price consideration and timing of the closing. A minimum of 10% of the purchase price consideration must be paid in cash, with the balance payable in either cash or new Series A Cumulative Convertible Preferred Stock to be issued by AHR in connection with the closing. The portion of the purchase price consideration paid in cash may be subject to a 7.5% or 5% discount, respectively, if the transaction closes prior to March 31, 2024 or December 31, 2024, respectively. In addition, the Company may be entitled to a supplemental cash payment of $25,600 per day for the period between July 1, 2023 until the closing date, for up to approximately $21 million, if the Trilogy Joint Venture does not distribute an equivalent amount to the Company during the interim period. AHR may terminate the agreement at any time, subject to payment of a termination fee equal to: (i) if terminated prior to the initial outside date, September 30, 2024, $3.9 million or, if a “Qualifying IPO” (i.e., an underwritten public offering of AHR’s common stock resulting in at least $200 million of net proceeds) has occurred, $7.8 million, (ii) if extended and terminated prior March 31, 2025, $11.7 million and (iii) if further extended and terminated prior to September 30, 2025, $15.6 million. There can be no assurance that AHR will consummate the purchase of the Company’s interests on these terms or at all.</span></div> 123 240500000 260000000 0.10 0.075 0.05 25600 21000000 3900000 7800000 11700000 15600000 false false false false ncludes $174.4 million and $180.2 million of assets and liabilities, respectively, of certain VIEs that are consolidated by the Operating Partnership. Refer to Note 2, “Summary of Significant Accounting Policies.” The Company issued 203,742 and 116,712 restricted stock units as of September 30, 2023 and September 30, 2022, respectively. The restricted stock units have been excluded from the diluted earnings per share calculation as their impact is anti-dilutive due to the net loss generated during the three and nine months ended September 30, 2023 and 2022. The Company reclassified the accumulated other comprehensive loss related to foreign currency adjustments for an unconsolidated venture ownership interest that was sold during the three months ended June 30, 2023. The accumulated balance was reclassified to gain (loss) on investments and other on the consolidated statements of operations. EXCEL 75 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 76 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 303 293 1 true 96 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.northstarhealthcarereit.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 6 false false R7.htm 0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY CONSOLIDATED STATEMENTS OF EQUITY Statements 7 false false R8.htm 0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 0000009 - Disclosure - Business and Organization Sheet http://www.northstarhealthcarereit.com/role/BusinessandOrganization Business and Organization Notes 9 false false R10.htm 0000010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Operating Real Estate Sheet http://www.northstarhealthcarereit.com/role/OperatingRealEstate Operating Real Estate Notes 11 false false R12.htm 0000012 - Disclosure - Investments in Unconsolidated Ventures Sheet http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVentures Investments in Unconsolidated Ventures Notes 12 false false R13.htm 0000013 - Disclosure - Borrowings Sheet http://www.northstarhealthcarereit.com/role/Borrowings Borrowings Notes 13 false false R14.htm 0000014 - Disclosure - Related Party Arrangements Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangements Related Party Arrangements Notes 14 false false R15.htm 0000015 - Disclosure - Equity-Based Compensation Sheet http://www.northstarhealthcarereit.com/role/EquityBasedCompensation Equity-Based Compensation Notes 15 false false R16.htm 0000016 - Disclosure - Stockholders' Equity Sheet http://www.northstarhealthcarereit.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 0000017 - Disclosure - Non-controlling Interests Sheet http://www.northstarhealthcarereit.com/role/NoncontrollingInterests Non-controlling Interests Notes 17 false false R18.htm 0000018 - Disclosure - Fair Value Sheet http://www.northstarhealthcarereit.com/role/FairValue Fair Value Notes 18 false false R19.htm 0000019 - Disclosure - Segment Reporting Sheet http://www.northstarhealthcarereit.com/role/SegmentReporting Segment Reporting Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.northstarhealthcarereit.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Subsequent Events Sheet http://www.northstarhealthcarereit.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPolicies 23 false false R24.htm 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPolicies 24 false false R25.htm 9954473 - Disclosure - Operating Real Estate (Tables) Sheet http://www.northstarhealthcarereit.com/role/OperatingRealEstateTables Operating Real Estate (Tables) Tables http://www.northstarhealthcarereit.com/role/OperatingRealEstate 25 false false R26.htm 9954474 - Disclosure - Investments in Unconsolidated Ventures (Tables) Sheet http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesTables Investments in Unconsolidated Ventures (Tables) Tables http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVentures 26 false false R27.htm 9954475 - Disclosure - Borrowings (Tables) Sheet http://www.northstarhealthcarereit.com/role/BorrowingsTables Borrowings (Tables) Tables http://www.northstarhealthcarereit.com/role/Borrowings 27 false false R28.htm 9954476 - Disclosure - Related Party Arrangements (Tables) Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTables Related Party Arrangements (Tables) Tables http://www.northstarhealthcarereit.com/role/RelatedPartyArrangements 28 false false R29.htm 9954477 - Disclosure - Fair Value (Tables) Sheet http://www.northstarhealthcarereit.com/role/FairValueTables Fair Value (Tables) Tables http://www.northstarhealthcarereit.com/role/FairValue 29 false false R30.htm 9954478 - Disclosure - Segment Reporting (Tables) Sheet http://www.northstarhealthcarereit.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.northstarhealthcarereit.com/role/SegmentReporting 30 false false R31.htm 9954479 - Disclosure - Business and Organization (Details) Sheet http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails Business and Organization (Details) Details http://www.northstarhealthcarereit.com/role/BusinessandOrganization 31 false false R32.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails Summary of Significant Accounting Policies - Narrative (Details) Details 32 false false R33.htm 9954481 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) Details 33 false false R34.htm 9954482 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails Summary of Significant Accounting Policies - Estimated Useful Lives (Details) Details 34 false false R35.htm 9954483 - Disclosure - Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details) Details 35 false false R36.htm 9954484 - Disclosure - Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details) Details 36 false false R37.htm 9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details) Sheet http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details) Details 37 false false R38.htm 9954486 - Disclosure - Operating Real Estate - Identifiable Assets and Liabilities (Details) Sheet http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails Operating Real Estate - Identifiable Assets and Liabilities (Details) Details 38 false false R39.htm 9954487 - Disclosure - Operating Real Estate - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails Operating Real Estate - Narrative (Details) Details 39 false false R40.htm 9954488 - Disclosure - Investments in Unconsolidated Ventures - Changes in Carrying Value (Details) Sheet http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails Investments in Unconsolidated Ventures - Changes in Carrying Value (Details) Details 40 false false R41.htm 9954489 - Disclosure - Investments in Unconsolidated Ventures - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails Investments in Unconsolidated Ventures - Narrative (Details) Details 41 false false R42.htm 9954490 - Disclosure - Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details) Sheet http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details) Details 42 false false R43.htm 9954491 - Disclosure - Borrowings - Schedule of Borrowings (Details) Sheet http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails Borrowings - Schedule of Borrowings (Details) Details 43 false false R44.htm 9954492 - Disclosure - Borrowings - Maturity Schedule (Details) Sheet http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails Borrowings - Maturity Schedule (Details) Details 44 false false R45.htm 9954493 - Disclosure - Related Party Arrangements - Transition Services (Details) Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails Related Party Arrangements - Transition Services (Details) Details 45 false false R46.htm 9954494 - Disclosure - Related Party Arrangements - Summary of Fees and Reimbursements (Details) Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails Related Party Arrangements - Summary of Fees and Reimbursements (Details) Details 46 false false R47.htm 9954495 - Disclosure - Related Party Arrangements - Incentive Fee (Details) Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails Related Party Arrangements - Incentive Fee (Details) Details 47 false false R48.htm 9954496 - Disclosure - Related Party Arrangements - Investments in Joint Ventures (Details) Sheet http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails Related Party Arrangements - Investments in Joint Ventures (Details) Details 48 false false R49.htm 9954497 - Disclosure - Equity-Based Compensation (Details) Sheet http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails Equity-Based Compensation (Details) Details http://www.northstarhealthcarereit.com/role/EquityBasedCompensation 49 false false R50.htm 9954498 - Disclosure - Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details) Sheet http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details) Details 50 false false R51.htm 9954499 - Disclosure - Stockholders' Equity - Distributions (Details) Sheet http://www.northstarhealthcarereit.com/role/StockholdersEquityDistributionsDetails Stockholders' Equity - Distributions (Details) Details 51 false false R52.htm 9954500 - Disclosure - Stockholders' Equity - Retirement of Shares (Details) Sheet http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails Stockholders' Equity - Retirement of Shares (Details) Details 52 false false R53.htm 9954501 - Disclosure - Non-controlling Interests (Details) Sheet http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails Non-controlling Interests (Details) Details http://www.northstarhealthcarereit.com/role/NoncontrollingInterests 53 false false R54.htm 9954502 - Disclosure - Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details) Sheet http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details) Details 54 false false R55.htm 9954503 - Disclosure - Fair Value - Nonrecurring Fair Value (Details) Sheet http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails Fair Value - Nonrecurring Fair Value (Details) Details 55 false false R56.htm 9954504 - Disclosure - Fair Value - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails Fair Value - Narrative (Details) Details 56 false false R57.htm 9954505 - Disclosure - Segment Reporting - Segment Statement of Operations (Details) Sheet http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails Segment Reporting - Segment Statement of Operations (Details) Details 57 false false R58.htm 9954506 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details) Sheet http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails Segment Reporting - Summary of Assets by Segment (Details) Details 58 false false R59.htm 9954507 - Disclosure - Segment Reporting - Schedule of Properties (Details) Sheet http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails Segment Reporting - Schedule of Properties (Details) Details 59 false false R60.htm 9954508 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 60 false false R61.htm 9954509 - Disclosure - Subsequent Events - Narrative (Details) Sheet http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails Subsequent Events - Narrative (Details) Details 61 false false All Reports Book All Reports nshi-20230930.htm nshi-20230930.xsd nshi-20230930_cal.xml nshi-20230930_def.xml nshi-20230930_lab.xml nshi-20230930_pre.xml nshi-20230930_g1.jpg nshi-20230930_g2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nshi-20230930.htm": { "nsprefix": "nshi", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "dts": { "inline": { "local": [ "nshi-20230930.htm" ] }, "schema": { "local": [ "nshi-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "nshi-20230930_cal.xml" ] }, "definitionLink": { "local": [ "nshi-20230930_def.xml" ] }, "labelLink": { "local": [ "nshi-20230930_lab.xml" ] }, "presentationLink": { "local": [ "nshi-20230930_pre.xml" ] } }, "keyStandard": 253, "keyCustom": 40, "axisStandard": 36, "axisCustom": 3, "memberStandard": 37, "memberCustom": 51, "hidden": { "total": 10, "http://fasb.org/us-gaap/2023": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 303, "entityCount": 1, "segmentCount": 96, "elementCount": 623, "unitCount": 12, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 987, "http://xbrl.sec.gov/ecd/2023": 4, "http://xbrl.sec.gov/dei/2023": 28 }, "report": { "R1": { "role": "http://www.northstarhealthcarereit.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R3": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestmentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": null }, "R6": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R7": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-15", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-22", "name": "nshi:StockRedeemedorCalledDuringPeriodSharesPaymentofAdvisorAssetManagementFees", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R8": { "role": "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfDebtDiscountPremium", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R9": { "role": "http://www.northstarhealthcarereit.com/role/BusinessandOrganization", "longName": "0000009 - Disclosure - Business and Organization", "shortName": "Business and Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.northstarhealthcarereit.com/role/OperatingRealEstate", "longName": "0000011 - Disclosure - Operating Real Estate", "shortName": "Operating Real Estate", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RealEstateDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVentures", "longName": "0000012 - Disclosure - Investments in Unconsolidated Ventures", "shortName": "Investments in Unconsolidated Ventures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.northstarhealthcarereit.com/role/Borrowings", "longName": "0000013 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangements", "longName": "0000014 - Disclosure - Related Party Arrangements", "shortName": "Related Party Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.northstarhealthcarereit.com/role/EquityBasedCompensation", "longName": "0000015 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.northstarhealthcarereit.com/role/StockholdersEquity", "longName": "0000016 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.northstarhealthcarereit.com/role/NoncontrollingInterests", "longName": "0000017 - Disclosure - Non-controlling Interests", "shortName": "Non-controlling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.northstarhealthcarereit.com/role/FairValue", "longName": "0000018 - Disclosure - Fair Value", "shortName": "Fair Value", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.northstarhealthcarereit.com/role/SegmentReporting", "longName": "0000019 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.northstarhealthcarereit.com/role/CommitmentsandContingencies", "longName": "0000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.northstarhealthcarereit.com/role/SubsequentEvents", "longName": "0000021 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrTrmntdFlag", "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.northstarhealthcarereit.com/role/OperatingRealEstateTables", "longName": "9954473 - Disclosure - Operating Real Estate (Tables)", "shortName": "Operating Real Estate (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "nshi:ScheduleofRealEstateInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nshi:ScheduleofRealEstateInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesTables", "longName": "9954474 - Disclosure - Investments in Unconsolidated Ventures (Tables)", "shortName": "Investments in Unconsolidated Ventures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.northstarhealthcarereit.com/role/BorrowingsTables", "longName": "9954475 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTables", "longName": "9954476 - Disclosure - Related Party Arrangements (Tables)", "shortName": "Related Party Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.northstarhealthcarereit.com/role/FairValueTables", "longName": "9954477 - Disclosure - Fair Value (Tables)", "shortName": "Fair Value (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.northstarhealthcarereit.com/role/SegmentReportingTables", "longName": "9954478 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "longName": "9954479 - Disclosure - Business and Organization (Details)", "shortName": "Business and Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R32": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)", "shortName": "Summary of Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "nshi:FinanceLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R33": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)", "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-112", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "nshi:RealEstateOwnedPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-112", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "nshi:RealEstateOwnedPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails", "longName": "9954483 - Disclosure - Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details)", "shortName": "Summary of Significant Accounting Policies - Future Minimum Lease Payments from Capital Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails", "longName": "9954484 - Disclosure - Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details)", "shortName": "Summary of Significant Accounting Policies - Deferred Costs and Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails", "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details)", "shortName": "Summary of Significant Accounting Policies - Schedule of Future Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "nshi:DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nshi:ScheduleofDeferredCostsandIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "nshi:DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nshi:ScheduleofDeferredCostsandIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails", "longName": "9954486 - Disclosure - Operating Real Estate - Identifiable Assets and Liabilities (Details)", "shortName": "Operating Real Estate - Identifiable Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nshi:ScheduleofRealEstateInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:Land", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "nshi:ScheduleofRealEstateInvestmentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails", "longName": "9954487 - Disclosure - Operating Real Estate - Narrative (Details)", "shortName": "Operating Real Estate - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "longName": "9954488 - Disclosure - Investments in Unconsolidated Ventures - Changes in Carrying Value (Details)", "shortName": "Investments in Unconsolidated Ventures - Changes in Carrying Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-140", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R41": { "role": "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "longName": "9954489 - Disclosure - Investments in Unconsolidated Ventures - Narrative (Details)", "shortName": "Investments in Unconsolidated Ventures - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-150", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R42": { "role": "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "longName": "9954490 - Disclosure - Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details)", "shortName": "Investments in Unconsolidated Ventures - Summary of Investments in Unconsolidated Ventures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "nshi:ProceedsFromEquityMethodInvestmentDistributionOperatingAndInvestingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R43": { "role": "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "longName": "9954491 - Disclosure - Borrowings - Schedule of Borrowings (Details)", "shortName": "Borrowings - Schedule of Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-192", "name": "nshi:NumberofHealthcareRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R44": { "role": "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails", "longName": "9954492 - Disclosure - Borrowings - Maturity Schedule (Details)", "shortName": "Borrowings - Maturity Schedule (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails", "longName": "9954493 - Disclosure - Related Party Arrangements - Transition Services (Details)", "shortName": "Related Party Arrangements - Transition Services (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-194", "name": "nshi:RelatedPartyTransactionTermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-194", "name": "nshi:RelatedPartyTransactionTermOfAgreement", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails", "longName": "9954494 - Disclosure - Related Party Arrangements - Summary of Fees and Reimbursements (Details)", "shortName": "Related Party Arrangements - Summary of Fees and Reimbursements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-195", "name": "us-gaap:OtherLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-195", "name": "us-gaap:OtherLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "longName": "9954495 - Disclosure - Related Party Arrangements - Incentive Fee (Details)", "shortName": "Related Party Arrangements - Incentive Fee (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-199", "name": "nshi:IncentiveFeePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-199", "name": "nshi:IncentiveFeePercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "longName": "9954496 - Disclosure - Related Party Arrangements - Investments in Joint Ventures (Details)", "shortName": "Related Party Arrangements - Investments in Joint Ventures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-149", "name": "nshi:PaymentsForDivestitureOfInterestInJointVenture", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R49": { "role": "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails", "longName": "9954497 - Disclosure - Equity-Based Compensation (Details)", "shortName": "Equity-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-13", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "link:footnote", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R50": { "role": "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails", "longName": "9954498 - Disclosure - Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details)", "shortName": "Stockholders' Equity - Common Stock and Distribution Reinvestment Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-214", "name": "us-gaap:SalesCommissionsAndFees", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R51": { "role": "http://www.northstarhealthcarereit.com/role/StockholdersEquityDistributionsDetails", "longName": "9954499 - Disclosure - Stockholders' Equity - Distributions (Details)", "shortName": "Stockholders' Equity - Distributions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-215", "name": "us-gaap:DividendsPayableAmountPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-215", "name": "us-gaap:DividendsPayableAmountPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails", "longName": "9954500 - Disclosure - Stockholders' Equity - Retirement of Shares (Details)", "shortName": "Stockholders' Equity - Retirement of Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-216", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-216", "name": "us-gaap:StockRepurchasedDuringPeriodShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "longName": "9954501 - Disclosure - Non-controlling Interests (Details)", "shortName": "Non-controlling Interests (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "longName": "9954502 - Disclosure - Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details)", "shortName": "Fair Value - Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-225", "name": "us-gaap:EquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R55": { "role": "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "longName": "9954503 - Disclosure - Fair Value - Nonrecurring Fair Value (Details)", "shortName": "Fair Value - Nonrecurring Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-233", "name": "us-gaap:RealEstateInvestmentPropertyNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R56": { "role": "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "longName": "9954504 - Disclosure - Fair Value - Narrative (Details)", "shortName": "Fair Value - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ImpairmentOfRealEstate", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-246", "name": "nshi:EquityMethodInvestmentsCapitalizedAcquisitionCosts", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R57": { "role": "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "longName": "9954505 - Disclosure - Segment Reporting - Segment Statement of Operations (Details)", "shortName": "Segment Reporting - Segment Statement of Operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-10", "name": "nshi:RentalandResidentFeeIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "nshi:RentalandResidentFeeIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails", "longName": "9954506 - Disclosure - Segment Reporting - Summary of Assets by Segment (Details)", "shortName": "Segment Reporting - Summary of Assets by Segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-270", "name": "us-gaap:Assets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "unique": true } }, "R59": { "role": "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails", "longName": "9954507 - Disclosure - Segment Reporting - Schedule of Properties (Details)", "shortName": "Segment Reporting - Schedule of Properties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:NumberOfRealEstateProperties", "unitRef": "property", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRealEstatePropertiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.northstarhealthcarereit.com/role/CommitmentsandContingenciesNarrativeDetails", "longName": "9954508 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "longName": "9954509 - Disclosure - Subsequent Events - Narrative (Details)", "shortName": "Subsequent Events - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-295", "name": "nshi:NumberOfSeniorCareHomesOwned", "unitRef": "campus", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-295", "name": "nshi:NumberOfSeniorCareHomesOwned", "unitRef": "campus", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "nshi-20230930.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r540" ] }, "us-gaap_ForeignCurrencyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r17", "r99", "r100", "r101", "r106", "r246" ] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of below market debt", "label": "Amortization of Debt Discount (Premium)", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } }, "auth_ref": [ "r9", "r114", "r148", "r404" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r231", "r235", "r236" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r540" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "nshi_EquityMethodInvestmentsCapitalizedAcquisitionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "EquityMethodInvestmentsCapitalizedAcquisitionCosts", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capitalized acquisition costs", "label": "Equity Method Investments, Capitalized Acquisition Costs", "documentation": "Equity Method Investments, Capitalized Acquisition Costs" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "nshi_StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment of advisor asset management fees", "label": "Stock Redeemed or Called During Period, Value, Payment of Advisor Asset Management Fees", "documentation": "Stock Redeemed or Called During Period, Value, Payment of Advisor Asset Management Fees" } } }, "auth_ref": [] }, "us-gaap_LandImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovementsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements [Member]", "documentation": "Additions or improvements to real estate held." } } }, "auth_ref": [] }, "nshi_WinterfellPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "WinterfellPortfolioMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Winterfell Portfolio", "label": "Winterfell Portfolio [Member]", "documentation": "Winterfell Portfolio [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions declared per share of common stock (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r163" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r540" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r155", "r563" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r540" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r244", "r245", "r386", "r414", "r551", "r765", "r766" ] }, "nshi_DisposalGroupIncludingDiscontinuedOperationTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationTerminationFee", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, not discontinued operation, termination fee", "label": "Disposal Group, Including Discontinued Operation, Termination Fee", "documentation": "Disposal Group, Including Discontinued Operation, Termination Fee" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1 through December 31, 2023", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r961" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments for Capital Leases", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r961" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrecurring", "label": "Fair Value, Nonrecurring [Member]", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r509", "r510", "r512", "r513", "r514", "r516" ] }, "nshi_QualifyingIPOOf200MillionHasOccurredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "QualifyingIPOOf200MillionHasOccurredMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Qualifying IPO Has Occurred", "label": "Qualifying IPO of $200 Million Has Occurred [Member]", "documentation": "Qualifying IPO of $200 Million Has Occurred" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-place lease value", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r155", "r564" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r98", "r165", "r215", "r217", "r225", "r578", "r600" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance leases for equipment", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r531" ] }, "nshi_OtherPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "OtherPropertiesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Properties [Member]", "documentation": "Other Properties" } } }, "auth_ref": [] }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeGainLossOnDerivativeNet", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, gain (loss) on derivative, net", "label": "Derivative, Gain (Loss) on Derivative, Net", "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement." } } }, "auth_ref": [ "r954" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments related to investment in unconsolidated venture", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r156" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r16", "r23", "r214", "r217", "r224", "r520", "r521", "r526", "r577", "r599", "r893", "r894" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments under finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r534", "r536" ] }, "nshi_OperatingCostsPaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "OperatingCostsPaidMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Paid", "label": "Operating Costs Paid [Member]", "documentation": "Operating Costs Paid" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_VariableInterestEntityMeasureOfActivityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityMeasureOfActivityAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity, Measure of Activity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "negatedLabel": "Comprehensive (income) loss attributable to non-controlling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r88", "r98", "r215", "r217", "r226", "r579", "r601" ] }, "nshi_UnconsolidatedInvestmentsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "UnconsolidatedInvestmentsSegmentMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unconsolidated Investments", "label": "Unconsolidated Investments Segment [Member]", "documentation": "Unconsolidated Investments Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted cash", "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r889", "r901", "r972", "r976" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition and retirement of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r37" ] }, "nshi_RochesterNYNonrecourseFebruary2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RochesterNYNonrecourseFebruary2025Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester, NY Non-recourse, February 2025", "label": "Rochester, NY Non-recourse, February 2025 [Member]", "documentation": "Rochester, NY Non-recourse, February 2025 [Member]" } } }, "auth_ref": [] }, "us-gaap_RealEstateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateAbstract", "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Abstract]", "label": "Real Estate [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 6.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "General and administrative expenses", "negatedTerseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r146", "r693" ] }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r10", "r20" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets acquired under capital lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r537", "r790" ] }, "us-gaap_BuildingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building", "label": "Building [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r156" ] }, "nshi_DisposalClosingDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DisposalClosingDateDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Closing Date [Domain]", "label": "Disposal Closing Date [Domain]", "documentation": "Disposal Closing Date [Domain]" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r150" ] }, "nshi_DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Two", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Two" } } }, "auth_ref": [] }, "nshi_DirectInvestmentsOperatingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DirectInvestmentsOperatingMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating", "label": "Direct Investments - Operating [Member]", "documentation": "Direct Investments - Operating" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash-beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash-end of period", "totalLabel": "Total cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r150", "r237" ] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Building and Building Improvements", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "nshi_GeneralAndAdministrativeExpensesAndTransactionCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "GeneralAndAdministrativeExpensesAndTransactionCostsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses/ Transaction costs", "label": "General And Administrative Expenses And Transaction Costs [Member]", "documentation": "General And Administrative Expenses And Transaction Costs" } } }, "auth_ref": [] }, "nshi_AmortizationofDeferredCostsandIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "AmortizationofDeferredCostsandIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for in-place leases and deferred costs", "label": "Amortization of Deferred Costs and Intangible Assets", "documentation": "Amortization of Deferred Costs and Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r437", "r548", "r549", "r662", "r663", "r664", "r665", "r666", "r687", "r689", "r721" ] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests - contributions", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r14", "r77", "r85" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Resident fee income", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r286", "r287", "r298", "r303", "r304", "r310", "r312", "r313", "r428", "r429", "r562" ] }, "nshi_RelatedPartyTransitionServicesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RelatedPartyTransitionServicesAgreementMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transition Services Agreement", "label": "Related Party Transition Services Agreement [Member]", "documentation": "Related Party Transition Services Agreement" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r131" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r86", "r427", "r908", "r909", "r910", "r984" ] }, "nshi_OperatingRealEstateNetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "OperatingRealEstateNetMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating real estate, net", "label": "Operating Real Estate, Net [Member]", "documentation": "Operating Real Estate, Net [Member]" } } }, "auth_ref": [] }, "nshi_AvamereHealthServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "AvamereHealthServicesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avamere Health Services", "label": "Avamere Health Services [Member]", "documentation": "Avamere Health Services [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r196", "r206", "r207", "r208", "r241", "r265", "r266", "r273", "r275", "r279", "r280", "r321", "r369", "r372", "r373", "r374", "r380", "r381", "r412", "r413", "r416", "r419", "r426", "r518", "r627", "r628", "r629", "r630", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r669", "r691", "r714", "r746", "r747", "r748", "r749", "r750", "r881", "r902", "r912" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Domain]", "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r18" ] }, "nshi_DisposalGroupIncludingDiscontinuedOperationDiscountOnPurchaseConsiderationPaidInCash": { "xbrltype": "percentItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationDiscountOnPurchaseConsiderationPaidInCash", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, not discontinued operation, discount on purchase consideration paid in cash", "label": "Disposal Group, Including Discontinued Operation, Discount On Purchase Consideration Paid In Cash", "documentation": "Disposal Group, Including Discontinued Operation, Discount On Purchase Consideration Paid In Cash" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_PaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToMinorityShareholders", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions to non-controlling interests", "label": "Payments to Noncontrolling Interests", "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [ "r36" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r86", "r87", "r96", "r197", "r198", "r220", "r248", "r249", "r250", "r252", "r258", "r323", "r324", "r427", "r475", "r476", "r477", "r487", "r488", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r520", "r522", "r526", "r544", "r619", "r620", "r635", "r671", "r688", "r715", "r716", "r751", "r803", "r904", "r917", "r960", "r984" ] }, "nshi_DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Three", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Three" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Approach and Technique [Axis]", "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r18" ] }, "us-gaap_RealEstatePropertiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstatePropertiesLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Properties [Line Items]", "label": "Real Estate Properties [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Company\u2019s Stockholders\u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "nshi_TerminatedPriorToMarch312025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminatedPriorToMarch312025Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminated Prior To March 31, 2025", "label": "Terminated Prior To March 31, 2025 [Member]", "documentation": "Terminated Prior To March 31, 2025" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r430", "r438", "r467", "r468", "r469", "r560", "r561", "r617", "r659", "r660", "r723", "r725", "r727", "r728", "r740", "r758", "r759", "r772", "r779", "r785", "r792", "r795", "r919", "r926", "r967", "r968", "r969", "r970", "r971" ] }, "nshi_MilfordOHNonRecourseSeptember2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "MilfordOHNonRecourseSeptember2026Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milford, OH Non-recourse, September 2026", "label": "Milford, OH Non-recourse, September 2026 [Member]", "documentation": "Milford, OH Non-recourse [Member]" } } }, "auth_ref": [] }, "nshi_FloatingRateDebtOneMonthLIBORMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FloatingRateDebtOneMonthLIBORMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "One-Month LIBOR", "label": "Floating Rate Debt, One-Month LIBOR [Member]", "documentation": "Floating Rate Debt, One-Month LIBOR [Member]" } } }, "auth_ref": [] }, "nshi_NorthstarHealthcareIncomeOperatingPartnershipLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "NorthstarHealthcareIncomeOperatingPartnershipLPMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Northstar Healthcare Income Operating Partnership, LP", "label": "Northstar Healthcare Income Operating Partnership, LP [Member]", "documentation": "Northstar Healthcare Income Operating Partnership, LP [Member]" } } }, "auth_ref": [] }, "nshi_NumberOfFacilitiesImpaired": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "NumberOfFacilitiesImpaired", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of facilities impaired", "label": "Number Of Facilities Impaired", "documentation": "Number Of Facilities Impaired" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Accumulated depreciation", "label": "Real Estate Investment Property, Accumulated Depreciation", "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes." } } }, "auth_ref": [ "r584" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r92", "r492", "r493", "r496", "r497" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r438", "r561", "r617", "r659", "r660", "r723", "r725", "r727", "r728", "r740", "r758", "r759", "r772", "r779", "r785", "r792", "r926", "r966", "r967", "r968", "r969", "r970", "r971" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r430", "r438", "r467", "r468", "r469", "r560", "r561", "r617", "r659", "r660", "r723", "r725", "r727", "r728", "r740", "r758", "r759", "r772", "r779", "r785", "r792", "r795", "r919", "r926", "r967", "r968", "r969", "r970", "r971" ] }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityOwnershipPercentage", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Limited partnership interest in operating partnership", "terseLabel": "Ownership interest in operating partnership", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r141" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "nshi_ArborsPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ArborsPortfolioMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arbors Portfolio", "label": "Arbors Portfolio [Member]", "documentation": "Arbors Portfolio [Member]" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r244", "r245", "r386", "r414", "r551", "r764", "r766" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r204" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r365", "r366", "r367", "r368", "r438", "r561", "r617", "r659", "r660", "r723", "r725", "r727", "r728", "r740", "r758", "r759", "r772", "r779", "r785", "r792", "r926", "r966", "r967", "r968", "r969", "r970", "r971" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Expenses", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "nshi_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r865" ] }, "us-gaap_FurnitureAndFixturesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesGross", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment", "label": "Furniture and Fixtures, Gross", "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r156" ] }, "nshi_ArcadiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ArcadiaMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Arcadia Management", "label": "Arcadia [Member]", "documentation": "Arcadia [Member]" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r867" ] }, "nshi_DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearOne", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year One", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year One" } } }, "auth_ref": [] }, "nshi_SolsticeSeniorLivingLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "SolsticeSeniorLivingLLCMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Solstice", "verboseLabel": "Solstice Senior Living", "label": "Solstice Senior Living LLC [Member]", "documentation": "Solstice Senior Living LLC [Member]" } } }, "auth_ref": [] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r877" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of equity-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r79", "r80", "r442" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Compensation Related Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r78" ] }, "nshi_MilfordOHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "MilfordOHMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milford, OH", "label": "Milford, OH [Member]", "documentation": "Milford, OH" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r806" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations." } } }, "auth_ref": [ "r121" ] }, "nshi_TerminalCapitalizationRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminalCapitalizationRateMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminal capitalization rate", "label": "Terminal Capitalization Rate [Member]", "documentation": "Terminal Capitalization Rate [Member]" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r317", "r318", "r320" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r842" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r865" ] }, "nshi_RentalandResidentFeeIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RentalandResidentFeeIncome", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and other revenues", "label": "Rental and Resident Fee Income", "documentation": "Rental and Resident Fee Income" } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r842" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r865" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r139", "r152", "r177", "r201", "r213", "r216", "r221", "r241", "r251", "r253", "r254", "r255", "r256", "r259", "r260", "r271", "r285", "r299", "r305", "r308", "r321", "r369", "r370", "r372", "r373", "r374", "r376", "r378", "r380", "r381", "r507", "r518", "r598", "r690", "r712", "r713", "r771", "r802", "r922" ] }, "us-gaap_OperatingLeaseVariableLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseVariableLeaseIncome", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease revenues", "label": "Operating Lease, Variable Lease Income", "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable." } } }, "auth_ref": [ "r277", "r543" ] }, "nshi_DirectInvestmentsNetLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DirectInvestmentsNetLeaseMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Lease", "label": "Direct Investments - Net Lease [Member]", "documentation": "Direct Investments - Net Lease" } } }, "auth_ref": [] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r844" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r230", "r253", "r254", "r255", "r256", "r262", "r263", "r272", "r275", "r285", "r299", "r305", "r308", "r771" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r865" ] }, "nshi_March312024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "March312024Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "March 31, 2024", "label": "March 31, 2024 [Member]", "documentation": "March 31, 2024" } } }, "auth_ref": [] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "nshi_LandParcelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "LandParcelMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land Parcel", "label": "Land Parcel [Member]", "documentation": "Land Parcel" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r865" ] }, "nshi_LoansAndLeasesReceivableAllowanceForLoanLossesAndImpairmentOnInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "LoansAndLeasesReceivableAllowanceForLoanLossesAndImpairmentOnInvestmentsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment on Operating Real Estate and Investments in Unconsolidated Ventures", "label": "Loans and Leases Receivable Allowance for Loan Losses and Impairment on Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit losses and impairment on investments." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r806" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r843" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r865" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r844" ] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from unconsolidated ventures", "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r233", "r898" ] }, "nshi_NumberOfSeniorCareHomesOwned": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "NumberOfSeniorCareHomesOwned", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of senior care homes owned", "label": "Number Of Senior Care Homes Owned", "documentation": "Number Of Senior Care Homes Owned" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Schedule of Equity Method Investments [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available." } } }, "auth_ref": [ "r201", "r241", "r317", "r318", "r320", "r321", "r518" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income (loss) before equity in earnings (losses) of unconsolidated ventures and income tax expense", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r285", "r299", "r305", "r308", "r604", "r771" ] }, "nshi_ProceedsFromEquityMethodInvestmentDistributionOperatingAndInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ProceedsFromEquityMethodInvestmentDistributionOperatingAndInvestingActivities", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Distribution", "label": "Proceeds From Equity Method Investment, Distribution, Operating And Investing Activities", "documentation": "Proceeds From Equity Method Investment, Distribution, Operating And Investing Activities" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Domain]", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r19" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Amount representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r540" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of mortgage notes", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r38" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CommitmentsandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r364", "r883" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of minimum lease payments", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r532", "r540" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r241", "r317", "r318", "r320", "r321", "r518" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r866" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityDistributionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends payable", "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r128", "r129", "r172", "r801", "r974" ] }, "nshi_IncreaseDecreaseinEscrowPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "IncreaseDecreaseinEscrowPayable", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposits payable", "label": "Increase (Decrease) in Escrow Payable", "documentation": "Increase (Decrease) in Escrow Payable" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r845" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r869" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r34", "r215", "r217", "r227", "r580", "r602" ] }, "nshi_PaymentstoImproveRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "PaymentstoImproveRealEstate", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capital expenditures for operating real estate", "label": "Payments to Improve Real Estate", "documentation": "Payments to Improve Real Estate" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r196", "r206", "r207", "r208", "r241", "r265", "r266", "r273", "r275", "r279", "r280", "r321", "r369", "r372", "r373", "r374", "r380", "r381", "r412", "r413", "r416", "r419", "r426", "r518", "r627", "r628", "r629", "r630", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r669", "r691", "r714", "r746", "r747", "r748", "r749", "r750", "r881", "r902", "r912" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r865" ] }, "nshi_EclipseJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "EclipseJointVentureMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Eclipse", "label": "Eclipse Joint Venture [Member]", "documentation": "Eclipse Joint Venture [Member]" } } }, "auth_ref": [] }, "nshi_VotingInterestEntityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "VotingInterestEntityPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Voting Interest Entities", "label": "Voting Interest Entity [Policy Text Block]", "documentation": "Disclosure of accounting policy for voting interest entities." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r806" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease term (years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r538", "r790" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r866" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total minimum lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r540" ] }, "nshi_FinanceLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FinanceLeasePayments", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of finance lease obligations", "label": "Finance Lease, Payments", "documentation": "Finance Lease, Payments" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r48", "r50", "r111", "r112", "r313", "r754", "r887" ] }, "us-gaap_NoninterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoninterestIncome", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Other Revenues", "label": "Noninterest Income", "documentation": "The total amount of noninterest income which may be derived from: (1) fees and commissions; (2) premiums earned; (3) insurance policy charges; (4) the sale or disposal of assets; and (5) other sources not otherwise specified." } } }, "auth_ref": [ "r178" ] }, "nshi_ProceedsFromDivestitureOfEquityMethodInvestmentSupplementalCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ProceedsFromDivestitureOfEquityMethodInvestmentSupplementalCashPayment", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of equity method investment, supplemental cash payment, maximum", "label": "Proceeds From Divestiture Of Equity Method Investment, Supplemental Cash Payment", "documentation": "Proceeds From Divestiture Of Equity Method Investment, Supplemental Cash Payment" } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r845" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r868" ] }, "us-gaap_NonrecourseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrecourseMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Recourse", "label": "Nonrecourse [Member]", "documentation": "Liability for which creditor does not have recourse to debtor but rather has recourse only to property used for collateral in transaction or other specific property." } } }, "auth_ref": [ "r493", "r497" ] }, "nshi_OtherIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "OtherIncomeExpenseAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (loss)", "label": "Other Income (Expense) [Abstract]", "documentation": "Other Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r808", "r878" ] }, "nshi_PaymentsForDivestitureOfInterestInJointVenture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "PaymentsForDivestitureOfInterestInJointVenture", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments for divestiture of interest in joint venture", "label": "Payments For Divestiture Of Interest In Joint Venture", "documentation": "Payments For Divestiture Of Interest In Joint Venture" } } }, "auth_ref": [] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateCapMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Cap", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": [ "r761" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r846" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r533" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses on receivables", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r210", "r314", "r328", "r331", "r333", "r977" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r876" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Receivables, net", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r677", "r753", "r796", "r977" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r153", "r238" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized equity-based compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r953" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r51", "r52", "r53", "r188", "r189", "r190", "r191" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life (in years)", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r657", "r660", "r674", "r675", "r676", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r702", "r703", "r704", "r705", "r708", "r709", "r710", "r711", "r731", "r732", "r734", "r736", "r793", "r795" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r875" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained earnings (accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r133", "r163", "r592", "r621", "r623", "r631", "r670", "r791" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/NoncontrollingInterests" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r164" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LandImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandImprovements", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land improvements", "label": "Land Improvements", "documentation": "Amount before accumulated depreciation and depletion of additions or improvements to real estate held for productive use. Examples include, but are not limited to, walkways, driveways, fences, and parking lots." } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on investments and other", "negatedLabel": "(Gain) loss on investments and other", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r147", "r880" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1 through December 31, 2023", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": [ "r907" ] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r31", "r87", "r90", "r143" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r783", "r784" ] }, "nshi_TerminatedPriorToSeptember302025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminatedPriorToSeptember302025Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminated Prior To September 30, 2025", "label": "Terminated Prior To September 30, 2025 [Member]", "documentation": "Terminated Prior To September 30, 2025" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss)", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r202", "r763" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r957" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Restricted Cash", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r42" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r140", "r404", "r529", "r900" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r313", "r886" ] }, "us-gaap_MortgagesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MortgagesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgages", "verboseLabel": "Mortgage notes payable, net", "label": "Mortgages [Member]", "documentation": "A loan to finance the purchase of real estate where the lender has a lien on the property as collateral for the loan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r248", "r249", "r250", "r278", "r562", "r625", "r648", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r672", "r673", "r674", "r675", "r676", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r714", "r796" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r783", "r784" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r650", "r652", "r653", "r655", "r658", "r722", "r724", "r726", "r729", "r730", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r795" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r527", "r555" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration received", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r247", "r400" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r247", "r400" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r247", "r400" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r527", "r555" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r12", "r247", "r400" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r555" ] }, "us-gaap_TenantImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TenantImprovements", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant improvements", "label": "Tenant Improvements", "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants." } } }, "auth_ref": [ "r973" ] }, "us-gaap_ProceedsFromMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMinorityShareholders", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Contributions from non-controlling interests", "label": "Proceeds from Noncontrolling Interests", "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership." } } }, "auth_ref": [ "r35" ] }, "us-gaap_AdvancePaymentsByBorrowersForTaxesAndInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvancePaymentsByBorrowersForTaxesAndInsurance", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Escrow deposits payable", "label": "Advance Payments by Borrowers for Taxes and Insurance", "documentation": "Carrying amount of accumulated prepayments received by financial institutions from borrowers for taxes (for example, property taxes) and insurance (for example, property and catastrophe) which will periodically be remitted to the appropriate governmental agency or vendor on behalf of the borrower." } } }, "auth_ref": [ "r122" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distributions from unconsolidated ventures", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r7", "r9", "r138", "r595" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r48", "r50", "r111", "r112", "r313", "r754" ] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discounted cash flow method", "label": "Valuation Technique, Discounted Cash Flow [Member]", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r957" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r555" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r186" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions paid on common stock", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r37" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investee, cash consideration", "label": "Subsidiary or Equity Method Investee, Cumulative Proceeds Received on All Transactions", "documentation": "Cumulative amount of cash and other consideration received by subsidiary or equity method investee in exchange for shares or stock issued or sold. Include amounts of cash received, fair value of non-cash assets received, fair value of liabilities assumed, and fair value of any other forms of consideration." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsMaturityScheduleDetails", "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying Value", "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r24", "r173", "r395", "r410", "r775", "r776", "r975" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, fair value", "label": "Equity Method Investments, Fair Value Disclosure", "documentation": "Fair value portion of investments accounted under the equity method." } } }, "auth_ref": [ "r891", "r956", "r958", "r959" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of the Fees and Reimbursements Incurred to the Advisor and Dealer Manager", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_DerivativeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative", "label": "Derivative [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of shares of common stock outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r264", "r275" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r811", "r822", "r832", "r857" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Due to related party", "terseLabel": "Other liabilities", "periodStartLabel": "Due to related party, beginning balance", "periodEndLabel": "Due to related party, ending balance", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r123", "r583", "r663", "r664", "r804", "r981" ] }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationVariableInterestEntityPolicy", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)." } } }, "auth_ref": [ "r91", "r93", "r94" ] }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets:", "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Accounting", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r535" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r313", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r360", "r361", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r773", "r888", "r978" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r815", "r826", "r836", "r861" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r812", "r823", "r833", "r858" ] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateJointVentureMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in unconsolidated ventures", "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r298", "r299", "r300", "r301", "r302", "r308" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r914", "r962" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r812", "r823", "r833", "r858" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average number of shares of common stock outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r262", "r275" ] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairedLongLivedAssetsHeldAndUsedAssetNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "label": "Impaired Long-Lived Assets Held and Used, Asset Name [Domain]", "documentation": "The name of the impaired assets to be held and used by the entity." } } }, "auth_ref": [ "r68" ] }, "us-gaap_OtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Other Operating Income", "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r142" ] }, "us-gaap_NotesPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Notes Payable, Fair Value Disclosure", "documentation": "Fair value portion of notes payable." } } }, "auth_ref": [ "r25" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r247", "r287", "r298", "r299", "r300", "r301", "r302", "r304", "r308", "r369", "r370", "r371", "r372", "r374", "r375", "r377", "r379", "r380", "r922", "r923" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r813", "r824", "r834", "r859" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress, Gross", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r156" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, realized gain on disposal", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r896", "r897", "r900" ] }, "nshi_NumberOfTripleNetLeasePortfolios": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "NumberOfTripleNetLeasePortfolios", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of triple net lease portfolios", "label": "Number of Triple Net Lease Portfolios", "documentation": "Number of Triple Net Lease Portfolios" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r440", "r444", "r472", "r473", "r474", "r786" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r814", "r825", "r835", "r860" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r131" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r247", "r287", "r298", "r299", "r300", "r301", "r302", "r304", "r308", "r369", "r370", "r371", "r372", "r374", "r375", "r377", "r379", "r380", "r922", "r923" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NorthStar Healthcare Income, Inc. Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayable", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgage notes payable, net", "verboseLabel": "Carrying Value", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r24", "r173", "r975" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r32", "r33", "r137", "r209", "r591", "r622", "r623" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r692", "r760", "r768" ] }, "us-gaap_FinanceLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease Liability", "label": "Finance Lease, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r816", "r827", "r837", "r854", "r862" ] }, "us-gaap_ImpairmentOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfRealEstate", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment Losses", "label": "Impairment of Real Estate", "documentation": "The charge against earnings in the period to reduce the carrying amount of real property to fair value." } } }, "auth_ref": [ "r900", "r918" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value, 400,000,000 shares authorized, 185,712,103 and 195,421,656 shares issued and outstanding as of September\u00a030, 2023 and December 31, 2022, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r131", "r590", "r791" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r160", "r240", "r411", "r413", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r425", "r427", "r504", "r717", "r719", "r752" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r471", "r478" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r131", "r669" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r203", "r357" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r16", "r131", "r669", "r688", "r984", "r985" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r218", "r479", "r480", "r482", "r483", "r485", "r486", "r626" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r242", "r243", "r548", "r549", "r550", "r551", "r662", "r663", "r664", "r665", "r666", "r687", "r689", "r721" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial liabilities", "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r905", "r906" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r842" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r817", "r828", "r838", "r863" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Sales of other assets", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r885", "r899" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r793", "r794", "r795", "r797", "r798", "r799", "r800", "r908", "r909", "r955", "r979", "r984" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r816", "r827", "r837", "r862" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r149" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r69" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total NorthStar Healthcare Income, Inc. stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r131", "r134", "r135", "r154", "r671", "r688", "r715", "r716", "r791", "r804", "r904", "r917", "r960", "r984" ] }, "us-gaap_DividendsPayableAmountPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableAmountPerShare", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityDistributionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Special distribution (dollars per share)", "label": "Dividends Payable, Amount Per Share", "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date." } } }, "auth_ref": [ "r44" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r116", "r179", "r222", "r289", "r528", "r699", "r802", "r983" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in allowance for uncollectible accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r229", "r332" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r158", "r362", "r363", "r755", "r920" ] }, "nshi_EspressoJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "EspressoJointVentureMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Espresso Joint Venture", "verboseLabel": "Espresso", "label": "Espresso Joint Venture [Member]", "documentation": "Espresso Joint Venture [Member]" } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r107", "r109", "r110" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r818", "r829", "r839", "r864" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r527", "r555" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r40", "r43" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r439", "r911" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_LeasesAcquiredInPlaceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAcquiredInPlaceMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "In-place lease value", "label": "Leases, Acquired-in-Place [Member]", "documentation": "This element represents the amount of value allocated by a lessor (acquirer) to lease agreements which exist at acquisition of a leased property. Such amount may include the value assigned to tenant relationships and excludes the market adjustment component of the value assigned for above or below-market leases acquired." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r475", "r476", "r477", "r637", "r908", "r909", "r910", "r955", "r984" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net proceeds from issuance of common stock", "terseLabel": "Value of common stock issued", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r16", "r130", "r131", "r163", "r637", "r714", "r747", "r803" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r511" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r509", "r510", "r515" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r261", "r439", "r883", "r884", "r911" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Accounting", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of the Principal Amount, Carrying Value and Fair Value of Certain Financial Assets and Liabilities", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2." } } }, "auth_ref": [ "r107", "r167" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r437", "r548", "r549", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r662", "r663", "r664", "r665", "r666", "r687", "r689", "r721", "r963" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r261", "r439", "r883", "r911" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r49", "r313" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued capital expenditures", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r132" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r396", "r431", "r432", "r433", "r434", "r435", "r436", "r557", "r558", "r559", "r775", "r776", "r780", "r781", "r782" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r70", "r71", "r72", "r73", "r74", "r75", "r76", "r161", "r162", "r163", "r206", "r207", "r208", "r279", "r412", "r413", "r414", "r416", "r419", "r424", "r426", "r627", "r628", "r629", "r630", "r779", "r881", "r902" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r206", "r207", "r208", "r279", "r412", "r413", "r414", "r416", "r419", "r424", "r426", "r627", "r628", "r629", "r630", "r779", "r881", "r902" ] }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairedLongLivedAssetsHeldAndUsedByTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "label": "Impaired Long-Lived Assets Held and Used by Type [Axis]", "documentation": "This element represents the categories used to group impaired long-lived assets held and used by the type of asset." } } }, "auth_ref": [ "r68" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r234" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Retirement of common stock (Note 8)", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r16", "r130", "r131", "r163" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r16", "r130", "r131", "r163", "r627", "r714", "r747" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r281", "r282", "r283", "r284", "r285", "r297", "r302", "r306", "r307", "r308", "r309", "r310", "r311", "r313" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r234" ] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r200" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r150", "r151", "r152" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r396", "r431", "r436", "r510", "r558", "r775", "r776", "r780", "r781", "r782" ] }, "us-gaap_InvestmentBuildingAndBuildingImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentBuildingAndBuildingImprovements", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and improvements", "label": "Investment Building and Building Improvements", "documentation": "Aggregate of the carrying amounts as of the balance sheet date of investments in building and building improvements." } } }, "auth_ref": [ "r973" ] }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Assets by Segment", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets." } } }, "auth_ref": [ "r57", "r58" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r396", "r431", "r436", "r510", "r557", "r780", "r781", "r782" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "terseLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r170", "r205", "r241", "r285", "r300", "r306", "r321", "r369", "r370", "r372", "r373", "r374", "r376", "r378", "r380", "r381", "r492", "r496", "r518", "r587", "r682", "r791", "r804", "r922", "r923", "r964" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r441", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value, 50,000,000 shares authorized, no shares issued and outstanding as of September\u00a030, 2023 and December 31, 2022", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r130", "r589", "r791" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Segment Reporting", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r54", "r55", "r56", "r59" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share-Based Compensation Arrangements By Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r441", "r443", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r16", "r30", "r197", "r219", "r220", "r221", "r248", "r249", "r250", "r252", "r258", "r260", "r278", "r323", "r324", "r427", "r475", "r476", "r477", "r487", "r488", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r520", "r522", "r523", "r524", "r525", "r526", "r544", "r618", "r619", "r620", "r637", "r714" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r396", "r431", "r432", "r433", "r434", "r435", "r436", "r510", "r559", "r775", "r776", "r780", "r781", "r782" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r247", "r492", "r493", "r496", "r497", "r553", "r756", "r921", "r924", "r925" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r54", "r55", "r56", "r59" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "verboseLabel": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r197", "r248", "r249", "r250", "r252", "r258", "r260", "r323", "r324", "r475", "r476", "r477", "r487", "r488", "r498", "r500", "r501", "r503", "r505", "r618", "r620", "r637", "r984" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r247", "r492", "r493", "r496", "r497", "r553", "r756", "r921", "r924", "r925" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Distributions declared", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r5", "r163" ] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock as payment for asset management fees", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r9" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r22", "r168", "r976" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r317", "r318", "r320" ] }, "us-gaap_RealEstateInvestmentsUnconsolidatedRealEstateAndOtherJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentsUnconsolidatedRealEstateAndOtherJointVentures", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in unconsolidated ventures", "label": "Real Estate Investments, Unconsolidated Real Estate and Other Joint Ventures", "documentation": "The carrying amount of investments in unconsolidated real estate and other joint ventures not separately presented. This includes direct and indirect investments." } } }, "auth_ref": [ "r973" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Total Equity", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r16", "r197", "r219", "r220", "r221", "r248", "r249", "r250", "r252", "r258", "r260", "r278", "r323", "r324", "r427", "r475", "r476", "r477", "r487", "r488", "r498", "r499", "r500", "r501", "r502", "r503", "r505", "r520", "r522", "r523", "r524", "r525", "r526", "r544", "r618", "r619", "r620", "r637", "r714" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r808", "r878" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedLabel": "Retirement of common stock (in shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r16", "r130", "r131", "r163" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r15", "r33", "r499", "r502", "r544", "r618", "r619", "r893", "r894", "r895", "r908", "r909", "r910" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r509", "r510", "r515" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 12)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r29", "r124", "r588", "r668" ] }, "us-gaap_SalesCommissionsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesCommissionsAndFees", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling commissions or dealer manager fees paid", "label": "Sales Commissions and Fees", "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller)." } } }, "auth_ref": [ "r146" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r60", "r62" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r169", "r204", "r586", "r804" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r490", "r783", "r784" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r853" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Unconsolidated Ventures", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r7", "r113", "r318" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r846" ] }, "us-gaap_NumberOfUnitsInRealEstateProperty": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfUnitsInRealEstateProperty", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units Under Management", "label": "Number of Units in Real Estate Property", "documentation": "The number of units in a real estate property owned as of the balance sheet date." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r83", "r84", "r490", "r783", "r784" ] }, "us-gaap_BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAndOtherPurchaseOfBusinessTransactionsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition Fees and Expenses", "label": "Business Combinations and Other Purchase of Business Transactions, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for business combinations and other business acquisition transactions not accounted for using the purchase method, such as an exchange of shares between entities under common control." } } }, "auth_ref": [ "r0", "r1" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r846" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r805" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "% of Total Property and Other Revenues", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r48", "r50", "r111", "r112", "r313" ] }, "us-gaap_NumberOfRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfRealEstateProperties", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Properties Under Management", "label": "Number of Real Estate Properties", "documentation": "The number of real estate properties owned as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValue" ], "lang": { "en-us": { "role": { "verboseLabel": "Fair Value", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r508" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share of common stock, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r228", "r253", "r254", "r255", "r256", "r257", "r265", "r273", "r274", "r275", "r276", "r506", "r507", "r581", "r603", "r769" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r846" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganization" ], "lang": { "en-us": { "role": { "verboseLabel": "Business and Organization", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r187", "r194" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r23", "r33", "r220", "r520", "r523", "r526", "r893" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r61", "r63", "r563" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r846" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate (percent)", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r539", "r790" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate value for restricted common shares granted to independent directors", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Identified Intangibles", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r13", "r59" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of accumulated other comprehensive loss", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r23", "r33", "r220", "r520", "r525", "r526", "r893" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r808", "r878" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets, Net", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r61", "r63" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r847" ] }, "nshi_TerminationScenarioDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminationScenarioDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Scenario [Domain]", "label": "Termination Scenario [Domain]", "documentation": "Termination Scenario [Domain]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r484" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r130", "r412" ] }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVentures" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in Unconsolidated Ventures", "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]", "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group." } } }, "auth_ref": [ "r195", "r319", "r322", "r882" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r847" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "terseLabel": "Net income (loss)", "verboseLabel": "Net income (loss)", "netLabel": "Net income (loss)", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r201", "r213", "r216", "r232", "r241", "r251", "r259", "r260", "r285", "r299", "r305", "r308", "r321", "r369", "r370", "r372", "r373", "r374", "r376", "r378", "r380", "r381", "r491", "r494", "r495", "r507", "r518", "r582", "r596", "r636", "r690", "r712", "r713", "r771", "r788", "r789", "r803", "r895", "r922" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Receivables", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r847" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r847" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r130", "r669" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r130", "r669", "r688", "r984", "r985" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_ScheduleOfRealEstatePropertiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Real Estate Properties [Table]", "label": "Schedule of Real Estate Properties [Table]", "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property." } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r847" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r554", "r556" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r102", "r103", "r104", "r105", "r657", "r660", "r674", "r675", "r676", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r702", "r703", "r704", "r705", "r708", "r709", "r710", "r711", "r731", "r732", "r734", "r736", "r766", "r793", "r795" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r848" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property operating expenses", "negatedTerseLabel": "Property operating expenses", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r144", "r562" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Real Estate Estimated Useful Life", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r11" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "negatedTerseLabel": "Transaction costs", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": [ "r82" ] }, "us-gaap_Land": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Land", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestmentPropertyAtCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land", "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale." } } }, "auth_ref": [ "r892" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r850" ] }, "us-gaap_TangibleAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TangibleAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tangible asset impairment charges", "label": "Tangible Asset Impairment Charges", "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value." } } }, "auth_ref": [ "r126", "r157" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net (income) loss attributable to non-controlling interests", "terseLabel": "Net income (loss) attributable to non-controlling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r97", "r166", "r213", "r216", "r259", "r260", "r597", "r895" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r89", "r767" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r849" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r650", "r652", "r653", "r655", "r658", "r722", "r724", "r726", "r729", "r730", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r795" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r851" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r130", "r412" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_OperatingLeaseLeaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncome", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Rental income", "label": "Operating Lease, Lease Income", "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r277", "r541", "r542" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r852" ] }, "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditLossFinancialInstrumentPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Losses on Receivables", "label": "Credit Loss, Financial Instrument [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status." } } }, "auth_ref": [ "r192", "r325", "r326", "r327", "r329", "r330", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesRelatedParty", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset management fees - related party", "negatedTerseLabel": "Asset management fees - related party", "label": "Costs and Expenses, Related Party", "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties." } } }, "auth_ref": [ "r145" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r24", "r127", "r128", "r171", "r173", "r247", "r383", "r384", "r385", "r386", "r387", "r389", "r394", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r530", "r774", "r775", "r776", "r777", "r778", "r903" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r854" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/Borrowings" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r159", "r239", "r382", "r388", "r389", "r390", "r391", "r392", "r393", "r398", "r405", "r406", "r408" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholder's Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative asset", "verboseLabel": "Derivative asset - interest rate caps", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r211", "r212", "r517", "r649", "r650", "r651", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r675", "r676", "r731", "r733", "r734", "r735", "r736", "r737", "r766", "r795", "r980" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r548", "r549", "r963" ] }, "us-gaap_ScheduleOfRealEstatePropertiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRealEstatePropertiesTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Real Estate Properties", "label": "Schedule of Real Estate Properties [Table Text Block]", "documentation": "Tabular disclosure of real estate properties and units in those properties that are included in the discussion of the nature of an entity's operations." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease liability." } } }, "auth_ref": [ "r533" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r247", "r383", "r384", "r385", "r386", "r387", "r389", "r394", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r530", "r774", "r775", "r776", "r777", "r778", "r903" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization", "negatedTerseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r290" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r73", "r76", "r114", "r115", "r117", "r125", "r161", "r162", "r247", "r383", "r384", "r385", "r386", "r387", "r389", "r394", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r530", "r774", "r775", "r776", "r777", "r778", "r903" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r24", "r173", "r409" ] }, "us-gaap_RealEstateDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstate" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Real Estate", "label": "Real Estate Disclosure [Text Block]", "documentation": "The entire disclosure for certain real estate investment financial statements, real estate investment trust operating support agreements, real estate owned, retail land sales, time share transactions, as well as other real estate related disclosures." } } }, "auth_ref": [ "r180", "r181", "r182", "r183", "r184" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r316" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r806" ] }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments in Unconsolidated Ventures", "label": "Equity Method Investments and Joint Ventures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestments", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating real estate, net", "label": "Real Estate Investments, Net", "documentation": "Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented." } } }, "auth_ref": [ "r585", "r982" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r27", "r384" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r854" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r806" ] }, "us-gaap_RealEstateInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment on Operating Real Estate and Investments in Unconsolidated Ventures", "label": "Real Estate Investments, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) per share of common stock, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r228", "r253", "r254", "r255", "r256", "r257", "r262", "r265", "r273", "r274", "r275", "r276", "r506", "r507", "r581", "r603", "r769" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r841" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r806" ] }, "nshi_AvamerePortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "AvamerePortfolioMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Avamere Portfolio", "label": "Avamere Portfolio [Member]", "documentation": "Avamere Portfolio [Member]" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r854" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r810", "r821", "r831", "r856" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r806" ] }, "nshi_RealEstateMeasurementInput": { "xbrltype": "percentItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RealEstateMeasurementInput", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement input (percentage)", "label": "Real Estate, Measurement Input", "documentation": "Real Estate, Measurement Input" } } }, "auth_ref": [] }, "nshi_RealEstateOwnedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RealEstateOwnedPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Real Estate", "label": "Real Estate Owned [Policy Text Block]", "documentation": "Disclosure of accounting policy related to real estate owned." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r854" ] }, "us-gaap_RealEstateInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate Investment", "label": "Real Estate Investment [Member]", "documentation": "This element represents direct equity investments in real estate projects (Land, buildings and improvements owned for income production and capital accretion potential) and certain loans accounted for as real estate investments. For loans accounted for as real estate investments, the entity (lender) has virtually the same risks and rewards as those of owners or joint venture participants. Such arrangements are treated as if the entity actually has an ownership interest in the property. In such arrangements, the entity (lender) participates in expected residual profits, which may be in the form of an equity kicker or a higher than usual effective interest rate. At the outset and during the construction and development of the property, the borrower generally has little or no equity in the property and the entity's (lender's) only source of repayment is the property. The entity (lender) generally (a) agrees to provide substantially all funds to acquire, develop, and construct the property, (b) funds the commitment or origination fees or both, and (c) funds interest during the development and construction of the property." } } }, "auth_ref": [ "r743", "r744", "r745", "r762" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r819", "r827", "r837", "r854", "r862", "r866", "r874" ] }, "nshi_ScheduleofDeferredCostsandIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ScheduleofDeferredCostsandIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense", "label": "Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Schedule of Deferred Costs and Intangible Assets, Future Amortization Expense [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetIncludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetIncludingGoodwillAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Identified Intangibles", "label": "Intangible Assets, Net (Including Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r247", "r383", "r384", "r385", "r386", "r387", "r389", "r394", "r395", "r396", "r397", "r399", "r400", "r401", "r402", "r403", "r404", "r530", "r774", "r775", "r776", "r777", "r778", "r903" ] }, "nshi_FinancialStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FinancialStatementLocationDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Statement Location [Domain]", "label": "Financial Statement Location [Domain]", "documentation": "Information by location in the financial statement." } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r819", "r827", "r837", "r854", "r862", "r866", "r874" ] }, "nshi_IncentiveFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "IncentiveFeePercentage", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive fee distributions, percent of net cash flows", "label": "Incentive Fee, Percentage", "documentation": "Incentive Fee, Percentage" } } }, "auth_ref": [] }, "us-gaap_RealEstateOwnedValuationAllowanceComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateOwnedValuationAllowanceComponent", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated impairment", "label": "Real Estate Owned, Valuation Allowance, Component", "documentation": "The valuation allowance loss on real estate owned or any impairment losses taken against real estate investments held for use or resale." } } }, "auth_ref": [ "r64", "r65", "r120" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r809", "r820", "r830", "r855" ] }, "nshi_ShareBasedCompensationArrangementsByShareBasedPaymentAwardPeriodOfCumulativePerformanceGoalsConsideredUnderPlan": { "xbrltype": "durationItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardPeriodOfCumulativePerformanceGoalsConsideredUnderPlan", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted common shares grant vesting period", "label": "Share Based Compensation Arrangements by Share Based Payment Award, Period of Cumulative Performance Goals Considered under Plan", "documentation": "Represents the period established by the Committee for achieving cumulative performance hurdles or target stock prices under the incentive compensation plan." } } }, "auth_ref": [] }, "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsandFiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Deferred Costs and Finite-Lived Intangible Assets, Net", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Net" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyAtCost", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_RealEstateInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateIdentifiableAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Subtotal", "label": "Real Estate Investment Property, at Cost", "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r585" ] }, "nshi_DisposalGroupIncludingDiscontinuedOperationPercentageOfConsiderationPaidInCash": { "xbrltype": "percentItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationPercentageOfConsiderationPaidInCash", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal group, not discontinued operation, percentage of consideration paid in cash", "label": "Disposal Group, Including Discontinued Operation, Percentage Of Consideration Paid In Cash", "documentation": "Disposal Group, Including Discontinued Operation, Percentage Of Consideration Paid In Cash" } } }, "auth_ref": [] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit, outstanding (in shares)", "label": "Common Unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Borrowings", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r28", "r73", "r76", "r114", "r115", "r117", "r125", "r161", "r162", "r775", "r777", "r907" ] }, "nshi_SpecialUnitsHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "SpecialUnitsHolderMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Special Unit Holder", "label": "Special Units Holder [Member]", "documentation": "Represents information pertaining to the enitity which is the holder of a separate class of non-controlling interests in the registrant." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RealEstateInvestmentPropertyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateInvestmentPropertyNet", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating real estate, net", "label": "Real Estate Investment Property, Net", "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments." } } }, "auth_ref": [ "r973" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax expense", "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r185", "r193", "r259", "r260", "r293", "r481", "r489", "r605" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r47" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r809", "r820", "r830", "r855" ] }, "nshi_December312024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "December312024Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 31, 2024", "label": "December 31, 2024 [Member]", "documentation": "December 31, 2024" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "nshi_FriscoTXMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FriscoTXMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Frisco, TX", "label": "Frisco, TX [Member]", "documentation": "Frisco [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r870" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, amounts of transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r119", "r548" ] }, "nshi_IntegralMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "IntegralMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Integral Senior Living", "label": "Integral [Member]", "documentation": "Integral [Member]" } } }, "auth_ref": [] }, "nshi_RochesterPortfolioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RochesterPortfolioMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester Portfolio", "label": "Rochester Portfolio [Member]", "documentation": "Rochester Portfolio" } } }, "auth_ref": [] }, "nshi_DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "October 1 through December 31, 2023", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basis spread on variable interest rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r871" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r872" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of deferred financing costs", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r36" ] }, "nshi_FinancialStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FinancialStatementLocationAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Statement Location [Axis]", "label": "Financial Statement Location [Axis]", "documentation": "Information by location in the financial statement." } } }, "auth_ref": [] }, "nshi_TotalPropertiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TotalPropertiesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Total Properties [Member]", "documentation": "Total Properties" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r875" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange of ownership interests in unconsolidated ventures for common stock", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction." } } }, "auth_ref": [ "r44", "r45", "r46" ] }, "nshi_TerminatedPriorToInitialOutsideDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminatedPriorToInitialOutsideDateMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminated Prior To Initial Outside Date", "label": "Terminated Prior To Initial Outside Date [Member]", "documentation": "Terminated Prior To Initial Outside Date" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r872" ] }, "nshi_NumberofHealthcareRealEstateProperties": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "NumberofHealthcareRealEstateProperties", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of healthcare real estate properties", "label": "Number of Healthcare Real Estate Properties", "documentation": "Number of Healthcare Real Estate Properties" } } }, "auth_ref": [] }, "nshi_TerminationScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TerminationScenarioAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Scenario [Axis]", "label": "Termination Scenario [Axis]", "documentation": "Termination Scenario" } } }, "auth_ref": [] }, "nshi_FinanceLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesFutureMinimumLeasePaymentsfromCapitalLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, To Be Paid, after Year Four", "documentation": "Finance Lease, Liability, To Be Paid, after Year Four" } } }, "auth_ref": [] }, "nshi_TrilogyEspressoSolsticeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TrilogyEspressoSolsticeMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trilogy, Espresso, Solstice", "label": "Trilogy, Espresso, Solstice [Member]", "documentation": "Eclipse, Envoy, Diversified US/UK, Espresso, Trilogy [Member]" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r67" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Independent Directors", "label": "Director [Member]" } } }, "auth_ref": [ "r914", "r981" ] }, "nshi_DiversifiedUSUKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DiversifiedUSUKMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diversified US/UK", "label": "Diversified US/UK [Member]", "documentation": "Griffin-American Joint Venture [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r248", "r249", "r250", "r278", "r562", "r625", "r648", "r661", "r662", "r663", "r664", "r665", "r666", "r669", "r672", "r673", "r674", "r675", "r676", "r678", "r679", "r680", "r681", "r683", "r684", "r685", "r686", "r687", "r689", "r692", "r693", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r714", "r796" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r199", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r308", "r313", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r359", "r360", "r361", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r773", "r888", "r978" ] }, "nshi_DividendReinvestmentPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DividendReinvestmentPlanMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityCommonStockandDistributionReinvestmentPlanDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend Reinvestment Plan", "label": "Dividend Reinvestment Plan [Member]", "documentation": "Dividend Reinvestment Plan [Member]" } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r872" ] }, "nshi_LeaseTermsDaysNoticeRequiredForTermination": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "LeaseTermsDaysNoticeRequiredForTermination", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Days notice required for lease termination", "label": "Lease, Terms, Days Notice Required For Termination", "documentation": "Lease, Terms, Days Notice Required For Termination" } } }, "auth_ref": [] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset Class [Axis]", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r107", "r108" ] }, "nshi_AdvisoroftheRegistrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "AdvisoroftheRegistrantMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advisor", "label": "Advisor of the Registrant [Member]", "documentation": "Represents information pertaining to the advisor (external manager) of the registrant." } } }, "auth_ref": [] }, "nshi_IncentiveFeeNonCompoundedAnnualPreTaxReturnOnInvestedCapitalMinimum": { "xbrltype": "percentItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "IncentiveFeeNonCompoundedAnnualPreTaxReturnOnInvestedCapitalMinimum", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive fee distributions, minimum non-compounded annual pre-tax return on invested capital", "label": "Incentive Fee, Non-Compounded Annual Pre-tax Return on Invested Capital, Minimum", "documentation": "Incentive Fee, Non-Compounded Annual Pre-tax Return on Invested Capital, Minimum" } } }, "auth_ref": [] }, "nshi_RochesterNYNonrecourseAugust2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RochesterNYNonrecourseAugust2024Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester NY Nonrecourse August 2024", "label": "Rochester NY Nonrecourse August 2024 [Member]", "documentation": "Rochester NY Nonrecourse August 2024" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r396", "r431", "r432", "r433", "r434", "r435", "r436", "r510", "r557", "r558", "r559", "r775", "r776", "r780", "r781", "r782" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r118", "r119", "r694", "r695", "r698" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r563" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Arrangements", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r545", "r546", "r547", "r549", "r552", "r632", "r633", "r634", "r696", "r697", "r698", "r718", "r720" ] }, "nshi_TheTrilogyJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "TheTrilogyJointVentureMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trilogy", "label": "The Trilogy Joint Venture [Member]", "documentation": "The Trilogy Joint Venture [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r519" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueScheduleofthePrincipalAmountCarryingValueandFairValueofCertainFinancialAssetsandLiabilitiesDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in unconsolidated ventures ($3,075 held at fair value as of September\u00a030, 2023)", "verboseLabel": "Carrying value", "netLabel": "Investment in Espresso joint venture", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r295", "r315", "r890", "r916" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 3.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 7.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment loss", "negatedTerseLabel": "Impairment loss", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r66" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedParties", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related party", "label": "Increase (Decrease) in Due to Related Parties", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r8" ] }, "us-gaap_NotesReceivableNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNetAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable, after Allowance for Credit Loss", "label": "Financing Receivable, after Allowance for Credit Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityDistributionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r81" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "nshi_DisposalClosingDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DisposalClosingDateAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Closing Date [Axis]", "label": "Disposal Closing Date [Axis]", "documentation": "Disposal Closing Date" } } }, "auth_ref": [] }, "nshi_OperatingCostsIncurredMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "OperatingCostsIncurredMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred", "label": "Operating Costs Incurred [Member]", "documentation": "Operating Costs Incurred" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETSParentheticals" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "verboseLabel": "Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r26", "r241", "r321", "r369", "r370", "r372", "r373", "r374", "r376", "r378", "r380", "r381", "r493", "r496", "r497", "r518", "r667", "r770", "r804", "r922", "r964", "r965" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "nshi_RelatedPartyTransactionTermOfAgreement": { "xbrltype": "durationItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RelatedPartyTransactionTermOfAgreement", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, term of agreement", "label": "Related Party Transaction, Term Of Agreement", "documentation": "Related Party Transaction, Term Of Agreement" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "nshi_StockRedeemedorCalledDuringPeriodSharesPaymentofAdvisorAssetManagementFees": { "xbrltype": "sharesItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "StockRedeemedorCalledDuringPeriodSharesPaymentofAdvisorAssetManagementFees", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment of advisor assets management fees (in shares)", "label": "Stock Redeemed or Called During Period, Shares, Payment of Advisor Asset Management Fees", "documentation": "Stock Redeemed or Called During Period, Shares, Payment of Advisor Asset Management Fees" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Total property and other revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r223", "r241", "r286", "r287", "r298", "r303", "r304", "r310", "r312", "r313", "r321", "r369", "r370", "r372", "r373", "r374", "r376", "r378", "r380", "r381", "r518", "r582", "r922" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsTransitionServicesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r694", "r695", "r698" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Principal on Borrowings based on Final Maturity", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r12" ] }, "nshi_DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, After Year Four", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, After Year Four" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r807" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r355", "r356", "r357", "r358", "r563", "r564" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_ProceedsFromRentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRentsReceived", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from rents received", "label": "Proceeds from Rents Received", "documentation": "Cash received for rents during the current period." } } }, "auth_ref": [ "r39" ] }, "nshi_ProceedsFromDivestitureOfEquityMethodInvestmentSupplementalDailyCashPayment": { "xbrltype": "monetaryPerDurationItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ProceedsFromDivestitureOfEquityMethodInvestmentSupplementalDailyCashPayment", "presentation": [ "http://www.northstarhealthcarereit.com/role/SubsequentEventsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from divestiture of equity method investment, supplemental cash payment", "label": "Proceeds From Divestiture Of Equity Method Investment, Supplemental Daily Cash Payment", "documentation": "Proceeds From Divestiture Of Equity Method Investment, Supplemental Daily Cash Payment" } } }, "auth_ref": [] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/FairValueNonrecurringFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r509", "r510", "r512", "r513", "r516" ] }, "nshi_RelatedPartyTransactionDuetoRelatedPartiesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RelatedPartyTransactionDuetoRelatedPartiesRollForward", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsSummaryofFeesandReimbursementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction, Due to Related Parties [Roll Forward]", "label": "Related Party Transaction, Due to Related Parties [Roll Forward]", "documentation": "Related Party Transaction, Due to Related Parties [Roll Forward]" } } }, "auth_ref": [] }, "nshi_DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails": { "parentTag": "nshi_DeferredCostsandFiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesScheduleofFutureAmortizationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Four", "documentation": "Deferred Costs and Finite-Lived Intangible Assets, Amortization Expense, Year Four" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsToMinorityShareholders", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/BusinessandOrganizationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interest investment in operating partnership", "label": "Proceeds from (Payments to) Noncontrolling Interests", "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [] }, "nshi_ScheduleofRealEstateInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ScheduleofRealEstateInvestmentsTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Real Estate", "label": "Schedule of Real Estate Investments [Table Text Block]", "documentation": "Schedule of Real Estate Investments [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 }, "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings (losses) of unconsolidated ventures", "negatedLabel": "Equity in (earnings) losses of unconsolidated ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r138", "r176", "r292", "r315", "r595" ] }, "nshi_DebtInstrumentNumberOfInstrumentsDefaulted": { "xbrltype": "integerItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DebtInstrumentNumberOfInstrumentsDefaulted", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of debt instruments", "label": "Debt Instrument, Number of Instruments Defaulted", "documentation": "Debt Instrument, Number of Instruments Defaulted" } } }, "auth_ref": [] }, "nshi_RochesterNYMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RochesterNYMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester, NY", "label": "Rochester, NY [Member]", "documentation": "Rochester, NY [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and other revenues", "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSParenthetical", "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares granted to independent directors (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r459" ] }, "nshi_FriscoTXNonRecourseFebruary2026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FriscoTXNonRecourseFebruary2026Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Frisco, TX Non-recourse, February 2026", "label": "Frisco, TX Non-recourse, February 2026 [Member]", "documentation": "Frisco, TX Non-recourse [Member]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesDeferredCostsandIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r61", "r63" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "nshi_FormerSponsorAndAffiliatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FormerSponsorAndAffiliatesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Former Sponsor and Affiliates", "label": "Former Sponsor and Affiliates [Member]", "documentation": "Former Sponsor and Affiliates" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested shares (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r456", "r457" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r840" ] }, "nshi_RochesterNYNonRecourseJuly2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "RochesterNYNonRecourseJuly2023Member", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester, NY Non-recourse, July 2023", "label": "Rochester, NY Non-recourse, July 2023 [Member]", "documentation": "Rochester, NY Non-recourse, August 2027 [Member]" } } }, "auth_ref": [] }, "nshi_ProceedsFromSaleOfRealEstateInvesting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "ProceedsFromSaleOfRealEstateInvesting", "crdr": "debit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Sales of real estate", "label": "Proceeds From Sale Of Real Estate, Investing", "documentation": "Proceeds From Sale Of Real Estate, Investing" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesNarrativeDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Ownership interest (as a percentage)", "terseLabel": "Ownership interest (as a percentage)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r317" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-controlling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r31", "r174", "r241", "r321", "r369", "r372", "r373", "r374", "r380", "r381", "r518", "r593", "r671" ] }, "nshi_FacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "FacilityMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility", "label": "Facility [Member]", "documentation": "Facility" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/FairValueNarrativeDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesSummaryofInvestmentsinUnconsolidatedVenturesDetails", "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment recognized", "label": "Equity Method Investment, Other than Temporary Impairment", "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment." } } }, "auth_ref": [ "r915" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r873" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingSegmentStatementofOperationsDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingSummaryofAssetsbySegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r21", "r299", "r300", "r301", "r302", "r308", "r913" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r136", "r175", "r594", "r791", "r904", "r917", "r960" ] }, "us-gaap_RealEstateTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateTable", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Table]", "label": "Real Estate [Table]", "documentation": "Disclosure of information about real estate investment companies including, but not limited to, real estate investment trusts, real estate owned, retail land sales, and time share transactions." } } }, "auth_ref": [ "r758" ] }, "nshi_IncentiveFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "IncentiveFeesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsIncentiveFeeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incentive Fee", "label": "Incentive Fees [Member]", "documentation": "Incentive Fees [Member]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r874" ] }, "nshi_MortgagesAndOtherNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "MortgagesAndOtherNotesPayableMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/BorrowingsScheduleofBorrowingsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mortgages and other notes payable", "label": "Mortgages And Other Notes Payable [Member]", "documentation": "Mortgages And Other Notes Payable" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r48", "r50", "r111", "r112", "r313", "r754" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to NorthStar Healthcare Income, Inc. common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r230", "r264", "r267", "r268", "r269", "r270", "r272", "r275" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r874" ] }, "nshi_DiversifiedUSUKAndEclipseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "DiversifiedUSUKAndEclipseMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diversified US/UK and Eclipse", "label": "Diversified US/UK and Eclipse [Member]", "documentation": "Diversified US/UK and Eclipse" } } }, "auth_ref": [] }, "us-gaap_RealEstateLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RealEstateLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/OperatingRealEstateNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Real Estate [Line Items]", "label": "Real Estate [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r758" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.northstarhealthcarereit.com/role/NoncontrollingInterestsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [ "http://www.northstarhealthcarereit.com/role/CONSOLIDATEDSTATEMENTSOFEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-controlling interests - distributions", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": [ "r163" ] }, "nshi_WatermarkRetirementCommunitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.northstarhealthcarereit.com/20230930", "localname": "WatermarkRetirementCommunitiesMember", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Watermark Retirement Communities", "label": "Watermark Retirement Communities [Member]", "documentation": "Watermark Retirement Communities [Member]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r48", "r50", "r111", "r112", "r313", "r624", "r754" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.northstarhealthcarereit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.northstarhealthcarereit.com/role/EquityBasedCompensationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r787" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Domain]", "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r757", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.northstarhealthcarereit.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r879" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.northstarhealthcarereit.com/role/StockholdersEquityRetirementofSharesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased during period (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r16", "r130", "r131", "r163", "r630", "r714", "r749" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Name of Property [Axis]", "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r757", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r874" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.northstarhealthcarereit.com/role/InvestmentsinUnconsolidatedVenturesChangesinCarryingValueDetails", "http://www.northstarhealthcarereit.com/role/RelatedPartyArrangementsInvestmentsinJointVenturesDetails", "http://www.northstarhealthcarereit.com/role/SegmentReportingScheduleofPropertiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest, ownership percentage by parent (as a percentage)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "4", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479455/805-10-15-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "6", "SubTopic": "50", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-6" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20,22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "35", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-17" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "35", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482190/360-10-35-43" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b),(f(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "2AA", "Subparagraph": "a", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.10(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "970", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//970/tableOfContent" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "972", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//972/tableOfContent" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "974", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//974/tableOfContent" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "976", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//976/tableOfContent" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "978", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//978/tableOfContent" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.M.Q4)", "SubTopic": "20", "Topic": "326", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483530/326-20-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "323", "Publisher": "FASB", "URI": "https://asc.fasb.org//323/tableOfContent" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-4A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479391/326-20-30-5A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479366/326-20-35-8A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-17" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-21" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3C" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479175/326-30-30-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "13A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-13A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479148/326-30-35-7A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3C" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-3D" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r880": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r881": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r882": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "323", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r884": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 82 0001503707-23-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001503707-23-000034-xbrl.zip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�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�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end